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Preface to ”Cell-Free Nucleic Acids”
Liquid biopsy has recently become a very popular, noninvasive sampling procedure. The main
advantage of this method is the possibility of easy cell-free nucleic acids isolation from different
fluids, primarily blood, and their use in diagnostic or screening processes. The other advantage is
the possibility to follow up on patients’ treatments. Liquid biopsies are applicable in the diagnosis of
oncological, cardiovascular, and infectious diseases and in the use of noninvasive prenatal testing
(NIPT). Gene expression studies on gDNA, mtDNA, miRNA, and lncRNA can provide valuable
information to researchers and clinicians. Currently, it is very popular to obtain exosomes from liquid
biopsies and use them in similar studies. Understanding their role in different pathological conditions
could provide us with valuable information on cell–cell-tissue communication. The identification of
new extra- and intra-cellular signaling of nucleic acid molecules and pathways could help in the
diagnosis and treatment of patients. Cell-free DNAs are widely used in the prenatal detection of
genetic diseases. Recently oncological diseases have been a focus of research and the newest area to
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The discovery of cell-free DNA (cfDNA) dates back to 1948, when Mandel and Metais found it in
the sera of cancer patients [1]. Later, Tan et al. observed a correlation with the cfDNA concentration and
development of autoimmune disease in 1966 [2]. Leon et al. started to use cfDNA in tumor diagnosis
in 1977, but unfortunately due to the molecular biological technical possibilities they were not very
successful [3]. A break through occurred in 1997, when Dennis Lo started to detect RhD and fetal sex in
maternal plasma by using real-time PCR [4]. The real spread of non-invasive detection of fetal genetic
diseases started in 2011, when massive parallel sequencing was introduced [5]. Nowadays, about half
of the prenatal genetic examination is performed by so-called non-invasive prenatal testing (NIPT).
The clinical application of cfDNA has been rapidly growing in the field of oncology; it gives
the possibility of the early detection of cancer in different body fluids via liquid biopsy. Cancer type
specific molecular signatures could be detected in very early stages of tumor development. Drug
resistance is a burning problem during the treatment of patients. In addition to the mutation screening
methylation profile, there has been increasing interest in the use of surrogate markers for follow up in
cancer patients with metastasis [6].
Alongside the increasing application of cfDNA, interest is growing in the utilization of cell-free
RNAs (cfRNAs), such as microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA
(circRNA), in different types of diseases [7]. Their concentrations are surprisingly stable in sera or plasma
due to their encapsulation into extracellular vesicles (microvesicles, exosomes). From these, it seems
that exosomes could tremendously improve the current diagnostic arsenal. While the exact nucleic
acid, protein, and lipid contents of these small microvesicles are still under investigation, it has been
shown that exosomes play important roles in intracellular, cell-cell, and cell-tissue communication [8].
MiRNAs are important small non-coding RNAs that are 18–25 base pairs (bp) in size. They
are able to bind to proteins such as Argonaute-2, HDL, and LDL, and a single miRNA can regulate
the expression of several of genes [9,10]. Disturbances in the regulation of key miRNAs can have
tremendous effects on gene expression and on normal and pathophysiological processes [6].
LncRNAs, which are >200 bp in size, are new players in this field. It seems that they have an even
higher diagnostic and prognostic value due to their specific expression in different type of tissues and
diseases; importantly, they are very stable in different conditions [11]. It has been shown that they are
useful in the diagnosis of different types of cancer and cardiovascular diseases [11].
CircRNAs are newly discovered non-coding RNAs with the size of couple of thousands base pairs.
They have a closed circular structure with a function of tumor suppressor or promoter in several types
of cancer. They can be used as biomarkers or therapeutic targets [12]. They can also serve as sponges
to inhibit miRNAs [13]. Altered expression of circRNAs has been reported recently [14,15].
This exciting field of research is expected to produce a lot of diagnostic and new generation
treatment possibilities. The high interest in this topic shows in the enormous quantity of published
papers in different journals. Coincidentally, there was a Special Issue in the Journal of Biotechnology
earlier this year dealing with this subject. Researchers from Central-Eastern Europe showed their work
on cell-free nucleic acids [16–19].
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This Special Issue contains eight original research studies [20–27], and five review papers [28–32];
the diversity of the papers demonstrates how many different topics are covered by cell-free nucleic
acid research.
Three research papers deal with the prenatal application of cfDNA. Pös et al.’s “Identification of
Structural Variation from NGS-Based Non-Invasive Prenatal Testing” shows that copy number variants
(CNVs) are important subjects for the study of human genome variations, as CNVs can contribute to
population diversity and human genetic diseases [20]. Additionally, CNVs are useful in NIPT, as they
are a source of population specific data [20].
Gazdarica et al. studied the reliability of NIPT, which depends on the accurate estimation of
fetal fraction [21]. They propose several improvements in fetal fraction estimation to get more reliable
results [21].
In their other work, Gazdarica et al. demonstrated a new, more stable prediction method for NIPT
that provides highly divergent inter-sample coverage [22].
Preeclampsia is a mysterious disease—despite intensive research, we still do not know the exact
details of its development. It seems that cell-free nucleic acids could serve as biomarkers for the early
detection of this disease. Hromadnikova et al. measured exosomal C19MC microRNAs and found
them to be important 6in the detection of pregnancy associated complications [23].
Improving the success rate of vitro fertilization (IFV) and embryo transfer (ET) is an important
goal. Timofeeva et al. reported a very interesting application of small non-coding RNAs to improve the
efficiency of embryo transfer (ET) by measuring embryo-specific sncRNAs in the culture media [24].
Ovarian cancer is one of the leading serious malignancies among women, with high incidence of
mortality; the introduction of new diagnostic markers could help in its early detection and treatment.
Penyige et al. showed their results from using the NanoString technique to get information on the
expression of 800 miRNAs in one run, and they checked the reliability of the obtained results by
conventional real-time PCR [25].
Epigenetic regulation is very important during the development of diseases and drug resistance.
Dvorská et al. found that methylation changes are important signs during ovarian cancer development
and that the CDH1 gene is a potential candidate for being a non-invasive biomarker in the diagnosis of
ovarian cancer [26].
We received interesting reviews on the application of cell-free nucleic acids. Zubor at al. reviewed
the deficits of mammography and demonstrated the potential of non-invasive diagnostic testing using
circulating miRNA profiles [27].
Exosomes are important in the transfer of genetic information. Konečná et al. discussed the
current knowledge on not only exosome-associated DNA but on vesicles-associated DNA, and their
role in pregnancy-related complications [28]. It seems that a major obstacle is the lack of a standardized
technique for exosomes isolation and measurement [28].
Kubiritova et al. summarized what we know about cell-free nucleic acids in inflammatory bowel
disease (IBD). Despite extensive research, the etiology and exact pathogenesis are still unclear, although
similar to the cfNAs (cell-free ribonucleic acids) observed in other autoimmune diseases, it seems to be
relevant in IBD. The authors collected literature on cfDNA and cfRNA and on exosomes and neutrophil
extracellular traps and their association with IBD. Based on the information from the reported literature,
they propose the use of cfNAs (cell-free nucleic acids) in the management of IBD as biomarkers and as
a potential therapeutic target [29].
Dvorska et al. reviewed the utility of liquid biopsy as a tool for the differentiation of leiomyomas
and sarcomas of corpus uteri [30]. They collected the most important knowledge of mesenchymal
uterine tumors and showed the benefits of liquid biopsy [30].
Microchimerism has also recently become a hot topic too. Andrikovics et al. discuss
microchimerism in the context of various forms of transplantation and transplantation-related advanced
therapies, and they show the available cfNA (cell-free nucleic acid) markers and detection platforms [31].
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There is only one article in this issue related to animal studies. Janovičová et al. showed that sex,
age, and bodyweight are not determinants of cfDNA variability in healthy mice, and they call attention
to the importance of understanding the production and cleavage of cfDNA [32].
I would like express my thanks to all of the authors for their valuable contributions to this Special
Issue, and would also like to express my gratitude to the editorial staff members and anonymous
reviewers who helped to improve the quality of the submitted manuscripts. I hope readers will find
this issue to be both interesting and useful.
Conflicts of Interest: The author declares no conflict of interest.
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Abstract: In the global context, the epidemic of breast cancer (BC) is evident for the early 21st century.
Evidence shows that national mammography screening programs have sufficiently reduced BC
related mortality. Therefore, the great utility of the mammography-based screening is not an issue.
However, both false positive and false negative BC diagnosis, excessive biopsies, and irradiation
linked to mammography application, as well as sub-optimal mammography-based screening, such as
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in the case of high-dense breast tissue in young females, altogether increase awareness among the
experts regarding the limitations of mammography-based screening. Severe concerns regarding the
mammography as the “golden standard” approach demanding complementary tools to cover the
evident deficits led the authors to present innovative strategies, which would sufficiently improve
the quality of the BC management and services to the patient. Contextually, this article provides
insights into mammography deficits and current clinical data demonstrating the great potential of
non-invasive diagnostic tools utilizing circulating miRNA profiles as an adjunct to conventional
mammography for the population screening and personalization of BC management.
Keywords: breast cancer; screening; liquid biopsy; omics; multi-level diagnostics; individualized
patient profile; miRNA; mammography; predictive and preventive approach; personalized medicine
1. Introduction
Cancer is one of the leading healthcare burdens worldwide. In 2018 18.1 million (95% UI:
17.5–18.7 million) new cases of cancer (17 million excluding non-melanoma skin cancer) and 9.6 million
(95% UI: 9.3–9.8 million) cancer related deaths (9.5 million excluding non-melanoma skin cancer)
have been estimated worldwide. Figure 1 summarizes most frequent cancer types [1]. To this end,
a big portion of cancer-related deaths can be avoided at the level of primary prevention: innovative
screening programs and targeted preventive measures are essential tools to identify and mitigate
modifiable risks individually and in a timely manner [2–4].
Figure 1. Global cancer statistics demonstrating the most prevalent cancer types; the image is based on
the data published by 2019 [1].
Further, at the level of secondary prevention, cancer-diagnosed patients could demonstrate longer
survival rates and have much better quality of life if the disease-management process would adapt
treatment algorithms that are tailored exactly to the individualized patient profiles [5,6]. For the
population screening, early and predictive diagnosis, as well as prognosis and disease monitoring,
a multi-level diagnostics (multi-omics, sub-cellular and medical imaging) method utilizing the great
information potential of liquid biopsy is considered to be the most appropriate tool [7] and is thoroughly
analyzed in the current paper using the example of breast cancer (BC) management.
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2. Breast Cancer in the Context of Global Cancer Mortality
The 28 Member States of the European Union (EU-28) with a population of 504.6 million had
5.0 million deaths in 2012 with more than one fourth attributable to cancer [8,9]. Detailed analyses
revealed 29.2% of deaths among men and 22.5% of deaths among women were caused by cancer alone
in 2012. Next to the disorders of the circulatory system (cerebrovascular and heart diseases), cancer is
the second most common cause of deaths in the EU, being one of the major public health burdens in
the European Union (EU). According to the International Agency for Research on Cancer (IARC, 2012),
out of 1.26 million cancer-related deaths in the EU-28, breast cancer (BC) alone is responsible for
91,500 deaths annually [10]. In the global context, the epidemic of BC is associated with a number of
external and internal risk factors attributed to the early 21st century [11].
BC is the most frequent tumor in female populations worldwide, with an incidence rate of
43.1 per 100,000 world age-standardized rate (ASR-W), a mortality rate of 12.9 per 100,000 ASR-W,
and a 5-year prevalence of 239.9. In low-, middle- and high-income countries the incidence rates
are persistently increasing [12]. To this end, the contribution to the BC incidence by the European
Region is higher than the global average [13]. Specifically for the EU-28, the incidence and mortality
rates are as high as 80.3 and 14.4 per 100,000 ASR-W, respectively [14]. Most of EU-28, including
the biggest sufferers such as the UK [15], France [16], Italy [17], Germany [18], and Belgium [19],
have established national programs for BC screening by mammography as the golden standard for
reducing mortality from BC. Evidence shows that national mammography screening programs have
sufficiently reduced BC related mortality [20,21]. Therefore, the adequacy and usefulness of the
mammography-based screening for women aged by 50 to 74 years is generally well-accepted [22].
Therefore, the great utility of the mammography-based screening is not an issue. However, it is
important to decide for which population the mammography-based screening should be considered to
be optimal i.e., the “golden standard” approach (see Table 1). Both false positive and false negative
BC diagnosis [23], excessive biopsies and irradiation linked to mammography application, as well
as sub-optimal mammography-based screening, e.g., in case of high-dense breast tissue in young
females [24], altogether increases awareness among the experts regarding the mammography-based
screening limitations. Severe concerns regarding the mammography as the “golden standard” approach
demanding complementary tools to cover the evident deficits [25] led us to present innovative strategies,
which would sufficiently improve the quality of the BC management and services to the patient.
Table 1. Categories of women and mammography screening applicability.
Categories of Women Applicability of Mammography
Postmenopausal with fatty breasts The breast density gradually decreases after menopause,applicable every two years
Young with very dense breast parenchyma Low diagnostic sensitivity
Pregnancy
Mammography is not contraindicated in the first and second
trimesters (sufficient shading of the uterus is necessary); USG
and MRI are predominant diagnostic methods
Family history of BC An annual mammography, supplemental imaging (MRI, USG) indense breast tissue
Genetic predisposition to BC An annual mammogram starting at age 25
Diagnosis of atypical hyperplasia or
lobular carcinoma in situ An annual mammogram beginning at the time of diagnosis
Average BC risk with no symptoms An annual mammogram combined with USG in dense breasttissue
BC, breast cancer; MRI, magnetic resonance imagining; USG, ultrasonography.
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Contextually, this article is aiming to provide insights into mammography deficits and current
clinical data demonstrating the great potential of non-invasive diagnostic tool utilizing circulating
miRNA profiles as an adjunct to conventional mammography for the population screening and
personalization of BC management [6]. To this end, innovative screening strategies should consider
primary [11] and secondary [26] levels of predictive and preventive medical approach, including both
non-modifiable and modifiable risk factors [27] based on comprehensive individual patient profiles
that means application of multi-omics [28,29], big data processing [30] and artificial intelligence such as
machine learning approach [5]. Table 1 summarizes the categories of women with the mammography
screening applicability.
3. Breast Cancer Screening by Mammography: An Evolution
Radiography is the oldest and most common form of medical imaging. A mammography is an
x-ray medical method examining the breast using lower doses of radiation. Because these x-rays do
not pass through breast tissue easily, the mammogram machine has two plates that compress the breast
to spread the tissue apart, resulting in a more accurate image with less radiation [31]. Over the past
decades, technology changed over from the analog to digital picturing.
The analog mammography used film as both a receptor and a display for the image to produce
static, fixed images. The advantage of analog mammography linked with computed radiographic
systems included much less costs than digital mammography, however the main disadvantage, that the
image is far inferior to digital mammography and also the storage in protective sleeve required large
amounts of space, was the reason for leaving it worldwide. Thus, the digital technology fluently
re-placed the analog mammograms.
Digital mammography uses detectors that change x-rays into electrical signals (pixels), which are
transferred into a digital receptor and converts x-rays energy into numbers. It produces an image
displayed on a monitor or printed on high-resolution printer. In comparison with analogue film,
digital mammography provides images with more contrast, allows image manipulation, and archive
films which reduces the risk of misplacement or damage. Moreover, the digital detector provides a crisp
image with no limitations on breast size and detects cancer cells earlier than analog mammography.
This makes this method superior to film mammography [32,33]. Digital breast tomosynthesis
mammography (DBT) is relatively new technology being developed to improve detection and
characterization of breast lesions, especially in women with non-fatty breasts. The x-ray dose for
a tomosynthesis image is similar to that of a regular mammogram. DBT creates a 3-dimensional (3D)
picture of the breast using several low dose x-rays obtained at different angles. The breast is positioned
and compressed in the same way as in a regular mammography, but unlike for regular mammography,
the x-ray tube moves in a circular arc around the breast in DBT [34,35]. DBT provides an advantage
in detection of breast masses compared to 2-dimensional (2D) mammography, since it allows the
separation of the tissue layers and the noticeable reduction of occlusions caused by overlapping
anatomical structures. While DBT slice images provide advantages for detecting mass lesions, it is
more difficult to get an overview and evaluate the distribution of microcalcifications compared to
2D mammography images. Therefore, the parallel using of 2D mammography and DBT slice images
seems to be necessary in clinical diagnostic practice. Due to the cumulative patient dose, using both
2D mammography and DBT at one session is not an acceptable screening method. However, the DBT
method offers a possibility of reprocessing the tomosynthesis data to create a 2D mammography-like
image (synthetic mammography, SMMG) from DBT image data at the dose level of a single DBT
screening. The use of SMMG with DBT provides significant benefit of increased diagnostic accuracy
compared with regular mammography [36]. Here, the initial evidence suggests that SMMG may
reduce recall rates and increase cancer detection rates when added to digital MMG screening [37].
Figure 2 describes the advantages and disadvantages of analog versus digital mammography.
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Figure 2. Advantages and disadvantages of digital versus analog mammography.
Regular screening for BC with mammography (along with other examinations such as breast
self-examinations) is widely recommended with the aim to reduce mortality of BC. Although controversy
remains over the best screening programs and to whom it should be offered (e.g., for the primary cancer
free population, screening of secondary cancer after previous BC surgery, screening of population
with different genetic background or different age-groups of screened population), these methods are
regularly used in clinical practice, following local or national guidelines. Reflecting this, there are
multiple approaches for BC screening. E.g., according to the Canadian Task Force on Preventive
Health Care, the use of mammography for women at average risk of BC aged 40–74 years includes
following recommendations: for women aged 40–49 years, it is recommended to not routinely screen
with mammography; for women aged 50–69 years and also 70–74 years, it is recommended to routinely
screen with mammography every two to three years [38].
Although the results of mammographic screening in women aged 50–70 years are sometimes
disputed [39], there is a consensus among clinicians that BC screening of women in this age group is
effective. On the other hand, there is no consensus about the value of BC mammographic screening
among women who are aged 40–49 years having denser breasts compared to postmenopausal
women [40]. Regarding women under 40 years of age, in which BC is rare and typically presents
symptomatically, the best imaging modality is controversial. Routine screening of women in this age
group in the absence of significant BC risk factors is not recommended. Some authors showed the
superior sensitivity of ultrasound screening for BC in women under the age of 40 years; however,
they noted that mammography and/or MRI remain essential adjuncts, particularly in the identification
of multifocal disease [41]. The large body of analysis comparing ultrasound and mammography
to evaluate women aged 30–39 with symptoms of possible BC has demonstrated that ultrasound
screening is a superior diagnostic tool [42], which may impact on the consideration of current clinical
practice guidelines that nowadays recommend mammography as the first evaluation in these women.
A special group for screening is women under 50 years who underwent breast conservation
therapy, as those women may benefit from breast screening as an adjunct method to MMG. In this
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regard, the addition of MRI to annual MMG screening improves the detection of early-stage but
biologically aggressive BC [43].
The last group, where much of the variability in BC screening programs exists, represents the
high-risk population. The annual mammography in women with one or two first degree relatives with
invasive BC starts 5 to 10 years younger than the youngest case in the family, but no earlier than age
25 and no later than age 40. Women with a breast biopsy showing atypical hyperplasia or lobular
carcinoma in situ and following surgical management to rule out invasive carcinoma have annual
mammography. Women with a history of chest wall radiation (i.e., mantle radiation for treatment of
Hodgkin’s lymphoma) at age 30 or younger have an annual mammography and breast screening MRI
starting 5 to 10 years after radiation given, but starting no earlier than age 25 and no later than age 40.
For women with BRCA1 or BRCA2 genes mutations, current guidelines recommend annual screening
by clinical breast examination and mammography starting at age 30 [44]. However, these approaches
may vary from country to country.
4. Breast Cancer Screening by Mammography and Profiling of Genetic Risk
Routine BC screening is recommended for women from the age of 50 years; however, high-risk
individuals (with a strong family history of the disease) may be included for screening at earlier
age. About twenty percent of all BCs occur in women under 50 years old, and the vast majority
of these women do not have any family history of the disease. Most of these tumors have poorer
prognosis, therefore early diagnosis by mammography screening, irrespective of known family history,
can be clinically beneficial due to reduced BC mortality [45]. Covering the genetic risk assessment
into mammography screening programs (by modification of screening frequency or using alternative
modalities such as MRI and USG) has been supposed as the way which maximize benefits and minimize
harms [46]. Therefore risk-stratified mammography screening based on genetic risk seems to be more
effective compared to prevailing age-stratified approaches [47].
4.1. Low- and Intermediate-Risk Women
Intermediate-risk women include cases with a breast biopsy that shows changes such as atypical
ductal or lobular hyperplasia, or lobular carcinoma in situ. A calculated risk of BC in these women is
ranged from 20% to 29% based upon family history, personal health history, or certain genetic markers.
Average-risk women (low-risk women) with none of the above risk factors have a 10–13% lifetime
risk of BC [48]. Mammography screening in low-or intermediate-risk women aged less than 50 years
is intensively discussed. Arguments for the lower age of mammographic screening include the
individual and societal gains linked with increased survival rates, greater work life participation,
and lower treatment costs due to early detection. On the other hand, arguments against the lower
age of mammography screening include the possible harms and higher costs of full population
screening. In this regard, screening in this specific age group of women is accompanied by more cases
of false-positive results and unnecessary biopsies because of lower screening specificity. A recent
review by Nelson et al. [49] assessed the studies of screening in intermediate-risk women, including
mammography screening. Results demonstrated that false-positive results are common and are higher
for annual screening, younger women, and women with dense breasts. It seems that the absolute
benefits (e.g., number of deaths prevented) are smaller than for older women, because of general lower
BC incidence and lower sensitivity of mammography in women aged 40–49 years [33,50].
Several older clinical studies did not demonstrate a significant reductions in BC mortality resulting
from screening low-risk women aged 40–50 years [51,52]. A more recent study of Moss et al. [53]
enrolled women aged 39–41 years from 23 UK NHS Breast Screening Programme units. Participants
were randomly assigned to intervention groups with annual screening by mammography up to
an age of 48 years, or to a control group receiving usual medical care (invitation for screening at age
50 years and every 3 years thereafter) respectively. Results showed a significant reduction in BC
mortality in the intervention group compared with the control group in the first 10 years after diagnosis
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but not thereafter from tumors diagnosed during the intervention phase. The overall BC incidence
during 17-year follow-up was similar between the groups. A meta-analysis of eight trials revealed
that mammography screening reduces BC mortality by 15% for intermediate-risk women aged 39 to
49 years [54].
4.2. High-Risk Women
Validated risk assessment models demonstrated that high-risk women are considered to be
those with lifetime risk of BC that is greater than 20% and very high-risk women with a 30% or
greater risk for the disease [55]. High-risk individuals include women with a known BRCA1 or
BRCA2 mutation and their first-degree relatives, women with a personal history of invasive BC
or ductal carcinoma in situ and lobular carcinoma in situ or atypical hyperplasia, Li-Fraumeni,
Cowden/PTEN or Bannayan-Riley-Ruvalcaba syndrome (and first-degree relatives), mutation in
specific genes (ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11 or TP53), and a history of chest
irradiation between the age of 10 and 30 [56]. A germline gene mutation in BRCA1 or BRCA2 results
in a significantly elevated lifetime risk of developing breast and ovarian cancer estimated at up to
7 and 25 times, respectively, compared to average risk population. It is supposed that more than
90% of hereditary cases of BC (and also ovarian cancer) are a result of a mutation in BRCA1/2 [57].
The estimated prevalence of BRCA1 and BRCA2 mutations is dependent on the population and can
vary between 1 in 300 and 1 in 800, respectively [58].
Meta-analysis of the three studies that compared MRI plus mammography versus mammography
alone in screening of young women at high BC risk revealed the sensitivity of MRI plus mammography
to be 94% (95%CI 86–98%) and the incremental sensitivity of MRI to be 58% (95% CI 47–70%) [59].
Regarding the high-risk healthy women over the age of 50, there are no clear-cut guidelines for how to
continue screening them. Most clinicians continue to screen these women with annual MRI, moreover,
in some older women, mammary gland tissue becomes less dense, making it easier to recognize lesions
using mammography [60].
Management of high-risk women for the development of BC is debatable, mainly in women
carrying a BRCA1/BRCA2 or p53 genes mutation because they can develop cancer at an earlier
age [61]. This is because mammography alone has limitations in screening younger women with
a specifically denser mammary gland tissue or with special tumor phenotypes [60]. Therefore, magnetic
resonance imaging can be used along with mammography in these women to increase sensitivity of
the screening program. Regarding the high-risk individuals with BRCA1 or BRCA2 mutations, current
guidelines suggest to begin annual MRI imaging at age 25 and to add mammography at age 30 [44].
Recent meta-analysis of Phi et al. [62] showed that additional screening sensitivity from mammography
above that from MRI is limited in BRCA1 mutation carriers. On the other hand, mammography
contributes to screening sensitivity in BRCA2 mutation carriers, especially those over 40 years. Authors
summarized that a differential screening schedule by BRCA status is worth considering [62]. The results
of a prospective multicenter trial enrolling 296 carriers of the BRCA1/2 mutation showed that carriers
of the BRCA mutation younger than 40 years may not benefit from full-field digital mammography
surveillance in addition to dynamic contrast agent-enhanced MR imaging [63].
Based on above-mentioned clinical data, we can conclude than women at high-risk of BC require
a close breast surveillance. On the other hand, there is no evidence that more frequent mammography
screening or screening with other modalities actually reduces the risk of BC mortality in women with
an intermediate or low BC risk (including women with extremely dense breast at mammography) [64].
In addition, mammographic screening has several weaknesses: (a) the risk of false positives; (b) the risk
of false negatives; (c) X-ray radiation exposition may trigger BC in high-risk women; (d) mammography
performance is operator dependent [65–67].
Moreover, clinical practice demonstrates common diagnostic problems in the distinguishing the
pure atypical ductal hyperplasia from advanced lesions, such as DCIS and/or invasive ductal carcinoma
following a mammography, and even combined with follow-up core needle biopsy. In this regard,
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accumulating evidence from oncological research confirming the role of miRNAs in BC progression
should be helpful. Therefore, it seems logical to use the potential of miRNA molecules as biomarkers
in early BC detection as a follow up of mammography and core needle biopsy [68].
For women who are at high risk for BC and are unable to undergo an MRI evaluation (or are
pregnant), ultrasonography of the breast is considered as a useful diagnostic tool. Moreover, ultrasound
has been suggested as an adjunct screening method that can detect BC that is missed when using
mammography. In this regard, Health Quality Ontario [69] investigated the benefits of ultrasound
as an adjunct to mammography compared with mammography alone in women at average and
high BC risk. After including five prospective studies, authors concluded that there is low-quality
evidence that screening with mammography and adjunct ultrasound detects additional cases of disease,
with improved sensitivity compared to mammography alone. Moreover, the results did not show
that the use of ultrasound as an adjunct to mammography might reduce BC-related mortality in
high-risk women. Due to certain limitations of mammography, particularly in women with dense
breasts, ultrasound in combination with contrast-enhanced magnetic resonance imaging, are suggested
to supplement mammography for the early detection of BC [70].
4.3. Genetic Profiling as a Tool for the Risk Assessment
Another method focused on the more specific and early detection of BC itself and its risk
assessment involves genetic signature profiling. It includes either only genetic variants, or gynecological
characteristics or it combines all these factors together. The first mentioned genetic model is mainly
the BRCAPRO with several modifications [71] and BOADICEA [72]. Both are able to predict the
risk of the disease by mutations analyses in highly penetrant genes, such as BRCA1 and BRCA2.
These variants have high individual benefit, but due to rare incidence, they are not suitable for
general screening. Therefore, other genetic models include several single nucleotide polymorphisms
(SNPs) in low penetrant genes, as they are more frequent in the general population and thus are
preferable in the primary screening programs. Some models analyze 7 [73], 12 [74], 51 [72], 77 [75],
88 [76] or 153 SNPs [77]. However, the predictive ability of these genetic models, explained by an area
under the ROC curve (AUC) is individually low, ranging from 0.53 to 0.68 [75,77]. When combined
multiplicatively with other risk models (i.e., BRCAT / Gail model), a substantial improvement in
specificity and sensitivity was observed [72,73,76,78]. Addition of a genetic risk model (12 SNPs) to
the BRCAT had a greater effect among African Americans than in whites as it reclassifies the high-risk
status of several women undergoing screening mammography [74].
Comparative analyses focusing on the evaluation of the best model’s discriminative ability explained
by the area under the ROC curve, including genetic, Gail/demographic, and mammography models,
revealed the domination of single mammography model above other models. Better identification of
women with elevated risk for BC could be attained by the combination of these models as it increases
the AUC values by a statistically significant amount [79–81]. It seems that BC risk-stratification based
on the combination of mammography screening, genomics and classical risk factors could augment
comprehensive risk prediction, provide many benefits in further treatment or monitoring and facilitate
tailored preventive intervention.
4.4. Proteomic Profiling as a Tool for Screening Guidelines
The clinical complications due to increased breast density lead to confusion for physicians in
the management of women with dense breasts and their follow-up. In this regard, the discussion
between patients and health-care providers regarding the need for supplemental screening is necessary.
A biochemical clinical approach not affected by density of mammary gland or risk profile of the women
would provide an important tool in the management of women with dense breasts or other risks
and doubtful imaging results. With the discovery of key biomarkers and protein signatures for BC,
proteomic technologies are fully available to provide an ideal diagnostic adjunct to imaging. Research
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studies have demonstrated that breast tumors are linked with complex changes in the levels of both
serum protein biomarkers (SPB) and tumor associated autoantibodies (TAAb) [82].
Recently, Videssa® Breast as a combinatorial proteomic biomarker assay has been comprised
of SPB and TAAb integrated with patient-specific clinical data to produce a diagnostic score that
reliably detects BC as an adjunctive tool to imaging. Certain blood-based biomarkers are associated
with higher mammographic density [83], therefore it is unknown whether the biomarkers included
in Videssa® Breast might be impacted as well. Reese et al. [84] aimed to assess the performance of
Videssa® Breast in women with dense and non-dense breasts and determine whether this test could
help as an additional tool to clinicians in managing women with dense breasts and questionable
imaging results. Results of this study demonstrated that Videssa® Breast has high sensitivity and
specificity in detecting BC, irrespective of density status. Moreover, a negative Videssa® Breast test
gives an assurance to women with dense breasts that they likely do not have BC.
In addition to above mentioned study, Lourenco et al. [85] conducted two prospective clinical
trials with the aim to assess a blood-based Videssa Breast test for accurately detection of BC and reduce
false positives imaging results. Moreover, they used the Videsa test to detect BC for use in conjunction
with imaging to aid healthcare providers in making informed decisions on treating young women
(under 50 years old) with difficult-to-assess imaging findings. Authors showed that Videssa Breast
can effectively detect BC when used in combination with imaging, improves the management of BC
in individuals under 50 years old with challenging or absent imaging findings, and can apparently
decrease undesirable clinical procedures. The aforementioned results pointed to the benefit of the
integration of SPB and TAAb data in BC diagnosis. Moreover, these data sustain the further progress
of combinatorial proteomic approaches for detecting BC.
5. Liquid Biopsy as Marker for Breast Cancer Control and Management
Traditional BC diagnostic tools include clinical and physical examinations, imaging mammography,
ultrasound, and/or magnetic resonance imaging, followed by histopathology. Ultrasound as
a non-invasive and safe tool is very helpful, but since it is unable to screen the general population for
cancer, it cannot replace mammograms, especially in women above 40. Nevertheless, once a suspect
lesion in the breast is diagnosed, the bioptic verification is necessary.
Histopathology as an invasive approach to examining cancerous tissues once the disease is
installed has for decades been a golden standard for assessment of the tumor biology and if available
can also facilitate assessment of ipsilateral lymph node status and serve as a decision-making tool in
disease management. Currently, the histological and partial genetic profile of solid tumors is achieved
from biopsy or surgical excisional specimens, but these invasive techniques cannot always be performed
routinely. It is well-known that tumors consist of subpopulations of cells and needle biopsy takes only
a small amount of tumor tissue that does not reflect its full heterogeneity, making the capturing of
aggressive clones problematic. Moreover, neither tumor cells show heterogeneity, nor their metastases,
which carries different genomic aberrations. As core biopsy of tumor tissue reveals only the portion of
this heterogeneity, especially in patients with metastases and in overall assessment it does not seems to
be fully representative [86,87], except of full excisional biopsy.
Knowledge, that cancer tissue is associated with mutations in genes, specific genetic alterations and
protein expressions, together with those needle biopsies in BC diagnostics have some disadvantages
leading to false decisions, sets the identification of other tumor biology markers as useful tools for
diagnostic, prognostic and therapeutic purposes. In line with this, other information indicates that
surgically resected primary tumor alone does not provide sufficient information about the future
diseases biology and seeding of metastases, which can be dissociated at different sites and can harbor
unique genomic characteristics that are not detectable in the corresponding primary tumor of the same
patient. Thus, the international oncology community is in active pursuit of non-invasive methods for
the diagnosis and monitoring of BC patients, which could be introduced in clinical practice. Nowadays
efforts are focusing on monitoring specific bodily fluid biomarkers for early and minimally invasive
13
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detection [88]. The background for this is the natural behavior of the malign disease, leading to its
spread. As disease advances, tumor cells are released from primary tumors (e.g., circulating tumor
cells – CTC) and/or metastases or tumor cells release their own nucleic acids (DNA, RNA, miRNA,
etc.) into the circulation (circulating free DNA – cfDNA). Analysis of these particles with tumor origin
has led to a new diagnostic procedure known as the Liquid Biopsy [89,90].
Early detection of BC disease, treatment of BC, and metastasis monitoring are of eminent
importance to ensure favorable prognosis in an individual. Although conventional diagnostic methods,
i.e., breast X-ray mammography is precise (“gold standard”) clinical method, they may bring about
radioactive/invasive harms in patients. In this regard, liquid biopsy as a noninvasive approach is
convenient for repeated sampling in clinical oncology practice. Emerging interests in “liquid biopsies”
have encouraged researchers to recognize and develop clinically-valid noninvasive genomic and
epigenomic signatures that can be exploited as biomarkers capable of detecting premalignant and
early-stage tumors, or as biomarkers for prognostic and metastatic evaluation, including cancer relapse
monitoring [91]. Importantly, these genomic and epigenomic signatures that are frequently deregulated
in cancers, have great potential to serve as promising entities for multifarious purposes within clinical
oncology [92].
The term “liquid biopsy” refers to the use of circulating (cell-free) tumor DNA (ctDNA), circulating
tumor cells (CTCs), and other non-invasive biomarkers such as long non-coding RNAs (lncRNA),
messenger and microRNAs (mRNAs and miRNAs), proteins (soluble or membrane-associated proteins
and glycoproteins) and exosomes for the early diagnosis, prognosis, monitoring of clinical progression
and response to treatment [93] as was demonstrated in various cancer types including HPV-Associated
oropharyngeal cancer [94], and BC [95–97]. Thus, liquid biopsy can be used as an additional diagnostic
tool to core or excisional biopsy of primary tumor or its metastasis, or indirect diagnostic tool in case of
technically non-performable, non-achievable localization of tumor/metastasis. The high importance
for wide clinical application of liquid biopsy supports the results from the studies analyzing temporal
and spatial heterogeneity of the tumor tissue. Several studies have described the important role
of CTCs in the clinical management of BC disease, notably the ones in association with primary
metastases [98,99]. On the other hand, Mansouri et al. [100] evaluated whether CTCs may serve as
a clinical prognostic marker for survival in primary BC. Their meta-analysis pointed to CTCs as valid
prognostic marker in primary BC prior to any systemic therapy mainly when it is studied through
CellSearch® using, concluding that the more the CTCs are linked with increased death and relapse rates
in patients. In another study, the prognostic value of CTCs with an epithelial-mesenchymal transition
(EMT) phenotype (expression of TWIST1, SNAIL1, SLUG, ZEB1 transcription factors was analyzed) in
primary BC patients were assessed [101]. CTC EMT was determined in 77 from 427 (18.0%) patients.
Considering all subgroups of patients, individuals without detectable CTC EMT in peripheral blood
manifested longer disease-free survival compared to patients with detectable CTC EMT. Likewise,
plasma DNA mutations in ER + MBC seems very promising markers in the early prediction of
therapeutic response. In this regard, Kumar et al. [102] used digital PCR-based target enrichment,
which was followed by next-generation sequencing to analyze plasma DNA mutations in ESR1,
PIK3CA, and TP53 in a prospective cohort of 58 patients with ER + MBC. This assay found ESR1,
PIK3CA, and TP53 plasma ctDNA mutations in 55%, 32%, and 32% of individuals and revealed ctDNA
mutant allele fractions that were frequently discordant among the analyzed genes.
Despite the initial optimism and expectancy due to identification of CTCs and ctDNA from liquid
biopsies in cancer patients, most recent data indicate that although these markers provide a high grade
of cancer specificity, both groups of clinical indicators are rare in body fluids. Thus, these markers may
be insufficient as clinically valid diagnostic markers. In general, ctDNA represents only less than 1% of
the total cfDNA detected in body fluids. In this regard, the ratio of CTCs to white blood cells consists
approximately 1:1 million [103]. Thus, a study that assessed the ability of ctDNA to recognize specific
mutations in patients with primary tumors demonstrated positive result in only 73% of colorectal,
57% of gastroesophageal, and 48% of pancreatic carcinomas [104]. These data may be considered
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rather disappointing contemplating the fact that each of these mutations were known apriori before
screening [105]. Importantly, other molecules derived from tumor mass, such as non-coding RNAs
(including miRNA) that are far more plentiful than ctDNA or CTCs in body fluids, are relatively stable
in biofluids. These RNA molecules are often deregulated, even in the initial stages of carcinogenesis.
These features favor RNA markers (when compared to CTCs and cfDNA) for further methodical
development as noninvasive liquid biopsy diagnostic and prognostic biomarkers for cancer disease,
including BC. In addition, liquid biopsy miRNA biomarkers are applicable only for cancer patients
but for also healthy individuals with benign diseases. Thus, cancer screening, staging, and response
to treatment may be more effectively assessed by evaluating specific miRNA expression levels in
body fluids [106]. The role of liquid biopsy analyzing miRNA signatures as adjunct to conventional
screening of BC is summarized in Figure 3.
Figure 3. Liquid biopsy miRNA adjunct to conventional screening of BC within personalized diagnosis
and improved management of the disease.
Extracellular miRNA Molecules as an Important Tool of Liquid Biopsy in BC Screening
Circulatory tumor cells (CTCs) come either from primary or metastatic cancer tissue (Figure 4).
In addition to previously studied ctDNA and CTCs there are also other circulating nucleic acids.
The presence of circulating cell-free miRNA (cfmiRNA) molecules in plasma is the latest knowledge in
the liquid biopsy era studied in BC patients.
MicroRNAs (miRNAs) are short, non-coding RNAs of typically 22 nucleotides in length,
which regulate gene expression at the post-transcriptional level and thus are responsible for proteome
shaping [107,108], regulating post-transcriptional gene expression by binding to the 3′ untranslated
regions of mRNA [109]. The sequence that is crucial for this binding is known as the ‘seed sequence’,
situated mostly at positions 2–7 of the miRNA 5′-end [110]. MiRNAs are encoded by genomic DNA
and are located mostly in intergenic regions (about 52%), intronic regions of genes (40%) and within
exons (8%) [111,112]. They represent the human genome information, previously considered to be junk
DNA, nowadays believed to be the hidden treasure regarding their potential relevance in diagnosis,
prognosis, treatment and follow-up of cancer [113], including BC [6]. The miRNAs were initially
discovered in 1993 [114]. A few years later, human studies were launched when its role in cancer was
described [115,116]. Since then, an enormous number of studies of miRNA role in various disease’s
ethiopathogenesis was conducted, describing their roles in or connection to them, including women’s
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cancers. Nowadays, the miRBase, a searchable database of published miRNAs contains more than
1800 human miRNAs sequences [117,118].
The first reports describing the existence of a miRNA signature characterizing human BC
were published in 2005, suggesting the involvement of miRNAs in the pathogenesis of this human
neoplasm [119,120]. The following years of research showed that miRNAs play a vital role in tumor
initiation, progression, drug resistance and disease metastasis. Moreover, the tissue and cancer
specificity of several miRNAs enabled us to generate miRNA fingerprints for several cancer types in
women, reflecting their reproductive organs [110,121–123], and this specific miRNA expression profile
can better classify tumors as compared with the mRNAs. MiRNAs thus have not only important
diagnostic purposes, but also high prognostic value, while opening new possibilities in the cancer
management, treatment stratification, and in the designing of personalized therapy [108,110,124],
most of all in BC [6].
Figure 4. The background of the natural behavior of the malign BC disease leading to its spread
through the circulating tumor cells and consequent secretion of cell free nucleic acids.
6. Circulating miRNA
Apart from the tumor microenvironment, miRNAs can be found and isolated from various
body fluids including serum, plasma, saliva, urine, breast milk, seminal fluid, cerebrospinal fluids
and others [125–127]. The miRNA molecules found in the circulation are derived from tumor tissue
cells, cells with short half-life as platelets, broken cells after tissue injury, apoptotic or necrotic
cells and chronic inflammation [128,129]. These miRNAs, called circulating miRNAs or extracellular
miRNAs (ECmiRNAs), are typically contained within exosomes and vesicles or protein bound
complexes, which are shed from tumor cells into the circulation. Packaging complexes protect RNA
from degradation, making them remarkably stable [130] and resistant to RNases, fluctuations in
pH, long storage periods and to multiple freeze/thaw cycles [125,131]. The stability is most probably
caused by the transport mechanisms as miRNAs are conjugated in complexes, providing them the
protection. ECmiRNAs can be released and transported a) in the membrane-derived vesicles - either in
microparticles (microvesicles) or in smaller exosomes b) in HDL or LDL lipoprotein complexes c) in
AGO protein complex or d) wrapped in large apoptotic bodies [132–134]. Such exported extracellular
miRNAs can be taken up by variety of recipient even distant cells, where they can alter target gene
expression. ECmiRNAs thus represent cell-cell communication, which contributes in carcinogenesis to
tumor progression, metastasis and therapy resistance [107,108,125,135,136]. The export of miRNAs
most likely has selective patterns and is not only passive. Cells secrete specific miRNAs due to cellular
signals or environmental cues and load them into specific vesicles. Moreover, some miRNAs seem to
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be expressed only to be exported, as they were not detected in the parent cell, only in the extracellular
vesicles [132,137].
Due to the above mentioned characteristics of the ECmiRNAs and non-invasive method of
acquisition, and despite it only being several years since its discovery, extracellular miRNAs represent
excellent detectable biomarkers and seem to be very promising useful biomarkers in non-invasive
monitoring and management of BC [135,138,139].
Considering this, to evaluate extracellular miRNAs as a biomarker in BC, the sensitive detection
method is essential. This is possible with several methods, e.g., high-throughput sequencing,
quantitative real-time PCR (qPCR), digital PCR (dPCR) or microarrays on chip. All these techniques
are now fully available, differing only in some requirements. For example, in qPCR experiments
it is necessary to find a stable extracellular miRNA reference in plasma or serum of BC patients.
To achieve this, a few miRNAs as miR-10b, -16, -30a, -103, -148b, -191, -192 or RNU6 are usually used
as endogenous reference markers [140,141].
7. miRNAs as Potential Blood-Based Biomarkers for Early Breast Cancer Detection
It was proved that miRNA has a crucial role in development of breast tumors and that miRNA
expression is highly deregulated either in tumor tissue, metastatic tissue, or in plasma from BC
patients. It causes a loss of control for many biological processes such as proliferation, differentiation,
apoptosis, epithelial-mesenchymal transposition with cell migration, and miRNA can play a specific
role as a regulator of metastasis in many levels of metastatic cascade as well. On the other side,
except oncogenic activities, miRNA also exhibits oncosupressor characteristics by targeting miRNA
coding oncoproteins [142]. Reflecting this knowledge, circulating miRNAs can serve as one of the
most promising biomarkers in oncology for early diagnosis, prognosis and therapeutic response
prediction [143]. Thus, the biological employ of miRNAs in BC management as liquid biopsy marker
recently obtained major interest due its advantages compared to other markers, both in translational
and clinical research.
Malignant tumors can stay clinically asymptomatic for quite a long time, until they reach the
size to be clinically detected or spread to the distant organs forming metastases. There has been
a worldwide effort to identify BC in its early stages for decades. This involved self-examination for
a palpable mass and mammography screening (MMG), enriched by ultrasound. The advance in primary
screening, mainly thanks to modification of approaches (MMG + genetic risk subdivided populations),
enabled us to detect BC quite quickly, however, it is still necessary to undergo core-cut biopsy or fine
needle aspiration to set the diagnosis and biological profile of the cancer [144]. Nevertheless, as was
shown recently, mammography could not be an early screening tool exclusively, and there exist other
possibilities, overcoming its limited specificity and sensitivity, e.g., liquid biopsy technology [68]. Thus,
an ideal approach should be a combination of MMG and some sensitive based “liquid biopsy” biomarker.
The definition of biomarker states that it is “a biological molecule found in blood, other body fluids,
or tissues that is a sign of a normal or abnormal process or of a condition or disease” [145]. Such a marker
should be readily accessible, sensitive enough to detect all types of tumors, and specific enough to not
give false positive results [109]. Based on their usage, we can classify the BC biomarker as including
risk screening, prognostic, predictive and diagnostic and disease monitoring biomarkers. Thanks to
developments in molecular biology, new circulating biomarkers (ctDNAs, mRNAs, cell surface
receptors, transcription factors, and secreted proteins) have been discovered and they have been
proved to be extremely valuable tools for establishing reliable and early BC diagnosis in a minimally
invasive way [146], and this potential of peripheral blood based liquid biopsy can be also fully used
in the follow-up testing after anti-cancer treatment [147].The question “why this race is favoring
miRNAs” is answered by their biology. The miRNAs have many properties and characteristics,
such as low complexity of their molecules, tissue-specificity, stability and easy quantification and
amplification, making them excellent potential biomarkers for many pathological and physiological
processes. Therefore, miRNAs are becoming a point of interest in cancer detection, since they have
17
Int. J. Mol. Sci. 2019, 20, 2878
been proven to be selectively secreted from malignant cells in the mammary gland, and are expressed
differently in the blood of healthy individuals, and patients affected with BC [133]. Their onset and
progress in BC detection, profiling and management thus consequently shows great promise for new
options in screening, diagnosis and therapeutic interventions [148].
8. Tumor vs Serum miRNA Profile as a Background for miRNAs Based Screening
Cookson and al. [149] tried to answer the question of whether the circulating miRNA profiles
resemble those miRNAs inside the tumor. The study analyzed plasma and tissue from patients
before and after tumor resection. There were 210 miRNAs overall. Those miRNAs that have been
overexpressed in plasma could be matched with those in tumors. This fact suggests that the presence
of circulating miRNA can represent the solid tumor [149]. This finding has become the basis for
subsequent studies focusing on BC tissue and circulating miRNAs in clinically oriented research.
Many characteristics used for their detection have been identified using RNA-seq to generate profiles
of miRNA expression in paired samples tumor-serum from patients with carcinoma. This resulted in
a set of differently expressed miRNA between the tumor and the corresponding serum, suggesting
that only a small amount of miRNA is released from primary tumor into circulation [150].
The first effort for clinical utilization of miRNAs was therefore oriented on BC screening,
subsequently modified according to molecular subgroups, and later, adding the predictive potential
to determine tumor biological features and aggressiveness. Initially, a wide panel of miRNAs was
profiled, followed by spectra of selected miRNAs in validating studies. First of all, it was necessary to
find the difference in miRNAs profiles between BC tissue and normal breast healthy tissue, e.g., miR-21,
miR-125b, miR-145, mir-155 [119], followed by the finding of positive linkage between miRNAs present
in the primary BC and patients plasma. Here, matching miRNAs have been subsequently validated
for screening purposes, describing their expression profile or signaling function [150]. Contuinuing
this approach, Heneghan et al. [148] analyzed miRNA from tumor tissues and blood samples by
qRT-PCR. They quantified the level of 7 candidate miRNA of 148 patients with BC and 44 health
controls. Overexpressed levels of miR-195 and let-7a reflected the presence of tumors and when these
2 miRNAs were evaluated two weeks after surgery, their expression was very low [148]. Others have
conducted similar studies analyzing circulating miRNAs in patients with BC compared to healthy
controls. They concluded that a plasmatic level of miRNAs could be a valid distinguishing biomarker
for BC, finding a significantly higher level of several miRNAs for this purpose in their studies [151].
Nowadays, circulating miRNAs associated with neoplasia have the potential to detect cancer
even in its earliest stages. It was proved that miRNAs can be used as screening tool for BC (e.g., panel
of miR-127-3p, miR-148b, miR-376a, miR-376c, miR-409-3p, miR-652 and miR-801), having high
distinguish ability between healthy women, and those with benign, as well as malign breast tumors,
especially with better discriminatory power in younger women [148,152]. Moreover, circulating
miRNAs are also to differentiate between various tumors, e.g., in compliance with their histological
features such as hormone receptors or the state of lymph nodes in BC patients (expression of miR-10b,
miR-373, miR299-5p, miR-411, miR-215 and miR-452 in nodal positive patients) [153], showing high
specificity and sensitivity indicating metastatic disease [154]. Furthermore, a panel including miR-200a,
miR-200b, miR-200c, miR-210, miR-215 and miR-486-5p can predict the onset of metastasis for up to
2 years prior to clinical diagnosis in BC patients [155].
The extremely valuable predicting role of circulating miRNAs showed that some of them,
e.g., overexpression of miR-302b and miR-425, can be associated with early BC stage [151],
or miR-182 [156], miR-155 [157], and miR-21 [158]. In particular, miR-155 and multifunctional miR-21
have recently been of high scientific interest. Meta-analyses based on relevant articles collected from
several scientific databases showed that high levels of their expression correlate with detection of
early stages of the disease in screening approach, and also with creating distant metastases [159–161].
For interest, meta-analysis involving 3 studies with 184 patients showed a screening biomarker
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diagnostic value with sensitivity of 79% (95%CI: 72–84%) and a specificity of 85% (95%CI: 75–92%) for
mi-R155 [162]. In addition, plasmatic miR-21 and miR-155 correlate with tumor receptor status.
Another important feature of miRNAs presented in extracellular liquids is fact that they can play
a role in cross-talk of cancer cells with cells of surrounding tissue, potentiating their use as biomarkers
in BC [163,164]. From the known circulating miRNAs and miRNAs expressed in tissues, the evidence
of abnormal activation in BC patients extends to the circulating miR-16, miR-18a, miR-21, miR-145,
let-151a, miR-155 and the tissue-specific miR-7, miR-21, miR-145, miR-155/154, miR-182, miR-203,
miR-213 suggesting their values as non-invasive marker, and in addition as a potential approach to
overcome chemo-resistance [165].
Others correlate with treatment response and may have significant utility as predictive markers
or may serve as non-invasive predictors for tumor relapse and overall survival, e.g., in triple-negative
BC patients (miR-18b, miR-103, miR-107 and miR-652). Furthermore, this 4-miRNAs signature is
capable of distinguishing tumors from patients with early relapse to those without recurrence [166].
This therefore makes this blood-based signature a potential risk predictor for distinguishing metastatic
disease from recurrence in the early disease stage, serving as blood-based screening tool for BC relapse.
This concept is nor predictive in general, nor cancer type specific. E.g. high levels of serum miR-19a
may represent a biomarker for favorable clinical outcome in patients with metastatic HER2-positive
BC [167].
Singling out the current knowledge in these molecules, provides blood-based miRNA liquid biopsy
also the most valuable opportunity to forgo invasive methods such as tissue biopsy and associated
complications in BC diagnosis, and the screening of relapse in clinical praxis [168]. Circulating miRNAs
associated with BC screening approach are summarized in Table 2.
Table 2. Circulating miRNAs associated with BC screening approach.
miRNA Expression (BC vs. Normal) Sample Type References
miR-15a Upregulated serum [169]
miR-18a Upregulated serum [169–171]
miR-107 Upregulated serum [169]
miR-425 Upregulated serum [169]
miR-139-5p Downregulated serum [169]
miR-143 Downregulated serum [169]
miR-145 Downregulated serum [169,172]
miR-365 Downregulated serum [169]
miR-155 Upregulated serum [157,162,172–177]
miR-1 Upregulated serum [178]
miR-133a Upregulated serum [178,179]
miR-133b Upregulated serum [178]
miR-92a Upregulated serum [178]
miR-148b Upregulated plasma [152,179,180]
miR-376c Upregulated plasma [180]
miR-409-3p Upregulated plasma [152,179,180]
miR-801 Upregulated plasma [180]
miR-16 Upregulated plasma [181,182]
miR-21 Upregulated plasma/serum [133,175,176,181,183–185]
miR-451 Upregulated plasma [184]
miR-145 Downregulated plasma [184]
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Table 2. Cont.
miRNA Expression (BC vs. Normal) Sample Type References
miR-222 Upregulated serum [170,182]
miR-127 Upregulated plasma [152]
miR-376a Upregulated plasma [152]
miR-652 Upregulated plasma [152]
miR-801 Upregulated plasma [152]
miR-484 Upregulated serum [186]
miR-1246 Upregulated serum [187]
miR-1307 Upregulated serum [187]
miR-6861 Upregulated serum [187]
miR-4634 Downregulated serum [187]
miR-6875 Downregulated serum [187]
miR-181b Upregulated serum [173]
miR-24 Upregulated serum [173]
miR-505 Upregulated plasma [133]
miR-125 Upregulated plasma [133]
miR-96 Upregulated plasma [133]
miR-195 Upregulated serum [148]
miR-199a Upregulated serum [188]
Let-7a Upregulated serum [148]
miR-106a Upregulated serum [175]
miR-126 Downregulated serum [175]
miR-335 Downregulated serum [175]
Let-7c Downregulated serum [189]
miR-182 Upregulated serum [156]
miR-25 Upregulated serum [182]
miR-324 Upregulated serum [182]
9. The Role of Circulating miRNAs in Profiling of BC at the Time of Sampling for Screening
As positivity of hormone receptors and estrogen signaling pathway play an important role in
cancer development, progression and therapeutic response, neither tissue specific nor circulatory
miRNAs reflect the endocrine tumor status. It was proved that miRNA serum profile is dependent
on tumor endocrine status and may be differentially expressed (e.g., miR-21, miR-155) in the serum
of women with hormone sensitive compared to women with hormone insensitive BC. Its serum
concentration was found to be lower in PR tumor positivity [190]. Contrary to that, concentration of
miR-182 levels was significantly increased in patients with PR + BC. Considering this fact, miR-155
and miR-182 were suggested as valued plasma biomarker for Luminal type BC diagnosis [156].
A validating study providing deeper insight into the underlying molecular portrait of Luminal
A-like BC subtype selected from initial 76 deregulated miRNAs for further analysis 10 miRNAs
(miR-19b, miR-29a, miR-93, miR-181a, miR-182, miR-223, miR-301a, miR-423-5p, miR-486-5 and
miR-652). The biomarker potential was confirmed by RQ-PCR for four miRNAs (miR-29a, miR-181a,
miR-223, and miR-652) and by binary logistic regression for three miRNAs (miR-29a, miR-181,
and miR-652). A combination of these three miRNAs could reliably differentiate between cancers and
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controls. The expression profiles of these three miRNAs in plasma in combination with mammography,
could have potential to facilitate accurate subtype-specific BC detection [191]. As with the luminal
type, plasmatic miRNAs (e.g., miR-130a, miR-146a, miR-373) also differed between HER2-positive
and -negative tumors [192–194], and the miRNAs distinguishing potential for plasma-based screening
was also showed for TNBC. Mishra et al. [195] proclaimed miR-195-5p and miR-495 as prospective
circulating surrogate molecular markers for early detection of either Luminal or TNBC [195]. In addition,
the other circulating miRNAs (miR-16, miR-21 and miR-199a-5p) have proved this concept, finding
them to be underexpressed when compared with non-TNBC. Moreover, plasma miR-199a-5p expression
in TNBC significantly differed in pre and postoperative levels, and the expression levels were associated
with disease stage. These results suggest that the miR-199a-5p is a TNBC-specific marker with diagnostic
value and strong insight into targeted therapy during the treatment of TNBC [196]. All above mentioned
just confirmed the strong leading role of miRNAs in non-invasive approach for BC screening and
management. Moreover, Zhu et al. [190] highlighted that the stability of miRNAs as such screening
biomarkers, by examining differential expression in the samples of patients, is safe even for samples
have been conserved for 10 years [190], and if Zang et al. [197] showed the sensitivity and specificity
for BC diagnosis for miRNA-30a at 74.0 and 65.6%, respectively, overweighting the sensitivities of
conventional circulating tumor markers CEA and CA153 being 12.0 and 14.0%, respectively [197].
miRNAs based screening and prediction of BC is very valuable for clinical management and also in
patients with a genetically increased risk for disease development. To identify a prognostic marker
among asymptomatic women without a BC diagnosis, however with high risk predictive factors for
developing the tumor, was an aim of a study by Taslim et al. [198], who performed genome analysis
of 41-miRNA model expression in breast tissue in women without tumor with high and low BC
risk (based upon Gail risk model), they have revealed miRNAs correlating with high risk for BC
developing. Moreover, it was reported that altered or disrupted serum concentration of selected
miRNAs, led to development of BC among these women within next 18 months [198]. All these results
serve as proof-of-principle that miRNAs in women without BC may be useful for predicting BC risk
and/or as an adjunct biomarker for BC early detection in screening programs among those who already
developed cancer. The miRNAs identified herein may be involved in breast carcinogenic pathways
because they were first identified in the breast tissues of healthy women. Circulating serum miRNAs
predicting BC profile (ER, PR, TNBC, Her2+ status, stage, nodal affection) are shown in Table 3.
Table 3. Circulating serum miRNAs predicting BC profile.
miRNA Expression ER+/ER− PR+/PR− HER2+/HER2− TNBC+/− Nodal Affection Stage of BC References
miR-10b up − − − + yes early [153,199,200]
miR-18a up − − − + [199,201]
miR-18b up − − − + [199,202]
miR-20a up + − yes early [200,203,204]
miR-21 up − − + − yes early/advanced [184,200]
miR-29a down + + − − early [191]
miR-34a up − − + − yes [200,205]
miR-103 down + + − − yes [154,199]
miR-107 down + + − yes [154,199]
miR-125a down − − + − early [119,199]
miR-125b down − − + − early [119,199]
miR-138 up + yes early [206]
miR-143 down − − − + early [196,202]
miR-153 up − − − + [199]
miR-155 up − − − + yes early [119,199,200]
miR-181a down + + − − early [191]
miR-193b up − − + − yes [155,205]
miR-200a up + − yes [200,205]
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miRNA Expression ER+/ER− PR+/PR− HER2+/HER2− TNBC+/− Nodal Affection Stage of BC References
miR-200b up + − yes [200,205]
miR-200c up + − yes [200,205]
miR-342 up + + + − early [109,199]
miR-373 up + − yes [193,200]
miR-375 up − − + − yes [154,205]
miR-429 up − − + − yes [155,199]
miR-484 up + yes early [206]
miR-486-5p up + + − − yes [155,191]
miR-642-3p up early [207]
miR-652 down + + − − yes early [152,154,191]
miR-801 up + yes early [152,160,206]
miR-1202-5p up early [207]
miR-1207-5p up early [207]
10. Pros and Cons for miRNAs in BC Screening and Management
In the context of personalized medicine, the achievement of CTC cultures and cell free nucleic
acids via the liquid biopsy provides outstanding potential to noninvasively diagnostics, prediction,
and monitoring of the changing patterns of drug susceptibility in individual patients as their cancer
cells acquire new mutations [104,200] Analysis of cfDNA in BC individuals provides an opportunity for
non-invasive sampling of tumor DNA and supports its clinical validity as a promising ‘liquid biopsy’
tumor biomarker [201]. Despite that the quantification of miRNAs and cfDNAs within BC screening
in dual use mammography does not exist in literature, the clinical diagnostic may serve as a useful
tool in BC diagnosis. Specific attention is placed on short miRNAs, therefore miRNA profiling in
individuals may be a promising biomarker and prediction tool that could be utilized in all phases
of carcinogenesis within personalized management of breast carcinoma [6,208]. However, miRNA
detection as a part of liquid biopsy biomarkers still needs to be validated. There are various limitations
of circulating microRNAs as biomarkers of BC. Up to now, a number of studies have been focusing on
selected miRNAs that could be applicated as prognostic or predictive biomarkers. Interestingly, certain
levels of potential miRNAs occur in healthy subjects as well as in patients’ blood or plasma samples.
Therefore, alterations of miRNAs expression levels between controls and patients are generally quite
low [207]. Importantly, the origin of miRNAs as a part liquid biopsy can influence the effectiveness
of this non-invasive diagnostic method. It is well-known that the majority of miRNAs in blood are
packed in extracellular vesicles such as macrovesicles or exosomes [209]. Numerous studies analyzed
different miRNA expression profiles in plasma, serum and peripheral blood exosomes in BC patients in
comparison with healthy individuals [207,210]. These findings suggest the fundamental importance of
selecting proper sampling methods for the quantification of circulating miRNAs. Furthermore, single
miRNA as a diagnostic and prognostic biomarker has limitations in attributes, including specificity and
sensitivity. Moreover, levels of individual miRNA could be overlapped between patients and healthy
controls and lead to generation of false positive or false negative results [211]. Nowadays, it is an active
field of cancer research because it is necessary to clarify its biological context in body fluids. Moreover,
even though several miRNAs have been identified as biomarkers solely or in signatures in multiple
studies, many reports differ in their opinion on the detected miRNA. The reason for this is most likely the
variability in the design of the studies, cohort characteristics, isolation and detection methodologies or
data analysis [212]. Thus, here is an urgent need for to standardize detection and quantification assays
with appropriate normalization controls. Actually, for determination of circulating BC biomarkers,
there are currently extensively used genomic and proteomic methods. However, they have limited
multiplexing capabilities and involve multi-step, high-cost, and time-consuming processes demanding
skilled people, which limits significantly their applicability for point-of-case diagnosis [146]. Therefore,
there is an urgent need to develop portable, easy handling, time-efficient, cost-effective and quantitative
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tools for reliable determination of circulating biomarkers at different molecular levels. These analytical
tools should be afterwards implemented in decentralized and resource-limited settings. Afterwards,
a panel of cancer-specific circulating miRNAs should be created with corresponding tumor grades,
responses to treatment, recurrence, and patient survival, which in combination with other biomarkers
detectable in liquid biopsies could increase the sensitivity and specificity of cancer detection. Equally,
more research studies are necessary for the establishment of feasibility of these applications between
patients’ subgroups.
11. Conclusions and Expert Recommendations
Despite the extensive use of mammography as the gold standard for breast cancer (BC) screening,
the occurrences of both – false-positive and false-negative diagnosis, as well as over diagnosis and the
high expenditures, is an issue in gynecological oncology. Consequently, BC management demands
new strategies to for compensate the existing deficits. New strategies should consider:
- unmet needs of young populations such as innovative screening programs for early and predictive
diagnosis, for example in case of planned pregnancies to avoid pregnancy associated BC [213]
- new diagnostic tests with more predictive power for both – primary BC prevention (by risk
assessment to mitigate modifiable risks) and secondary prevention to mitigate the risk of metastatic
disease [26,29,214]
- the great potential of multi-level diagnostics by phenotyping and multiomics, in order to adapt
the treatment algorithms to the individualized patient profiles [3,28,215,216].
Contextually, the overall concepts of predictive, preventive and personalized medicine are strongly
recommended to advance the overall BC management [217].
Early and predictive diagnostic approaches (specifically in premenopausal women), extended and
innovative screening programs focused on young female populations (with dense breast parenchyma),
targeted prevention in high-risk groups, and optimized treatment concepts are necessary for better
controlling of BC. A multiomics clinical approach using liquid biopsy and based on the utilization of
the circulating biomarkers has a great potential to improve and enrich the cancer screening and its
later management. Promising candidate biomarkers include proteins, RNA, DNA, also autoantibodies,
metabolites, and lipids, which can be applied in the detection (involving the pre-invasive and
early stages of the disease), diagnosis, and treatment monitoring of BC. While protein-based cancer
biomarkers have been introduced in routine pathological practice for many years, nucleic acids-based
biomarkers such as miRNAs are relatively new. Blood-based biomarkers for BC screening are still
at the early phases of development, and many clinical/preclinical issues including cost effectiveness
need to be resolved before their standard introduction into clinical practice. However, despite this,
a novel approach for BC screening based on the combination of mammography with liquid biopsy
based methods (miRNAs or other) is very promising for specific clinical settings, which may refine the
diagnosis and lead to more personalized cancer treatment.
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Abstract: Despite a large number of studies, the etiology of pregnancy complications remains
unknown. The involvement of cell-free DNA or fetal cell-free DNA in the pathogenesis of pregnancy
complications is currently being hypothesized. Cell-free DNA occurs in different forms—free;
part of neutrophil extracellular traps; or as recently discovered, carried by extracellular vesicles.
Cell-free DNA is believed to activate an inflammatory pathway, which could possibly cause pregnancy
complications. It could be hypothesized that DNA in its free form could be easily degraded by
nucleases to prevent the inflammatory activation. However, recently, there has been a growing interest
in the role of exosomes, potential protectors of cell-free DNA, in pregnancy complications. Most of
the interest from recent years is directed towards the micro RNA carried by exosomes. However,
exosome-associated DNA in relation to pregnancy complications has not been truly studied yet. DNA,
as an important cargo of exosomes, has been so far studied mostly in cancer research. This review
collects all the known information on the topic of not only exosome-associated DNA but also some
information on vesicles-associated DNA and the studies regarding the role of exosomes in pregnancy
complications from recent years. It also suggests possible analysis of exosome-associated DNA in
pregnancy from plasma and emphasizes the importance of such analysis for future investigations of
pregnancy complications. A major obstacle to the advancement in this field is the proper uniformed
technique for exosomes isolation. Similarly, the sensitivity of methods analyzing a small fraction of
DNA, potentially fetal DNA, carried by exosomes is variable.
Keywords: cell-free DNA; exosomes; extracellular vesicles; fetal DNA; preeclampsia;
growth retardation; gestational diabetes mellitus
1. Introduction
Pregnancy complications are often associated with spontaneous preterm birth and might result
in mortality or morbidity of the mother and/or the child. Despite significant improvements in
monitoring and prevention in other areas of health care, the etiology of complications associated with
pregnancy, such as preeclampsia (PE), intra-uterine growth retardation (IUGR), spontaneous abortion,
or gestational diabetes mellitus (GDM), still remains unknown. However, a discovery of cell-free fetal
DNA in the circulation of the mother represents the most important finding in this research field [1].
Since then, the noninvasive prenatal testing for chromosomal abnormalities can be performed using
only a blood sample collected from the mother, which brings about new possibilities for prenatal
diagnostics. Such a new technique is beneficial also when the increased concentrations of cell-free fetal
DNA are detected in the circulation of mothers with various pregnancy complications [2]. Before this
discovery, prenatal tests were performed by invasive methods such as amniocentesis or chorionic
villus sampling. Unfortunately, these invasive procedures are associated with 1–2% fetal loss [3].
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The noninvasive prenatal DNA diagnosis based on the analysis of cfDNA isolated from maternal
plasma is rapidly evolving the research area; and using the latest methods for DNA analysis, various
noninvasive prenatal tests are implemented into clinical practice. Currently, the determination of
fetal gender, fetal Rhesus D (RhD) genotyping, aneuploidies, micro-deletions, and the detection of
paternally-inherited monogenic disorders are available for pregnant women worldwide [4]. However,
the clinical utility of cfDNA for noninvasive prenatal testing is even higher. In recent years, advanced
investigation approaches have allowed to reconstruct the whole fetal genome [5,6] and methylome [7].
Based on the biological characteristic of cfDNA (its origin, fragment size and methylation), it presents
also a potential new approach for pregnancy complication prediction and diagnosis [8].
Cell-free DNA (cfDNA) can be found in the circulation of every healthy individual. It has either
nuclear or mitochondrial origin. It is released after cell death, such as necrosis or apoptosis [9], and is
released as free fragments. Additionally, during inflammatory states, neutrophils produce net-like
structures, which also cause the death of a neutrophil. These so-called neutrophil extracellular traps
(NETs) are formed in order to kill pathogens. CfDNA, including histone proteins attached to the DNA,
is incorporated into these structures [10]. CfDNA can also be released from the living cells through
the process of exocytosis. Exocytosis is the process of releasing small vesicles, termed exosomes [11].
Exosomes are a subtype of extracellular vesicles (EVs). Recently, it was found that among other
structures, EVs also contain DNA [12]. Since the DNA inside of vesicles is protected by the vesicular
double membrane, EVs have been hypothesized to function in horizontal gene transfer.
Fetal cfDNA is produced mainly by the apoptosis of placental cells of the trophoblast [13].
It is produced during normal pregnancies; however, the process of apoptosis is likely increased
during complicated pregnancies, due to increased oxidative stress and inflammatory response [14].
Phillipe et al. [15] were the first to hypothesize that fetal cfDNA could have a pro-inflammatory effect.
Similar to bacterial DNA, fetal cfDNA is hypomethylated [2,16]. Toll-like receptor 9, expressed mainly
on immune cells, is sensitive to hypomethylated DNA. The interaction of toll-like receptor 9 with
fetal cfDNA triggers the innate immune response. This was experimentally proven on a mice model,
in which free fetal DNA was injected into pregnant mice [16].
Living cells of the trophoblast also release EVs. It was published by Gupta et al. [17] that such
vesicles contain both DNA and RNA. The aim of this review is to examine the role of fetal cfDNA
from EVs in the pathogenesis of pregnancy complications. This review will present a summary of
potential effects of fetal cfDNA in pregnancy complications; evidence of cfDNA being contained in
EVs, specifically in exosomes; and a role of these exosomes in pregnancy complications. Since most
recent cell-free nucleic acids papers focus on RNA, these studies are also mentioned; however, RNA
is not a main focus of this review. The end this review concludes the possible techniques for the
isolation of placental EVs and potential options for analysis of EVs that are beneficial for the field of
pregnancy complications.
2. CfDNA and Pregnancy Complications
Preeclampsia (PE) is the most common of pregnancy complications. It is associated with the highest
rate of morbidity and mortality among pregnant women worldwide. Clinically, it is characterized
by hypertension, proteinuria and edema [18]. Spiral artery remodeling, altered angiogenesis and
endothelial damage are believed to be involved in pathogenesis [19]. Recent meta-analysis [20] pointed
out that cell-free fetal DNA is a predictive marker of both early and late onset PE. However, the most
reliable detection time is at the beginning of the second trimester since the fetal fraction is the highest.
It means that already in the first trimester, not much fetal DNA circulates in maternal blood compared
to maternal DNA; and, on the other hand, in the third trimester, maternal DNA concentration increases
with weight gain and concentration of fetal DNA becomes extinct [20]. Fetal RNA has also been
studied as a potential biomarker of PE, especially at the beginning of the second trimester. A panel of
specific mRNAs can serve as a predictor of PE by monitoring endothelial growth factor and endoglin,
which are highly sensitive biomarkers [21,22]. Recently, the deportation of trophoblast was studied,
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and it was found that fetal trophoblast cells as well as immune cells were present in the lungs of the
mother, which may have an immunomodulatory effect [23]. Interestingly, placental NETs have also
been hypothesized to trigger the autoimmune reaction in PE [24]. Unfortunately, it is still not clear
what causes PE and whether a high concentration of fetal cfDNA is a consequence or a cause.
Intrauterine growth restriction (IUGR) is characterized when the fetus does not achieve the
normal growth due to placental causes, most often by placental insufficiency, which is associated
either with hypoxia or with blood vessel morphology [25]. Other common causes of IUGR include
maternal malnutrition as in vegan or vegetarian mothers [26] or exposure to toxic substances such
as drugs or alcohol during pregnancy [27]. The causes cannot be exhaustively completed in this
review, since except for the above-mentioned, more than 150 genetic disorders might be linked
to IUGR [28]. Endocrine dysregulations along with other epigenetic factors might also contribute
to IUGR. Nevertheless, the IUGR condition is often linked with PE. Maternal causes such as too
young or too old maternal age; various maternal diseases and fetal causes such as chromosomal
abnormalities; or multiple gestations and genetic factors are known key factors in IUGR. IUGR is
another pregnancy complication as well as PE that might be associated with increased number of fetal
cells and subsequently, an increased concentration of fetal nucleic acids in the circulation of a mother.
Hahn et al. [29] described how fetal cfDNA might be used to study alterations in placentation, which is
believed to be a cause of IUGR. However, the primary cause of altered placentation is probably due to
a modification of maternal spiral arteries. Again, it is not clear whether high concentrations of cell-free
fetal DNA contribute to the complication or if they result from it. A recent study discussed that even
though cfDNA is higher during IUGR, it is important to consider the activity of deoxyribonuclease
I, which is important for cfDNA elimination. This study showed that the activity of this enzyme is
increased and therefore it is difficult to monitor cfDNA concentrations properly [30]. Considering the
possible severe consequences of IUGR such as vascular, pulmonary, cardiac or neurological problems
it is necessary to search for a predictor of IUGR and improvement of antenatal treatments [31].
Pregnancies are often complicated by spontaneous abortions, which are associated with increased
stress or inflammation [32,33]. Although the terminology is not clear and standardized, spontaneous
abortion may be defined as noninduced loss of an embryo or fetus or passage of conception products
before the 20 weeks of gestation [34]. The major cause is chromosomal abnormalities [35]. Recently,
it was shown that low progesterone metabolite concentrations contribute to spontaneous abortions
due to triggering of inflammation [33,36]. Lim et al. [37] analyzed blood from 268 women and
observed the association of spontaneous abortions with high fetal cfDNA concentrations. Similarly,
Jakobsen et al. [38] observed that high concentrations of fetal cfDNA at the 25th week of pregnancy
could predict the preterm delivery. The latest study of NETosis associated with spontaneous abortion
showed that chorioamniotic NETs were found to be increased in women with chorioamnionitis and
preterm delivery [39]. Similarly, it was recently found that cfDNA of both mitochondrial and nuclear
origins were elevated in amniotic fluids in pregnancies complicated by preterm prelabor rupture of
membranes [40]. Certain inflammatory cytokines and chemokines contribute to the pathogenesis of
spontaneous abortions, which is associated with inflammatory mechanisms, and are possibly associated
with cfDNA [36].
Gestational diabetes mellitus (GDM) is a spontaneous glucose intolerance developed during
gestation. Chronic insulin resistance leads to β cells dysfunction, leading to glucotoxicity and later to
macrosomia and lasting type II diabetes after delivery [41,42]. Nine miRNAs involved in placental and
fetal development were discovered to be dysregulated during GDM. These miRNAs were of placental
tissue origin [43]. However, other serum miRNAs were also found to be involved in the development of
GDM and even possibly used as predictors of insulin resistance [44] or predictors of GDM in pregnancies
associated with obesity [45,46]. CfDNA in the form of NETs has been associated with GDM [47].
A study by Stoikou et al. [48] showed that tumor necrosis factor alpha as a proinflammatory factor
elevates NET formation in women with GDM compared to healthy controls. Also, Thurik et al. [49]
pointed out the association between cfDNA and GDM in the first trimester of pregnancy. To the best of
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our knowledge, there are no other studies investigating cfDNA in GDM; however, such an association
is often mentioned as a co-factor of other pregnancy complications.
Even though prenatal testing has been practiced for years already, using cfDNA as a marker from
maternal blood is still in its initial studies. All the above-mentioned studies are only from recent years.
However, this raises many questions and hypotheses that are yet to be answered or tested.
3. CfDNA Associated with Exosomes
EVs can be classified into three broad classes based on their size, endocytic origin, biogenesis and
sedimentation properties—exosomes, microvesicles and apoptotic bodies. The exosome subclass is
commonly defined as bilipid membrane-bound nanovesicles (size 40–120 nm in diameter) that are
derived from multivesicular bodies. Under physiological and pathophysiological conditions, they
are actively released from almost all types of cells into the extracellular space and body fluids [50,51].
Current research on circulating nucleic acids has shown that the circulating mRNA and miRNA
molecules detected in plasma, serum and other biofluids are packaged in EVs [52,53], reflecting
cells of origin and the disease state of the tissue. For example, exosomes from the plasma of
pregnant preeclamptic women were analyzed, and it was demonstrated that their proteins [54] and
microRNAs [55,56] could be used as biomarkers to predict PE. It was also found that preeclamptic
placentas produce more extracellular vesicles in comparison to normal pregnancy [57,58], which could
also be used as an indicator of the disease. For further comprehensive detailed information, there are
several review articles available that deal with the biogenesis of all kinds of EVs [59–62].
Several studies have shown that exosomes also contain DNA molecules [63–66]. Thakur et al.
revealed for the first time that tumor-derived exosomes contain double-stranded DNA, indicating
that exosomal DNA reflects the mutational status of paternal tumor cells [66]. In other studies,
double-stranded DNA was identified in exosomes isolated from the serum or plasma of pancreatic and
prostate cancer patients [64,65]. This finding illustrates the translational potential of DNA isolated
from exosomes as a circulating biomarker for the early detection of cancers and the monitoring
of treatment response. Another newer study compared the concentrations of total DNA isolated
from plasma and plasma exosomes and provided evidence that a large proportion (more than
90%) of plasma cfDNA is localized in exosomes rather than being truly free and circulating in
plasma [67]. Apart from nuclear DNA, studies have also shown that cells release exosomes containing
mitochondrial DNA (mtDNA) [68,69]. Guescini et al. reported that exosomes, constitutively released
by glioblastoma cells and astrocytes, carry mtDNA, which can be further transferred between the
cells [69]. The full mitochondrial genome was identified in plasma exosomes from patients with
hormonal therapy-resistant metastatic breast cancer. It was further demonstrated that the horizontal
transfer of mtDNA from vesicles acts as an oncogenic signal promoting an exit from the dormancy of
therapy-induced cancer stem-like cells [70].
Despite the evidence of cfDNA association with exosomes, the discussion about its localization
is still ongoing. Until now, most studies have been focused on intra-exosomal DNA. The exosomes
have been shown to carry intra-vesicular DNA protected by a phospholipid bilayer membrane and
the mutation status of this DNA was comparable to that of the cell origin [64–66,71]. In contrast,
Shelke et al. [72] showed that DNase I-sensitive DNA could be associated with the outside of exosomes
isolated from a human mast cell line. They have suggested that DNA can cause aggregation of
these vesicles, possibly influencing their effects in recipient cells. Also, Nemeth et al. showed that
ciprofloxacin-induced release of mitochondrial and chromosomal DNA is associated with the surface
of exosomes [73]. Nevertheless, the above-mentioned studies showed that exosomes-associated DNA
might be important in terms of physiological or pathophysiological states. CfDNA associated with
EVs, especially exosomes, could be utilized as a biomarker in cancer, signal molecule or a molecule
triggering the process of aggregation. However, the latest publication questions the real presence of
DNA in exosomes and co-isolation of histone-bound DNA together with the isolation of exosomes [74].
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It seems that the smallest vesicles, i.e., exosomes, do not carry DNA. On the contrary, DNA is released
through autophagy, and endosomal mechanisms are independent from exosomal release [75].
4. Exosomes in Pregnancy Complications
Secretion of EVs, including exosomes, has also been reported in placental cells as a response to
changes in the extracellular environment. The release of exosomes during pregnancy is modulated by
particular features of the cellular microenvironment such as low oxygen tension (i.e., hypoxia) or high
glucose concentration [76]. It was shown that placenta-derived exosomes regulate the migration and
invasion of target cells; play an important role in intracellular communication; and potentially contribute
to the placentation and development of maternal-fetal vascular exchange [77,78]. Placental exosomes
are distinguished according to the placental alkaline phosphatase (PLAP) marker and are supposed
to be released under placental dysfunctions [79]. Even animal models demonstrate fetal-maternal
trafficking and signaling via exosomes [80]. It was shown that exosomes deliver paracrine cargo that
signals labor and delivery of fetuses in mice [81]. Additionally, another study showed by quantitative
proteomics that human maternal plasma exosomes physiology could possibly reflect the homeostasis
in pregnancy and indicate preterm birth [82].
Placental-specific exosomes have been identified in maternal blood of healthy pregnant women.
Beside PLAP, placental exosomes can be distinguished from maternally-derived exosomes by the
presence of specific miRNAs [83–85]. Their concentration significantly increases during the first
trimester of pregnancy and as early as the sixth gestational week [86], but the contribution of placental
exosomes to total plasma exosomes and exosomes’ bioactivity decreases in late pregnancy [87].
Recent studies suggest a role of exosomes in pregnancy complications development. It has been shown
that in pregnancy complications, such as PE and GDM, the number of secreted vesicles change [88–90].
A higher number of exosomes in the blood of pregnant women with early and late onset-PE compared
with normal pregnancies was detected, which also suggests a possible pathophysiological role of
placenta-derived exosomes in PE. The study showed a higher relative number of placental-derived
exosomes in early onset-PE, but a lower relative number of placental-derived exosomes in late onset-PE
in relation to total exosomes in maternal circulation [89]. Similarly, a 10-fold higher concentration of
exosomes is present in the circulation of obese patients leading to proinflammatory pathways and
insulin resistance when compared with normal weight patients [91].
As well as the placental origin, the origin of vesicles can be determined in more detail. The vesicles
could be divided into embryo, oviduct, endometrial epithelium, and stroma-derived vesicles, all of
which are involved in the communication with cells of trophoblast [92]. Extravillous trophoblast releases
extracellular vesicles containing specifically human leukocyte antigen-G (HLA-G) that is only expressed
in these cells. It was demonstrated that these vesicles are both exosomes and microvesicles [50,93].
HLA-G is known to protect the fetus from invasion by maternal immune system [94]; therefore, it is
supposed that its function in exosomes is to signal and interact with responsible receptors [93]. It is
believed that at the beginning of pregnancy EVs are mainly produced by cells of the endometrium,
embryo and trophoblasts but later they are produced by syncytiotrophoblast cells, all having an
immune-suppressing effect on the maternal immune system [95].
Many studies have focused on the differential expression of miRNAs in extracellular vesicles in
placental tissue and blood from normal and preeclamptic pregnancies. They are summarized in a
recently published review article of Chairello et al. [96]. A recent study showed various miRNAs cargo
in maternal plasma exosomes obtained in the first trimester of pregnancy, which regulates different
signaling pathways in pregnancy [97]. Also, Salomon et al. in their newest study of miRNA profiles
of preeclamptic pregnant women suggested that the quantification of placenta-derived exosomes
present in maternal blood and the measurement of specific miRNAs expression may improve our
ability to identify asymptomatic women at risk for development of PE [98]. In addition to miRNAs,
other potential molecular markers, such as placental proteins, angiogenic factors and fetal cfDNA,
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were investigated as potential predictive markers for PE development. The overview of all studies
investigating small vesicles, exosomes, during pregnancy complications is summarized in Table 1.






Chang 2018 [99] PE Plasma Antiangiogenic factors
Jayabalan 2018 [100,101] GDM Plasma, adipose tissue Proteomics
Wang 2018 [102] PE Serum miR-548c-5p
Menon 2018 [103] Preterm birth Plasma Micro RNA
Luo 2018 [104] IUGR Umbilical cord blood Micro RNA
Motawi 2018 [105] PE Umbilical cord bloodand cell media Micro RNA
Nair 2018 [106] GDM Placenta, plasma,skeletal muscle Micro RNA
Hu 2018 [107] PE Urine Expression of renalsodium transporters
Zhao 2018 [108] IUGR, abortion Plasma Micro RNA
Miranda 2018 [109] IUGR Plasma Basic characterization
Beretti 2018 [110] Immune response Amniotic fluid stem cellexosomes Basic characterization
Shen 2018 [111] PE Serum miR-155
Saez 2018 [112] GDM Plasma Cargo
Biro 2017 [113] Hypertension, PE Plasma Micro RNA
Ermini 2017 [114] PE Plasma Cargo
Rodosthenous 2017 [115] IUGR Plasma Micro RNA
Motta-Mejia 2017 [116] PE Plasma Endothelial factors
Salomon 2017 [98] PE Plasma Micro RNA
Truong 2017 [97] PE, preterm birth Plasma Micro RNA
Elfeky 2017 [117] Obesity Plasma Basic characterization
Shi 2017 [118] GDM Plasma Micro RNA
Pillay 2016 [89] PE Plasma Concentration
Sheller 2016 [119] Preterm birth Amniotic membrane Cargo
Gysler 2016 [120] Autoimmune disorders Plasma Micro RNA
Ospina-Prieto 2016 [121] PE Trophoblast cells miRNA-144
Sandrim 2016 [56] PE Plasma miR-885-5p
Salomon 2016 [90] GDM Plasma Concentration
Panfoli 2016 [122] Preterm birth Umbilical cord cells Characterization
PE—preeclampsia, IUGR—intra-uterine growth retardation, GDM—gestational diabetes mellitus.
To the best of our knowledge, there are no studies showing the presence of fetal cfDNA associated
with exosomes circulating in maternal blood. Only a recent review described in detail the crosstalk
between mother and the fetus, however, they discussed extracellular vesicles in general, not exosomes
specifically [92]. A pilot study from our group showed that exosomes isolated from the blood of
pregnant women contain not only DNA of maternal but also of fetal origin [123]. These results are
raising new questions and provide the basis for further investigation of the localization of the vesicles
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and their function in healthy and complicated pregnancies. Nevertheless, the overview of studies
regarding DNA in any relation to EVs or exosomes and pregnancy are summarized in Table 2.





Fernando 2018 [124] Pregnant vs.Non-pregnant Plasma Fragment size pattern of cfDNA
Sheller-Miller 2017 [125] Term labor Amnion ephithelial cells Cargo
Tong 2017 [126] PE Placental explants Concentration of EVs
Sheller 2016 [119] Term delivery Amnion ephithelial cells Cargo
Orozco 2009 [127] PE Plasma EVs containing DNAconcentrations
Orozco 2008 [128] PE Extravillous trophoblastand plasma
EVs containing DNA basic
characterization
Gupta 2005 [129] PE Placental explants andneutrophils NETs formation
5. Methods to Analyze cfDNA from Exosomes and Implications for Pregnancy Complications
High variability in the isolation as well as exosome characterization techniques used contributes
to the diversity of published data [130]. Thakur et al. found that nucleic acid content in exosomes
reflects the whole genomic DNA of parental cell lines [66]. They also compared different cancer cell
lines suggesting that exosomal DNA could be used as a potential indicator of the disease reflecting
its origin depending on the type of the cancer. It was already known that there is fetal DNA inside
of exosomes isolated from placenta [119]. We hypothesize that exosome-associated fetal DNA in
the circulation could also be used as a potential diagnostic marker for pregnancy complications.
However, since no well-established method exists there have been problems with reproducibly
isolating plasma exosomes. Also, the high abundance of plasma albumin interferes with several
analyses of exosomes [131]. The most common isolation method is ultracentrifugation; however,
size-exclusion chromatography [132] or different commercial kits [133–135] are also used.
Until now, the cancer research field has used cfDNA as a potential liquid biopsy biomarker to
reflect the status of the organism [136]. There already exist protocols to obtain the highest yield of cfDNA
since the concentration has to be high enough to make the analyses [137,138]. It was already published
that 90% of cfDNA in plasma is hidden in exosomes [67]. So far, the common techniques of plasma
exosome isolation followed by DNA analysis have been ExoQuick exosome precipitation solution [139],
ExoLution Plus extraction technology [140] and differential centrifugation [141]. However, there have
not been many studies analyzing fetal cfDNA in exosomes isolated from plasma. Other groups also
hypothesize that fetal DNA could be carried in exosomes, which could therefore serve as suitable
material for Y chromosome detection and fetal DNA quantification [127,142]. Our preliminary data
showed that fetal DNA is packaged inside of exosomes and using the ultracentrifugation protocol
for exosomes isolation we were able to quantify it [123]. Our study was the first one that attempted
experimentally to quantify fetal DNA in exosomes. The results showed that the concentration of fetal
DNA in plasma was 10 times higher than in plasma exosomes after the usage of DNase, that degraded
any surface-bound DNA. The dynamics of fetal cfDNA in pregnancy is already known. Fetal DNA
continuously rises throughout trimesters [143]. It is debatable whether cfDNA from the fetus is localized
in exosomes or other vesicles. Perhaps more fetal DNA could be present in exosomes in the second
trimester in comparison to other trimesters since it was found that the concentration of exosomes is the
highest during this part of gestation [144]. However, potentially more fetal DNA could be localized
inside of exosomes rather than being free, although, better optimization of isolation techniques
is needed as well as more sensitive quantification methods. Extracellular RNA Communication
Consortium has already started projects dealing with the isolation methods focused on RNA and of
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EVs in general [145]. Pregnancy complications are believed to be associated with an increased number
of exosomes in maternal blood; therefore, it would be interesting to analyze plasma samples from
women with PE, GDM or IUGR by a standardized method and obtain comprehensive information.
6. Conclusions
Every cell releases cfDNA. Fetal DNA is released from the cells of the placenta and circulates in
the blood of the mother. Currently, it is known that fetal cfDNA could be used as a potential biomarker
of several pregnancy complications. PE, IUGR, spontaneous abortions, or GDM are usually associated
with increased concentrations of cell-free fetal DNA. Researchers in the field of exosomes have recently
discovered that these small EVs also carry DNA. Such DNA is probably protected by their double
membrane against the degradation by nucleases. As it is probably more stable, it could be used as
a biomarker, and, therefore, is a source of information. However, the proper isolation method of
placental exosomes followed by a proper isolation of vesicular fetal DNA needs to be optimized. As of
now, the fetal cfDNA of exosomal origin is believed to have the potential to become a biomarker of
pregnancy complications, along with the potential to explain the pathogenesis of various pregnancy
complications in the future.
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Abstract: Cell-free nucleic acids (cfNAs) are defined as any nucleic acids that are present outside the
cell. They represent valuable biomarkers in various diagnostic protocols such as prenatal diagnostics,
the detection of cancer, and cardiovascular or autoimmune diseases. However, in the current
literature, little is known about their implication in inflammatory bowel disease (IBD). IBD is a
group of multifactorial, autoimmune, and debilitating diseases with increasing incidence worldwide.
Despite extensive research, their etiology and exact pathogenesis is still unclear. Since cfNAs were
observed in other autoimmune diseases and appear to be relevant in inflammatory processes, their role
in the pathogenesis of IBD has also been suggested. This review provides a summary of knowledge
from the available literature about cfDNA and cfRNA and the structures involving them such as
exosomes and neutrophil extracellular traps and their association with IBD. Current studies showed
the promise of cfNAs in the management of IBD not only as biomarkers distinguishing patients from
healthy people and differentiating active from inactive disease state, but also as a potential therapeutic
target. However, the detailed biological characteristics of cfNAs need to be fully elucidated in future
experimental and clinical studies.
Keywords: cell-free nucleic acids; circulating nucleic acids; cell-free DNAs; cell-free RNAs; exosomes;
inflammatory bowel disease; neutrophil extracellular traps; NETosis
1. Introduction
Inflammatory bowel disease (IBD), which involves Crohn’s disease (CD) and ulcerative colitis
(UC), is a group of multifactorial disorders characterized by chronic inflammation affecting the
gastrointestinal tract in variable extent, typically leading to multiple symptoms such as weight
loss, abdominal pain, recurrent diarrhea, and bleeding. Despite extensive research in this field, the
exact pathogenesis of IBD is still unknown. According to current knowledge, IBD develops due
to deregulated complex interactions between genetic, environmental, and immunological factors,
including the complex interactions between the gastrointestinal microbiota and the host organism [1,2].
The clinical diagnosis of IBDs is based on numerous investigations, including ultrasonography,
endoscopy, as well as laboratory analyses such as biochemical blood and stool markers, or histological
tests of affected tissues. The diagnostic procedures can be time consuming and uncomfortable for
patients, especially for the continuous monitoring of their health status, disease progression, or
therapeutic effectiveness. Moreover, therapeutic possibilities are limited to the suppression of acute
inflammation and maintaining remission, while a marked interindividual variability of effectiveness
Int. J. Mol. Sci. 2019, 20, 3662; doi:10.3390/ijms20153662 www.mdpi.com/journal/ijms51
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was reported for each line of actually available therapeutics [3,4]. Therefore, current research related to
IBD is strongly focused on various aspects of the disease with the aim to elucidate the exact mechanisms
of the pathogenesis, as well as to identify either novel biomarkers (for both disease status evaluations,
prognostics, and therapeutic response predictions and monitoring) or new therapeutic targets and
agents. One of the highly progressing fields that has an impact in each of these aspects is genomics and
nucleic acids research in general. Besides the direct analyses of genomic material obtained from cells,
the possibility of identification and analysis of cell-free nucleic acids (cfNAs) in the circulation, or in
other body fluids, is now attracting particular attention in several biomedical fields. In a broader context
of complex care, the analysis of nuclear genomic material offers the identification of yet asymptomatic
individuals having high risk for certain types of IBD [5], while the identification of cfNAs seems to
represent promising non-invasive biomarkers to distinguish patients having active disease from those
in inactive phase or from healthy people, allowing to track disease onset, progression, and remission
following therapy. However, still little is known about the specific cfNAs and their exact roles and
associations in the pathogenesis of IBD. Therefore, the aim of this review is to collect and integrate
available information about these important aspects.
2. Cell-Free Nucleic Acids and their General Recognition and Use
Our knowledge about the existence of cfNAs is not new. Since their first description in 1948 [6],
their presence was observed in various biological fluids, such as blood, urine, saliva, but also in stool.
Their biological significance and usability as biomarkers of health status is given by several factors.
The two main advantages are their differential presence in healthy individuals versus patients having
certain diseases, or specific physiological conditions, as well as their convenient accessibility from
liquid biopsy, saliva, or stool sampling. Moreover, their differential patterns of methylation status or
fragmentation may serve as information about the organism, organ, tissue, or mechanism of origin of
particular fractions of cfNAs [7–10].
Although not the first, probably the most popular and most rapidly adopted use of cfNAs globally
is the so-called non-invasive prenatal testing (NIPT) [11]. This method opened a completely new era of
prenatal care, especially following its housing with advanced DNA analytical technologies, such as
massively parallel genome-scale DNA sequencing. However, prenatal testing-based analyses of cfNAs
started to show also other utilities, even going beyond conventional prenatal testing. The spread of
cfNAs analyses already took place also into unrelated clinical fields, such as oncology, in a form of liquid
biopsy-based non-invasive cancer detection (NICD), since cfDNA levels are typically elevated in cancer
patients [12]. The possible relevance of cfNAs has been previously reported also for a range of other
diseases and pathological conditions, such as trauma, myocardial infarction, stroke, transplantation,
diabetes, sickle cell disease, sepsis, and aseptic inflammation [13]. Moreover, in addition to cancer
and inflammation, other aging-related degenerative processes, such as cellular senescence, were also
suggested to be associated with age-related increasing levels of cfNAs (specifically cfDNA), possibly
through DNA damage response-induced higher genome instability [14].
3. Origin and Basic Types of Cell-Free Nucleic Acids
There are plenty of different types of cfNAs molecules that can both originate from various
biological processes and participate on various physiological and pathophysiological processes in a
complex yet poorly understood manner. According to their origin, cfNAs can be divided into various
categories. At first, it is important to differentiate between endogenous and exogenous cfNAs. While
endogenous cfNAs originate from tissues and the cells of the organism of interest itself, exogenous
cfNAs may typically come from the host microbiome, from different infections and parasites, as well as
from the ingested food of the host organism [15]. On the border between these are cfNAs originating
from developing fetuses in maternal organisms [16] which, although having endogenous origin, are
coming from a different individual of the same biological species. Moreover, in humans, the transfusion
origin of cfNAs should also be taken into account [17].
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When considering the type of the macromolecule of interest, cfNAs are generally divided into
DNAs or RNAs. Endogenous cfDNA includes nuclear (genomic) DNA (cf-ncDNA) as well as
mitochondrial DNA (cf-mtDNA), whereas exogenous DNA is usually represented by microbial and
specifically bacterial DNA. It is hard to universally describe the length range and exact composition
of cfDNAs, since their extremely dynamic nature and various extraction methods result in variable
recovery rates. However, they were described in the range from ultrashort, <100-bp fragments, up to
several thousands of bps, both for nuclear as well as for mitochondrial DNA [12,18]. Nuclear cfDNA
fragments have predominancy under physiological conditions, and are highly fragmented molecules
to the size of approximately 166 bp, which is approximately the length of a segment of DNA wound
around a protective histone octamer. They mainly come from the apoptosis of hematopoietic cells [19];
however, they can also be released from necrotic cells—but only through phagocytosis [20]. Another
process of the formation of circulating cfDNA is NETosis (name comes from neutrophil extracellular
traps) [21], but the active release of newly synthesized DNA via vesicles and lipoproteonucleotide
complexes was also reported [22]. In a comparison to cf-ncDNA, cf-mtDNA is much smaller. Its
predominant size ranges approximately from 30 bp to 80 bp, because mtDNA is, unlike ncDNA, a
small molecule that is not protected by histones. Similar to cf-ncDNA, cf-mtDNA can be transported
by extracellular membrane vesicles (EMVs) [12]. Similar to cfDNAs, cfRNAs can also be divided
into many other types. According to the functionality, we differentiate coding RNAs (mRNAs) and
non-coding RNAs. Non-coding RNAs are further divided into many subtypes, including lncRNAs
(long non-coding), miRNAs (micro), tRNAs (transfer), YRNAs, piRNAs (PIWI-interacting), circRNAs
(circular), other small non-coding RNAs (ribosomal, small nuclear, small nucleolar); however, these are
present in amounts less than 1% [12]. Among cfRNAs, the cf-mRNAs are fragmented and less abundant;
therefore, many studies focus on the analysis of small non-coding RNAs, which are more stable and
therefore also more abundant. As cfRNAs are relatively unstable molecules that are susceptible to
degradation by ribonucleases, they can generally be found encapsulated within EMVs (apoptotic
bodies, exosomes, microvesicles) or form ribonucleoprotein complexes (by binding to high-density
lipoprotein or RNA-binding proteins) [23,24].
Based on some of the above-mentioned properties, both endogenous and exogenous cfNAs in
circulation can be further divided into free cfNA fragments (naked sequences having no specific
vesicles), vesicle-bound cfNA fragments (nucleic acids in EMVs divided into exosomes, microvesicles,
and apoptotic bodies) and cfNA macromolecular complexes (e.g., nucleosomes, virtosomes, and
neutrophil extracellular traps), all of which have specific origin and routes of transport (Figure 1) [12].
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Figure 1. Origin, organization, routes of transfer, and availability for convenient sampling of cell-free
nucleic acids (cfNAs). CfNAs can be readily isolated from various body fluids, including blood, saliva,
urine, and stool, in which they are either naked or carried by various types of vesicles. Depicted are the
most common sources of cfNAs in the circulation, which are relevant for inflammatory bowel disease
(IBD), including endogenous sources (such as apoptotic bodies, exosomes, microvesicles, neutrophil
extracellular traps (NETs), necrosis) as well as exogenous sources (such as diet and the intestinal
microflora, including bacteria, fungi, nematodes, and viruses). Endogenous cfNAs most commonly
originate from regulated or unregulated cell death (necrosis, mechanical damage vs. apoptosis, NETosis),
or are secreted during processes of cell–cell communications (exosomes, microvesicles). Those of
exogenous origin may reach the circulation by several processes such as hijacking the physiological
transport machineries, transcytosis (vesicular uptake on one side of the epithelial barrier and release on
the opposite side), continuous immunological sampling of antigens by dendritic cells, but also as a
result of inefficient epithelial barrier functions during pathological processes. Common sources such as
developing a fetus or tumors are not depicted, although the detection of colitis-to-cancer transition
may have specific relevance for IBD patients. Apoptotic bodies may include also cellular organelles;
however, these are not depicted. Since the figure focuses on the cfNAs content of the blood, content
having endogenous origin in the intestinal lumen is not depicted, even though stool analysis may have
specific relevance for the monitoring of health status and therapeutic effectiveness in IBD patients.
Note that this depiction did not differentiate between single-layered and double-layered vesicles, and
also that all the graphical components are illustrative and are not representative of real dimensions.
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4. Exosomes in IBD
Exosomes are endosomal-derived nanovesicles that are secreted from many types of cells in
both physiological and pathological conditions. They are not produced by “simple” budding from
the plasma membrane, as microvesicles are; rather, their highly regulated biogenesis is connected to
the endolysosomal pathway. This starts with an endocytosis-based generation of an early-endosome
that matures to a late-endosome, a multivesicular body, through endosomal membrane budding. By
exocytosis, such multivesicular bodies can fuse with the plasma membrane, releasing their individual
vesicles (exosomes) from the cell. Alternatively, multivesicular bodies can fuse with lysosomes to
become degraded, and the function of their cargos can be lost [25,26]. Since these exosomes can
transport various molecules long distances inside the body, such as proteins, lipids, and nucleic
acids (mainly miRNAs and mRNAs), they are generally involved in various biological activities,
such as cell–cell communication and cell–environment interactions. These include the modulation
of immune responses, intestinal barrier functions, and regulation of the intestinal microbiome. The
specific functions of exosomes in these complex interactions, not only in IBD, depend primarily on their
functional components and exosome structure [27]. While the transferred proteins can directly activate
or inhibit biological pathways [28], transferred regulatory NAs can modulate pathways through the
specific regulation of gene expression in target cells [29]. Exosomes have been previously isolated
from plasma, colonic luminal fluid aspirates, intestinal epithelial cells, and saliva [30–33]. As they are
released by different tissues and can be collected from several body fluids and biological materials, the
information carried by their specific cargos may represent potential disease biomarkers, while they
themselves may represent possible therapeutic targets or therapeutic agents [34].
Several studies focus on the analysis of protein content of exosomes from IBD patients and healthy
controls or mouse models of colitis. When comparing their cargos, exosomes from the saliva of IBD
patients, for example, revealed several proteins presenting exclusively in just one of the studied groups,
i.e., only in UC patients, CD patients, or healthy controls. From these, for example, proteasome
subunit alpha type 7 (PSMA7) was selected to be a promising biomarker, since this exosomal protein
is related to proteasome activity and inflammatory response [33]. Tens of differentially expressed
proteins in serum exosomes were also found in mice with acute colitis when compared to exosomes
isolated from control mice. The majority of them were involved in the complement and coagulation
cascade, which has been implicated in macrophage activation, pointing thus to specific roles in the
pathogenesis of IBD [35]. Moreover, alterations of intestinal exosome proteomes were associated also
with aberrant host–microbiota interactions in IBD. It was demonstrated that exosomes released from
intestinal epithelial cells are involved in activating host innate immune responses and in subverting
the intracellular replication control of adherent-invasive Escherichia coli. It is known that these strains
are in a high prevalence in the intestinal mucosa of patients with CD, and enhance intestinal epithelial
permeability by modulating and/or disorganizing cell junction proteins [36,37]. Along with altered
protein profiles, distinct mRNA profiles were also found in exosomes shed from sites of inflammation
in patients with IBD. These were shown to have pro-inflammatory effects on the colonic epithelium
in vitro, which is mainly due to an increase of interleukin-8 (IL-8) [31].
The above-mentioned associations point toward an increased involvement of exosomes in
pro-inflammatory cascade in IBD pathogenesis. However, exosomes from normal intestine were
found to have immunosuppressive effects with a potential to prevent the development of IBD in a
murine model of colitis, for example by inducing T-regulatory and dendritic cells. On the other hand,
their inhibition can exacerbate murine IBD [30]. Besides exosomes from intestinal epithelial cells,
exosomes secreted by mesenchymal stem cells derived from a human umbilical cord were shown to
have a repairing effect on inflamed intestinal tissue. It was proven that they have profound effects on
alleviating a dextran sulfate sodium (DSS)-induced colitis through the modulation of IL-7 expression
in macrophages, or by regulating the ubiquitin modification level [38,39]. In the serum of patients
with active IBD, elevated levels of secreted annexin A1-(ANXA1-) containing extracellular exosomes
were detected, most likely as a result of systemic distribution in response to the inflammatory process.
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Endogenous ANXA1 is released as a component of extracellular exosomes derived from intestinal
epithelial cells, while these ANXA1-containing exosomes have the potential to activate wound repair
circuits [32].
Taken together, these findings suggest that exosomes, through the specific constellation of their
cargos, may exert both pro-inflammatory as well as anti-inflammatory effects on tissues, including
intestinal tissues. Since exosomes with pro-inflammatory contents seems to be enriched during active
IBD (or experimentally induced colitis), while those with anti-inflammatory cargos are dominant in
healthy patients (or control mice), their precise balance in different physiological situations likely
plays a crucial role in inducing, maintaining, or regulating the required functions of intestinal tissues.
Therefore, exosomes or their specific cargos can be considered when looking for biomarkers of intestinal
mucosal inflammation, but also when looking for potential therapeutic strategies in situations of
chronic mucosal injury. Moreover, in the latter case, their involvement can be considered both as
possible targets for inhibition (in case of pro-inflammatory contents), or as possible therapeutic agents
(in case of anti-inflammatory contents), to induce and/or maintain intestinal homeostasis. The biological
significance and clinical potential of exosomes as markers and therapeutic tools in IBD has been
recently reviewed [26,27,40]. However, knowledge of the role of exosome-specific NAs has been
generally limited to microRNAs as the major human plasma-derived exosomal RNA species. The role
of miRNAs is discussed later in this text.
5. Neutrophil Exracellular Traps in IBD
Neutrophil extracellular traps (NETs) are complex structures released from neutrophils due
to chromatin decondensation and spreading. These so-called “traps” are being released into the
environment, consisting of a tangle of released nucleic acids, histones, and proteases [41]. Then,
these traps are able to capture the bacteria and kill them. Despite being macromolecular complexes,
NETs, or their degradation products, were found to contribute to the total pool of cfDNAs [21].
They were described by Takei et al. in 1996 as a pathway of cellular death that is different from
apoptosis and necrosis [42], and in 2004, Brinkmann et al. described a process named NETosis,
which is one of the mechanisms that neutrophils undertake for host defense [43]. There are several
known models of NETosis, which are either dependent or independent of reactive oxygen species
(ROS), and also they differ in releasing either nuclear or mitochondrial DNA. Neutrophils and NETs
protect hosts from infectious diseases, while the aberrant formation and/or clearance of NETs may
have pro-inflammatory characteristics and may be implicated in many infectious and non-infectious
diseases, such as cancer, cardiologic, metabolic, inflammatory, and lung diseases [44]. The nuclear
material released from NETs could be more immunogenic than the apoptotic one. Both native and
oxidized endogenous DNA bound to NETs activate dendritic cells to synthetize interferon-α in a TLR
(toll-like receptor)-dependent manner. NETs also increase the T-cell response to antigens and activate B
cells to induce immunoglobulin (Ig) class switching and antibody production. Oxidized DNAs are also
more resistant to degradation, contributing thus to sustain a dysregulated immune response, while the
NET-mediated activation of the inflammasome further amplifies the inflammatory response through a
feed-forward loop [41].
Despite the implication of NETs in various pathologies, very little is known about their association
with IBD, although several studies have proposed their role in the pathogenesis of IBD of both
adults [45,46] and pediatric patients [47]. Gut proteome analysis in patients with ulcerative colitis
showed a high expression of proteins that are associated with NETs [45]. Whether NETs formation
is causative, or is rather a result of the inflammation, is still not completely known. Although ROS
production is enhanced in CD, and neutrophils may be more prone to NET formation [48], their
formation in CD is still controversially described. For example, a recently published small-scale study
proved the enhanced presence of NETs in the intestinal tissues of pediatric CD and UC patients [47].
Lehmann et al. also reported upregulated proteins belonging to the main components of NETs in both
diseases (UC and CD) compared to controls [49]. However, in other studies NETs have been observed
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and correlated with inflammation in UC, but not in CD, pointing to the stimulation of the innate
immune system in the etiology of UC [45]. There are also studies suggesting that the presence of NETs
in IBD does not have to be necessarily considered as a detrimental factor [50]. On the other hand, there
are studies pointing to a detrimental role of NETs in IBD. Anti-neutrophil cytoplasmic autoantibodies
(ANCAs) are biomarkers for the diagnosis and prognosis of IBD that are considered to activate,
complement, and cause endothelial damage. They are known to target neutrophil proteins, which all
are released during NET formation, suggesting this process might be the general cause of ANCAs
production in IBD [51]. For example, ANCAs against myeloperoxidase were detected in the serum of
many IBD patients [52], and against leukocyte proteinase 3 were also detected in IBD patients, but more
frequently in UC than in CD [53]. The results of Dinallo et al. showed that NET-associated proteins
were over-expressed in the inflamed colon of UC patients as compared to CD patients, suggesting
a role for NETs in sustaining mucosal inflammation in UC. The same authors described also NETs’
production from the circulating neutrophils of UC patients in response to stimulation by TNF-α, with
diminishing NETs formation following successful anti-TNF-α treatment [46,54]. Interesting findings
came from He et al., who found that NETs facilitate pro-coagulant activity in patients with IBD as
well as thromboembolic events that are known to exacerbate this disease [55]. In their extended
study, they found that patients with active UC or CD had significantly increased levels of cfDNA,
nucleosomes, and NETs formation compared to patients with inactive disease. They demonstrated
that NETs represent a central component in the initiation and progression of colitis through mediating
inflammation cell infiltration, driving cytokines release and thrombotic tendency.
In this context, the presence of NETs, their relative abundance, as well as their specific content
seems to provide candidate biomarkers for the differential diagnosis of various types of IBD. Moreover,
they may also represent the possible therapeutic targets of IBD and UC specifically [56], possibly
through the specific inhibition of NET release, which was shown to be able to attenuate DSS-induced
colitis in mice [46]. However, a detailed association of NET formation with different types and severities
of IBD remains to be elucidated.
6. Cell-Free DNA in IBD
As was mentioned above, cfDNAs are present in various body fluids and biological materials.
They are detectable under physiological conditions, but their presence during various diseases and
physiological states is more interesting, at least for biomedical implications [57,58]. However, there are
only a few publications regarding cfDNA in association with IBD.
It is known that cfDNA activates innate immunity through the activation of several DNA-sensing
pathways, including toll-like receptor 9 (TLR9), stimulator of interferon protein (STING), and a
protein called absent in melanoma 2 (AIM2) [59]. CfDNAs are able to bind to TLR9 and induce
the cascade, leading to an inflammatory response, indicating that cfDNA could serve as a potential
marker of inflammation. Experiments to study the role of these pathways in IBD have already been
performed on knock-out mice that are deficient in these receptors. Some of them have paradoxically
confirmed the protective role of these pathways in IBD [60,61]. This effect is probably mediated by
intestinal microbiota, although detailed mechanisms are not yet known. Likewise, it was shown
that the activation of TLR9 with the agonist administered prior to the induction of colitis induced
anti-inflammatory effects [62]. On the other hand, a different study showed that the administration of
oligodeoxynucleotides with CpG motifs (bacterial cfDNA) that activate TLR9 significantly exacerbates
the course of DSS-induced colitis [63]. It is clear that bacterial ecDNA derived from intestinal microbiota
is a heterogeneous group of various DNA molecules with potentially diverse roles in the pathogenesis
of IBD.
Molnár et al. indicated that the intravenous administration of colitic cfDNA into healthy mice
displays protective effects against DSS-induced colitis by altering the expression of several TLR9-related
and inflammatory cytokine genes [64,65]. Thus, cfDNA found in the plasma of mice with DSS-induced
colitis seems to have anti-inflammatory properties, but only in a preventive manner, as was shown by
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its transfer to healthy mice before the onset of the disease. It is known that the activation of TLRs in
response to pathogen or damage-associated molecular patterns is associated with autophagy [66], and
that autophagy contributes to NETosis [67]. This suggests a direct link between cfDNA and autophagy.
In fact, TLR9-mediated autophagy might be the underlying phenomenon behind the protective effect
of colitic cfDNA preconditioning [68]. However, the detailed mechanisms of action, as well as the
origin of such cfDNA, is not fully understood.
In 2003, Rauh et al. showed for the first time that it is possible to detect cfDNA in the serum of UC
patients, and that this cfDNA contained a microsatellite alteration previously identified in mucosa
cells from UC patients [69]. A valuable study came from Koike et al., who detected a significantly
higher amount of cfDNA in the circulation of mice with DSS-induced colitis compared to the control
group. They also found a positive correlation between plasma cfDNA concentration and clinical
severity of UC [70]. These findings are consistent with our recent study, which demonstrated a higher
concentration of plasma cfDNA in mice with DSS-induced colitis group compared to the control.
Moreover, the levels of plasma cfDNA negatively correlated with deoxyribonuclease (DNase) activity
in the colon tissue [71]. These findings indicate that colon cells might represent one of the major sources
of colitic plasma cfDNA, which further triggers downstream events that contribute to the pathogenesis.
However, these findings are in discrepancy with a previous study in which no difference in cfDNA
concentrations was found between DSS colitic mice and healthy controls [72]. On the other hand, recent
results further demonstrated that the concentration of total cfDNA in the plasma of mice is increasing
in parallel with the progression of the disease [73]. However, the increase of total plasma cfDNA levels
did not correspond with an increase in plasma cf-ncDNA or cf-mtDNA. On the other hand, the total
amount of cfDNA produced specifically by colon tissue was only increased in the early stages of the
disease, and the increase corresponded to the increase of nuclear and mitochondrial cfDNA subtypes.
These data suggest the crucial role of local colonic processes in triggering the inflammation. However,
the later stage-associated increase in plasma cfDNA seems to be of a different than colonic origin.
Low amounts of human DNA released from the epithelial cells of the gastrointestinal wall can be
detected in human fecal matter. However, in the state of inflammation or presence of infectious agents,
when greater amounts of damaged and dead cells are exfoliated from the intestinal wall, the amount of
DNA rises. Vincent et al. demonstrated that the excretion of large amounts of human DNA in feces is
a general outcome of intestinal inflammation and is associated with the risk of C. difficile infection [74].
Casellas et al. showed that fecal and also gut lavage fluid DNA correlated with the clinical index and
endoscopic score in patients with UC. Such fecal DNA excretion was significantly higher in patients
with active disease, suggesting that it could be used as a non-invasive technique for the assessment of
disease activity [75] and, because fecal DNA concentration increased in relapsed patients, also as an
objective instrument to use in the follow-up of patients [76]. In addition, it was recently revealed that
DNA methylation plays an important role in autoimmune-related chronic inflammatory diseases [77].
DNA methylation is an important epigenetic modification, which can silence genes, but also can lead
to the increase of gene copy number and induce tumors. It is also known that IBD increases the risk of
colorectal cancer, which is known as colitis-associated cancer [78]. The study of Lehmann-Werman et al.
suggested that methylation patterns can be used to detect cfDNA derived from intestinal epithelial cells.
Based on their results, intestinal DNA markers in healthy plasma and stool reflect the established route
of clearance of intestinal DNA via the lumen of the gut. However, unlike Casellas et al., they detected
only a minimal baseline intestinal cfDNA signal in IBD patients, which was indistinguishable from
that of healthy individuals, compared to patients with advanced colorectal cancer, which had a strong
intestinal signal [79]. On the other hand, Bai et al. detected a gradientally increased level of cfDNA
in colitis and colon cancer mice, compared with control. They also studied the level of circulating
DNA methylation, which decreased in colitis and colon cancer compared with control. Their results
suggest that cfDNA and its methylation level can be considered new markers for colitis-to-cancer
transformation [80].
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7. Mitochondrial and Nuclear Cell-Free DNA in IBD
Mitochondria play an important role in inflammatory processes as they participate in metabolism
and cell death signaling. Stress conditions can lead to damage to mitochondria and formation and the
release of mitochondrial-derived vesicles (MDVs) containing mtDNA [81]. Such cf-mtDNA can act as
a damage-associated molecular pattern (DAMP) that activates neutrophils through TLR9 because of
the similarity with bacterial DNA [82,83]. Inflamed gut mucosa in IBD represents an enriched source
of DAMPs; however, the role of cf-mtDNA in IBD is relatively unknown [84]. It has been proven
that cf-mtDNA can activate various inflammatory responses via TLR9 receptors, including NLRP3
inflammasomes and neutrophils, as well as other downstream pro-inflammatory signaling proteins
such as TNFα and NFκB [85,86]. Circulating cf-mtDNA was observed in a variety of inflammatory
diseases and in patients with acute injury [83,87–91]. Boyapati et al. published the first report showing
that cf-mtDNA is released during active IBD [92]. Increased levels of cf-mtDNA in UC and CD patients
were detected, which significantly correlated with blood, clinical, and endoscopic markers and diseases
activity. Inflammatory cells in lamina propria expressing TLR9 were also higher in active IBD patients.
Apart from that, mitochondrial damage in inflamed UC mucosa and higher levels of fecal cf-mtDNA
were observed. In parallel, these results were identified in a mouse model of DSS-induced colitis
and recently, they confirmed these findings and demonstrated that deletion of the Tlr9 gene in mice
results in the attenuation of acute DSS-induced colitis, suggesting cf-mtDNA-TLR9 signaling as an
important and targetable pathway in IBD [92]. Another study showed that in mice with DSS-induced
colitis, levels of plasma cf-ncDNA increased with the increased duration of colitis, and were directly
proportional to the number of NETs [70].
Our group has recently tried to determine the dynamics of total cfDNA as well as cf-ncDNA and
cf-mtDNA during an animal model of IBD. However, the concentration of circulating cf-mtDNA and
cf-ncDNA in mice with colitis was not significantly different throughout the course of colitis compared
to control mice [73]. On the other hand, cf-mtDNA released specifically from the colon tissue increased
significantly during the early stages of the disease, indicating that colon-derived mt-DNA might be
a significant factor that drives the local colonic inflammation, whereas other subtypes are primarily
involved in the systemic inflammation.
8. Cell-Free DNA as a Therapeutic Target
DNases are enzymes cleaving DNA, which were proposed for the therapy of diseases with
increased levels of cfDNA [93]. DNase I deficiency results in the difficulty of removing DNA from
nuclear antigens, and consequently promotes susceptibility to autoimmune disorders [94]. DNase I
deficiency was found in patients with systematic lupus erythematosus [95], and the administration of
DNase I has been shown to be an efficient therapeutic agent in cystic fibrosis [96]. A reduced DNase I
activity was also observed in patients with IBD [97]. Thus, in the view of the above-mentioned findings,
the targeted digestion of cfDNA using DNase represents a potential novel therapeutic approach for
IBD. DNase can directly cleave the circulating cfDNA, but can also break the structure of NETs, thereby
reducing their pro-inflammatory properties [98,99]. The administration of DNase was shown to be
effective in several immune-mediated experimental models, including sepsis [98] and hepatorenal
injury [100]. In our recent study, intravenous DNase I injection was tested as potential therapy of
DSS-induced colitis. Despite some improvement in the biochemical markers of colitis, the overall
therapeutic effect was not proved, possibly due to the rapid half-life of the enzyme in circulation [72].
In the light of decreased DNase activity in the colon of mice with colitis [71], the topical colonic
administration of DNase might be an interesting approach to further clarify the role of colon-derived
cfDNA and test the rationale of cfDNA-targeted therapy.
NETs as higher structures may also represent possible therapeutic targets in IBD, and UC
specifically [56], possibly through the specific inhibition of NET release, which was shown to be able
to attenuate DSS-induced colitis in mice [46]. One of the principles to prevent the action of NETs
is also disrupting their structure using DNase. Other approaches include preventing the oxidative
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burst of neutrophils that are necessary for the release of decondensed chromatin from neutrophils into
the environment (e.g., by inhibitors of NADPH oxidase), or preventing the citrullination of histones
(inhibitors of PAD4-peptidyl arginine deiminase type 4) [101].
At last, another means of possible cfDNA-based therapy relies on the administration of exosomes
from healthy intestine, which were found to have immunosuppressive effects with a potential to
prevent the development of IBD in a murine model of colitis. On the other hand, their inhibition can
exacerbate murine IBD [30]. In light of recent findings proving the absence of cfDNA in exosomes, the
possible therapeutic effect of exosomes might as well have been mediated by structures other than
cfDNA [102]. In addition, exogenous exosome-like extracellular vesicles released by nematodes were
also described to possess immunoregulatory molecules, proteins, and specific miRNAs, which were
able to protect mice against chemically-induced colitis. Such specific proteins and miRNAs have great
potential in the development of drugs to prevent chronic inflammatory diseases such as IBD [103].
9. Cell-Free miRNA in IBD
The studies focusing on the role of cfRNA mostly analyze the role of small non-coding RNAs,
which are more stable than mRNA. Hence, the majority of publications regarding the role of cfRNA in
IBD are related mainly to miRNA. MiRNAs are short (18 to 24 nucleotides in length), endogenous,
non-coding single-stranded RNAs [104]. The sequences of miRNAs are evolutionary conserved across
species, and at the post-transcriptional level, they regulate the expression of nearly one-third of the
genes in the human genome and are involved in many biological processes (e.g., development, cell
differentiation, proliferation, apoptosis), suggesting their important role in the pathogenesis of various
diseases [105]. MiRNAs act primarily as post-transcriptional regulators via mRNA degradation
and/or translational repression via the formation of miRNA-induced silencing complex (miRISC).
MiRISC post-transcriptional control occurs through the inhibition of translation elongation, protein
degradation, ribosome drop-off, or reducing the number of ribosomes on target mRNAs. However,
miRNAs also have specific nuclear functions, including the miRNA-guided transcriptional control of
gene expression. The mechanisms of miRNA-mediated transcriptional control of gene expression have
not been completely elucidated [106].
The aberrant expression of miRNAs in IBD was, for the first time, reported in 2008 by Wu et al.
Since then, many other studies were published that focused on the altered expression of miRNA in IBD,
on the specific miRNAs and their association with target genes, or on single nucleotide polymorphism
present in miRNAs implicated in the pathogenesis of IBD [107]. Among them, the most interesting
studies (preliminary) are related to circulating miRNAs (here referred to as cf-miRNAs) identified in
IBD patients, as they are considered promising biomarkers of disease severity, activity, or as a potential
therapeutic target in IBD (for more information, see below). Cf-miRNAs are stable compared with
mRNAs, and because they are packaged in exosomes or microvesicles, they are resistant to nuclease
digestion. They were detected in serum and plasma samples, but also in urine or saliva [108,109].
In association with IBD, many studies have been published that detected either increased or
decreased levels of specific cf-miRNA in patients with UC or CD compared with healthy controls.
Some studies have focused on the relationships between altered miRNA expression in circulation and
those at the diseased tissues, since sometimes, the altered miRNA expression in the diseased tissue is
different from that observed in the peripheral areas where the cf-miRNA were quantified [110]. In 2011,
Wu et al. showed for the first time that cf-miRNAs can be used to distinguish active CD and UC from
healthy controls [111]. Since then, others have identified various dysregulated cf-miRNAs [112–116],
and confirmed that there are several cf-miRNAs that are able to distinguish CD from UC or IBD from
healthy controls (Table 1). Among them, some of these cf-miRNAs identified by Paraskevi et al. were
consistent with those identified by Wu et al. and two cf-miRNAs that can differentiate CD from UC,
identified by Netz et al., seem to have a biological basis for their differential expression based on the
literature and acquired knowledge. An increase of specific cf-miRNAs was identified also in pediatric
CD patients, which significantly decreased after six months of treatment, suggesting their role as
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non-invasive biomarkers of disease state [117]. However, Jensen et al. did not confirm findings that
cf-miRNA can differentiate CD patients from healthy controls. They identified six downregulated
and three upregulated cf-miRNAs in patients with CD compared with controls. However, in their
validation cohort, only one from these, has-miR-16, was significantly downregulated in CD patients,
with an inadequate discriminative power [118]. Interesting findings came from Polytarchou et al., who
not only identified differentially expressed cf-miRNAs in patients with UC compared with controls,
but also detected four cf-miRNAs correlating with disease activity, which were found to have higher
sensitivity and specificity values than C-reactive protein (CRP) [114]. Similar results were found during
analysis of patients with CD, where 10 cf-miRNAs were differentially expressed in patients compared
with controls; two of these cf-miRNAs also correlated with CD disease activity and exhibited higher
correlation values compared with CRP. Furthermore, distinct miRNA signatures between CD patients
with ileal and colonic involvement were also revealed [115]. A distinct signature was also observed in
mouse models and consequently validated using sera from UC patients. Based on obtained results, it
seems that such a signature could be an ideal biomarker for IBD, since it can distinguish individuals
at risk, predict the type of inflammation and disease status in patients, and evaluate the response to
therapeutics [119]. These findings point to increasing evidence that cf-miRNAs play a key role in the
pathogenesis of IBD, as many specific cf-miRNAs were identified to have different expression within
UC compared with CD or within active phase in comparison to inactive disease, and some of these
cf-miRNAs were shown to better reflect mucosal inflammation than CRP (Table 1) [120–124].
Table 1. Summary of identified nuclear (genomic) miRNAs (cf-miRNAs) deregulated in IBD. CD:
Crohn’s disease, UC: ulcerative colitis.
cf-miRNA Observed Change Reference
miRs-199a-5p, miRs-362-3p,
miRs-532-3p, miRplus-E1271 ↑ in active CD patients Wu et al., 2011 [111]
miRplus-F1065 ↓ in active CD patients Wu et al., 2011 [111]
miR-340* ↑ in CD patients Wu et al., 2011 [111]





↑ in active UC patients Wu et al., 2011 [111]
miRs-103-2*, miRs-362-3p,
miRs-532-3p, ↑ in UC patients Wu et al., 2011 [111]





↑ in CD patients Paraskevi et al., 2012 [113]
miR-16, miR-21, miR-28-5p,









↑ in UC patients Duttagupta et al., 2012 [112]
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Table 1. Cont.




↓ in CD patients Jensen et al., 2015 [118]
hsa-miR-200c, hsa-miR-181-2 #,





↑ in UC patients Polytarchou et al., 2015 [114]






↓ in CD patients Oikonomopoulos et al., 2016 [115]
hsa-miR-30e-5p ↑ in CD patients Oikonomopoulos et al., 2016 [115]
miR-598, miR-642 ↑ in UC patients Netz et al., 2017 [116]
miR-595, miR-1246 ↑ in active IBD Krissansen et al., 2015 [120]
miR-223 ↑ in IBD Wang et al., 2016 [121]
miR-16, miR-21, miR-223 ↑ in IBD, strongly in CD patients Schonauen et al., 2017 [122]
miR-106a, miR-362-3p ↑ in IBD Omidbakhsh et al., 2018 [123]
miR-146b-5p ↑ in IBD Chen et al., 2019 [124]
10. Cell-Free lncRNA in IBD
LncRNAs represent molecules longer than 200 nucleotides, and are localized mainly in the nucleus,
but also in the cytoplasm and in extracellular fluids. Their role in gene regulation includes the control
of the flux of genetic information, such as chromosome structure modulation, transcription, splicing,
mRNA stability, mRNA availability, and post-translational modifications. In addition, they present
interaction domains for DNA, mRNAs, miRNAs, and proteins. The mechanism of action of lncRNAs
is given by their cellular and temporal specificity. LncRNA also contribute to the mRNA and protein
content in the cell by regulating adjacent protein-coding genes expression [125].
LncRNAs can be categorized into sense, antisense, intronic, bidirectional, and intergenic
lncRNAs [126]. Their expression is lower than those of protein-coding genes and depends on
tissue and development-stage characteristics, pointing to their regulatory role [127,128]. Therefore,
they have been studied in association with various diseases, such as cancer, cardiovascular, and
neurological diseases. To date, hundreds of lncRNAs have been shown to be differentially expressed in
IBD patients in comparison with healthy controls, and in active versus inactive disease state [129–131].
In many of these genes, various single nucleotide polymorphisms were identified and were found to be
associated with transcription binding factors, expression quantitative trait loci, or DNase peaks [132].
There is a growing body of evidence that cf-lncRNAs play a key role in the pathogenesis of various
diseases, and could be used as non-invasive biomarkers [133–135]. Recently, deregulated lncRNAs
in the plasma samples of CD patients were observed [136], and Wang et al. identified significantly
upregulated cf-lncRNAs (KIF9-AS1, LINC01272) and significantly downregulated cf-lncRNA DIO3OS
in IBD patients compared with healthy controls (Table 2) [137]. Therefore, cf-lncRNAs could be
potentially used as non-invasive biomarkers also in IBD; however, further investigation and studies
are needed.
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Table 2. Summary of identified nuclear (genomic) long non-coding (cf-lncRNAs) deregulated in IBD.
cf-lncRNAs Observed Change Reference
KIF9-AS1, LINC01272 ↑ in IBD Wang et al 2018 [137]









010037, LOC283761, XLOC 013142
↓ in CD Chen et al., 2016 [136]
11. Clinical Relevance of cfNAs in IBD Care
Beyond cfDNAs as therapeutic targets, which was discussed in previous sections, another potential
utility of cfNAs in clinical care can be found in differential diagnostics of clinically not typical or
borderline cases of IBD, in monitoring the subclinical phases of disease onset in patients having a
high risk of IBD, or those in remission, and also in monitoring the effectiveness of therapy used
in IBD patients. All of these are basically connected to the continuous non-invasive monitoring of
disease activity from blood, stool, or salivary samples of IBD patients, or those at risk. Although
yet not extensively covered in the literature for IBD, cfNAs as biomarkers of therapy response were
described in diseases such as metastatic colorectal cancer [138], non-small cell lung cancer [139],
minimal residual disease [140], or in organ transplant monitoring [141]. However, a high potential for
IBD activity tracking, and therefore also for therapy monitoring, can be anticipated from several of
the above-described findings, which are mainly based on the total amount of cfNAs or on the specific
dynamics between different types and origins of cfNAs identified. The main findings are as follows (for
citations, see the relevant paragraphs of this review): (1) elevated levels of total cfNAs during active
IBD; (2) specific balance between exosomes having pro-inflammatory and anti-inflammatory contents;
(3) presence, relative abundance, and specific content of NETs discriminating various types of IBD;
(4) presence and relative abundance of exogenous cfNAs as a reaction to the impaired barrier function
of the intestinal epithelium; and (5) higher amounts of human DNA in feces as a general outcome
of intestinal inflammation and epithelial cell damage when IBD is active. Another possibility of
therapeutic response monitoring can be hypothesized also through the detection of anti-inflammatory
content (immunoregulatory proteins and cfNAs) of hookworm-released exosomes [103] in the stool of
IBD patients undergoing helminthotherapy.
Specific cfNAs-based application, having extremely high value in the clinical care of IBD patients,
can be the non-invasive monitoring of colitis-to-cancer transformation. Such application was shown to
be feasible by the monitoring of cfDNA and its methylation level [80].
12. Conclusions
As we reviewed here, different types of cfNAs can be released to different body fluids by several
regulated or unregulated processes under specific physiological and pathophysiological conditions.
When considering the endogenous cfNAs in blood, these include “passive” processes of cell death
(necrosis, mechanical damage, etc.), “active” processes of cell death (apoptosis, NETosis), and “active”
processes of cell–cell communications (exosomes, microvesicles). In the case of exogenous cfNAs in
circulation (from microbiome, parasites, or ingested food), on the other hand, these processes can
include “active” transport (hijacking the physiological transport machineries of the host organism, or
through the immunological sampling of antigens by dendritic cells) and “passive” transport (because
of inefficient epithelial barrier functions resulting from pathology or injury). Other specific processes
can take place in body fluids that are different from blood, such as lymph, cerebrospinal fluid, saliva,
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urine, or stool. In each case, they represent signals from the processes taking place in the organism as
well as signals to make reactions of the organism happen. Knowing the exact meaning of these signals
can be exploited to actively step in the relevant processes or passively observe these processes. In
IBD, for example, this takes place through inhibiting pro-inflammatory signal generation/transduction,
strengthening anti-inflammatory signal generation/transduction, or monitoring disease onset and
therapeutic efficiency. Therefore, it is evident that cfNAs play important roles in various diseases,
including IBD. These specific molecules can be used as potential markers of disease state, and can
even differentiate between the active and inactive phases of the disease. Their analysis is relatively
easy and cheap, given their presence in body fluids. Therefore, CfNAs represent a significant tool
of liquid medicine, which is reaching clinical care. It promises a non-invasive, low-risk diagnostic
technique for patients. However, a number of various cfNAs types are known; yet regarding their role
in IBD, only a limited number of publications are available. Nevertheless, these represent a significant
basis for future research, as they demonstrated that cfNAs can be a valuable tool to stratify patients
and distinguish them from healthy people. Further research is needed in order to identify the overall
pool of cfNAs, but it is equally, if not more important to characterize these molecules in terms of
their information value, cellular and subcellular origin, molecular pathways, and biological aspects in
general. By achieving this, they could contribute to the elucidation of the pathogenesis of IBD and to
the development of new therapeutic strategies.
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Abstract: Utilization of liquid biopsy in the management of cancerous diseases is becoming more
attractive. This method can overcome typical limitations of tissue biopsies, especially invasiveness,
no repeatability, and the inability to monitor responses to medication during treatment as well as
condition during follow-up. Liquid biopsy also provides greater possibility of early prediction of
cancer presence. Corpus uteri mesenchymal tumors are comprised of benign variants, which are
mostly leiomyomas, but also a heterogenous group of malignant sarcomas. Pre-surgical differentiation
between these tumors is very difficult and the final description of tumor characteristics usually
requires excision and histological examination. The leiomyomas and malignant leiomyosarcomas
are especially difficult to distinguish and can, therefore, be easily misdiagnosed. Because of the
very aggressive character of sarcomas, liquid biopsy based on early diagnosis and differentiation
of these tumors would be extremely helpful. Moreover, after excision of the tumor, liquid biopsy
can contribute to an increased knowledge of sarcoma behavior at the molecular level, especially on
the formation of metastases which is still not well understood. In this review, we summarize the
most important knowledge of mesenchymal uterine tumors, the possibilities and benefits of liquid
biopsy utilization, the types of molecules and cells that can be analyzed with this approach, and the
possibility of their isolation and capture. Finally, we review the typical abnormalities of leiomyomas
and sarcomas that can be searched and analyzed in liquid biopsy samples with the final aim to
pre-surgically differentiate between benign and malignant mesenchymal tumors.
Keywords: liquid biopsy; cell-free nucleic acids; circulating tumor cells; leiomyomas; sarcomas;
leiomyosarcomas; exosomes
1. Introduction
Uterine mesenchymal tumors (UMT) are a very heterogeneous group comprised of benign variants,
which are mostly leiomyomas (ULM) and also malignant sarcomas. ULM are very common, affecting
over 50% of Caucasian women and up to 80% of African origin women and they are one of the main
causes of hysterectomy [1,2]. The incidence may be even higher, particularly in developing countries,
because ULM can be asymptomatic in more than 50% of women who are, therefore, unaware of their
presence [1,2]. Although they do not primarily endanger patients´ lives, ULM can markedly decrease
the quality of life if they become symptomatic [3]. In contrast, sarcomas are very rare, with an estimated
incidence of three to seven per 100,000 women [4], comprising only up to 8% of all corpus uteri
malignancies [5]. Sarcomas are also very aggressive. They spread rapidly and have a low five-year
survival rate and high rates of recurrence with low therapeutic efficacy [5–7].
UMT heterogeneity causes complicated classification. The most common form of UMT is
“conventional” or “typical” ULM. This covers 90–95% of all lesions and these are considered benign
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without signs of malignancy [1,3,8]. This group is also heterogeneous, so that “conventional” ULM can
differ in the following characteristics: (1) in histological degenerative changes such as myxoid, hyaline,
fatty, hemorrhagic, and cystic changes [8]; (2) their localization in the uterus [3]; and (3) the type of
genetic driver alternations [9].
In addition to strictly benign ULM forms, the remaining 5–10% can mimic malignancy and,
therefore, display some of typical malignant traits such as higher mitotic index, nuclear atypia or the
presence of coagulant necrosis [8,10]. There are also smooth muscle proliferations with unusual growth
patterns, including benign metastatic ULM or intravenous leiomyomatosis [11]. The most common
variants of non-conventional ULM are atypical, bizarre-cellular and mitotically active [8,10]. The most
unpredictable, but still considered non-malignant UMT, are the smooth muscle tumors of uncertain
potential, abbreviated STUMP [12]. In addition, inflammatory myofibroblastic tumors are quite rare
in the uterus, but can closely mimic both benign and malignant variants of UMT [13]. Debate also
continues concerning whether uterine leiomyosarcomas (LMS) arise from malignant transformation of
ULM [14–16], but, herein, we consider ULM and LMS two separate entities, as generally assumed [5].
The malignant sarcoma group is also very heterogeneous; comprising histologically different
tumors of various origin. These are divided into nonepithelial and mixed epithelial-nonepithelial
categories dependent on the type of cancerous cell and its presumed originating tissue [7]. However,
a better explanation of the variability of these tumors is characterized by sarcoma division into the
four previously traditional categories: (1) homologous sarcomas composed only of uterine tissue;
(2) heterogeneous types with mixed uterine and non-uterine tissues, typically striated muscle, bone,
and cartilage; (3) pure types which comprise only mesodermal structures; and (4) mixed types with
mesodermal and non-mesodermal structures; mainly epidermal [17]. These categories could have been
combined, for example, LMS were categorized as homologous pure tumors. Nonetheless, this traditional
classification incorrectly included several mixed mesenchymal tumors such as carcinosarcomas which
are currently listed as tumors of endometrial origin [18]. Moreover, the variability of sarcomas means
that future reclassification cannot be excluded. According to present-day classification, the most
common type of sarcomas are LMS, comprising up to 60%, followed by up to 20% endometrial
stromal sarcomas (ESS), up to 10% adenosarcomas, and the remaining 10% comprises other types
of sarcomas [19].
UMT heterogeneity makes it very difficult to pre-surgically distinguish particular types without
histopathologic confirmation after excision; including diagnosis of mitotic index, coagulant necrosis,
and cytological atypia [5,6]. It is still difficult to distinguish mesenchymal lesions, even with the help
of standard imaging devices—variable types of ultrasonography, magnetic resonance or computed
tomography (1) malignant sarcomas from benign ULM [1,3] and (2) one type of malignant tumor from
other types [5], and even when helpful clinical indications, for example, usual sarcomas occurrence and
ULM nonoccurrence after menopause are available [20]. Moreover, non-imaging clinical diagnostic
approaches also cannot identify UMT type with certainty; these methods are more suited to identifying
endometrial lesions [5,21].
Importantly, ULM are especially difficult to differentiate from the LMS [3,5], because imaging
and collateral symptoms are very similar; notably those of abnormal uterine bleeding, abdominal
and pelvic pain, dysmenorrhea, and urinary problems [1,7]. Furthermore, ULM and LMS have
some common features connected with their formation, especially higher ER receptor expression
and activity [22], higher incidence in African origin and obese women [2,7], and both tumor types
are more frequent in women with diabetes mellitus [23]. The many similarities between ULM and
LMS include also their same origin by transformation of the same cells [24]. Therefore, it would be
very beneficial to utilize molecular approaches to distinguish between particular UMT types and this
could overcome insufficiencies in pre-surgical clinical diagnosis, especially in ULM and LMS [25].
These factors have inspired the main focus of this article on the use of a noninvasive approach to
differentiate between these two tumor groups and we also present brief information on other sarcoma
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types. This mainly includes ESS, which can be differentiated from other UMT types, and, especially,
LMS through molecular approaches [26].
2. Liquid Biopsy
The presence of tumorous cells released into the bloodstream was first described in the nineteenth
century by Thomas Ashworth [27]. This can be considered the discovery of the phenomenon now
known as liquid biopsy (LB). In general terms, LB is described as a noninvasive technique which
enables analysis of molecular biomarkers sampled from body fluids. While this primarily concerns
blood [28], it also includes cerebrospinal fluid, pleural effusion, broncho-alveolar lavage fluid, saliva,
urine, and sputum [29]. The main concept of LB is to enable more simple, efficient, faster and
less-expensive monitoring of disease status, response to treatment, metastasis progression, and early
differentiation of particular tumor types. All this can be achieved by analyzing the body fluid targets
which are described in greater detail in the following section. Finally, LB is a revolutionary technique
that uses modern and precise medical principles, which can help clinicians in therapeutic decisions
and make the diagnostic process less stressful for patients. LB has mainly arisen because of invasive
method limitations which include the following: (1) it can have unexpected complications and cannot
be performed when clinical conditions have worsened or when a tumor is inaccessible [30], (2) it is
often unrepeatable and provides only information on the tumor at one point in time and precludes
monitoring responses to medication during both treatment and follow up, (3) it cannot be used for
screening or early prediction of cancerous disease, and (4) it is generally performed after incidental
early-stage tumor identification or following clinical examination resulting from exacerbated patient
symptomatology [28,31]. In addition, many patients fear invasive procedures, prefer noninvasive
diagnosis, and medicated non-surgical treatment. Furthermore, over 50% women with UMT want to
preserve their uterus and fertility [32].
In contrast, the test results from LB are more suitable for early diagnosis because these are usually
available much earlier, they have potential to estimate the risk of metastasis progression and relapse
more precisely, and they are usually less expensive [28,31]. Simply taking the blood or other body
fluids and analyzing target molecules and cells is, therefore, beneficial in many ways, but despite
the above mentioned benefits it is important to realize that LB is often used only for assessment of
tumor characteristics, but when the LB diagnoses the tumor as malignant it still requires surgical
excision [33,34]. In addition, the detection ability of LB still remains challenging and further studies
are required to test its accuracy and ability to correctly identify various tumor types. It also remains
uncertain if LB constantly provides a representative sampling of the whole tumor mass or only its
parts. However, intratumoral and spatial heterogeneity can also often limit precise interpretation of
the molecular profile in tissue biopsies [33]. Finally, there is, in some aspects a lack of established
consensus to guide its utilization [33,34] and despite the LB approach being beneficial and becoming
more and more popular, in some aspects, confirmation of its precise, advanced, and reliable use in
clinical praxis is required.
3. Cells and Molecules That Can Be Analyzed from LB Samples
The following cells and molecules can be analyzed using the LB approach: circulating tumor
DNA (ctDNA); circulating tumor cells (CTC); exosome vesicles; circulating RNAs, i.e., messenger
RNA (mRNA); microRNA (miRNA); long non-coding RNA (lncRNA); and also proteins, peptides,
and metabolites [29,31].
3.1. ctDNA
The ctDNA is tumor derived and fragmented DNA which should preserve the abnormal molecular
pattern present in the primary tumor [35–39]. Nonetheless, some studies also claim that ctDNA’s pattern
of abnormalities generally differs from those in primary tumors [40–42]. The ctDNA is primarily
released from tumors by apoptosis and necrosis (programmed and not programmed cell death),
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but also by tumor secretion [43]. Various factors affect the total composition of ctDNA circulating in
the bloodstream; it is especially dependent on tumor status, burden, and histopathology [44].
3.2. CTC
CTC can be valuable disease indicators because they are exfoliated from both primary tumors
and metastatic lesions. Their numbers and concentration can be used as a predictive marker, and as
with exosomes, they contain variable nucleic acids, proteins, and metabolites which can be utilized in
molecular analyses at the mutational, transcriptional, and epigenetical levels [45,46].
3.3. Exosomes
Exosomes are membrane-bound phospholipid vesicles, actively secreted by a variety of cells,
including cancer cells, and they contain proteins as well as the following nucleic acids: miRNAs,
lncRNAs, and mRNAs from tumors. Although the half-life of exosomes in bloodstream is still analyzed
and debated, Boukoris et Mathivanan [47] considered exosomes highly stable in stored conditions,
and therefore compared to freely circulating nucleic acids (CNA), those molecules encapsulated in
exosomes should also be more stable in stored conditions. However, miRNAs, which can also be
contained in exosomes, are generally considered very stable and their activity should remain the same,
regardless if they are encapsulated in exosomes or incorporated in ribonuclear complexes [48].
3.4. mRNAs, miRNAs and lncRNAs
mRNAs, miRNAs and lncRNAs are present in the bloodstream through both active secretion
in exosomes and apoptotic/necrotic cell lysis. However, apart from miRNAs, the half-life of other
RNAs in the bloodstream is presumed to be very short and their utilization for LB, therefore, requires
further analysis [49,50].
All the above elements, however, are very rare. For example, ctDNA comprises only 0.1% to 10%
of all circulating free DNA (cfDNA) released into the bloodstream from all human cells. Especially
leucocytes [51] and cfDNA concentration is itself quite low at 10 to 100 ng/mL [52]. The ctDNA
concentration, therefore, ranges from 0.01 ng/mL to 10 ng/mL and while the half-life of unencapsulated
particles ranges usually from 15 minutes to 2.5 h [31,53], ctDNA half-time is considered relatively long,
i.e., at least two hours [51].
In addition, CTC have a frequency as low as 1 CTC per 106–107 leucocytes which is usually less
than 1 CTC per milliliter of blood [46]. Therefore, it is necessary to sample higher blood volumes,
usually ranging from 5 to 9 mL to detect at least one CTC. Their occurrence also depends on the tumor
stage, where lower numbers are more common in early-stage disease and this increases only slightly in
patients with advanced metastases [54,55].
Rajagopal et al. [56] considered that increased exosome number is a potent biomarker for abnormal
physiological states and that their total numbers increase in cancer patients as compared to healthy
subjects. However, precise exosome quantification is difficult to determine because, in addition to
total number, the variations in size, and protein and nucleic acid content, per vesicle can vary and
“quantification” of these latter variations should be considered in further molecular analysis [57].
4. Capture, Enrichment, and Isolation of Freely Circulating Vesicles, Molecules and Cells
Traditional exosome capture and enrichment includes ultrafiltration and size exclusion
chromatography, precipitation with polymers, and immunoaffinity purification by magnetic beads [58].
These methods can be utilized because exosomes have specific biological patterns, and their cellular
origin provides typical surface markers. These include the CD9, CD63, and CD81 members of the
tetraspanin family, heat-shock proteins such as HSP70, and the Rab protein family [59]. However,
the exosome surface protein profile can vary with both the character and origin of the cell that
released them, and therefore establishing more specific membrane biomarkers and the genetic profile
of exosomes would be beneficial for using exosomes as agents in novel targeted therapies [60].
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Microfluid-based systems are now becoming more popular than traditional exosome capturing
systems, because these can directly analyze blood samples and are, therefore, more practical for clinical
praxis [45]. However, regardless of the capture technique used, it is very important to the utilization of
exosomes in clinical diagnostics, and potentially also in tumor differentiation, that the nucleic acids
and metabolites encapsulated in these vesicles can be analyzed following the electron microscope
validation and isolation [60,61]. While most current analyzes have targeted the expression of RNA
transcripts, which are abundantly present in these exosomes [61,62], there is scant knowledge of the
genomic and epigenetic profile of DNAs encapsulated in these vesicles.
ctDNA isolation is relatively easier than capturing exosomes. The main ctDNA isolation limiting
factor is its separation from other cfDNA molecules, however, both of the following targeted and
untargeted approaches are now available for this separation [36].
(1) Targeted approaches are based on identifying the following mutations/abnormalities in the
ctDNA elements: (a) previously accepted abnormal patterns in ctDNAs (e.g., in different cancer type
or based on in silico prediction) and (b) the same pattern in the primary tumor and the released
ctDNA. Here, the “standard” methods of molecular biology such as variable PCR modifications and
pyrosequencing can be used [63–66], but precise and more sensitive methods including BEAMing,
droplet digital PCR, and next generation sequencing (NGS) are more suitable because of the very low
ctDNA levels as compared to cfDNAs [67–69].
(2) Nontargeted approaches require no prior knowledge of molecular alternatives and while
these are generally based on NGS techniques, the digital karyotyping and PARE methods can also be
utilized [36]. Whereas, both targeted and nontargeted approaches are used mainly for detecting point
mutations, insertions and deletions, amplifications, translocations, and copy number alterations [36,67];
identifying abnormal epigenetic patterns and especially changes in promoter region methylation levels
can be a suitable alternative to genomic alterations. It is supposed that ctDNA epigenetic patterns
should also usually remain the same as in the tumors from which they were released and also be
specific for both cancer type and progression [35,67,70–75].
The capture of CTC remains extremely challenging because of its rarity and short half-life.
There are still affinity-based methods used which take advantage of antigens that are differentially
expressed by CTC [46]. These include: (1) epCAM which is normally present on the surface
of cells released from epithelial carcinomas [45,46]; (2) the MUC1 present in breast and ovary
carcinomas [76,77]; and (3) the EphB4 which is typically over-expressed in advanced head and
neck cancers [46]. However, this approach remains specific for limited cancer types because these
markers are suitable for positive selection, and therefore knowledge of further CTC surface antigens
typical for different cancer types is essential. A further limitation is imposed by epithelial cells
which are undergoing epithelial-mesenchymal transition (EMT) and cannot be captured by positive
selection [45,46]. Negative selection is used to avoid selection bias and is based on capturing
and subsequent removal of non-CTC cells in the blood, most importantly, leucocytes. These are
commonly depleted through immunomagnetic targeting and removal against CD45 and other leucocyte
antigens [45,78]. To the best of our knowledge, no studies have focused on identifying CTC released
from any type of uterine sarcoma or ULM. However, there are some options for the identification of
CTC from different non-uterine sarcoma types, and this provides opportunities to determine CTC
from uterine sarcomas. For example, Benini et al. [79] were able to identify CTC released from Ewing
sarcomas by immunoseparation with CD99 antibody and magnetic microbeads. The origin of the cells
was verified by the presence of fusions typical for this tumor. The expression of cell-surface vimentin
provided an even better chance to identify CTC of various sarcomatous origins [80]. Most recently,
Hayashi et al. [81] recorded CTC identification from various sarcoma types based on positive vimentin
staining, negative CD45 staining, and nuclear morphology distinct from normal white blood cells.
The standard approaches for identifying CTC include using magnetic beads armed with antibodies
for positive or negative separation and employing columns or cartridges or microchips coated with
antibodies [82]. However, the CTC physical properties, such as electric charges, can also be used
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to enrich and isolate these cells with more practical microfluid cell sorters [83,84] or Microhall
platforms [85,86]. Finally, microfiltration systems, such as CellSieveTM, also provide great possibilities
for the identification of variable CTC with only minimal cell processing [81]. Interestingly, CTC were
previously thought to be released only from metastases, but it is now accepted that two CTC “types”
exist. This is contrary to previous claims, because the first type acts as a metastatic factor and the
other is only passively released into the bloodstream, and although it should not promote metastases
formation, its role in tumor spread remains undetermined [87].
5. Known Abnormalities in UMT
LB methodology enables analysis of various molecular targets over longer periods and this makes
it possible to monitor disease progression and response to treatment. Furthermore, it also provides the
possibility of differentiating particular tumor types. This can be very beneficial for early diagnosis of
cancer. For differentiation of UMT with the LB approach, there are two options: (1) assessment of the
mutational/transcriptional/epigenetic pattern in solid tumors and subsequent identification of the very
same abnormalities in LB samples and (2) determination of specific patterns of change in the candidate
markers directly in the LB samples and their connection with particular cancer diseases.
Unfortunately, specific LB biomarkers with the potential to non-invasively distinguish particular
UMT types have not been assessed. Further analysis is, therefore, required to find a successful
marker, but this is quite promising because the presence of ctDNA released from ULM and
malignant sarcomas has been noted in non-invasive prenatal testing (NIPT) [88–90]. Furthermore,
Hemming et al. [91,92] described the presence of ctDNA from LMS in LB samples and these correlated
with tumor progression. Moreover, many of the biomarkers of solid UMT described below have
previously been reported in LB from patients with different cancer diseases and these provide the
possibility of early diagnosis, prognosis, and therapeutic outcome. These include the identical
microRNAs [93–97], methylation changes [95,98,99], mutational changes [100–102], and even similar
chromosomal rearrangements [103–106]. We, therefore, suggest a way to identify LB biomarkers
suitable for UMT differentiation by searching for abnormal patterns already established in solid UMT
in LB samples. This possibility is very promising also because reports identify that solid tumor
abnormalities should remain unchanged in CNA [35–39,67,70–75] and eventually also in vesicles and
CTC. Therefore, all abnormal patterns listed below are noted in solid tumors and their summary can
form the basis for designing LB-based analysis in patients with UMT.
6. miRNAs
The miRNAs are short non-coding RNAs which can bind to target mRNAs and induce gene
silencing and repression of transcription [107]. The 2000 miRNA genes already identified in the human
genome is expected to increase in number and their abnormal activity has been connected with the
development of various cancerous diseases because they regulate the important cellular functions of
development, differentiation, growth and metabolism [107]. Analysis of miRNA abnormal activity is
currently attractive, however, in ULM and LMS tissues, it is still not sufficiently known. The most
notable abnormally expressed microRNAs in ULM and LMS tissues are listed in Table 1. There are some
interesting characteristics of miRNAs in these tumors including that treatment with 17β-oestradiol and
medroxyprogesterone acetate should result in the regulation of variable miRNAs’ activity, at least in
the ULM and LMS cell lines [108]. Liu et al. [109] noted that various miRNAs are differentially active
in African and Caucasian women. Wang et al. [110] considered that the abnormalities in microRNAs
activity should be associated with tumor size as well as ethnicity. Moreover, ULM typically have
an abnormal extracellular matrix, and miR-15b is more active in ULM tissue samples than in healthy
myometrium (MM), and also more active in ULM cell lines than in MM cell lines [111]. This miRNA
is supposed to regulate RECK protein expression in normal physiological status to ensure negative
regulation of matrix metalloproteinases [112,113]. In addition, the let-7 family miRNA family has the
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HMGA2 gene as a target and HMGA2 abnormal expression, especially from translocations, is considered
a typical ULM mark [114].
The activity of most analyzed miRNAs has been assessed in ULM. MicroRNA activity is less
understood in LMS and studies that could compare the activity of identical microRNAs in both
tumor types are widely lacking. Exceptions, however, include studies by de Almeida et al. [115]
and Schiavon et al. [116], which focused on assessing miRNA activity in both tumor types. In the
former study, the authors identified 24 oncomirs with de-regulated expression profile in both ULM
and LMS. The latter work recorded similar results in establishing widely different ULM and LMS
expression patterns. Danielsson et al. [117] also suggested that different miRNA activity should
contribute to separate ULM and LMS development, and they created a clustering system differentiating
ULM and LMS based on miRNA activity. Unfortunately, however, they accomplished this only in
cell lines. The most notably different ULM and LMS miRNAs recorded in these studies are listed
in Table 1, under the “observed in LMS/ULM tissue” section, and these can be considered the best
candidates for distinguishing between ULM and LMS on miRNA activity using LB. However, many of
the analyzed ULM miRNAs were not analyzed in malignant LMS, even in the two separate studies.
Therefore, the miRNAs summarized in Table 1 and reported as abnormal in ULM (listed under the
“observed in ULM/MM tissues”), could prove beneficial if analyzed in LMS. There are also studies
which assessed different miRNAs expression profiles in ESS. For example, Kowalewska et al. [118]
reported four miRNAs which were differentially active in ESS and the control group, but it is quite
interesting that they noted no significant differences in miRNA expression in LMS and control healthy
tissues. The additional study by dos Anjos et al. [119] compared LMS, carcinosarcoma, and ESS
miRNA profiles and identified both variable miRNA activity in these three tumor types and a variety
of miRNAs connected with lower cancer-specific survival rates. This may, however, be due to tumor
differences, whereas LMS are primarily smooth-muscle tumors. ESS, even of mesenchymal origin,
are mixed tumors with a large proportion of endometrial elements and carcinosarcomas are classified
as being of endometrial origin [18].








Let-7 family * [110] ULM/MM tissue Up miR-15a * [120] Primary/metastaticLMS tissue Up in metastases
miR-27a * [110] ULM/MM tissue Up miR-92a * [120] Primary/metastaticLMS tissue Up in metastases
miR-21 * [110] ULM/MM tissue Up miR-31 * [120] Primary/metastaticLMS tissue Up in primary
miR-23b * [110] ULM/MM tissue Up miR-122-5p [116] LMS/ULM tissue Up
miR-200a * [121] UtLM-hTert Up miR-206 * [116] LMS/ULM tissue Up
miR-542-3b [122] ULM/MM tissue Up miR-373-3p * [116] LMS/ULM tissue Up
miR-377 [122] ULM/MM tissue Up miR-144-3p [116] LMS/ULM tissue Up
miR-363 [123] ULM/MM tissue Up miR-372-3p * [116] LMS/ULM tissue Up
miR-490 * [123] ULM/MM tissue Up miR-34a-5p [116] LMS/ULM tissue Down
miR-137 [123] ULM/MM tissue Up miR-27b-3p [116] LMS/ULM tissue Down
miR-15b * [111] ULM/MM tissue;ULM/MM cell lines Up miR-135b-5p [116] LMS/ULM tissue Down
miR-30a [121] ULM/MM tissue;UtlM-hTERT cell lines Up miR-9-5p [116] LMS/ULM tissue Down
miR-32 [110] ULM/MM tissue Down miR-10b-5p * [115] LMS/ULM tissue Up
miR-29b * [110,124] ULM/MM tissue Down miR-125b-1-3p [115] LMS/ULM tissue Up
miR-542-5p [122] ULM/MM tissue Down miR-140-5p * [115] LMS/ULM tissue Up
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miR-642 [122] ULM/MM tissue Down miR-145-5p [115] LMS/ULM tissue Up
miR-93/106 [125] ULM/MM tissue Down miR-130b-3p * [92] LMS/ULM tissue Down
miR-486-5p * [123] ULM/MM tissue Down miR-148-3p [115] LMS/ULM tissue Down
miR-217 [123] ULM/MM tissue Down miR-204-5p [92] LMS/ULM tissue Down
miR-4792 [123] ULM/MM tissue Down miR-203a-3p [92] LMS/ULM tissue Down
miR-200a * [109] ULM/MM tissue;UtlM-hTERT cell lines Down miR-152 * [126]
LMS/ULM tissue
/SKLMS1cell lines Down
mir-143 * [108] ULM/MM tissue Down
miR-200c * [127] ULM/MM tissue Down
miR-197 * [128] ULM/MM tissue Down
miR-212 [121] ULM/MM tissue;UtlM-hTERT cell lines Down
* These were reported and analysed in LB samples in patients with different cancer diseases [93–97]; ULM—uterine
leiomyomas, MM—healthy myometrium, LMS—uterine leiomyosarcomas.
7. DNA Mutations and Chromosomal Aberrations in ULM and Sarcomas
ULM often result from gene mutations, but this occurs only on a small scale. The most mutated is
the MED12 gene observed in almost 70% of ULM, and the second most frequent is FH gene mutations
which comprise only approximately 1% [129,130]. In addition, non-sporadic germline mutations of
this gene occurred more often in women with both ULM and LMS [131,132]. Interestingly, malignant
uterine LMS also have MED12 gene mutation in almost 70% of tumors [133], and this can be, therefore,
considered a typical mark for these tumors. While this common mutation potentially distinguishes
the two tumor groups from healthy tissue, unfortunately it cannot be used as a distinguishing factor
of these tumors and is, therefore, unsuitable for LB diagnostics. In contrast to ULM, LMS have quite
often mutated TP53 gene [6,134]. Although mutations in this gene are typical for many cancerous
diseases, LB determination of TP53 mutation in women with previous image-diagnosed UMT should
always provoke rapid tissue biopsy, subsequent histological examination, and close observation of
the patient. Moreover, this gene should also be considered a potential candidate for gene therapy in
women with LMS [135].
The ATRX gene is also relatively often mutated in LMS tissues [134], and also in STUMP [136].
Furthermore, the RB1 gene is typically mutated in LMS [26] and in ULM with bizarre nuclei [137].
However, the percentage of mutations of both genes in LMS is less than 50% and the extent of ATRX
mutation in leiomyomatous tissues remains undetermined. In addition, ULM with bizarre nuclei
are quite rare and the RB1 gene is often mutated in a wide range of cancers [138]. In summary,
the mutation profiles of ULM and sarcomas are not well understood, and currently demonstrated
abnormalities provide only limited possibilities for LB differentiation of these tumors. However,
mutation changes in the TP53, ATRX, and RB1 genes have been detected and analyzed in LB samples
in patients with different cancer diseases [100–102]. In contrast to mutational changes, the ULM
and LMS chromosomal aberrations are quite different and better understood, so current knowledge
suggests that LB differentiation of these tumors based on chromosomal aberrations is more suitable
than just relying on mutational changes. Moreover, this identification from LB samples is feasible,
for example, with ultra-low passage whole genome sequencing [91,139,140]. The most important
recognized chromosomal aberrations in ULM and LMS are listed in Table 2.
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8. Methylation Changes in ULM and LMS
The methylation profiles of ULM and sarcoma promoter regions provide further possibilities for
tumor differentiation based on LB, because changes in DNA methylation patterns can be identified in
ctDNA and have been proposed as potential biomarkers for tumor staging, prognosis, and monitoring
of the treatment response [31,98,162]. It has also been suggested that abnormal methylation patterns
should remain identical in both the primary tumors and the ctDNAs released by the tumor [35,67,70–75].
Maekawa et al. [163] reported great variability in ULM methylation patterns. These authors reported
120 genes with different methylation pattern in ULM and MM, and 22 of these were estrogen receptor
alpha (ERα) target genes, thus, indicating that their abnormal methylation could contribute to abnormal
estrogen response. One of these genes is DAPK1 which is often abnormally methylated in various
cancer types [164] and importantly, it has also been reported abnormally methylated in the serum of
women with ULM [165].
Following bisulfide-sequencing of the ERα receptor gene promoter region, Asada et al. [166]
reported that seven CpGs in distal sites are often variably methylated in healthy and tumorous tissues.
It is quite likely that methylation variations in distal ERα regions are dependent on menstrual cycle
phases [167], and since this has already been assessed in solid tissues, it would be very interesting
and beneficial to analyze the status in LB samples. ULM also have differentially methylated sex
chromosomes [168] where the most notably hypomethylated was the TSPYL2 gene. In addition,
women of African origin have hypermethylated DLEC1, KRT1,9 and KLF11 genes in ULM as compared
to MM [169].
Importantly, methylation markers have already been used by Sato et al. [170] to distinguish
between ULM and LMS, especially by establishing a hierarchical clustering system able to discriminate
between these tumors with 70% accuracy. The system is based on different methylation levels in ten
genes. This study is also unique because it assesses the methylation status in both ULM and LMS
tumor types. In contrast, the remaining methylation markers listed in Table 3 were assessed either
for benign or malignant lesions, but not for both, and further analyses comparing the status of these
genes in both tumor types would be beneficial to determine how well they coud distinguish between
these tumor types. For LMS are typical aberrations altering the cell cycle [6], whereby promoter
region hypermethylation is supposed to induces loss of function of the important cell cycle regulator
CDKN2 [171] and hypermethylation also most likely causes the BRCA1 gene´s protein reduction in
almost 30% of uterine LMS [172].
Malignant LMS have abnormal estrogen receptor activity and sensitivity, but these are lower
than in benign ULM [22]. The LMS also have often hypomethylated ESR1 target genes [26] and the
polycomb group target genes [173]. Importantly, authors Miyata et al. [173] claimed that ULM and LMS
can be distinguished by their global DNA methylation levels, and also presumed that the methylation
pattern is different on a genome-wide level in ULM subtypes with different genetic driver aberration,
i.e., MED12 mutation, HMGA2 activation, and FH mutation [9,174]. These results make tumor
differentiation based on their ctDNA methylation levels very interesting, however, the bloodstream
ctDNAs are very fragmented and poorly represented, and therefore ctDNA methylation analyses
on either a genome-wide scale or a locus-specific level should preferably use very sensitive novel
sequencing approaches [67,98]. The hyper- and hypomethylated genes in ULM and LMS tissues are
listed in Table 3.
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Table 3. Abnormally methylated genes in ULM and LMS.
ULM LMS
Gene Methylation Change Gene Methylation Change
IRS1 [163] Hypermethylation MGMT * [175] Hypermethylation
COL4A1 [163] Hypermethylation BRCA1 * [172] Hypermethylation
GSTM5 [163] Hypermethylation CDKN2 * [137] Hypermethylation
DAPK1 * [165] Hypermethylation PTEN [6] Hypermethylation
KLF11 [169] Hypermethylation RASSF1A *a [176] Hypermethylation
DLEC1 * [169] Hypermethylation DAPK1 *a [177] Hypermethylation
KRT19 [169] Hypermethylation
ALX1 ‡ [170] Hypermethylation
CBLN1 ‡ [170] Hypermethylation
CORIN ‡ [170] Hypermethylation
DUSP6 [170] Hypermethylation
FOXP1 ‡ [170] Hypermethylation
GATA2 ‡* [170] Hypermethylation
IGLON5 ‡ [170] Hypermethylation
NPTX2 ‡* [170] Hypermethylation
NTRK2 ‡ [170] Hypermethylation
STEAP4 ‡* [170] Hypermethylation




* These were reported and analyzed in LB samples in patients with different cancer diseases [95,98,99]; ‡Methylation
status of these genes was compared between ULM and LMS in a study by Sato et al. [170]; a Methylation
changes were noted in variable types of leiomyosarcomas, including non-uterine. DAPK1 gene was reported as
hypermethylated in ULM and sarcomas as compared with healthy tissues, but it was not compared between ULM
and LMS; ULM—uterine leiomyomas, LMS—uterine leiomyosarcomas.
9. lncRNAs and mRNAs
ULM expression profiles are relatively well assessed in studies analyzing gene activity on the
mRNA levels in solid tumors [25,178–180]. The LMS mRNA expression profile is also relatively
sufficiently known [6,25,181,182] and variably expressed genes are recognized also in primary and
metastatic LMS [183] and in LMS as comparing to ESS [184]. Although mRNA molecules directly
released into the bloodstream after apoptosis or necrosis can technically reflect intracellular processes in
tumor cells and their levels can have some predictive value of tumor character, their very short half-life,
instability, low abundance, and regular contamination with other intracellular mRNAs severely limits
them as useful biomarkers [185]. In contrast, assessment of mRNA expression in CTC and exosomes
appears more suitable because of the newly developed approaches [186–189].
Genome-wide analyses of ULM lncRNA expression have demonstrated that hundreds of these
molecules are aberrantly active in ULM as compared to MM [190]. The number of abnormally
active lncRNAs correlates with tumor size, and lncRNA H19 was considered as the most important
abnormally active lncRNA in ULM [190]. lncRNA H19 contributes to MED12 and HMGA2 gene
regulation. It is assumed that lncRNA H19 should also affects the activity of various extracellular
matrix remodeling genes [191]. Therefore, further study of this lncRNA should shed more light on
the regulation of important ULM marker expression and this lncRNA could potentially be used as
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a reliable distinguishing marker of these tumors. Finally, further research of lncRNAs’ abnormal
activity in rare malignant sarcomas should also prove advantageous, but this is still currently lacking.
10. ULM and Sarcoma Metabolites
ULM are also the subject of metabolic studies because of their high occurrence, the search
for efficacious medication, and their great current cost. The very interesting study performed by
Heinonen et al. [192] assessed abnormal metabolomes and metabolic pathways in ULM, and they
associated these with particular molecular subtypes, which harbor different driver genetic abnormalities.
These were divided into the following four groups: those with the mutated MED12 gene, those with
HMGA2 gene translocations, the group with FH gene biallelic inactivation, and COL4A5-COL4A6
deletions [9]. In summary, Heinonen et al. [192] recorded 70 dysregulated metabolites in all ULM
types, and the characteristic dysregulations in particular ULM subtypes included: (1) the FH subtype
which has characteristic metabolic alterations in the tricarboxylic acid cycle and pentose phosphate
pathways and increased levels of multiple lipids and amino acids and (2) the MED12 subtype which
has markedly reduced levels of vitamin A and dysregulation of ascorbate metabolism. Interestingly,
the retinoid acid receptor pathways have previously been observed to be very dysregulated in ULM,
and this caused lower levels of biologically active retinoid acid and increased levels of its abnormal
metabolites [9,193,194]. In addition, it has been suggested that premenopausal parous women
with ULM share a wide range of metabolic syndrome features such as higher serum triglycerides
levels (TG ≥ 150 mg/dL), low serum-high density lipoproteins (<50 mg/dL), and hyperglycemia
(FPG ≥ 100 mg/dL) [195]. The obesity and high blood pressure observed in this syndrome have also
been previously and repetitively associated with ULM occurrence [1–3]. However, while it is generally
accepted [3] that vitamin D deficiency is strongly associated with ULM occurrence, its abnormal
metabolites were not confirmed in these tumors [192].
The uterine sarcoma metabolite profile is poorly understood due to its rare occurrence.
Paradoxically, some authors regard metabolomic markers more reliable than molecular markers
in sarcoma diagnostics, especially in the high-grade type which are more difficult to distinguish
histologically. Moreover, individual tumors often contain areas of different histologic grade, necrotic
regions, and variable inflammatory cell infiltrate, and this heterogeneity hinders the search for molecular
markers [196,197]. However, the preference for metabolomic markers over the molecular remains
disputed and subjective.
Lastly, the same pattern of precursor ion differences has been found in LMS, myxofibrosarcomas,
and undifferentiated pleiomorphic sarcomas. The two metabolite signals correlate with overall
survival, m/z 180.9436 and m/z 241.0118; and one with metastasis-free survival, m/z 160.8417. In addition,
FTICR-MSI identified m/z 241.0118 as inositol cyclic phosphate and m/z 160.8417 as carnitine [197].
11. Discussion and Conclusions
In this review, we based the differentiation of UMT on the LB approach because of the diverse
action of non-coding RNAs, and mutational and methylation changes and differences in metabolic
activity in ULM, other UMT, and MM. We also suggested searching for these previously known solid
tumor abnormalities in LB samples. However, the differentiation of two or more tumor types by
LB necessitates, in the final step, assessment of their altered patterns in the body fluid samples. For
example, hypermethylation or mutational changes can be considered proof of ULM rather than LMS
when a LB sample is abnormally hypermethylated or has particular mutations, and this abnormal
pattern was previously observed with high predictive value in ULM but not in LMS. This explanation,
however, is simplistic and follows only basic principles because the entire procedure for establishing
a particular marker to its utilization in clinical testing is a long and multistep process. While it is
debatable if there is sufficient knowledge of the differences in ULM, it is certainly lacking in sarcomas.
Therefore, to enable LB to determine tumor character and to monitor the response to treatment and
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tumor progression in malignant variants, it is essential to increase current knowledge of changes in
ULM and also to perform these analyses in uterine sarcomas, especially LMS.
Moreover, we based our suggestions on the assumption that changes in CNA should remain
the same as they are in the primary tumors which release them [35–39,67,70–75]. However, it should
be mentioned, some studies suggest that the changes can vary [40–42]. In addition, it is necessary
to realize that metastatic lesions can differ from primary tumors in their molecular patterns [183].
It would, therefore, be beneficial to perform more comparative analyses of primary and metastatic
sarcomas to understand the changes in their progression. In addition, it would also be helpful to use
more gene assays with high predictive value in LB screening, instead of sole ones. Finally, there is
still no successful tool for differentiating UMT, so even achieving lower predictive value would be
advantageous. An example here is that assays correctly assessing tumor type in eight out of 10 women
would be better than none.
It is quite intriguing that there is no interest in developing techniques that could differentiate
such frequent tumors as ULM and such aggressive tumors as sarcomas. The main reason appears
to be the very low incidence of sarcomas and most UMT lesions are ULM. These latter are not life
threatening and often asymptomatic. In addition, the statistical threat to life caused by uterine sarcomas
is low, and almost negligible in comparison to the “deadliest” cancer types such as breast, lung and
colon cancer. However, if sarcomatous lesions are primarily misdiagnosed as ULM, this can have
fatal consequences, especially when women refuse surgical excision and prefer medicated treatment.
Moreover, although uterine sarcomas are rare, these lesions still affect thousands of women globally
and can be easily misdiagnosed. Therefore, early noninvasive diagnosis could provide certainty that
lesions are really benign; and it could significantly prolong full-quality life even when the lesion
is malign. Moreover, appropriate LB approaches can monitor both the metastatic progression of
malignant lesions and response to treatment, and thus contribute to their better understanding.
Unfortunately, minimal analyses have focused directly on capturing and identifying circulating
elements from UMT and most findings have been incidental and collateral. It is known that NIPT
results can be affected by the presence of tumorous circulating elements [88]. The first study of
these discrepancies we are aware of was conducted by Osoborne et al. [198]. Woman with metastatic
neuroendocrine carcinoma gave birth to a healthy infant, and although both invasive testing during
pregnancy and postnatal placental histology revealed no abnormalities, NIPT testing indicated trisomy
in chromosomes 13 and 18. These trisomes, therefore, arose from release of tumor DNA into the
bloodstream and not due to infant chromosomal aberrations. A summary of a three-year period of
NIPT testing enabled identification of 55 samples with altered genomic profiles and thus not reportable
NIPT results [89]. All these discrepancies are presumed to arise due to the presence of various neoplasm
types, but importantly almost half of the identified discrepancies arose as a result of the presence of
benign ULM and only one because of uterine sarcomas presence.
One study focused directly on identifying circulating ctDNAs from uterine LMS and confirmed
ctDNA presence in five of 10 cases [91]. This number is considered quite low, but sarcomatous
ctDNA was identified in five of six patients with progressive disease. Therefore, ctDNA identification
correlated with tumor burden, and it was present in patients with both primary and metastatic lesions
but not identified in disease-free or stable subjects. This was a pilot study, so repetition and finding
new approaches and targets should increase the numbers of positively identified LMS ctDNAs.
In addition, Eastley et al. [199] confirmed the possibility of detecting and subsequently analyzing
ctDNAs released from soft tissue tumors, including two leiomyosarcoma samples. The authors found
TP53 and HRAS mutations in both primary tumors and plasma samples. However, it is necessary to
remember that the percentage of these mutations differs in tissue and plasma samples and the authors
do not mention if these leiomyosarcomas arise from uterine tissues or not.
The understanding of CTC and exosome release from ULM and sarcomas is still poor, and to the
best of our knowledge no miRNA profiles have been recovered from these tumors in LB samples despite
their abundance in primary tumors. More studies should, therefore, focus on assessing non-coding
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RNAs, especially miRNAs in LB samples and on the character of CTC and exosomes released from
UMT. From a positive perspective, however, combined approaches have already been developed for
the purposes of LB-based tumor diagnosis and prognosis, and these detect desired ctDNA changes in
mesenchymal tumors, including uterine LMS [200].
In conclusion, there are no currently known LB biomarkers that can be used for early and
noninvasive distinction between particular UMT types. However, (1) there are recorded nucleic acid
molecules released from both benign and malignant variants into the bloodstream [89–92]; (2) many
molecular biomarkers reported in solid UMT have been noted in LB samples in different cancer types
and these can be used for early diagnosis, prognosis, and therapeutic outcomes [93–102]; and (3) it is
presumed that abnormal patterns in solid tumors should remain the same in CNA [35–39,67,73–75].
On the basis of these facts, we can state that it is theoretically possible, and highly likely in practice,
to distinguish clinically between UMT types using the LB approach when appropriate molecular
markers are employed. Our review should, therefore, inspire further research and analysis of known
abnormalities in solid tissues in LB samples. The implication of the markers in these processes could
also help monitoring of both the progression of malignant variants and the response to treatment.
It is, therefore, essential in the future to establish as many molecular markers as possible for each type
of UMT and to evaluate them using LB approaches. This will be most beneficial when sufficiently large
patient cohort screening can be performed with a variety of advanced molecular methods. Performing
NGS-targeted approaches for identification of the markers highlighted in this review is suggested as
a most suitable option. Moreover, genome-wide studies would also be welcome to identify useful
markers, including epigenetic markers. Finally, any possible improvements in LB approaches for
women with UMT will benefit both patients and clinicians, because clinicians would then be able to
more precisely measure disease burden and better coordinate clinical treatment, providing greater
certainty to affected women that their lesion remains benign.
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Abstract: Primarily due to recent advances of detection techniques, microchimerism (the proportion
of minor variant population is below 1%) has recently gained increasing attention in the field of
transplantation. Availability of polymorphic markers, such as deletion insertion or single nucleotide
polymorphisms along with a vast array of high sensitivity detection techniques, allow the accurate
detection of small quantities of donor- or recipient-related materials. This diagnostic information can
improve monitoring of allograft injuries in solid organ transplantations (SOT) as well as facilitate early
detection of relapse in allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the present
review, genetic marker and detection platform options applicable for microchimerism detection are
discussed. Furthermore, current results of relevant clinical studies in the context of microchimerism
and SOT or allo-HSCT respectively are also summarized.
Keywords: microchimerism; solid organ transplantation; hematopoietic stem cell transplantation;
genetic marker; single nucleotide polymorphism; deletion/insertion polymorphism
1. Introduction
Co-existence of genetically distinct/discordant tissues or cells is termed chimerism after the
well-known Greek fusion creature. Based on the extent of the variant population, microchimerism is
usually mentioned as a subgroup of chimerism in which the proportion of foreign cells or tissue does not
exceed 1%. This proportion can readily be estimated in the circulation while quantitative comparison
of major and minor populations is more challenging in cases of scattered cells or transplanted tissue.
Based on origin, naturally occurring and therapy related microchimerism can be distinguished.
Naturally occurring microchimerism refers to the bidirectional interaction between the genetically
distinct mother and fetus(es) resulting in the long-lasting presence of small numbers (well below
1%) of fetal cells in the mother and vice versa. The interesting immunological consequences of these
coexistences have recently been elegantly reviewed [1] and is not discussed in the present review.
The term therapy related microchimerism describes situations primarily related to transplantations
and occasionally transfusions. Subsequent to solid organ transplantations (SOT) a well-defined organ
coexists with the recipient which rarely involves mixture of cells. In contrast, variable recipient–donor
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cell ratios are characteristic for patients treated by allogeneic hematopoietic stem cell transplantation
(allo-HSCT).
The quantitative detection of chimerism in the circulation might serve as a biomarker with clinical
relevance, which is based on polymorphic genetic structures (markers) similarly to those applied in
forensic medicine for person identification. Large scale population studies such as the 1000 Genome
Project characterized and classified millions of human variants in different populations allowing the
identification of appropriate markers with high heterozygosity rate and discriminatory power. In the
last decade, the development of highly sensitive, quantitative and accurate methods, e.g., digital
PCR or next generation sequencing (NGS) enabled the precise quantitation of unprecedently low
level molecular variants. As a result, the clinical application of these innovative technologies for
microchimerism detection has started to enter the daily practice. In general, the paradigm of marker
selection in transplantation dictates an allele choice as a marker that is not present in the dominant cell
or molecule population: after SOT the donor should be marker positive and the recipient negative,
while after allo-HSCT the opposite relationship is required.
Chimerism could be investigated on cellular or on cfDNA level. The latter consists mainly of small
sized (around 150 base-pairs) double-stranded DNA fragments resulting from apoptosis, necrosis,
immune-mediated cell damage, or release of nuclear DNA into the circulation predominantly from
hematopoietic cells [2]. In the circulation, these fragments have a short half-life of approximately 1.5 h
due to rapid hepatic and renal clearance [3].
In the present paper, we provide an extensive review of the available information about
microchimerism in the context of various forms of transplantation and transplantation-related advanced
therapies with a special emphasis on the available markers and the multitude of detection platforms in
this high sensitivity range.
2. Polymorphic Genetic Markers Applicable for Chimerism Detection
2.1. Short Tandem Repeats (STR)
So far, more than 700,000 STRs (short tandem repeats) are characterized in human genome, for the
most part they are considered as ‘junk DNA’, however some of them are located in protein coding
region and associated with genetic disorders [4–6]. STRs—also referred to as microsatellites—consist of
2 to 6 nucleotide tandem repeats distributed throughout the genome. These loci are highly polymorphic
and different alleles are determined by the varying number of nucleotide repeats (3 to 51 repeats).
Short tandem repeat (STR) analysis is a standard and approved method applied in forensics and in
hematopoietic chimerism quantification after allo-HSCT [7]. Nearly 100% informativity can be reached
with a panel of 12–16 STR markers (Core STR Loci), including loci on sex chromosomes, that allow
differentiation between individuals [8–10]. The major advantage of STRs is its multiallelic (up to
16 distinct variants) nature and consequential high informativity rate, which allows its application in
all donor–recipient pairs or furthermore in transplants with multiple donors.
2.2. Single Nucleotide Polymorphism (SNP)
These represent the most frequently observed variations in the human genome, around 1/1000
basepairs [11]. In an average individual there are ten times more SNPs to be found compared to deletion
insertion polymorphisms (DIP). Since the discrimination power of biallelic variants is lower compared to
STRs, more loci have to be simultaneously tested to reach an acceptable informativity range. Reportedly,
already seven SNP markers can be highly discriminative (97% informativity) in HLA-identical sibling
pairs [12]. On the other hand, a study using a combined panel of markers described only 80% overall
informativity with six SNPs, two null alleles (SRY, RhD) and two DIPs [13]. Almeida et al. calculated
81% informativity for eight biallelic SNP markers investigating 88 patient/donor pairs [14]. Fredriksson
et al. used an array consisting of 51 SNPs to reach 100% informativity [15]. In the context of SOT,
SNP assays have widely been used to detect donor-derived cfDNA (dd-cfDNA) amount in plasma
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with an early, method-focused application using digital PCR (see Section 3) in small sets of liver,
kidney, and heart transplanted patients [16]. This approach was further developed and characterized
in detail by Grskovic et al. [17] in the form of a commercial assay (CareDx, Brisbane, CA, USA)
employing 266 SNPs and NGS (see Section 3) with a convincing validation in a large group of heart
transplanted patients. The technical advances made possible a highly sophisticated approach of
massive multiplexing allowing the utilization of more than 13,000 SNP markers [18], as well as an
alternative commercial, NGS-based assay [19]. The enormous amount of information obtained from
massively parallel SNP-typing by NGS also allows donor–recipient distinction in the absence of
pre-testing potentially further simplifying the routine application [20,21].
2.3. Deletion Insertion Polymorphisms (DIP)
DIPs or INDELs are relatively short (up to about 50 bases in length), frequently biallelic variations
located in non-coding regions of the genome displaying a lower mutation rate compared to STRs. As a
consequence of the emergence of NGS technology and advanced software algorithms, the number of
identified and characterized DIPs is rapidly increasing [22–24]. While searching the world’s largest
public human variation database (dbSNP Build 152) and applying a filter for intergenic human DIPs,
not restrictive to the length of the polymorphism, nearly 9 million hits are found. Biallelic DIPs
are suitable and reliable markers which are now commonly used for monitoring donor–recipient
tissue proportions in transplantation as well in person-identification in forensic medicine [25,26].
To monitor chimerism after allo-HSCT, Alizadeh et al. utilized 19 specific markers located on 9 different
chromosomes reaching an informativity level of approximately 90%. This approach has been later
validated by others [27–29]. A further study extended this system with two additional DIP markers
and optimized their assay for SYBR green with a possible discrimination of 94% [30]. Subsequently,
Pereira et al. developed a DIP-based multiplex assay for human identification, which uses 38 biallelic
markers characterized by high heterozygosity rates in distinct population groups, reaching an
approximate informativity of 100% [26]. As an alternative to hybridization probes, Goh et al. analyzed
dd-cfDNA after liver transplantation by targeting DIPs by the amplification primers themselves [31].
The successful application of as few as 10 DIPs along with digital PCR for the detection of dd-cfDNA
in a small cohort of heart transplanted patients published as a less resource demanding approach [32].
Besides these publicly available marker collections, a large selection of commercial kits are also
available, indicating the importance of the approach [33–37]. Combinations of DIPs and SNPs (a total
of 26 markers) were also tested with a genotype identification rate of 97% [38] and with another
set (a total of 29 markers) resulting an informativity of 97% [39]. The major advantage of DIPs is
the potential to use these markers in high sensitivity assay such as quantitative PCR or digital PCR
(see Section 3) to reliably detect microchimerism equally important in SOT and allo-HSCT.
2.4. Other Special Markers Used in Monitoring
Evidently, application of sex determining markers (e.g., SRY, AMELY, DFFRY, SMCY) are
only useful and informative in sex-mismatched transplanted patients both in allo-HSCT and SOT.
The amelogenin gene has an X and Y linked variant (AMELY and AMELX). The basis of variability
in this case is a 6-basepair-long deletion segment found in X chromosome (AMELX). Utilization of
Y specific markers, e.g., SRY, rely on the detection of a gene exclusively located on chromosome Y.
Both sex-specific markers are informative in allo-HSCT when the recipient is a male and the donor is
a female [2,40,41], while in SOT the expected situation is exactly the opposite. Similarly, RhD blood
group (which is a 58 kilobase-long DIP, i.e., RhD-negativity is equal to a complete deletion) is also
a straightforward choice in monitoring RhD positive allo-HSCT patients with RhD negative donor.
The opposite is applicable in SOT (an RhD negative recipient with an RhD positive donor) [13,42].
Besides these, another informative marker set is the HLA which information for both donor and
recipient is readily available prior to transplantation. Disparate HLA-markers were successfully used
to detect elevations in dd-cfDNA plasma concentrations associated with lung transplant complications.
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However, the major obstacle of the widespread use of this approach may be the need for the practically
individual detection probe design depending on the actual HLA-disparities between the donor and
recipient [43].
2.5. Guidelines for Marker Selection to Detect Clinical Chimerism
An ideal marker should be located in non-coding region ruling out the chance it is linked to
genetic diseases, plays a role as genetic susceptibility factor or influences certain disease progression
or response to therapy. It should be biallelic, differing by at least 2 basepairs, with a minimum allele
frequency of at least 0.25 and a high level of heterozygosity (>0.4). Their chromosomal localization
should be as distant as possible or on different chromosomes and they should also be located in
sufficient distance from repetitive regions [25,26]. When designing SNPs as markers, loci with C/T and
G/A polymorphisms are preferred to achieve more specific allele discrimination [38]. The recommended
number of markers allowing sufficient informativity (>95%) for STR varies between 12 and 16, while for
DIPs and SNPs a larger set is required (up to 52 markers). For follow-up diagnostics, more than
one marker is recommended to avoid false negative results e.g., due to allele-dropout during the
polymerase chain reaction (PCR) or due to the deletion of chromosomal region of the chosen marker in
hematological malignancies [9,37]. Loss of chromosome Y was observed not only in hematological
malignancies, but also in aging healthy males.
3. Comparison of Microchimerism Detection Techniques
As allo-HSCT became widespread, an imperative need arose to repeatedly discriminate recipient
and donor cells in the circulation after allo-HSCT for which various techniques have been developed.
Initially, these approaches had limited sensitivity in the range of 10% recipient cells allowing only
to characterize chimerism and not microchimerism. The most commonly used chimerism-detection
methods in this time period were XY fluorescence in-situ hybridization and polymerase chain reaction
(PCR) based amplification of variable number of tandem repeats (VNTR) or short tandem repeats
(STR). The PCR-based technologies more recently predominantly use fragment analyses (FA) making
it possible reach a sensitivity range of 1% still unsuitable for the reliable detection of microchimerism
(see the detailed review of Clark et al. [9]). Systematic comparison of three most widely used
microchimerism detection technologies with reference to the gold-standard chimerism detection
technique, fragment analysis is shown in Table 1.
Table 1. Comparison of chimerism/microchimerism laboratory detection techniques.
Technique Fragment Analysis # qPCR dPCR NGS
Targeted Genetic Variant limited number ofmultiallelic markers (STR)
limited number of biallelic
markers (SNP, DIP)




Limit of Detection >1% 1–0.01% 1–0.01% 1–0.01%
TAT short shortest short longer
Equipment Cost considerable relatively lower considerable considerable
Allo-HSCT Marker




















low no. of variants
dependent on DNA
concentration;





# Fragment analysis has been used for the longest time albeit due to its low sensitivity it is not suitable for
microchimerism detection. * Minimum number of markers for allo-HSCT follow-up. Abbreviations: dPCR: digital
PCR; DIP: deletion insertion polymorphism; HSCT: hematopoietic stem cell transplantation; MRD: measurable
residual disease; NGS: next generation sequencing; qPCR: real time quantitative PCR; SNP: single nucleotide
polymorphism; STR: short tandem repeat; TAT: turnaround time.
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3.1. Real-Time Quantitative PCR (qPCR)
To increase the sensitivity of chimerism monitoring in transplanted patients, several studies
proposed real-time quantitative PCR (qPCR) method to detect single nucleotide polymorphisms
(SNPs) or short deletions/insertions (DIP). QPCR allows 0.1% sensitivity quantification of the minor
genotype [12,25,28,37,38,44]. The vast majority of studies employ TaqMan technology requiring a
hybridization probe labeled with two different fluorescent dyes: a reporter (FAM), and a quencher
(TAMRA). When the probe is intact, fluorescent energy transfer occurs and the reporter fluorescence is
readily absorbed by the quencher. In case of precise hybridization of the probe to its target, during the
extension phase of the PCR cycle, the 5’-3’ exonuclease activity of the DNA-polymerase cleaves the
TaqMan probe and releases the reporter dye, resulting in an increase of the reporter dye fluorescent
signal [45]. Probes can be labeled with alternative, distinguishable reporter dyes allowing duplexing
in a single reaction. The disadvantage of the qPCR technique is the requirement of labor-intensive
optimization and the need for replicates (duplicates, triplicates) in each run for each target to provide
the most accurate result [12,25].
3.2. Digital PCR (dPCR)
Digital PCR has initially been used to quantify low-copy number fetal DNA in maternal plasma [46].
This innovative approach is based on partitioning of the PCR in multiple nanoliter chambers or
droplets, and after the amplification, each chamber/droplet is counted positive or negative for a specific
polymorphism [47]. With increasing the number of partitions (e.g., performing replicates), sensitivity
of the test can be improved. A further innovation of this technique, droplet digital PCR (ddPCR),
is easily automated and does not require a dedicated PCR machine. In contrast to qPCR which allows a
real time approach, dPCR is an end-point assay with the determination of the positive droplet fraction
and Poisson statistics calculating the absolute number of starting copies making calibration curves
unnecessary [47,48]. Due to the simultaneous presence of reference amplification in each reaction
during dPCR, as well as a consequence of unprecedented precision, replicates are not needed in cases
with target concentrations above the limit of detection. This method is less sensitive to inhibitors
than fragment analysis or qPCR. The technique is highly suitable for the detection of rare events in
the presence of high background. Performing the quality control test on artificial chimerism mixture
samples Mika et al. found high correlation between the estimated and the observed percentage values
for two discriminating markers. The standard deviation of the four-time repeated measurements of a
dilution series with one discriminating marker ranged from 1.8% to 3.7%. Comparing dPCR to the
‘gold-standard’ STR by fragment analyzes indicated good agreement between these two techniques in
the detection range of 83–100% of donor chimerism [49]. The limit of detection of dPCR was estimated
to be as low as 0.008% allowing the reliable determination of microchimerism. Additionally, assay
precision was acceptable also in ranges of microchimerism, with a variation coefficient of 16% at 1:999
dilution [36]. The dPCR technique proved to be more sensitive in detection of relapse after allo-HSCT
compared to qPCR [35]. Similarly to allo-HSCT, dPCR has also been widely used in the context of
SOT to detect dd-cfDNA in combination with DIPs [32,50], SNPs [3], copy number variations [51],
or HLA-disparities [17,18,43,52].
3.3. Next Generation Sequencing (NGS)
Next generation sequencing (NGS) is a massively parallel or deep sequencing, where millions
of small fragments of DNA are sequenced in parallel affording an unprecedentedly high sensitivity.
Sequenced fragments are pieced together by mapping individual reads to the human reference genome
by bioinformatic tools. Several different NGS platforms exist with different chemistries and techniques.
NGS can be used to sequence individual genes, targeting the whole exome or even the entire genome [53].
This technique is more sensitive than fragment analysis (0.01% to 1% vs. >1%). Compared to STR
by fragment analyzes, NGS showed an excellent correlation [54,55]. The unprecedented capacity of
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NGS allows the simultaneous typing of large marker sets, predominantly SNPs, which has frequently
been used to perform dd-cfDNA detection in various SOT settings. The large number of SNP markers
applied clearly gives an unprecedented opportunity to distinguish two genomes, even in cases of
unavailable donor pre-transplant DNA sample or in cases with multiple numerical chromosomal
abnormalities. The main advantage of NGS is that it is applicable for simultaneous determination
of chimerism or microchimerism as well as multiple disease specific markers to detect measurable
residual disease (MRD). However, these techniques require substantial equipment background, reagent
cost, trained bioinformatics expertise, standardization, and currently they are not always characterized
with sufficiently short turn-around time to readily influence clinical decision making. The described
approaches belonged either to non-commercially designed systems [17,18,52] or to commercially
developed platform with an unequivocal intent of routine clinical application [56–58].
4. Sample Types, Preanalytics, and Isolation of Cell Free DNA
The volume of blood required for cfDNA analysis is usually between 6 and 10 mL. Concentrations
in paired plasma and serum samples have revealed significantly higher cfDNA concentrations in serum
than in plasma [59]. This is due to leukocyte damage during clotting in the serum tube with a single
cell containing about 6 pg of DNA and adding up to 65 ng of DNA per mL of blood. As a consequence,
serum samples are not advised, instead plasma from anticoagulated (predominantly EDTA) blood
sample is used [60]. The use of tubes containing preservatives (PAXgene cfDNA tubes (Qiagen
PreAnalytiX GmbH, Düsseldorf, Germany), Roche/Ariosa cfDNA collection tubes (Roche Diagnostics
GmbH, Rotkreuz, Switzerland) and Streck BCT tubes (Streck Inc., Omaha, NE, USA, see [61]) to
prevent hemolysis and to reduce the degradation of cfDNA is becoming increasingly common practice
allowing an extended time to blood processing [62]. Interestingly, in the case of timely (up to 12 h
at room temperature) processing, there was no significant difference between cfDNA concentrations
in samples shipped in EDTA collection tubes versus samples shipped in cell-free DNATM blood
collection tubes [63,64]. Plasma preparation typically involves two rounds of centrifugation: a classical,
low speed centrifugation at 1000–2000 × g followed by a high speed centrifugation (16,000× g) [65].
In cases of a single centrifugation step at 800 × g, cfDNA concentrations were contaminated by genomic
DNA [66].
Two main types of cfDNA extraction systems have frequently been used: column-based systems
and magnetic beads systems. Studies comparing cfDNA extraction methods and kits revealed
substantial differences in total DNA yield [67]. cfDNA samples may withstand three freeze-thaw cycles
and storage at −20 ◦C. Storage time has no influence on specific sequences or mutations in cfDNA,
and mutations can be detected several years after freezing plasma samples, but cfDNA content is
decreasing with storage time, so quantification or characterization of cfDNA fragmentation, is preferred
within 3 months after the extraction procedure [68].
Quantitation of extracted cfDNA may be performed with several techniques such as
fluoro-spectroscopy, Qubit (Thermo Fisher Scientific Waltham, MA, US) fluorometry and qPCR.
In addition, quality control of isolated cfDNA can be performed by fragment analysis by capillary
electrophoresis. Based on fragment size, the relative amount of nucleosome-protected cfDNA fragments
with 140–160 base pairs can be compared to degradation-fragments with higher molecular weight
DNA [69,70]. Single-tube multiplex digital droplet PCR assays have also been described as alternative
approaches to measure amplifiable DNA concentrations and fragment size of small amounts of
cfDNA [62,71].
5. Role of Microchimerism in Solid Organ Transplantation
In the context of solid organ transplantations (SOT), the meaningful use of the term microchimerism
is only possible for cfDNA in the circulation since intact graft cells are unlikely to survive in blood.
Appearance of low amounts (usually less than 0.1%) of donor hematopoietic (passenger) cells in the
recipient’s circulation has been repeatedly observed after SOT and prompted speculations about a
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potential favorable role of these cells in graft acceptance. However, later clinical studies failed to
find consistent associations and this cell based microchimerism also showed large inter-individual
variations (see the excellent review by Eikmans et al. [1]).
After SOT, beside cells of donor origin, recently an increasing attention has turned towards
dd-cfDNA since upon immune-mediated, apoptotic, or necrotic cell damage, its amount increases.
This may then be translated to elevated levels of absolute amount or of relative proportions of
dd-cfDNA. Such changes may serve as sensitive surrogate biomarkers to monitor the health of the
transplanted organ (graft). This has outstanding significance as the overall frequency of graft related
post-SOT complications—i.e., rejection—immunosuppressive treatment mediated toxicity or infection
can reach 50% of all SOT cases [72]. For the timely alleviation of these complications (e.g., appropriate
adjustments of immunosuppressive therapies), systematic utilization of appropriate biomarkers
is essential. To this end, monitoring the health of the allograft by a diverse array of laboratory
parameters as well as therapeutic drug monitoring of immunosuppressive drugs has traditionally
been used to assist therapeutic decision making. In addition, monitoring and characterization of donor
specific antibodies (DSA) have recently gained increasing attention as the major causative factor of
antibody mediated rejection (ABMR). However, the direct translation of DSA-profile data into clinical
decision making has been challenging. It has been reported that up to 80% of patients with DSA
do not have ABMR and additional factors, such as type and strength of DSA, IgG subclass, and the
ability to bind complement, are important further determinants [73]. Besides the above-mentioned,
non-invasive monitoring options, graft biopsy procedures have traditionally represented the gold
standard for graft-damage evaluation which are invasive and costly, limiting their use in clinical
practice. A significant proportion of biopsies yield inadequate specimen and major complications
also occur relatively frequently. Furthermore, biopsy results are often compromised by expert reader
variance and can lead to delayed diagnosis of active rejection, after which irreversible organ damage
may have occurred [74].
Monitoring of dd-cfDNA in plasma as a non-invasive indicator of graft damage after SOT was
first suggested as early as in 1998 by the most outstanding expert of the field, Lo et al. [75] followed
by several early studies focusing on SOT [76–79]. At this stage, the techniques applied did not
readily allow the accurate detection of dd-cfDNA below 1% corresponding to true microchimerism.
In addition, restricted availability of suitable markers for donor vs. recipient distinction also hampered
cohort studies of larger consecutive series. With dramatic technical advancement (see Sections 2 and 3)
both, the sensitivity and the informative marker availability problem has been solved allowing the
completion of a number of cohort studies in various SOT settings. Studies on one hand attempted to
characterize the precise behavior of dd-cfDNA in the early phase of SOT as well as to establish reference
ranges documenting a sharp decline in the initial days and a proportion typically between 0.3% and
1.2% of total cfDNA in stable kidney transplant patients [16,19]. While for liver and transplants these
proportion values are somewhat higher [16]. On the other hand, the majority of studies addressed the
more exciting question namely how dd-cfDNA serves as a rejection biomarker. Several reviews have
summarized these studies [72,80–83]. Out of these, in their recent systematic review, Knight et al. [84]
published a large collection of relevant literature searches. However, no consistent distinction has
been made between conference abstracts and peer-reviewed in extenso publications making it difficult
to realize the number and extent of truly independent cohort studies. In addition, potential patient
overlaps between cohorts are also impossible to identify in this manner.
Thus, we performed a focused literature overview of exclusively peer-reviewed papers addressing
the potential role of plasma dd-cfDNA as a potential rejection marker in various SOT settings with an
inclusion criteria of total cohort size equaling or exceeding n = 50 for kidney or n = 20 for other solid
organs respectively. As shown in Table 2, a total of 15 studies met these criteria.
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Table 2. Selected cohort studies focusing on the potential role of dd-cfDNA in SOT of various organs.







1 kidney 2017 Bloom [56] Cedars-Sinai. LA, USA prosp biopsy 102 27
2 kidney 2018 Jordan [58] Cedars-Sinai. LA, USA retro biopsy 87 16
3 kidney 2018 Sigdel [18] UCSF, SF, USA retro consec 178 38
4 kidney 2019 Huang [57] Cedars-Sinai LA, USA prosp biopsy 63 22
5 kidney 2019 Whitlam [51] Melbourne, Australia prosp consec 55 13
6 heart 2011 Snyder [78] Stanford, USA retro consec 112 12
7 heart 2014 DeVlaminck [85] Stanford, USA prosp consec 65 n/a
8 heart 2016 Grskovic [17] CareDX, Brisb., USA retro consec 101 27
9 heart 2018 Ragalie [86] Wisconsin, USA retro biopsy 88 16
10 heart 2019 Macher [32] Sevilla, Spain prosp consec 30 13
11 liver 2017 Schütz [87] Gottingen, Germany prosp consec 107 17
12 liver 2019 Goh [50] Melbourne, Australia prosp consec 20 3
13 lung 2015 DeVlaminck [88] Stanford, USA prosp consec 51 n/a
14 lung 2018 Agbor-Enoh [89] Stanford, NIH, USA prosp consec 157 34
15 lung 2019 Agbor-Enoh [90] Stanford, NIH, USA prosp consec 106 n/a
* consecutive (consec): transplanted patients are consecutively included regardless of rejection; biopsy =
biopsy-linked: sampling parallels biopsy indicated by organ-failure. Legend: Original studies were included if the
cohort size equaled or exceeded n = 50 for kidney or n = 20 for other solid organs. Studies are listed according
to organ transplanted then according to year published. Abbreviations: n/a: not available; prosp: prospective;
retro: retrospective.
As an overall conclusion, significantly positive role was exclusively found across all organs for
plasma dd-cfDNA as allograft injury biomarker, no study was found concluding the lack of association.
In kidney transplant, the paramount prospective trial of Bloom et al. called “Circulating Donor-Derived
Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients” (DART)
had the strongest impact with subsequent positive decision about health insurance reimbursement in
the US. By using a cut-off value of 1.0% of dd-cfDNA these authors found that this biomarker had
stronger discriminating power between ABMR and absence of ABMR compared to cell mediated
rejection versus lack that of [56]. The biopsy-linked patient selection design allowed the enrichment of
patients with documented rejection episodes. Using essentially the same cohort additional aspects
were also examined by the same center such as the joint diagnostic characteristics of dd-cfDNA and
DSA [58] as well as biomarker performance details of dd-cfDNA with partial overlap with the original
study [57]. The relevant UCSF and Australian studies indeed represent independent confirmations,
albeit in smaller cohorts [18,51].
Heart transplant could be viewed as a pioneer of the field with an early study of a sizeable
cohort from Stanford taking advantage of a large biorepository also containing plasma, allowing the
selection more than a 100 sex-mismatched heart transplant cases [78] later confirmed in an independent
prospective cohort using the novel NGS-based technique [85]. Among the further confirmatory studies
a diagnostic method oriented study can be found by Grskovic et al. [17] as well as a pediatric heart
transplant cohort examined with proprietary diagnostic [86] and a Spanish study using an alternative,
technically less challenging diagnostic approach [32]. Regarding liver TX, besides an early case
report [91] and small prospective cohorts [50,92], a larger (n = 115) multicentric study demonstrated
significantly elevated dd-cfDNA levels in acute rejection compared to transplanted patients in stable
phase or those with hepatitis C infection [87]. Similarly, in the field of lung TX, besides a few smaller
studies, only the Stanford group was able to collect larger cohort after the initial study [85] with a
multicentric prospective trial indicating markedly elevated dd-cfDNA prior to graft-rejection proven
by biopsy [89] supplemented by a further study on essentially the same cohort [90].
Besides plasma, alternative test materials have also been used to monitor cfDNA after SOT.
Sigdel et al. observed rather large inter-patient variations of cfDNA in urine samples of a sizeable
(n = 61) kidney transplanted cohort with limited potential as a general diagnostic biomarker [93].
cfDNA was also measured in broncho-alveolar lavage (BAL) fluid after lung TX among 60 patients
along with the chemokine CXCL10 and the combination of these markers significantly predicted
allograft survival [52].
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The most important limitation of plasma dd-cfDNA monitoring is its lacking specificity for
rejection subtype, or specific histopathological alteration. However, due to its non-invasive character,
the potentially rapid laboratory turn-around time, the increasing accessibility and the continuously
decreasing cost, this approach may represent an early contributing diagnostic tool supplementing
available classical indicators.
6. Role of Microchimerism in Allogeneic Hematopoietic Stem Cell Transplantation
6.1. General Applications of Chimerism Monitoring in Allo-HSCT
Chimerism analysis (detection of the relative ratio of donor and recipient hematopoiesis) from
peripheral blood or bone marrow aspirates is a standard diagnostic procedure following allo-HSCT.
The replacement of recipient cells by those of the donor called complete donor chimerism is an
evidence for the successful engraftment and the reconstitution of hematopoiesis after allo-HSCT.
After myeloablative conditioning, residual recipient hematopoiesis may indicate graft failure and/or
persisting disease. Remaining or re-emerging recipient cells in the circulation, called mixed chimerism,
after transplantation is mostly associated with relapse in cases of hematopoietic malignancies, although
long term mixed chimerism without relapse has been described [94]. Persisting mixed chimerism is
reported to reduce the graft versus leukemia (GvL) effect of alloreactive donor T cells [95–97]. In case
of non-malignant disorders treated with non-myeloablative regimens, increasing mixed chimerism is
an indicator of graft rejection.
The dynamics of serial chimerism monitoring facilitates therapeutic interventions such
as modulation of immunosuppression, donor lymphocyte infusions, chemotherapy, or second
transplantation both in myeloablative and in non-myeloablative settings [95]. Early, individualized
interventions have the potential to balance between competing risks of graft failure, recurring disease,
and the potentially life-threatening graft versus host disease (GvHD).
Analysis of STRs by fragment analysis (FA) is the most widely accepted choice of method for
post-HSCT monitoring. Detailed recommendations are available for proper laboratory performance
of STR chimerism monitoring [9]. The major disadvantage of STR chimerism monitoring is its low
sensitivity (limit of detection: 1–5%). To circumvent this limitation, frequent monitoring (even weekly
before day 200 after allo-HSCT in pediatric acute lymphoblastic leukemia), performing the analysis
in subpopulations for the detection of lineage specific split chimerism are recommended, as acute
leukemia relapse can occur within a relatively short time frame [98].
Chimerism monitoring provides a surrogate biomarker for tumor-specific measurable residual
disease (MRD). Chimerism testing is suggested to be applied in combination with MRD monitoring
in malignant hematopoietic diseases [99,100]. In several clinical settings, MRD assay is not available
(due to the lack of identified disease specific somatic mutation) or clonal heterogeneity, in these cases
chimerism testing remains the only follow-up marker after allo-HSCT.
6.2. Relevance of Microchimerism Monitoring in Allo-HSCT
In recent years, the sensitive detection of MRD (reaching at least 0.1% or deeper limit of
detection) gained increasing attention, as patients with MRD-positive morphologic remission showed
similar outcome to patients with active disease [99,101]. Introducing sensitive techniques like qPCR
or dPCR enabled the reliable detection of microchimerism, which is defined as the presence of
recipient cells below 1% in the circulation. Initially, this sensitivity was not a requirement for
chimerism detection [102]. Earlier, the clinical utility of microchimerism detection after allo-HSCT was
controversial and limited [39]. Low levels of undulating microchimerism might have been detected for
years after allo-HSCT, which may not have been necessarily related to relapse. Studies focusing on
the potential advantages and the clinical utility of sensitive chimerism detection are summarized in
Table 3.
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Several papers indicated that the dynamics of microchimerism was more closely correlated with
relapse in acute leukemia. The reappearance of recipient DNA after complete donor chimerism is
a warning sign, and increasing recipient chimerism in two consecutive samples reliably forecast
relapse [28,103]. Stable or decreasing microchimerism levels might not indicate relapse. In acute
leukemia, several lines of evidence regarding allo-HSCT chimerism monitoring suggest that sensitive
methods (e.g., qPCR, dPCR) are superior compared to classic STR-fragment analysis in the prediction
of hematological relapses: (i) the ratio of detected/all relapses for DIP/qPCR was 70–100% vs. 13–44%
for STR/fragment analysis; (ii) the time difference in favor of DIP/qPCR vs. STR/fragment analysis was
26–90 days [13,27,34,44,96,104,105]. At the same time, the lack of recipient genotype in highly-sensitive
chimerism analysis excludes the possibility of relapses with high certainty [28,103]. Systemic infections,
especially virus infections, and acute GvHD were also variably associated with a slight increase
in host microchimerism. Leukemia relapse is usually associated with a rapid expansion of host
hematopoiesis [34,103,106].
Dynamics of chimerism also influence survival: complete donor and decreasing mixed
chimerism present favorably, while increasing and stable mixed chimerism have adverse prognostic
significance [105,107]. Recent studies indicated that not mixed chimerism, but also microchimerism after
allo-HSCT show adverse overall survival compared to complete donor chimerism (mixed chimerism
p < 0.0002; microchimerism p = 0.0201). The introduction of sensitive chimerism monitoring allows
early detection of recipient hematopoiesis, early intervention, and the decrease of patients proportions
with mixed chimerism above 1% (23% before and 15% after the introduction of sensitive chimerism
test) [94].
Mixed chimerism, and also microchimerism, were found to strongly correlate with
MRD-monitoring inasmuch, both biomarkers show similar time-course, when analyzed from the same
sample type [29,96,100]. As a conclusion, chimerism including microchimerism monitoring is a reliable
indicator of incipient acute myeloid leukemia (AML) relapse, especially in patients where no other
specific molecular marker is available, which might affect up to 50% of allo-HSCT cases [34]. In case
of chimerism monitoring, the lack of identifiable marker or subclonal heterogeneity do not alter the
results however, cytogenetic alterations in the malignant clone resulting in the loss of the recipient
allele carrying the respective marker may cause a false negative chimerism result.
Table 3. Potential advantages and clinical applicability of sensitive microchimerism detection in
allo-HSCT based selected papers.
First Author Year Country n Marker * Clinical Utility of Microchimerism Detection
Jiménez-
Velasco [13] 2005 Spain 61 VNTR, DIP
qPCR superior to FA in relapse prediction:
88% vs. 44%, 20 days prior FA;
rising host chimerism kinetics in relapse
Koldehoff




qPCR superior to PAGE in relapse prediction:
90 days earlier; adverse overall survival in rising
kinetics;
SRY qPCR superior to XY FISH in relapse
prediction:
86% vs. 28%, 143 days prior relapse
Wiedermann
[107] 2010 Germany 75 DIP, SRY rising host chimerism kinetics in relapse
Chen
[27] 2011 Taiwan 126 STR, DIP qPCR superior to FA in relapse prediction
Horky [96] 2011 Czech 46 STR, DIP qPCR superior to FA in relapse prediction:87% vs. 39%, 26 days prior FA.
Bach [44] 2015 Germany 16 STR, DIP qPCR superior to FA in relapse prediction: 95days earlier
Jacque [28] 2015 France 85 DIP
stable qPCR complete chimerism = negative
predictor for relapse; rising host chimerism
kinetics in relapse
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Table 3. Cont.
First Author Year Country n Marker * Clinical Utility of Microchimerism Detection
Vicente [106] 2016 Brazil 41 DIP early rising host chimerism kinetics in relapse
Ahci [34] 2017 Germany 30 STR, DIP
qPCR superior to FA in relapse prediction:
100% vs. 38%, 6 months prior relapse;
rising or sustained host chimerism kinetics in
relapse
Waterhouse
[108] 2017 Germany 155 STR, SRY
dPCR superior to FA in relapse prediction: 90
days earlier
Cechova [94] 2018 Czech 474 STR, DIP adverse overall survival in microchimerismcompared to complete donor chimerism
Sellmann
[103] 2018 Germany 71 DIP
stable qPCR complete chimerism = negative
predictor for relapse; rising host chimerism
positive predictor for relapse
Waterhouse
[29] 2018 Germany 70 DIP, MRD similar kinetics for chimerism and MRD
Tyler
[37] 2019 USA 230 STR, DIP
combined STR-FA and DIP-qPCR in diagnostic
algorithm;
qPCR is more sensitive than FA
Valero-Garcia
[35] 2019 Spain 28 DIP dPCR superior to qPCR in relapse prediction
* STR, VNTR markers were tested with FA or PAGE; DIP, SNP, and SRY were tested with qPCR or dPCR. Legend:
Original in extenso studies were included if clinical outcome of allo-HSCT (relapse, survival measures) was indicated
in connection with chimerism levels below 1%. Studies are listed according to year published. Abbreviations: DIP:
deletion-insertion polymorphism; FA: fragment analysis; FISH: fluorescence in situ hybridization; MRD: measurable
residual disease; PAGE: poly-acrilamid gel-electrophoresis; qPCR: quantitative polymerase chain reaction; SNP:
single nucleotide polymorphism; SRY: sex determining region Y; STR: short tandem repeat; VNTR: variable number
tandem repeat.
6.3. Special Applications of Microchimerism Monitoring in Cellular Therapies
In hematology practice, special cellular therapies are becoming more and more frequent treatment
options: examples are ‘microtransplantation’ in elderly AML patients, natural killer (NK) cell infusion
or third-party donor antigen-specific T-cell infusions (virus specific T cells, VST) [109]. As these
allogeneic cellular therapies are not intended to achieve durable engraftment, they frequently result in
microchimerism not detectable with standard STR-based monitoring.
In a randomized, multicenter study of elderly AML patients, induction chemotherapy in
combination with mobilized HLA-mismatched donor cells without GvHD-prophylaxis improved
response rates with a low rate of mixed or complete donor chimerism (5/185) and severe acute GvHD
(2/185). Microchimerism was detectable in 31% (8/26) sex-mismatched, informative transplants by
SRY-qPCR (with up to 10 months follow-up) [110]. Microtransplantation was found to be inferior to
HLA-matched sibling donor transplantation in allo-HSCT eligible patients for intermediate/high-risk
AML in complete remission [111], but a case report described its utility as salvage therapy in refractory
AML [112]. Haploidentical natural killer cell therapy is a safe and feasible therapeutic option in pediatric
relapsed or refractory leukemia [113]. Adoptive transfer of VST cells aim to restore T-cell immunity
and cure allo-HSCT patients with refractory, life-threatening viral infections like cytomegalovirus,
Epstein–Barr virus, or adenovirus [114]. Kliman et al. described an ultrasensitive dPCR method capable
to detect donor microchimerism after cellular therapies such as microtransplantation or VST [36].
6.4. Cell-Free DNA Chimerism Following Allo-HSCT
Plasma cfDNA markers as diagnostic applications have been intensively studied in the context of
prenatal screening, solid tumors and SOT. The clinical usefulness of chimerism testing from plasma
cfDNA in allo-HSCT has been sparsely reported. Initially, sex-mismatched allo-HSCT patients were
screened to reveal the main cellular origin of plasma circulating cfDNA. Y-chromosome specific cfDNA
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was detected in plasma with a median of 6.9% in male patients with female donors, indicating the
hematopoietic compartment as the main origin of plasma cfDNA [2].
Plasma cfDNA was found to be more sensitive than cellular chimerism in detecting relapse in
leukemia patients with complete donor chimerism in polymorphonuclear cells. All patients with
clinical relapse (16/84, 19%) had more than 10% of recipient cfDNA in the plasma. Altogether 60% of
patients displayed various levels of mixed chimerism in plasma, including an additional 16 patients
with >10% mixed chimerism level and without clinical relapse [115].
A further study indicated that mixed chimerism was detectable in cfDNA in a higher percentage
of samples than in peripheral blood cells after allo-HSCT. Interestingly, plasma cfDNA-based
microchimerism was capable of detecting isolated extramedullar relapses (central nervous system,
n = 3), when in peripheral blood cells complete donor chimerism was observed [116]. Recipient derived
cfDNA was elevated not only in relapse, but also in transplant related complications, especially in
acute GvHD (aGvHD). The improvement of aGvHD symptoms during therapy coincided with the
decrease in recipient cfDNA, in contrast, the lack of aGvHD amelioration was associated with stable
or increasing levels of recipient cfDNA. This association suggested that recipient cell disruption in
GvHD target organs can be a source of cfDNA. No correlation was found between mean recipient
cfDNA percentage and aGvHD severity (grade I–II compared to grade III–IV), but organ specific
involvements have not been described. Chronic GvHD (cGvHD) did not show an association with
plasma cfDNA-based mixed chimerism in affected patients [116]. Plasma cell free mitochondrial
DNA (mtDNA) was reported to be elevated in allo-HSCT patients. As an endogenous inflammatory
signal, cell free mtDNA may activate a B-cell subset responsible for extensive cGvHD: the onset of
cGvHD was accompanied with significantly elevated levels of plasma cell free mtDNA in patients
with cGvHD [117].
7. Future Perspectives
In the context of SOT, additional independent, sufficiently large cohort studies are needed to
further confirm the diagnostic value of microchimerism characterized by dd-cfDNA proportion in
plasma. A further goal of these studies can be the targeting patients with subclinical graft damage for
which currently the only diagnostic tool is the invasive organ biopsy. Applicability of dd-cfDNA based
microchimerism detection as valuable information in the clinical decision-making process regarding
actual immunosuppression should also be tested in a prospective setting. Routine application and
comparisons of alternative detection techniques may also be attractive for future research since a
considerable number of transplantation diagnostic facilities may not have access to the most advanced
NGS-based determinations.
Although it is not widely accepted yet, monitoring of recipient cfDNA dynamics after allo-HSCT
may be a valuable diagnostic tool to detect relapses at earlier time points, with special emphasis
on extramedullary sites. Additionally, it can be utilized as a non-invasive biomarker for aGvHD
activity. Further studies involving larger patient cohorts, as well as applying more sensitive methods
than STR are necessary to address existing uncertainties regarding cfDNA chimerism testing in the
allo-HSCT field.
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Abstract: Ovarian cancer is one of the most common cancer types in women characterized by a
high mortality rate due to lack of early diagnosis. Circulating miRNAs besides being important
regulators of cancer development could be potential biomarkers to aid diagnosis. We performed the
circulating miRNA expression analysis in plasma samples obtained from ovarian cancer patients
stratified into FIGO I, FIGO III, and FIGO IV stages and from healthy females using the NanoString
quantitative assay. Forty-five miRNAs were differentially expressed, out of these 17 miRNAs showed
significantly different expression between controls and patients, 28 were expressed only in patients,
among them 19 were expressed only in FIGO I patients. Differentially expressed miRNAs were
ranked by the network-based analysis to assess their importance. Target genes of the differentially
expressed miRNAs were identified then functional annotation of the target genes by the GO and
KEGG-based enrichment analysis was carried out. A general and an ovary-specific protein–protein
interaction network was constructed from target genes. Results of our network and the functional
enrichment analysis suggest that besides HSP90AA1, MYC, SP1, BRCA1, RB1, CFTR, STAT3, E2F1,
ERBB2, EZH2, and MET genes, additional genes which are enriched in cell cycle regulation, FOXO,
TP53, PI-3AKT, AMPK, TGFβ, ERBB signaling pathways and in the regulation of gene expression,
proliferation, cellular response to hypoxia, and negative regulation of the apoptotic process, the GO
terms have central importance in ovarian cancer development. The aberrantly expressed miRNAs
might be considered as potential biomarkers for the diagnosis of ovarian cancer after validation of
these results in a larger cohort of ovarian cancer patients.
Keywords: ovarian cancer; circulating miRNA; blood plasma; NanoString; network analysis;
biomarker
1. Introduction
Ovarian cancer (OC) is one of the most frequent gynecological malignancy among women. Despite
recent progress that has been made in the treatment of patients, OC is still characterized by a high
mortality rate. It is the fifth leading cause of cancer-induced death in females in the world; the overall
five-year survival rate is still only 15%–30% according to recent reports [1–3]. The high mortality is at
least partially due to the difficulties of early detection of the tumor. The routine diagnostic procedures
Int. J. Mol. Sci. 2019, 20, 4533; doi:10.3390/ijms20184533 www.mdpi.com/journal/ijms116
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(pelvic examination, transvaginal ultrasonography, CA125 antigen measurement) carried out in clinics
are not suitable for early diagnosis [4–7]. During recent years several groups investigated the possibility
of using circulating miRNAs as candidate biomarkers for diagnosis in several different human cancers,
among them in OC. In addition to their diagnostic potential, the involvement of circulating miRNAs in
tumor formation might be an equally important topic to study [8–10].
MiRNAs are endogenously expressed, short (~22 nucleotides) non-coding single-stranded
regulatory RNA molecules, known to interfere with the translation of the mRNA coded by the
target genes. MiRNAs are negative regulators of gene expression, upon their sequence-specific binding
to the 3′-UTR region of mRNAs, they can repress the translation of target mRNA or facilitate its cleavage
and elimination [11]. MiRNAs are promiscuous post-transcriptional regulators, due to their short
“seed” sequence, a miRNA can interact with a large number of mRNAs, that way miRNAs are involved
in the regulation of almost all important cellular, developmental, and pathological processes [12]. It is
well established that miRNAs are present and can be reliably detected in blood plasma since these
circulating miRNAs are very stable, which is the result of their packaging into vesicles or interaction
with proteins that protect miRNAs from RNase digestion. These features could make them not only
ideal candidates for non-invasive plasma-based biomarkers but also regulatory factors contributing to
tumor progression [7,13].
Circulating miRNAs could be released from cells through an active, regulated secretion process
packaged into exosomes or microvesicles [14]. Exosomes were shown to be involved in intercellular
communication since they carry various bioactive molecules, among them miRNAs [7,15]. Exosomes
can interact, fuse with the membrane of cells, and deliver their cargo to recipient target cells and
thus modify their gene expression pattern [16–21]. Exosomes are considered as part of the tumor
environment playing important roles in pre-metastatic environment formation, tumor progression,
epithelial-to-mesenchymal transition, and the modulation of immune regulation [14]. MiRNAs could
be secreted from cells via binding to protein containing complexes like AGO2 or HDL. Although the
functional role of circulating miRNAs is still largely unknown, it is known that the dysregulation
of miRNA expression and the presence of circulating miRNAs have been linked to the formation of
cancer among them OC, as well [7,10,22]. It was shown that miRNAs could be oncomiRs or tumor
suppressors, however this categorization is not straightforward, due to their extensive palette of target
genes the same miRNA could play opposing roles in different processes [23].
Several differentially expressed miRNAs were found in the plasma of OC patients, like members of
the miR-200 family, miR-141, miR-125b, miR-222-3p or Let-7 among others [14,24,25]. Despite the large
number of reports no consensus regarding the circulating miRNA signature has been suggested so far,
which would unambiguously distinguish OC patients from healthy individuals and an explanation of
their potential biological significance in OC is still not clarified completely. The fact that ovarian cancer
cells are rarely disseminated through the vasculature makes the interpretation of the pathophysiological
role of circulating miRNAs difficult [1,15,26].
The aim of this study was to analyze the circulating miRNA expression profile in serous epithelial
OC patients and compare it to that of healthy individuals in order to contribute to the growing body of
data available to establish a useful miRNA set for OC diagnosis obtained by the non-invasive liquid
biopsy. We attempted to identify the miRNA expression profile, which is specific for tumor samples.
We have also aimed to investigate the possible involvement of circulating miRNAs in OC development
by analyzing the biological importance of miRNA targets and by the functional enrichment profile of
their target gene set.
2. Results
2.1. Expresion Levels of miRNAs in Plasma Samples of Ovarian Cancer Patients and Healthy Controls
In order to compare the plasma miRNA expression profile between healthy females and OC
patients, 18 patients and six healthy control females were recruited in the study. The age range of the
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patients was from 43 to 75 years with a mean age of 58.3 year, the same values for controls were 59.2
ranging from 62 to 71. The clinical stage and tumor subtype were established for patients and based on
their immunohistochemical analysis all patients belong to the serous epithelial ovarian cancer group.
Patients were stratified into FIGO I, FIGO III, and FIGO IV stages according to the recommendations
of the International Federation of Gynecology and Obstetrics. Six patients from each group were
included in the study together with six healthy females and their plasma samples were collected for
RNA extraction and miRNA analysis. The demographic and clinical data of the patients are shown in
Supplementary Table S1. Plasma miRNA profiles were determined by using the nCounter Human
v3 miRNA Panel of NanosString nCounter Analysis System (NanoString Technologies). Normalized
counts differed considerably for miRNAs and individuals, however, most miRNA counts were low,
especially in controls, with few exceptions. Hsa-miR-451a had the highest count with group mean
values ranging from 1217 up to 3392, followed by hsa-miR-4454 and hsa-miR-499a-5p (group mean
values: Between 36 and 89; 56 and 123, respectively). None of these highly expressed miRNAs showed
significantly different expression among the cohorts. It might be important to note that the miRNA
counts were the highest in samples of FIGO I stage patients.
Altogether 45 out of the 798 unique miRNAs showed significant differences in counts between
tumor and normal plasma samples. Among them, 17 miRNAs showed significantly different expressions
between controls and patients (Group 1 miRNAs). The rest, 28 miRNAs were expressed only in
patients, 19 out of 28 were found only in FIGO I stage samples (Group 2 miRNAs) and nine were
present in all FIGO stages (Group 3 miRNAs) (Table 1).
Table 1. List of microRNAs (miRNAs) showing significantly different expression patterns among
controls and the three ovarian cancer (OC) patient groups.
Group 1 1 Group 2 Group 3




















1 Group 1: Significantly differentially expressed miRNAs. Group 2: MicroRNAs expressed only in FIGO I stage
patients. Group 3: MicroRNAs expressed only in patients, but in all stages.
In Group 1 samples, the fold changes between the stage specific mean expression values were
calculated for all miRNAs showing that 16 miRNAs were upregulated and hsa-miR-584-5p was
downregulated in this group (Figure 1a). Typically, the largest fold change was found between
the control and FIGO I stage expression values for most of the significantly differentially expressed
miRNAs. Hierarchical clustering of the differentially expressed circulating miRNAs showed a distinct
expression pattern between the three groups (Figure 1b).
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Figure 1. (a) Stacked bar chart showing the fold changes between the stage specific expression of the
significantly differentially expressed miRNAs. (b) Heat map of the differentially expressed circulating
miRNAs. The expression cluster shows upregulated miRNAs in deeper color according to the scale on
the right of the figure. S1 represent controls, S2, S3, and S4 represent the FIGO I, FIGO III, and FIGO IV
samples, respectively.
2.2. Validation of Differentially Expressed Group 1 miRNAs by RT-qPCR
To validate our findings, six Group 1 miRNAs (hsa-miR-19b-3p, hsa-miR-25-3p, hsa-miR-26b-5p,
hsa-miR-144-3p, hsa-miR-148b-3p, and hsa-miR-301a-3p) were randomly chosen together with
hsa-miR-197, which did not show differential expression between the groups. The relative expression
of these miRNAs was determined by RT-qPCR measurements using hsa-miR-103-3p as the reference
miRNA. Expression of all six Group 1 miRNAs was significantly upregulated compared with those in
the control samples, while the expression of hsa-miR-197 did not show significant difference between
the groups (the Kruskal–Wallis p-values were the following: hsa-miR-19b-3p: 0.03572; hsa-miR-25-3p:
0.0071; hsa-miR-26b-5p: 0.0096; hsa-miR-144-3p: 0.01828; hsa-miR-148b-3p: 0.00014; hsa-miR-301a-3p:
0.01078; hsa-miR-197: 0,741) (Figure 2). Considering the perfect positive agreement between the results
obtained with the nCounter Human v3 miRNA Panel and PCR measurements, the RT-qPCR method
validated our results.
2.3. MIRNA Ranking, Target Gene Prediction and Analysis
To study the possible functional role of circulating miRNAs, the differentially expressed miRNAs
and their targets were analyzed. The fact that a single miRNA has several target mRNAs and translation
of a mRNA can be regulated by several miRNAs warrants a network-based analysis of the miRNA
function. First, the miRNet tool was used to predict miRNA targets and interactions between miRNAs
and targets in order to determine the importance of miRNAs in the network. The interaction networks
were constructed separately for the three groups of miRNAs. Table 2 shows the lists of miRNAs ranked
by their degree centrality value (betweenness centrality provided the same ranking) that represent
the importance of given miRNAs in the interacting network. (The complete networks are shown in
Supplementary Figure S1a–c)
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Figure 2. Validation of six randomly chosen significantly differentially expressed Group 1 miRNAs
using the RT-qPCR measurement. Expression levels of plasma miRNAs were compared between
ovarian cancer patients and control females. Total miRNA was isolated from plasma samples and the
amounts of mature hsa-miRNAs was determined by the miScript PCR System. The expression of PCR
products was normalized to hsa-miR-103-3p and relative miRNA expression levels were determined by
the 2-ΔCt method. All measurements were done in triplicate. Data distribution was analyzed by the
Kruskal–Wallis one-way ANOVA test with Dunn’s post-hoc analysis, p-values shown in the figure are
as follows: *: P < 0.05; **: P < 0.01.
To demonstrate and visualize the most important miRNA–target interactions, we have constructed
core miRNA–target networks to show the strongest interactions among the differentially expressed
miRNAs and target genes by the mirTargeLink tool (Figure 3). Just like in the miRNet network,
hsa-miR-19b-3p, hsa-miR-26b-5p, hsa-miR-25-3p, and hsa-miR-301a-3p have central importance in the
core network of Group 1 miRNAs. Their targets, PTEN, EZH2, KAT2B, BCL2L11, TP53, SMAD4, and
ERBB2 are known to be involved in tumorogenesis (Figure 3A).
Among Group 2 miRNAs, hsa-miR-23a-3p, hsa-miR-498, hsa-miR-331-3p, and hsa-miR-625-5p
have central importance. Hsa-miR-23a-3p targets HMGN2, FOXO3, PPP2R5E, LDHA, and
ATAT1. Hsa-miR-498, hsa-miR-331-3p, and hsa-miR-625-5p have two common targets, the tumor
suppressor FHIT gene and the proto-oncogene ERBB2 (Figure 3B). In the third miRNA group
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(Group 3) hsa-miR-223-3p and hsa-miR-497-5p have a central role. Their common target IGF1R
is a proto-oncogene, which is highly expressed in several tumor cells, CDK4 and CDC25A are
proto-oncogenes (Figure 3C) [27–30].
Table 2. Ranking of the differentially expressed miRNAs based on their degree centrality values in the
miRNet network.
Group 1 Group 2 Group 3
miRNA ID Degree miRNA ID Degree miRNA ID Degree
hsa-mir-26b-5p 1874 hsa-mir-331-3p 406 hsa-mir-497-5p 461
hsa-mir-19b-3p 714 hsa-mir-520g-3p 404 hsa-mir-125a-3p 310
hsa-mir-25-3p 518 hsa-mir-149-5p 397 hsa-mir-548h-3p 292
hsa-mir-1976 501 hsa-mir-498 320 hsa-mir-1305 195
hsa-mir-148b-3p 403 hsa-mir-23a-3p 249 hsa-mir-1281 180
hsa-mir-301a-3p 395 hsa-mir-625-5p 227 hsa-mir-500a-5p 145
hsa-mir-144-3p 211 hsa-mir-4455 165 hsa-mir-223-3p 98
hsa-mir-513a-3p 187 hsa-mir-1185-1-3p 117 hsa-mir-325 32
hsa-mir-552-3p 167 hsa-mir-3161 115 6
hsa-mir-146b-5p 121 hsa-mir-409-3p 111
hsa-mir-615-5p 70 hsa-mir-1197 74
hsa-mir-584-5p 67 hsa-mir-584-5p 67
hsa-mir-219a-2-3p 63 hsa-mir-590-5p 66





In addition to using miRNet, the TargetScan and miRTarBase databases were also used to predict
target genes of the differentially expressed miRNAs, only experimentally validated targets were chosen
from all three databases (Supplementary Table S2). In order to assess miRNA expression patterns in
OC, we further analyzed our data to recognize common patterns of targets among the different samples
to focus our analysis on their similarities. Intersections of common targets of the three differently
expressed miRNA groups revealed 54 miRNA targets that were simultaneously differentially targeted
by the different miRNA groups. Of these targets, we identified five genes that were targeted by all
three miRNA groups. Figure 4 and Table 3 show the intersections of common targets of the three









Figure 3. The core networks of differentially expressed miRNAs and their experimentally validated
target genes. Group 1, Group 2, and Group 3 miRNAs and their interacting targets are represented in
part A, B, and C, respectively. The networks were generated by the mirTargeLink tool using the strong
interaction option. Isolated networks are also shown in the figure. Color code: Orange, more than two
interactions; blue, two interactions in the full network.
122
Int. J. Mol. Sci. 2019, 20, 4533
Figure 4. Venn diagram showing the common targets of the three differentially expressed miRNA
groups. The SDE, FI, and FI-IV labels represent Group 1, Group 2, and Group 3 miRNAs, respectively.
SDE: significantly differentially expressed miRNAs; FI: miRNAs expressed in FIGO I stage patients;
FI-FIV: miRNAs expressed in all patients.
Table 3. Shared targets of the three differentially expressed miRNA groups.
Compared Groups Common Targets Genes
Gr1/Gr2/Gr3 5 MET SMAD7 EZH2 TERT IL6
Gr2/Gr1 18 TLR4 MTOR IGF1 ZEB1 SOX4 PTBP2 BIRC5 CCNE1 RHOB MMP16IGF1R MYC PXK SOCS1 PBX3 PRKAA1 CFTR FBXW7
Gr1/Gr3 21
ROCK1 KCNJ6 PTEN TGFBR2 HOTAIR PLEKHA1 ERBB2 FGA
CDH1 PPP2R5E FGG IRS1 RECK DDX3X FGB HLA-G WWP1 RB1
TCEAL1 HSP90AA1 ZFX
Gr2/Gr3 10 GIT1 NPM3 BRCA1 CHUK STAT3 SP1 FOXO3 VEGFA E2F1 MEF2C
In Table 3, the HOTAIR lncRNA is also present as the target of miRNAs. This is not the
only identified lncRNA target, significantly differentially expressed miRNAs interact with XIST,
HOTAIR, MALAT1, NEFL, KCNQ1OT1, and CTA-204B4.6, as major lncRNA hubs in the network
(data not shown).
2.4. Pathway and Gene Ontology Enrichment Analysis of miRNA Targets
To obtain a more precise understanding of the potential pathophysiological role of the differentially
expressed miRNAs in the OC development, a functional annotation and enrichment analysis of their
target genes in the gene ontology biological process (GO-BP) terms and in canonical pathways (in
the KEGG database) was performed using the database for annotation, visualization, and integrated
discovery tool (DAVID) [31]. Our analysis resulted in a large number of enriched functional categories
(pathways and GO terms, too), some of them very general including a large number of target genes
such as hsa05200:Pathways in cancer, hsa05206:MicroRNAs in cancer, hsa04110:Cell cycle; or for the
GO-BP terms: GO:0000165~MAPK cascade; GO:0045944~positive regulation of transcription from RNA
polymerase II promoter; GO:0043066~negative regulation of apoptotic process or GO:0008283~cell
proliferation. We have ranked the categories according to the significance of target enrichment and the
top 25 KEGG pathways and GO-BP terms are shown in Supplementary Table S3. Several cancer types
(glioma, prostate cancer, chronic myeloid leukemia, bladder cancer, non-small cell lung cancer, breast
cancer, colorectal cancer, renal cell carcinoma, among others) and viral infectious pathways (Hepatitis
C, HTLV-I infection, Epstein-Barr virus infection) were also identified in our analysis, however these
categories are not included in the Supplementary table. Some of the enriched KEGG pathways and
GO terms are shared by targets of more than one miRNA groups and these are shown in Tables 4
and 5, respectively.
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Table 4. Functional annotation of target genes based on their enrichment in specific Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathways. The top 25 most significant pathways are shown, which are
targeted by at least two miRNA groups.
Targets of All miRNA groups
Targets of Group 1 and
Group 2 miRNAs
Targets of Group 2 and
Group 3 miRNAs
Targets of Group 1 and
Group 3 miRNAs
hsa04068:FoxO signaling pathway hsa05213:Endometrial cancer hsa04066:HIF-1 signalingpathway hsa04110:Cell cycle





























Table 5. Functional annotation of target genes based on their enrichment in gene ontology
(GO_ biological processes. Those members of the top 25 GO terms are shown, which are enriched by
all three miRNA group targets.
GO Biological Process
GO:0010628~positive regulation of gene expression
GO:0008284~positive regulation of cell proliferation
GO:0008285~negative regulation of cell proliferation
GO:0071456~cellular response to hypoxia
GO:0045892~negative regulation of transcription, DNA-templated
GO:0042517~positive regulation of tyrosine phosphorylation of Stat3 protein
GO:0043066~negative regulation of apoptotic process
At the same time targets of the three differentially expressed miRNA groups are also enriched in
pathways unique to a given miRNA group. These unique pathways are shown in Table 6.
Table 6. The unique functional annotation of target genes of a given miRNA group based on their
enrichment in specific KEGG pathways.




pathway hsa04630:Jak-STAT signaling pathway
hsa05203:Viral carcinogenesis hsa04520:Adherens junction hsa04910:Insulin signaling pathway
hsa04620:Toll-like receptor
signaling pathway hsa04210:Apoptosis
hsa04660:T cell receptor signaling
pathway
hsa04014:Ras signaling pathway hsa04922:Glucagon signaling pathway hsa04062:Chemokine signaling pathway




pathway hsa04915:Estrogen signaling pathway
hsa04010:MAPK signaling pathway
2.5. Protein–Protein Interaction Network Analysis of miRNA Targets
Subsequently targets of the three different miRNA groups were collapsed into a single
non-redundant target list, which was used to construct protein–protein interaction (PPI) networks.
First, a general PPI network, then an ovary-specific PPI network was constructed from the target lists
by using the NetworkAnalyst tool. Both networks proved to be a large fuzzy network, in the general
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PPI there are 3168 nodes and 5379 edges, the ovary-specific network contains 2353 edges and 3361
nodes. In Figure 5a,b, the general and ovary-specific minimum networks are shown with major hubs
labeled, respectively.
 
( ) ( ) 
Figure 5. Topology of the general and ovary-specific protein–protein interaction (PPI) networks
constructed from the common targets of differentially expressed miRNAs using the NetworkAnalyst
tool. Part (a) and (b): The general and ovary-specific minimum PPI networks, respectively. Nodes
represent proteins, only the major hub nodes are labeled in the networks.
The size of the nodes in Figure 5 corresponds to their degree centrality (and betweenness centrality)
values and the nodes in the network with large degree centrality are considered to be key nodes or
hubs with biological importance. Most of the major hubs overlap in the two networks and represent
proteins, which are already known to be involved in tumorogenesis, such as HSP90AA1, MYC, SP1,
BRCA1, RB1, CFTR, STAT3, E2F1, ERBB2, EZH2, and MET among others. The ranking of nodes based
on degree centrality, however, is not identical in the two PPI networks: MYC, BRCA1, CFTR, EZH2,
and STAT3 have higher ranks in the ovary-specific network. These interacting proteins occupy a central
position in the network, so they could be considered as key biological factors in OC development. An
advantage of the network-based approach is that it provides a mean to discover novel proteins, which
interact physically and functionally with the seed proteins and may represent new cancer genes or
cancer biomarkers.
The NetworkAnalyst tool could carry out a network-based functional enrichment and pathway
analysis based on the gene ontology and KEGG databases, too. That way it was possible to compare
results of the general analysis with results of an ovary-specific enrichment analysis. The results are
shown in Tables 7 and 8.
These functional enrichment results suggest that circulating plasma miRNAs are not randomly
released from cells since many of their predicted target genes are enriched in critically important
pathways and biological processes contributing to tumorogenesis, such as TGFβ signaling pathway,
NF-kappaB signaling pathway, VEGF signaling pathway, Rap1 signaling pathway, Ras signaling
pathway, ErbB signaling pathway, Focal adhesion, MAPK signaling pathway FoxO signaling pathway,
Proteoglycans in cancer, PI3K-Akt signaling pathway, Focal adhesion, AGE-RAGE signaling pathway,
JNK cascade, Peptidyl-Tyr-phosphorylation, Phosphatidylinositol 3-kinase signaling, and SMAD
protein signal transduction. In the case of OC, the estrogen signaling pathway could have specific
importance [32]. The functional enrichment analysis also revealed several cancer types; however, those
are not listed in Tables 7 and 8.
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Table 7. KEGG pathways-based general and ovary-specific functional enrichment analysis of all target
genes of differentially expressed miRNAs.
General Analysis 1 Ovary-Specific Analysis
KEGG Pathway P Value KEGG Pathway P Value
Pathways in cancer 2.3564 × 10−29 Pathways in cancer 2.26 × 10−38
Central carbon metabolism in cancer 3.8587 × 10−11 Epstein-Barr virus infection 1.54 × 10−29
Endometrial cancer 1.1410 × 10−8 Cell cycle 5.79 × 10−25
Insulin resistance 5.5166 × 10−8 Cellular senescence 1.3 × 10−24
TGF-beta signaling pathway 2.0410 × 10−7 ErbB signaling pathway 3.01 × 10−24
Toll-like receptor signaling path. 2.1829 × 10−7 MAPK signaling pathway 5.21 × 10−24
NF-kappa B signaling pathway 3.3876 × 10−7 FoxO signaling pathway 3.67 × 10−23
AMPK signaling pathway 4.6513 × 10−7 Proteoglycans in cancer 8.67 × 10−23
Prolactin signaling pathway 7.7049 × 10−7 Ubiquitin mediated proteolysis 1.7 × 10−21
Ras signaling pathway 1.4145 × 10−6 PI3K-Akt signaling pathway 2.24 × 10−20
ErbB signaling pathway 1.8772 × 10−6 Prolactin signaling pathway 3.53 × 10−20
Focal adhesion 2.9277 × 10−6 Focal adhesion 7.12 × 10−20
mTOR signaling pathway 2.8262 × 10−6 AGE-RAGE signaling pathway 4.55 × 10−18
Insulin signaling pathway 1.1171 × 10−5 T cell receptor signaling pathway 1.02 × 10−16
T cell receptor signaling pathway 1.1184 × 10−5 Adherens junction 1.24 × 10−16
Chemokine signaling pathway 6.4640 × 10−5 TNF signaling pathway 1.47 × 10−16
VEGF signaling pathway 9.9975 × 10−5 Estrogen signaling pathway 2.35 × 10−16
cAMP signaling pathway 1.2228 × 10−4 NF-kappa B signaling pathway 3.44 × 10−16
Rap1 signaling pathway 1.7607 × 10−4 Transcriptional regulation in cancer 3.8 × 10−16
Estrogen signaling pathway 0.0022 TGF-beta signaling pathway 1.84 × 10−14
1 In general analysis tissue specific expression is not considered.
Table 8. Gene ontology-based general and ovary-specific functional enrichment of all target genes of
differentially expressed miRNAs.
General Analysis 1 Ovary-Specific Analysis
GO Biological Process P Value GO Biological Process P Value
Phosphatidylinositol-mediated signaling 4.5190 × 10−11 Phosphorylation 4.62 × 10−61
TGFβ receptor signaling pathway 1.9554 × 10−8 Regulation of protein modification process 1.14 × 10−51
MAPK cascade 4.6884 × 10−7 Regulation of transferase activity 2.69 × 10−46
Peptidyl-Tyr-phosphorylation 6.050 × 10−7 Regulation of kinase activity 2.5 × 10−45
Phosphatidylinositol 3-kinase signaling 7.1633× 10−7 Enzyme linked receptor protein signaling 1.45 × 10−43
Positive regulation of Tyr- phosphorylation of
Stat3 protein. 9.8981 × 10−7 Regulation of cell cycle 1.46 × 10−41
I-κB kinase/NF-kappaB signaling 2.9099 × 10−6 Regulation of protein kinase activity 6.19 × 10−41
IL6-mediated signaling pathway 5.8361 × 10−6 Cell proliferation 2.65 × 10−40
Positive regulation of pri-miRNA transcription 1.2812 × 10−7 Cellular response to stress 1.15 × 10−37
Positive regulation of EMT 2.7940 × 10−5 Intracellular protein kinase cascade 2.57 × 10−37
JNK cascade 5.6629 × 10−5 Cell cycle 3.26 × 10−37
Response to calcium ion 1.4710 × 10−4 Positive regulation of RNA metabolic process 1.38 × 10−36
SMAD protein signal transduction 2.0946 × 10−4 Regulation of programmed cell death 3.09 × 10−35
Insulin signaling pathway 2.0956 × 10−4 Positive regulation of signal transduction 4.45 × 10−35
T cell receptor signaling pathway 2.9929 × 10−4 Regulation of cell proliferation 1.18 × 10−34
Positive regulation of GTPase activity 8.5273 × 10−4 Negative regulation of apoptotic process 6.4 × 10−34
Toll-like receptor signaling pathway 9.5585 × 10−4 Intracellular signal transduction 8.73 × 10−34
Cell-matrix adhesion 0.0010 Reproduction 8.6 × 10−33
Heterotypic cell-cell adhesion 0.0012 Negative regulation of transcription 1.78 × 10−32
SMAD protein complex assembly 0.0017 Negative regulation of nucleobase_containingcompound metabolic process 3.1 × 10−29
1 In general analysis tissue specific expression is not considered.
3. Discussion
In recent years several groups examined the biological importance of cell free miRNAs present
in body fluids. It was suggested that circulating miRNAs have the potential to become non-invasive
biomarkers for the early diagnosis of cancer [9,10,24]. It is equally interesting however, to study the
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pathophysiological role of these miRNAs, since circulating miRNAs released from cells are known to
be involved in intercellular communication and dysregulation of miRNAs in tissues is known to be
associated with several cancers [7,9,10,14].
We have compared the expression profiles of circulating miRNA in blood plasma samples of
six healthy females and 18 OC patients. Patients were divided into FIGO I, FIGO III, and FIGO IV
stages, having six patients in each group. The nCounter Human v3 miRNA Panel of the NanoString
System was used to measure the miRNA levels. MiRNA counts were low for most of the miRNAs,
especially in the control samples. This might be due to the detection method, the NanoString method
does not require an amplification step, so it is clearly different from those methods that use PCR
for the miRNA measurement. It might suggest that the NanoString method is less sensitive for low
abundance miRNAs.
Comparing miRNA expression profiles in the control and OC patient samples we have identified
45 miRNAs showing different expression between controls and patients. Our data showed that 17
miRNAs out of 45 were present both in the control and patient plasma (Group 1 miRNAs), however
their expression levels differed significantly between the four groups. With the exception of the tumor
suppressor has-miR-584-5p all Group 1 miRNAs were upregulated. 19 miRNAs were found only in
samples of FIGO I patients (Group 2 miRNA) and nine miRNAs were detected in all three patient
groups but were absent in control samples (Group 3 miRNAs). The finding of miRNAs, which are
present only in patient samples might be important from a diagnostic point of view, as it shows that
circulating miRNAs have the potential to be used as non-invasive biomarkers. Our sample number,
however, is too low to draw any firm conclusions.
The large majority of our differentially expressed miRNAs have been previously reported to
play a role in different cancer types. A few of our differentially expressed miRNAs, however,
were found to be associated with OC in previous reports (i.e., hsa-miR-144-3p, hsa-miR-337-5p,
hsa-miR-500a-5p, hsa-miR-26b-5p, hsa-miR-125a-3p, hsa-miR-19b-3p) [7,14,24,26]. Using the miRNet
tool and a network-based approach we have constructed a miRNA–target interaction network for the
miRNA groups. MiRNAs were ranked based on their degree-centrality value in the network, which
reflects their biological importance. Hsa-mir-26b-5p, hsa-mir-19b-3p, and hsa-mir-25-3p were the top
three ranked miRNAs for Group 1, hsa-mir-331-3p, hsa-mir-520g-3p, and hsa-mir-149-5p for Group
2 and hsa-mir-497-5p, hsa-mir-125a-3p, and hsa-mir-223-3p were the top three miRNAs for Group
3. The key miRNA–target interactions were visualized by the miTargetLink tool. For the Group 1
miRNAs, PTEN, EZH2, KAT2B, BCL2L11, TP53, SMAD4, and ERBB2 are the main targets, all known
to be involved in tumorogenesis. PTEN and TP53 are known tumor suppressor proteins—impairing of
KAT2B activity may contribute to genome instability; both oncogenic and tumor suppressive effects of
EZH2 have been demonstrated in different cancer types and its expression is known to be regulated
by miRNAs [33,34]. BCL2L11 is a tumor suppressor, it is an important regulator of apoptosis; loss
of the SMAD4 activity may disrupt DNA damage response and repair mechanisms and enhance
genomic instability [35,36]. The downregulation of these genes is in agreement with tumor formation,
however the receptor tyrosine kinase ERBB2 is a proto-oncogene, the role of its downregulation by
has-miR-25-3p and hsa-miR-552-3p is not known [37].
HMGN2, FOXO3, PPP2R5E, LDHA, ATAT1, FHIT, and the ERBB2 genes are the main targets
for top Group 2 miRNAs, while the IGF1R, CDK4, CDC25A, SLC2A4/GLUT4, RHOB, CDC27, and
POLR3G are the major targets for miRNAs of the third group. HMGN2 is an anti-tumor effector
molecule of CD8+T cells, FOXO3 is a core tumor suppressor in breast cancer; downregulation of
PPP2R5E is a common event in acute myeloid leukemia [38–40]. However, the ATAT1 activity is
required for microtubule organization, it is specifically upregulated in colon cancer tissue and LDHA
has an aberrantly high expression in multiple cancers [41,42].
Overexpression of CDC25A is known to be associated with malignancy and poor prognosis in
cancer patients [30]. Hsa-miR-223-3p targets the EPB41L3, a potential tumor suppressor gene, the NFIX
gene that regulates both cell proliferation and migration, the SLC2A4/GLUT4 is a glucose transporter
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and a biomarker for many types of malignant tumors [43–45]. A dualistic role of RHOB was reported,
it could be a proto-oncogene or a tumor suppressor depending on the context of cancer development
and progression. CDC27 is a tumor suppressor, its downregulation inhibits the proliferation of
cancer cells [46], POLR3G is required for proliferation, its depletion triggers proliferative arrest and
differentiation of prostate cancer cells [47].
Considering the negative regulatory role of miRNAs, it is noteworthy to find that not only tumor
suppressor genes but proto-oncogenes are also present among the interacting targets. However, it is
known, that miRNAs could have dualistic effect, a given miRNA can be an oncomiR or tumor suppressor
depending on the cellular context [23]. The miRTarBase and TargetLink databases were also used to
predict experimentally validated targets of the differentially expressed miRNAs, several common targets
were identified for three miRNA groups, the MET, SMAD7, EZH2, TERT, and IL6 genes for example
are targeted by at least one member of each different miRNA group. The tyrosine–protein kinase MET
is a proto-oncogene, its role in cell migration and in epithelial–mesenchymal transition (EMT) is well
known [48]. SMAD7 has a tumor suppressing role through blocking the TGF-β-stimulated cancer
progression by increasing angiogenesis and inducing EMT [49]. The telomerase reverse transcriptase
TERT gene plays a crucial step in tumorogenesis, it is required to maintain the telomere length and
telomerase activity to gain immortality [50]. IL6 is an inflammatory cytokine which promotes metastasis
in OC [51].
The miRNA group specific target lists were used in a functional annotation analysis based on the
enrichment of miRNA targets in the KEGG pathways and gene ontology biological processes terms.
This analysis revealed that miRNA targets are enriched in known cancer pathways, signaling pathway
which are crucial pathways in tumorogenesis. To name a few, FoxO signaling pathway, p53 signaling
pathway, PI3-AKT pathway AMPK pathway, TGFβ signaling pathway, focal adhesion, proteoglycans
in cancer, Hippo signaling pathway, ERBB signaling pathway, JAK-STAT signaling pathway, Estrogen
signaling pathway, and MAPK signaling pathway were among the most significant ones. In GO-BP
terms the positive regulation of gene expression, positive regulation of cell proliferation, negative
regulation of cell proliferation, cellular response to hypoxia, negative regulation of transcription,
positive regulation of tyrosine phosphorylation of Stat3 protein, and negative regulation of apoptotic
process were the most significant ones based on target enrichment and over-representation. All of
these processes and terms are known players of tumorogenesis. The results of the enrichment analysis
show that most miRNA targets are involved in signaling pathways and biological processes, which are
critical for tumor formation, suggesting that circulating miRNAs could be potential regulatory factors
in tumorogenesis. At the same time these data also show that the identified enriched pathways and
GO terms are not specific for a given tumor type, our identified miRNA targets are associated with
regulatory and signaling processes which are important in several different tumor types.
The target lists generated by the three prediction tools were merged into a single list and
possible interactions between the target proteins and their functionally important interacting protein
partners were analyzed by constructing general and ovary-specific PPI networks. The major hub
proteins—HSP90AA1, MYC, SP1, BRCA1, RB1, CFTR, STAT3, E2F1, ERBB2, EZH2, and MET—were
basically the same in the two networks, suggesting that our differentially expressed miRNAs regulate
target genes which are involved in basic processes of tumor formation. This notion is strengthened by
our network-based functional enrichment analysis, which provided a very similar enrichment pattern
(both in KEGG and GO-BP terms) to those which were recognized by the DAVID tool for the different
miRNA target groups.
In conclusion, our pilot study identified significantly differentially expressed circulating miRNAs
in plasma samples of OC patients. Our functional annotation analysis showed that the experimentally
validated targets of the differentially expressed miRNAs are key regulators of tumor formation,
suggesting that circulating miRNAs might play an important pathophysiological role in the formation
of different tumor types. On the other hand, these results also show that the differentially expressed
miRNAs identified in our study have limited usefulness in the diagnosis of OC. A clear limitation of
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our study is the low sample size, however, we feel that our results would warrant validation in a large
cohort of OC patients.
4. Materials and Methods
4.1. Patients and Samples
Twenty-four blood samples (six disease-free healthy controls, 18 serous ovarian cancer patients)
were collected from the Department of Obstetrics and Gynecology, Faculty of Medicine, University
of Debrecen. All patients that underwent surgery and tissue samples were histologically diagnosed.
Pathological characterization of tumor stages was assessed according to the International Federation of
Gynecology and Obstetrics (FIGO) criteria. None of the patients received chemotherapy or radiotherapy
treatment prior to participation in the study. Each subject provided written informed consent. The study
was approved by the Scientific and Research Ethics Committee of the Medical Research Council of the
Ministry of Health, Budapest, Hungary (ETT TUKEB), (Project Identification Code: 30231-2/2016/EKU,
date: 06 June 2016) and was conducted in accordance with the Declaration of Helsinki. Controls were
followed up, none of them received gynecological treatment during the study period.
Peripheral blood (9 mL) was drawn into EDTA anticoagulated tubes (BD Vacutainer) from each
patient and from healthy volunteers and kept at 4 ◦C until further processing (within two hours of
collection). Plasma samples were subjected to a two-step centrifugation protocol (2500× g and 16,000×
g; 10–10 min, 4 ◦C) to obtain plasma. After separation, the cell-free plasma samples were homogenized,
aliquoted, and stored at −80 ◦C until further processing.
4.2. RNA Isolation and Purification for the NanoString Device
Prior to RNA isolation blood samples were thawed on ice, then circulating RNA was isolated
from 500 μL plasma samples using the miRNeasy Serum/Plasma RNA isolation kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. The quality of the RNA was analyzed using the
Nanodrop device (Thermo Scientific, Waltham, MA, USA).
4.3. RNA Expression Analysis
The miRNA content of all samples was analyzed using the nCounter Human v3 miRNA Panel of
NanoString nCounter Analysis System (NanoString Technologies, Seattle, WA, USA), which contains
798 unique hsa-miRNA barcodes. 100 ng RNA/sample was used as input for the measurements,
hybridization was carried out for 18 h, and miRNA counts were collected by scanning on the HIGH
mode. The background correction of data was performed by subtracting the mean ± 2 standard
deviation of the negative control set. Lane-by-lane technical variation was corrected by using
the geometric median value of the positive code-set. The complete data set was normalized by
calculating the geometric mean of 10 “housekeeping” miRNA counts for each sample to generate the
normalization factor.
4.4. Prediction and Analysis of Experimentally Validated Target Genes
First, a miRNA–target gene network was constructed using the web based miRNet tool [http:
//www.mirnet.ca]. Top miRNAs in the network were ranked by degree and betweenness centrality
values. The prediction of experimentally validated target genes of miRNAs was carried out by using the
web based miRNet, miRTarBase, and TargetScan software programs (http://miRTarBase.mbc.nctu.edu;
www.targetscan.org). Target intersections were further validated by the miRWalk2 database (www.http:
//zmf.umm.uni-heidelberg.deg). The general and ovary-specific protein–protein interaction (PPI)
network of target genes was constructed using the NetworkAnalyst 3.0 tool [www.networkanalyst.ca].
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4.5. Functional Annotation and Pathway Enrichment Analysis
The lists of miRNA targets was used as input and the online Database for Annotation, Visualization,
and Integrated Discovery (DAVID; https://david.ncifcerf.gov) software tool was used to perform gene
ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) based functional pathway
enrichment analysis for the predicted target genes of prioritized differentially expressed hsa-miRNAs.
The NetworkAnalyst tool was used to carry out ovary-specific enrichment analysis. A p-value of <
0.05 was considered statistically significant.
4.6. Validation of hsa-miRNA Expression by Quantitative Real-Time Polymerase Chain Reaction (RT-qPCR) on
Selected hsa-miRNAs
Circulating RNA was extracted from 200 μL plasma samples of 16 healthy control females and
18 OC patients by using the miRNeasy Serum/Plasma Kit (Qiagen, Hilden, Germany) including 3.5
μL miRNeasy Serum/Plasma Spike-In Control RNA, according to the manufacturer’s instructions.
A miRNA-specific fluorometric assay on a Qubit® 2.0 Fluorimeter (Thermo Fischer Scientific, USA)
was used to determine the concentration of RNA. To detect and measure the amounts of mature
miRNAs the miScript PCR System (Qiagen, Hilden, Germany) was used. The miScript II RT Kit
(Qiagen) was used for reverse transcription of miRNAs. The quantitative real-time PCR reaction was
used (LightCycler®96; Roche Molecular Systems Inc., Pleasanton, CA, USA) to determine the level of
hsa-miR-25-3p, hsa-miR-26b-5p, hsa-miR-144-3p, hsa-miR-19b-3p, hsa-miR-301a-3p, hsa-miR-148b-3p,
hsa-miR-553, and hsa-miR-197 by using the miScript SYBR Green PCR Kit (Qiagen). The PCR reaction
mixture contained 500 pg reverse transcription products. The reaction mixtures were first denatured at
95 ◦C for 15 min, followed by 50 amplification cycles of 94 ◦C for 15 s, 55 ◦C for 30 s and 70 ◦C for 30 s.
Finally, a melting curve was generated by taking fluorescent measurements every 0.2 ◦C for 25 s from
50 ◦C until 95 ◦C to detect a single PCR product. Cycle threshold (Ct) values above the determinable
range (up to 45) were assigned a Ct of 45. All measurements were performed in triplicate and the
amounts of PCR products were normalized to an internal control (hsa-miR103-3p). Relative expression
levels were calculated by the 2−ΔCt method.
4.7. Statistical Analysis
All data were analyzed using the GraphPad Prism statistical package (GraphPad Prism7, San
Diego, CA, USA). Descriptive column statistics of each data set were performed and the distribution of
data was analyzed by the Kolmogorov–Smirnov test. To assess the statistical significance of differences
in miRNA counts between the control and patient groups the nonparametric one-way ANOVA
Kruskal–Wallis test in combination with the post hoc Dunn’s test to adjust for multiple comparisons
was applied. In all tests the difference was considered significant at p < 0.05 value. Where applicable,
the Dunn’s p-values were indicated as: p < 0.05(*); p < 0.01(**). The fold change in the expression of a
miRNA between the control data and a given FIGO stage data was calculated as: (FIGO stage mean
count – Control mean count)/Control mean count.
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Abstract: Ovarian cancer is a highly heterogeneous disease and its formation is affected by many
epidemiological factors. It has typical lack of early signs and symptoms, and almost 70% of ovarian
cancers are diagnosed in advanced stages. Robust, early and non-invasive ovarian cancer diagnosis
will certainly be beneficial. Herein we analysed the regulatory sequence methylation profiles of the
RASSF1, PTEN, CDH1 and PAX1 tumour suppressor genes by pyrosequencing in healthy, benign and
malignant ovarian tissues, and corresponding plasma samples. We recorded statistically significant
higher methylation levels (p < 0.05) in the CDH1 and PAX1 genes in malignant tissues than in controls
(39.06 ± 18.78 versus 24.22 ± 6.93; 13.55 ± 10.65 versus 5.73 ± 2.19). Higher values in the CDH1 gene
were also found in plasma samples (22.25 ± 14.13 versus 46.42 ± 20.91). A similar methylation pattern
with positive correlation between plasma and benign lesions was noted in the CDH1 gene (r = 0.886,
p = 0.019) and malignant lesions in the PAX1 gene (r = 0.771, p < 0.001). The random forest algorithm
combining methylation indices of all four genes and age determined 0.932 AUC (area under the
receiver operating characteristic (ROC) curve) prediction power in the model classifying malignant
lesions and controls. Our study results indicate the effects of methylation changes in ovarian cancer
development and suggest that the CDH1 gene is a potential candidate for non-invasive diagnosis of
ovarian cancer.
Keywords: liquid biopsy; pyrosequencing; ovarian cancer; CDH1; PTEN; PAX1; RASSF1; cfDNA
1. Introduction
Ovarian cancer (OC) is one of the most lethal gynaecological cancerous diseases and the fifth leading
cause of cancer-related death in women. Although it is globally diagnosed in almost 240,000 women
annually and responsible for over 150,000 deaths each year [1], the incidence varies regionally and
it is generally higher in both developed countries and caucasian women. The following OC rates in
100,000 women have been established: (1) Eastern Europe has 11.4 women diagnosed with OC in
Int. J. Mol. Sci. 2019, 20, 4119; doi:10.3390/ijms20174119 www.mdpi.com/journal/ijms134
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every 100,000, (2) the Central Europe and North America have over 8, (3) Central and South America
have up to 6 and (4) the lowest rates are observed in Asia and Africa, at less than 3, usually [1,2]. It is
also important that OC incidence has been slightly decreasing in developed countries since 1990 but
increasing in developing countries [3–5]. OC is also very heterogeneous, with a variety of benign,
borderline and malignant variants, almost all of which arise from transformation of epithelial, stromal
and germ cell types [6]. Of these, the most common malignant neoplasms have their origin in the
epithelium in up to 90% OC while the germ cell type are very rare with only 2–3% [6].
Ovarian tumours (OT) were traditionally divided into five groups: Serous, mucinous,
endometrioid, clear cell and transitional [7]. However, each of those also comprised variable forms
of benign, borderline and malignant lesions, with a total of over 40 tumour types. This classification
primarily focused on the ovarian mesothelial surface as the point of origin for epithelial OT [7], but the
more recent 2014 WHO classification, established in parallel with new FIGO staging implementation,
excluded transitional cell tumours, but added the new sero-mucinous tumour group [7]. This latest
classification is considered more consistent and it also comprises only 28 tumour types. While
Meinhold-Heerlein et al. [7] have compared the traditional and new classification in detail many
analyses have been based on older classification, and the results from those studies quoted herein
are in their original form. However, it is essential to remember that OC is a very variable group of
cancerous diseases and their formation is affected by many epidemiological factors [2]. It is especially
typical in its lack of early signs and symptoms, and almost 70% of these cancers are diagnosed in
advanced stages [8].
Diagnosed OC is primarily treated surgically with subsequent application of platine and taxane
based adjuvant chemotherapy [9], but the efficacy of surgical treatment followed by chemotherapy
rapidly decreases with the identified stage of the tumour [8]. The statistics for variable OC histotypes
highlight that only 20% of women in advanced stages have five-year survival after diagnosis, while 89%
diagnosed in stage I and 71% in stage II survive five years [8]. Moreover, OC metastases spread very
quickly using two strategies: (1) Transcoelomic passive dissemination of tumour cell spheroids in
the peritoneal cavity through ascites and (2) haematogenous metastasis of OC cells in the systemic
circulation followed by the preferred seeding of the omentum [10–12]. It is therefore essential to
use the robust, sensitive and non-invasive liquid biopsy (LB) approach for early OC diagnosis and
differentiation. This methodology overcomes the typical limitations of solid tumour biopsies, such as
invasiveness connected with unexpected complications during surgical procedures, difficulties in
operating on organs that lie deep within the body, false negativity from sampling bias and the
impossibility of repeating the same intervention [13]. Most importantly, solid biopsies provide no
possibility for early tumour diagnosis and differentiation; they give tumour information only at
particular points in time and they preclude monitoring the response to medication during treatment
and follow up. In contrast, these are all possible with the LB approaches focused on detection and
characterisation of abnormalities in circulating tumour cells (CTC), circulating tumour DNA (ctDNA),
circulating cell-free microRNAs (cfmiRNA) and released exosome vesicles [10].
This cross-sectional study focuses on epigenetic changes, particularly alterations in methylation
levels in primary tumours and the paired plasma samples. It then analyses the model’s predictive
power in distinguishing between diagnoses so that this can be used in clinically predicting the risk of
OC. For this purpose, four tumour-suppressor genes: Ras Association Domain Family Member 1 (RASSF1),
Paired Box 1 (PAX1), Cadherin 1 (CDH1) and Phosphatase and Tensin Homolog (PTEN) were analysed.
RASSF1 inactivation is connected with the development and progression of many cancer
types, and while this inactivation can be caused by deletions and point mutations, it most often
arises from methylation changes [14,15]. RASSF1 encodes a protein similar to the RAS effector
proteins [16] and this product regulates cell-cycle progression and apoptosis pathways, especially the
Ras/PI3K/AKT, Ras/RAF/MEK/ERK and Hippo apoptosis pathways [16]. It also regulates Bax-mediated
cell death [17], interacts with the XPA DNA repair gene [18] and inhibits accumulation of cyclin
D1 [19]. In addition, it inhibits anaphase-promoting complex (APC) activity and mitotic progression
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following interaction with CDC20 [20]. PTEN is a multifunctional tumour-suppressor gene encoding
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, which de-phosphorylates phosphoinositide
substrates, and it is also an important regulator of insulin signalling, glucose metabolism and the
PI3K/AKT/mTOR pathway [21]. The CDH1 gene encodes the cadherin–calcium dependent cell adhesion
protein which regulates the mobility and proliferation of epithelial cells [22], and abnormalities in this
gene are connected with the development of colorectal [22], breast [23], gastric [24] and most likely
also OC [25]. The PAX1 gene is a member of the paired-box transcriptional factor gene family which
regulates proper tissue development and cellular differentiation in embryos [26]. Although its role in
cancer development and progression has not been sufficiently established [27], this gene is aberrantly
hyper-methylated and down-regulated in different types of cancer [28], and is suggested to inhibit
the phosphorylation of multiple kinases, especially after challenges with the EGF and IL6 oncogenic
growth factors [28]. In addition, PAX1 has the ability to activate variable phosphatases, including
DUSP-1, 5, and 6, and to inhibit EGF/MAPK signaling. Its interaction with SET1B increases histone
H3K4 methylation and the DNA demethylation of numerous phosphatase-encoding genes [28].
Finally, changes in DNA methylation were repeatedly noted in OC and these affected the
activity of variable genes, and therefore contributed to the tumorigenesis of variable histotypes.
Furthermore, methylation changes in OC can be prognostic for shorter progression-free survival
(PFS) and chemotherapy resistance [29–31]. Importantly for this study, all four selected genes have
previously been observed to be abnormally methylated in primary OC tumours [25,32–40]. Moreover,
lower mRNA expression in at least one OC histotype in the RASSF1 and PTEN genes [41–43] and
lower CDH1 gene protein expression [44] in OC have been noted. Decreased CDH1 gene expression
also correlated with the methylation levels and all these genes can, therefore, be suitable candidates for
methylation analysis of LB samples from women with OC.
2. Material and Methods
Our sample collection consists of 128 variable types of ovarian tissues and paired plasma samples
from central European caucasian women who underwent surgical excision as part of their treatment.
This includes healthy (mean age 63.83 ± 11.23 years), benign (64.57 ± 16.40 years) and malignant
samples (57.20 ± 11.12 years), and also a few ovarian cancers subsequent to breast cancer (BC-OC)
(59.25 ± 12.74 years) (Table 1). The histological characteristics of the OC samples are summarised by
FIGO staging and subtype in Tables 2 and 3. Personal and gynaecological anamnesis information
was obtained during medical examination and the study was approved by the ethical committee
of Jessenius Faculty of Medicine in Martin Slovakia under number 1933/2016, and the research was
performed in compliance with the Declaration of Helsinki.
Table 1. Number of samples according to the diagnosis.
Tissue Diagnosis Plasma Paired Samples
n % n % n
17 13.3 Control 9 7.0 7
8 6.3 Benign 5 3.9 5
49 38.3 OC 33 25.8 33
4 3.1 BC-OC 3 2.3 3
Note: OC—ovarian cancer; BC-OC—ovarian cancer subsequent to breast cancer.
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No data 7 14.3
Table 3. Histopathological subtypes of OC samples.
Subtype n %




Serous papillary 25 51.0
2.1. DNA Isolation and Bisulfite Conversion
Immediately after section, the OT and healthy control tissues were stabilised in RNAlater solution
and kept at −20 ◦C. DNA from tissue and plasma was isolated by DNeasy Blood and Tissue Kit
(Qiagen GmbH, Hilden, Germany) and QIAamp® DSP Virus Kit (Qiagen GmbH, Hilden, Germany).
The concentration was measured by NanodropTM 2000 (Thermo Fisher Inc, Wilmington, DE, USA)
and QuBit (Thermo Fisher Inc, Wilmington, DE, USA). Finally, subsequent bisulfite DNA conversion
was performed by the Epitect Bisulfite Kit (Qiagen Inc., Valencia, CA, USA) and the converted DNA
was stored at −20 ◦C.
2.2. Methylation Analyses
Methylation of bisulfite modified DNA from control tissues, primary tumours and plasma samples
were analysed by pyrosequencing on Pyromark Q96ID (Qiagen GmbH, Hilden, Germany). This is a
very practical and reliable method and it provides quantitave methylation levels relatively quickly.
Sequencing was preceded by PCR amplification by Pyromark PCR Kit® (Qiagen GmbH). The total
reaction volume was 25 μL and comprised 21 μL Pyromark PCR Kit mixture (12.5 μL MasterMix,
2.5 μL CoralLoad Concetrate, 1μL MgCl2, 5μL Q-Solution), 2.5 μL primer pairs, 0.5 μL RNAse free
water and 1 μL bisulfite modified DNA.
The PCR reaction steps were as follows: Activation of polymerase (95 ◦C, 15 min), 45 cycles
(RASSF1) or 50 cycles (PTEN, CDH1, PAX1) of denaturation (94 ◦C, 15 s), annealing (56 ◦C (RASSF1,
PAX1)/62 ◦C (PTEN, CDH1) for 30 s), extension (72 ◦C, 30 s) and final extension at 72 ◦C for 10 min.
The qualitative and quantitative amplicon parameters were subsequently assessed by 1.5% agarose
gel electrophoresis. The amplification process was the same for both DNA from tumorous tissue and
circulating DNA. The PCR amplification primers were modified so that the reverse primer had a
biotinylated 5′ end. This enabled separation of the strand for pyrosequencing analysis.
The PCR product was subsequently used for pyrosequencing. This was first mixed with
streptavidin-coated sepharose beads (GE Healthcare Life Sciences, Chalfont, UK), binding buffer
(Qiagen GmbH) and nuclease free water in a total volume of 80 μL in a Pyromark plate and shaken
for 10 min at 2,500 rpm. The 5′-biotinylated strand for sequencing was immobilised by Pyromark
working station, transferred to a mixture of 0.4 M sequencing primer and binding buffer (Qiagen
GmbH) and incubated for 2 min at 80 ◦C. Finally, the pyrosequencing results were interpreted by
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Pyromark Q96 software version 2.5.8 (Qiagen GmbH). The commercially available CpG methylation
assays® (Qiagen GmbH) were used herein to analyse methylation levels in the following sequences
(Table 4):
Table 4. Analysed sequences of genes RASSF1, PTEN, CDH1 and PAX, and their location in human genome.






Exploratory data analysis was performed by standard summary statistics; the methylation data
was visualised by boxplot overlain with swarmplot; and the heat map provided methylation level mean
values. Data normality was assessed by a quantile-quantile plot with 95% bootstrap confidence band,
and robust ANOVA tested the hypothesis of equality of population methylation medians in the disease
levels. Null hypothesis rejection was followed by the Tukey HSD post-hoc test. The discriminative
ability of the methylation indices and age for various pairs of disease level was then assessed by the
random forest learning algorithm. This quantified the importance of the individual predictors by
minimal depth. The trained random forest discriminative ability was visualised by the ROC curve
based on “out-of-bag” data and the AUC area under the ROC curve and the 95% AUC confidence
interval quantified the discriminative ability of methylation indices and age. Finally, we determined
sample size and performed power analysis for the one-way ANOVA test, assuming balanced design.
All data analysis was performed in R, version 3.5.2 [45].
3. Results
3.1. CpG Sites Methylation Status of the RASSF1, PTEN, CDH1 and PAX1 Gene Regulatory Regions
DNA methylation profiling of 21 CpG sites in four genes, comprising six CpG sites in the RASSF1
gene and five CpG sites in each of the PTEN, CDH1 and PAX1 genes was performed by pyrosequencing
on the four different tissue types—healthy ovarian tissues, benign OT, OC and BC-OC, and also on the
corresponding plasma samples. The mean value, median and standard deviation of each CpG site is
provided in Supplementary Table S1 for tissues and Table S2 for plasma.
Figure 1 shows the methylation value of each CpG site in the tissue (A) and plasma samples (B)
according to diagnosis. The general overview provides information on the hypomethylation of PTEN
CpG sites for all diagnoses and tissue and plasma samples. Greater variability is obvious in the RASSF1
and PAX1 CpG sites, and the highest methylation was detected in the CDH1 CpG sites. The comparison
of tissue samples (Figure 1A) shows the increasing methylation trend from the control sample group to
cancer samples in the RASSF1, CDH1 and PAX1 genes. The statistical comparison of means revealed
the most significant differences between controls and OC samples in two CDH1 and three PAX1 gene
CpG sites and between controls and BC-OC in three PAX1 gene CpG sites. The increasing mean values
for RASSF1 were not statistically significant because of the wide variance in values (detailed statistical
data is contained in Table S1). Figure 1B depicts variability in the plasma group methylation values,
with no visible linear trends detected between the diagnostic groups. Finally, the statistically significant
higher methylation levels were detected in OCs in four CDH1 gene CpG sites compared to controls,
and all detailed statistical data is listed in Table S2.
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Figure 1. Heat map of each CpG site methylation values in tissue (A) and plasma samples (B) according
to diagnosis. OC—ovarian cancer; BC-OC—ovarian cancer subsequent to breast cancer.
3.2. DNA Methylation Indices of the RASSF1, PTEN, CDH1 and PAX1 Gene Regulatory Regions
The methylation index (MI) is the mean percentage of methylation across all CpG sites analysed
per gene, and that was calculated for each gene and diagnostic group in the tissue and plasma samples.
The MI values of each diagnostic group are depicted by the heat maps in Figure 2A for tissue and 2B for
plasma. Although PTEN gene methylation indices were very low, they were statistically significantly
different between benign tumours (3.90 ± 4.10) and malignant OC (3.00 ± 2.60) in the tissue samples.
No statistically significant differences were determined in RASSF1 MI between diagnostic groups in
either the tissue or plasma samples. In the tissue samples, the CDH1 and PAX1 gene methylation
indices had increasing tendency toward OC, with statistically significant difference between controls
(24.22 ± 6.93 for CDH1 and 5.73 ± 2.19 for PAX1) and OCs (39.06 ± 18.78 and 13.55 ± 10.65) in
both genes, and also between controls (5.73 ± 2.19) and BC-OC samples (22.90 ± 13.56) in the PAX1
gene. In the plasma samples, there was only one statistically significant difference between controls
(22.25 ± 14.13) and OC samples (46.42 ± 20.91), in the CDH1 gene. Detailed data is provided in
Supplementary Table S3.
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Figure 2. Heat map of MI values in tissue (A) and plasma (B) samples according to diagnosis.
MI—methylation index, OC—ovarian cancer; BC-OC—ovarian cancer subsequent to breast cancer.
Analysed sample distribution is depicted in Figure 3 according to the sample type and diagnosis
for all four studied genes. Wider variance in the mean values is obvious in the PTEN methylation
index, and that explains the small differences between groups.
Figure 3. The swarmplots of methylation indices of RASSF1, PTEN, CDH1 and PAX1 genes, showing the
mean values of all observations. MI—methylation index; 0—control tissues (green squares); 1—benign
tumours (blue triangles); 2—ovarian cancers (pink circles); 3—ovarian cancers subsequent to breast
cancer (purple crossed circles).
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3.3. Methylation Pattern by FIGO Staging and Histological Type
The methylation levels of all CpG sites revealed little statistically significant differences between the
compared FIGO stages (data not shown) and the MI data pattern is depicted in Table 5. Two following
trends were observed: The RASSF1 and PAX1 methylation indices decreased with disease severity
increase, and the CDH1 and PTEN values had increasing tendency, thus followiing the stages. Statistical
comparison of the mean values revealed significant differences only in the PTEN gene and between
stages I and II, and stages I and IV in the PTEN gene.
Table 5. MI averages of CpG sites in regulatory regions of the RASSF1, PTEN, CDH1 and PAX1 genes
in tissue samples according to FIGO stage.
Stage I (n = 9) Stage II (n = 21) Stage IV (n = 12)
p-Value
Mean Median SD Mean Median SD Mean Median SD
MI_RASSF1 19.24 5.33 20.46 17.24 7.50 19.80 8.01 6.83 3.95 ns
MI_PTEN 2.09 2.00 1.37 3.47 3.60 1.49 3.63 3.60 1.37 a, b
MI_CDH1 32.89 29.00 16.81 39.98 30.50 20.72 48.38 44.25 17.76 ns
MI_PAX1 17.11 13.60 17.36 11.56 10.40 5.42 10.98 8.50 6.28 ns
Note: Due to number of cases in each category, we created only three groups, based on the FIGO stage numbers (for
example 1A, 1B and 1C were merged into stage I); ns—non significant difference between groups; a—statistically
significant difference (p < 0.05) between FIGO I and II; b—between FIGO I and IV.
Comparison of the methylation levels and indices between histological subtypes revealed only
sporadic differences and indicated possible uniform methylation of the studied genes in this OC group.
3.4. Comparison of Methylation Indices in Tissue and Plasma Paired Samples
The MI values of paired tissue and plasma samples were compared to assess if the plasma
methylation status reflects those observed in the primary tumours. Figure 4 shows similarities and
differences in the methylation indices of all RASSF1, PTEN, CDH1 and PAX1 gene paired samples,
and statistical analysis determined significant plasma and tissue correlation only in the CDH1 and
PAX1 genes. The correlation coefficient of CDH1 MI was negative in controls (r = −0.812, p = 0.05),
but positive in benign samples (r = 0.886, p = 0.019) and OC samples (r = 0.428, p = 0.015). However,
strong correlation was established between plasma and tissue in all PAX1 CpG sites and between PAX1
methylation indices, but only in the OC pairs (r = 0.771, p < 0.001).
The results for sample size determination, including the effect size and the number of observations
in each group needed to maintain 80% power level, are included in Supplementary Table S4 for tissue
samples and Table S5 for plasma samples.
3.5. Evaluation of the Diagnostic Predictive Model Using ROC Analyses
Finally, we used the random forest algorithm with ROC analysis to evaluate if the studied
methylation indices combined with age could significantly distinguish between diagnoses. Table 6
provides the AUC values with 95% confidence intervals for tandem discriminations. The “Important
variable” column denotes the most relevant variables based on importance measured by minimal
graph depth. The best AUC values were obtained in the model which discriminate between controls
and OC samples based on both the MI of the four genes in tissues (AUC = 0.932) and in plasma
(AUC = 0.822). The first “tissue” model had perfect sensitivity (98%), but specificity was weak (34%).
The same was observed in the “plasma” model, with 91% sensitivity and 56% specificity. Based on
the AUC values and 95% CI, these models indicate strong predictive power, and can, therefore, be
considered for diagnostic discrimination clinically.
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Figure 4. Methylation indices of RASSF1, PTEN, CDH1 and PAX1 genes in paired tissue and
plasma samples. MI—methylation index; C—control samples; B—benign; OC—ovarian cancer;
BC-OC—ovarian cancer subsequent to breast cancer.









Benign 0.738 0.391–1.000 15.38 PAX1
Control vs. OC 0.932 0.823–1.000 9.09 PAX1





Benign 0.778 0.512–1.000 21.43 CDH1
Control vs. OC 0.822 0.667–0.976 16.67 CDH1
Benign vs. OC 0.630 0.309–0.951 13.16 PTEN
Note: OC—ovarian cancer, AUC—area under the curve, CI—confidence interval.
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4. Discussion
OC is one of the most lethal cancerous diseases, and despite the progress in surgical techniques,
better management, advanced chemotherapy and targeted therapy, the OC patient survival rate is
still very low and almost 70% of all patients are diagnosed in advanced stages. This is mainly due to
the lack of early symptoms in this disease [8]. Early OC screening approaches have been traditionally
based on serum CA-125 concentration and trans-vaginal ultrasound, but both these methods lack
sufficient sensitivity and specificity [46,47]. Therefore, non-invasive biomarkers able to predict early
OC presence and monitor response to treatment and cancer progression are imperative. However,
those with sufficient predictive power are still lacking and most possible candidates require further
investigation [46,48,49]. Moreover, further use of the tumour markers is crucial in all gynaecological
cancerous diseases [50–52]. For example, CTC, ctDNA, cfmiRNAs and released exosome vesicles can
be analysed in the assessment of molecular markers. This assessment can be performed by a variety of
methods, from basic PCR modifications to advanced multi-parallel sequencing approaches [10].
Herein, we focused on the epigenetic impact on OC formation by analysing the methylation
levels of the RASSF1, PTEN, CDH1 and PAX1 tumour suppressor genes’ regulatory sequences. We
compared the methylation status of normal tissue, benign, OC and BC-OC samples. We then assessed
the methylation levels in these genes in the corresponding plasma samples in order to estimate their
potential for LB utilisation. Finally, we compared the methylation patterns in the tissue samples and
the paired plasma samples to assess if these patterns were markedly different.
Previously published articles reported the importance of some genes’ plasma methylation status
in OC management. For example, the C2 CD4 D, WNT6 and COL23 A1 genes’ methylation status
is not only significantly altered in OC patients’ ctDNA, but different responses to platinum-based
therapy can also be associated with their methylation levels [53]. Moreover, Giannopolou et al. [54]
discovered altered ESR1 gene methylation levels in the ctDNA samples of high-grade serous OC
patients, and these abnormalities are very similar to those in primary tumours [54].
The most notable methylation changes in solid OT are in the BRCA1 [29,55], OPCML [56],
HOXA9 [33] and P16 INK4α genes [57]. BRCA1 is methylated in up to 30% [29,55] of these tumours
and OPCML is methylated in over 80% of OT [56]. Interestingly, RASSF1 A is the major RASSF1
gene isoform and this has been repeatedly analysed for methylation changes in both OC tissues and
plasma samples. For example, de Caceres et al. [32] noted methylation of the RASSF1 A gene in 50% of
primary OT and detected an identical pattern of gene hyper-methylation in 41 of 50 (82%) matched
plasma DNA. In addition, hyper-methylation of this gene was recorded in all OC histological types,
grades and stages. Wu et al. [33] reported very similar results in solid tissues, with hyper-methylation
in 49% of patients with various OC types and grades. In contrast, Agathanggelou et al. [58] found
hyper-methylation in only 10% of solid OT.
Methylation changes in the RASSF1 A promoter have already been analysed for utilization in
non-invasive differentiation of epithelial ovarian carcinoma from healthy controls. For example,
90% sensitivity and 86% specificity for cancer detection was determined when methylation levels of
the RASSF1 A, EP300 and CALCA genes were used in combination [59]. In addition, the multiplex
methylation specific PCR (MSP) assay of seven different genes, including RASSF1 A, achieved 85.3%
sensitivity and 90.5% specificity in differentiating epithelial OC from healthy controls in serum
samples [60]. Variable RASSF1 A methylation has also been noted in tissue samples of serous and
non-serous types and benign tumours [61].
Herein, the RASSF1 A MI differed in all four tissue types. It was higher in primary malignant
tumours (17.98 ± 19.73) than in healthy tissue (9.50 ± 6.21), but the opposite was found in plasma
ctDNA. Here, the controls have higher MI (11.74 ± 8.34) compared to malignant samples (8.93 ± 4.54).
However, no statistically significant differences were established between particular CpGs or mean
methylation indices. Importantly, although these differences proved insignificant, they can indicate
wide methylation changes in RASSF1 gene regulating sequences and the important role of methylation
in silencing this gene in OC development as is generally suggested [29].
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Although the methylation status of the PTEN CpG sites and methylation indices was generally low
and homogenous, there were statistically significant differences between benign and malignant lesions.
The decreasing tendency in methylation indices was observed in both tissue and plasma samples,
but comparison between FIGO stages revealed a statistically significant increase in methylation indices
only in the higher FIGO stages. This theoretically indicates its important role in cancer formation and
spread. Herein, however, we compared only the main FIGO categories where subtypes were merged
in one main category, because of the small sample size. In addition, the differences between the FIGO
stages were not only low, but the methylation indices themselves also had low values. This leads to
debate if such small increases in methylation levels can contribute to tumour progression from stage I
to stage IV. This is especially pertinent when previous very low PTEN methylation levels have occurred
without differences in OC FIGO stages [34].
Yang et al. [34] and Zuberi et al. [35] recorded relatively low methylation values in the PTEN
gene with higher methylation in only 16% and 8.2% of the samples, respectively. Schondorf et al. [62]
suggested that PTEN methylation should have only a subordinate role in OC progression and only the
one study by Qi et al. [36] reported relatively higher methylation levels of this gene in OC. Overall,
the low and homogeneous PTEN methylation concord with the most of previous studies, and the
small increase in methylation should not reflect progression from stage I to stage IV, though statistical
significance is established between the FIGO stages. Our results also indicate the potential effect
of PTEN methylation changes in benign lesion formation. That suggests that further analysis of
the methylation changes will be beneficial, because there is no rule that benign lesions must be less
methylated than malignant lesions, and different mechanisms can lead to abnormal methylation in
benign and malignant tumours [63].
In comparison to RASSF1 and PTEN, the PAX1 gene had greater variation in methylation levels with
statistically significant differences between controls, OC and BC-OC. There was also wide variability
in particular CpG islands, especially in the control and malignant samples. This gene’s methylation
provides a potential biomarker for cervical cancer screening [64–66], but important methylation
changes in this gene were also noted in OC. In particular, Su et al. [37] reported 50% PAX1 methylation
rates in OC, but only 14.3% in borderline tumours and 4% in benign, and Hassan et al. [38] found
hyper-methylation in 50%, 50%, 46.6% and 78% of patients depending on the FIGO stage of epithelial
OC. In addition, the authors associated methylation levels with the presence of HPV16/18 infection.
Neither of these studies can be quantified in the same manner as our quantitative pyrosequencing
results because they used MSP in their assessment, but the significant differences we achieved between
healthy tissues and cancer samples can be interpreted quite similarly—that dynamic methylation
changes indicating OC’s presence occur in the aforementioned gene’s regulation sequences. Although
our results established no statistical significance, they can certainly help move the debate on how this
gene’s methylation changes affect the formation of benign lesion because the methylation levels were
as high they are in cancerous tissues.
Finally, the CDH1 gene had statistically significant variability in methylation levels between
control and malignant tissue samples, and this agrees with previous analyses [25,39,40]. Importantly,
this gene also had statistically significant plasma samples differences in both mean methylation levels
and those of particular CpG dinucleotides in both healthy and cancerous groups. Therefore, the CDH1
gene could be considered a very promising candidate for non-invasive LB-based diagnosis of malignant
OC, but its potential for non-invasive investigation of benign tumour presence requires further analysis.
It is important to realize that even non-significant, but observable differences in plasma samples
methylation levels were revealed also in the RASSF1, PTEN and PAX1 genes, and this could inspire
additional analyses of these genes. The large deviation in the final methylation levels of these genes
was very likely the main obstacle to achieving statistical significance. However, larger sample collection
could help to solve this problem.
One of the issues in the analysis of plasma samples is the lack of definition and accepted consensus
if changes, including those in ctDNA methylation, remain exactly the same as in the primary tumours
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that released them. While some authors consider that the aberrant patterns remain identical to those
in the primary tumour [53,67–72], others support diverse patterns [73–75]. Herein, we conform to
similarity because of the strong correlations between tissue and plasma samples in the CDH1 and PAX1
genes, and also in several RASSF1 and PTEN gene samples. Discrepancies in tissue and plasma sample
methylation levels could have also occurred herein because circulating cfDNA of cancer patients
contains a mixture of DNA from both normal and cancerous cells. The ratio of ctDNA in the entire
cfDNA fraction can vary because this depends on several tumour parameters [76]. Our methodology
cannot estimate how plasma sample results are affected by the presence of non-tumorous cfDNA
elements, and we cannot exclude that this is responsible for the variability obtained in the results.
Although the ctDNA ratio is generally quite low it can vary widely, and some estimations of ctDNA
abundance reach 90% [76,77]. Importantly, it has been demonstrated that the concentration of all
circulating free molecules, and not only ctDNA, is associated with a tumour volume which gives
shorter overall survival (OS) for OC patients [78].
Previously performed LB-based methylation analyses assessing the methylation pattern in
OCs using non-NGS approaches have provided very interesting results. Those include (1)
Teschendorff et al. [79], when they used a methylation-array based study and observed significant
differences in the blood of healthy and cancerous patients, and (2) Flanagan et al. [80], who utilised
the pyrosequencing approach and determined significant correlation of SFN gene methylation with
PFS. In addition, their subsequent study [81] noted specific CpGs’ alterations in blood DNA following
relapse from platinum-based chemotherapy, and their results proved an independent significant
association with survival. Moreover, both pyrosequencing and MSP have previously been used to
assess methylation abnormalities in plasma samples from different cancer types, and some of these
achieved significant results assessing the profiles of all circulating DNAs, not only ctDNA [82–86].
Therefore, even methodology which is unable to distinguish ctDNAs in the whole cfDNA fraction can
be useful in assessing disease characteristics from LB samples. We also incline toward the consensus
that changes in primary tumours should remain preserved in ctDNA elements and the changes noted
in primary tumours could then be used as inspiration for initiating further experiments utilising LB
samples. Therefore, known abnormalities in primary tumours can be very helpful because these can
be searched and analysed in LB samples.
OC is widely recognised as a very heterogeneous group and it should, therefore, be important to
analyse and interpret the results of each histotype. However, the rarity of some morphological subtypes
causes study limitations, and the small numbers in some histotypes herein prevented performance
of statistical analysis. Only the serous and serous papillary histotypes were sufficient for analysis,
and these recorded no significant differences in their methylation levels and were even almost identical.
While studies have confirmed that some differences are typical for all OC histotypes [25,32–34,56], it
cannot be ignored that unintentional variance in our results is due to the heterogeneity of our collection
and also the impossibility of separating and analysing particular histotypes.
The effect size and the number of observations in each group required to maintain 80% power
were assessed by power analysis, and these are listed in supplementary Tables S4 and S5. Herein,
the number of malignant tissues was mostly sufficient, but we occasionally noted a lack in the number
of healthy controls and the number of benign lesions was quite often lower than proposed. Therefore,
although the power analysis results may limit our study through having a sample size insufficient to
assess methylation levels in all CpGs with sufficient statistical power, it can help design the same or
similar experiments. The highest number of required observations, excluding three PTEN gene CpG
sites in plasma samples, was 64, and it is quite possible to collect at least that number of samples for
future analysis.
It has been noted that there are generally higher cfDNA levels in malignant OC patients than in
healthy patients and in those with benign lesions [87,88]. The cfDNA levels are also lower in FIGO I–II
stages than in the III–IV stages [78]. Although we assessed only four genes’ methylation indices and
not the entire cfDNA levels, and therefore cannot directly associate these parameters, analysis of the
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relationship between methylation changes, tumour stage and general cfDNA levels could most likely
provide clinical implications. It would be beneficial, therefore, to design further studies which assess
these relationships.
The cfDNA characteristics can also vary depending on age [89] and the presence of concomitant
disease [90]. Furthermore, it is presumed that length of cfDNA fragments correlates with shorter PFS,
and also OS [91]. Unfortunately, we can neither confirm nor preclude that our results are affected by
other clinical attributes, such as the presence or absence of other patient disease. However, further
studies should establish associations between a wide variety of clinical parameters, methylation and
also cfDNA levels, as previously suggested.
Herein we evaluated the predictive performance of the combined model of DNA methylation
signature (MI of the genes) and the age (in years) using ROC analyses computed by the random forest
algorithm. We ran six models separated for sample type. The model which discriminated between
control and OC samples had the highest predictive power—at 0.932 AUC in tissue samples and 0.822 in
plasma. This initially appeared a perfect model with high sensitivity and clinical application potential,
but 34% specificity for tissue samples and 56% for plasma samples means that too many healthy
women would be incorrectly classified as cancer patients. The most likely reason for these results was
the small number of controls, and this could have affected statistical analyses and hindered efforts to
ensure a strong statistical model. Adequate AUC values were obtained in the model discriminating
control samples and benign samples (tissue: AUC = 0.729, 85.7% sensitivity and 83.3% specificity;
plasma: AUC = 0.778, 100% sensitivity and 66.7% specificity). Our last discrimination model of benign
and OC samples had insufficient classifiers. In these models, PAX1 MI and CDH1 MI were selected
as the most important variables for tissue and plasma respectively, and this indicates the previously
described results about tissue and plasma non-conformity. Although these analyses promised a
high-quality classifier, other possibilities should now be also considered. The most important would
be the inclusion of additional control samples, as this would provide more accurate specificity. It is
also worth considering the inclusion of more variables in the model, such as gynaecological anamnesis,
life style risk factors and also CA-125 or other novel biomarkers with the potential to detect serous OC
at earlier stages and predict patient survival prognosis [92–94]. Although this is beyond the scope
of this pilot project, it should provide inspiration for further analyses focused on specific variables
identified by a multinomial approach and offer personalised tailored therapy. Because of the great
variability in this disease, the management of OC should be individualized, and performance status of
the patient should be considered. This is best reflected in necessity for different treatment option for
younger and older women [95,96]. In addition, future individual OC treatment should also be based
on different patient physiological and health parameters.
In conclusion, our study confirmed higher methylation levels in several CpG sites and also higher
methylation index in RASSF1 A, PAX1 and CDH1 genes in OC tissues compared to control tissues.
However, no statistical significance was noted in the RASSF1 gene because of high variance. Statistically
significant higher MI and CpG sites methylation levels were detected in plasma samples only in the
CDH1 gene. PTEN gene was slightly and homogenously methylated. In addition, we recorded similar
methylation patterns with strong correlations in the CDH1 and PAX1 genes in OC plasma and tissue,
and the results suggest that the CDH1 gene is a prospective candidate for non-invasive, LB-based
differentiation in OC. Our diagnostic discrimination model combined the methylation indices of all four
genes with age, and this revealed the highest AUC 0.932 predictive power in the model, comparing OC
subjects with controls. Finally, it will prove highly beneficial to employ as many LB-based approaches
as possible in cancer detection and treatment, especially in OC, which has such high risk and generally
delayed diagnosis. LB is capable of providing early OC diagnosis which can help decrease the global
expense of fighting this disease, but most importantly it can save lives, or at least prolong them with
greater life quality for the thousands of women affected by this lethal cancer.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/17/
4119/s1.
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Abstract: Copy number variants (CNVs) are an important type of human genome variation, which play
a significant role in evolution contribute to population diversity and human genetic diseases. In recent
years, next generation sequencing has become a valuable tool for clinical diagnostics and to provide
sensitive and accurate approaches for detecting CNVs. In our previous work, we described a
non-invasive prenatal test (NIPT) based on low-coverage massively parallel whole-genome sequencing
of total plasma DNA for detection of CNV aberrations ≥600 kbp. We reanalyzed NIPT genomic
data from 5018 patients to evaluate CNV aberrations in the Slovak population. Our analysis of
autosomal chromosomes identified 225 maternal CNVs (47 deletions; 178 duplications) ranging from
600 to 7820 kbp. According to the ClinVar database, 137 CNVs (60.89%) were fully overlapping with
previously annotated variants, 66 CNVs (29.33%) were in partial overlap, and 22 CNVs (9.78%) did
not overlap with any previously described variant. Identified variants were further classified with
the AnnotSV method. In summary, we identified 129 likely benign variants, 13 variants of uncertain
significance, and 83 likely pathogenic variants. In this study, we use NIPT as a valuable source of
population specific data. Our results suggest the utility of genomic data from commercial CNV
analysis test as background for a population study.
Keywords: copy number variants; next generation sequencing; non-invasive prenatal testing;
population study
1. Introduction
Copy number variation (CNV) is a segment of DNA with length ≥1 kbp which is presented at
a variable copy number in comparison to the reference genome. CNVs include insertions, deletions
and duplications, which result in copy number gain or copy number loss [1]. It was shown that
CNVs are important cause of structural variations in the human genome [2]. Research of the past
decades revealed that these variations are functionally and evolutionary significant and contribute to
the population diversity and human genetic diseases [3,4].
Various methods for CNV detection have been developed, from the conventional cytogenetic
analysis (e.g., G-banded karyotype) through microarray-based methods (e.g., comparative genomic
hybridization) to next-generation sequencing (NGS) [5]. Genomic microarrays provide a genome-wide
coverage at a much higher resolution than a conventional cytogenetic analysis. This is the reason why
microarray-based methods have been standard for CNV detection [6,7]. However, this method has
limited resolution, accuracy, and several other limitations are noted in the literature [8]. In recent
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years, NGS has become a valuable tool for clinical diagnostics and to provide sensitive and accurate
approaches for detecting genomic variations, e.g., CNVs. With the reducing cost of this method,
numbers of NGS based CNV detection tests is increasing [9,10].
In our previous study, we described non-invasive prenatal test (NIPT) based on analysis of plasma
DNA from pregnant women [11–13]. This test uses low-coverage massively parallel sequencing of
whole-genome for detection of CNV aberrations [14]. With the informed consent of these patients
we generated an amount of credible genomic data from thousands of pregnant women. Since these
patients represent a relatively standard sample of local female population, we hypothesized this data
could be used not only for primary purpose as prenatal screening but also as a valuable source of data
for population study. The objective of the present study is based on our previous work which suggests
the use of NIPT as a valuable source of population specific allelic frequencies [15].
2. Results
We obtained CNV profile for 22 autosomes from 5018 pregnant women (Figure 1). Together,
we identified 225 CNVs ranging from 600 kbp to 7820 kbp with median size 820 kbp (Table S1).
These variants include 178 duplications (79.11%) and 47 deletions (20.89%) with median size 830 kbp
for duplications and 800 kbp for deletions. As can be seen, the majority of identified CNVs were
approximately 600–700 kbp long (Figure 2a). Most variants (28) were found on the chromosome
2, while on the chromosome 15 we detected only one variant. We did not identify any deletions
on chromosomes 11, 15, 20, and 22 (Figure 2b). The identified CNVs came from 212 individuals,
corresponding to frequency 4.2% of CNV ≥ 600 kbp in our cohort. The vast majority of individuals
(95.28%) displayed a single CNV; only 4.72% exhibited more than one variant. The most frequently
detected variant was the CNV duplication in chromosome location 2p22 with a total of 11 detection
events; however, the frequency of every CNV was calculated as less than 1%, thus all variants
were considered to be rare. The largest CNV was duplication spanning 7820 kbp in chromosome
location 10q21.1.
Figure 1. Chromosomal location of maternal CNVs identified by NIPT. The length of blue (duplication)
and red (deletion) bars corresponds to the frequency of CNV ranging from minimum of 1 to maximum
of 11 detections.
Variants were compared with ClinVar database records and following results were obtained.
Together, 137 CNVs (60.89%) were overlapping with previously described variants in full extent,
66 CNVs (29.33%) were partially overlapping and 22 CNVs (9.78%) did not overlap with any previously
described variant according to ClinVar. Some of our CNVs overlap with variants previously observed
among patients with pathogenic phenotypes, e.g., developmental delay, intellectual disability, etc.
(Table 1).
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Figure 2. Characteristics of maternal CNVs identified from the NIPT. (a) Size distribution of detected
CNVs ranging from ≥600 kbp to ≥7000 kbp. (b) Genomic distribution of CNV deletions (red) and
duplications (blue) ≥600 kbp in Slovak population within the chromosomes.
Table 1. Variants overlapping with CNVs that were previously observed among patients with
pathogenic phenotypes. Data acquired from the ClinVar database.
Variant Type Location Identifier Phenotype Events Reference
Duplication 1q21.1-21.2 dbVar:nsv531885
Developmental delay AND/OR other
significant developmental or morphological
phenotypes, Global developmental delay
1 [16,17]
Duplication 2q33.1 OMIM:609728.0002




delay, Muscular hypotonia 1 [17]
Deletion 13q12.12 dbVar:nsv491643
Developmental delay AND/OR other
significant developmental or morphological




Developmental delay AND/OR other




















Short stature, Macrocephalus, Abnormality
of the face, Intellectual disability 2 [16]
The identified variants were classified based on criteria in AnnotSV database [19]. In summary,
we identified 129 likely benign variants, 13 variants of uncertain significance and 83 likely pathogenic
variants. According to AnnotSV, 207 CNVs overlap with known genes and only 18 CNVs were localized
in non-coding areas. Regarding the type of CNV, we identified approximately 3.8 times more CNV
gains than CNV losses. These variants were more frequently present in non-coding regions; however,
duplications overlap coding regions nearly 6.4 times more frequently than the deletions (Table 2).
Table 2. Data shows number of identified CNVs sorted by the type of variant and number of Mega
base pairs (Mbp) attributed to specific genomic location.







CNV gain 178 191.54 3.27 188.27
CNV loss 47 46.98 0.44 46.54
Sum 225 238.52 3.71 234.81
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3. Discussion
Knowledge of population genetic studies, e.g., Human Genome Project, has changed genomics
and had tremendous impact on current medicine [20,21]. Detection of CNVs within and between
populations is important to understand the plasticity of our genome and to elucidate its possible
contribution to disease management [22]. Based on these statements, we are suggesting the additional
utility of genomic data generated through routine NIPT screening based on low-coverage massively
parallel whole-genome sequencing of total plasma DNA from pregnant women. This test provides
a lot of credible genomic data that can be used as background for population studies. Our results
show that 4.2% of individuals carry CNV ≥ 600 kbp, suggesting a relatively high frequency of large
CNVs in the Slovak population. These findings are consistent with results from Cooper et al., which
presented one of the largest studies investigating the role of rare CNVs in intellectual disability and
developmental delay, analyzing data from 15,767 affected individuals and 8329 controls. They showed
that 25.7% of affected individuals and 11.5% of controls harbor CNVs > 400 kbp [23].
Overall, there were approximately four times higher frequency of duplications compared to
deletions (Table 2). The underrepresentation of deletions is consistent with previous reports, where
large deletions were less common than large duplications when considering CNVs > 500 kbp [24,25].
These results are concordant with the hypothesis that CNV losses are more deleterious [26]. All variants
together span 238.52 Mbp; however, only 3.71 Mbp (1.56%) were identified in coding regions. These
3.71 Mbp were spread through 207 CNVs (92%) overlapping with coding sequences. Since the gene
density is calculated at 5–23 genes per Mbp [27], there is a low probability that a CNV ≥ 600 kbp will
occur exactly in the non-coding region. Therefore, we expected most CNVs of such length to be at
least partially overlapping the coding regions. We have shown that duplications affect coding regions
approximately two times more frequently than deletions (1.71% vs 0.93% for duplications and deletions,
respectively). Sudmant et al. also found that duplications and deletions exhibit fundamentally different
population-genetic properties. Duplications are subjected to weaker selective constraint, hence affect
genes four times more likely than deletions, indicating that they provide a larger target for adaptive
selection [3].
Clinically relevant CNVs can be found in databases such as ClinVar, DECIPHER, ECARUCA and
the International Standards for Cytogenomic Arrays Database. When we compared our results with
ClinVar database, we found at least 22 variants (17 CNV gains; 5 CNV losses) in regions without any
previous record (Figure S1). For example, we have identified a CNV loss on the chromosome location
3q26.3 that is present consistently in three of our samples, but it was not previously described in the
database. This deletion encompassing approximately one half of sequence from the 3′ end of a gene
N-acetylated alpha-linked acidic dipeptidase-like 2 (NAALADL2). It has been shown that deletions
involving NAALADL2 are found in the general population [28]. On a closer view, we found that our
largest duplication in chromosome 10q21.1 overlaps the complete sequence of gene Protocadherin
Related 15 (PCDH15). Duplications in this gene have been shown to be associated with Usher syndrome
type 1 (OMIM: # 601067), which is characterized by deafness, vestibular areflexia, and prepubertal
onset of retinitis pigmentosa [29,30]. Although the NIPT enables the detection of maternal CNVs,
current analyses do not interpret these findings. Maternal aberrations can be clinically actionable or
potentially harmful for the fetus. Brison et al. suggest reporting these variants if clinically relevant
because it can improve pregnancy management and promote the health of the fetus or the mother or
both [31]. On the other hand, the identification and reporting of such CNVs represent a big challenge
for genetic counselors; thus, further guidelines to improve patient counseling are needed [32]. It is
also known that performing NIPT may incidentally lead to the diagnosis of maternal malignancy.
Giles et al. showed, 80% of genetic counselors recognized it would be beneficial in the future to use
NIPT for neoplasm screening, however, more than 90% affirmed that guidelines are necessary to better
prepare for these cases [33].
Performing large numbers of parental samples is expensive, but the need for parental testing
will diminish by accumulating data about benign CNVs [16]. Recently, an updated, higher resolution
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map of CNVs that are not associated with adverse phenotypes, based on 55 studies, was developed.
Zarrei et al. estimated that up to 9.5% of the genome contributes to CNV. Additionally, they have found
approximately 100 genes that can be homozygously deleted without producing apparent phenotypic
consequences. This map is a great contribution to the interpretation of new CNV findings, for clinical
and research applications [34]. As clinical laboratories adopt CNV analysis, these resources will
become invaluable for the clinician to discriminate pathogenic from non-disease associated CNVs [8].
However, there is still a need for appropriate recommendations or guidelines related to evaluation
of CNV findings and for their classifications. The main limitation of our study remains the size of
detected CNVs; however, with improving laboratory and computational methods, as well as lowering
the cost of sequencing, this limit should decrease. Currently, our method was validated to CNVs
with minimal length 600 kbp, while the vast majority of CNVs are smaller than 500 kbp [35]. On the
other hand, CNVs larger than 500 kbp are strongly associated with morbid consequences such as
developmental disorders and cancer [22]. Despite mentioned limitation, we showed, NIPT may be
utilized for the identification of common structural variations in population, and it could contribute to
the interpretation of CNV findings in clinical research.
4. Materials and Methods
In our previous work we described non-invasive prenatal test (NIPT) based on low-coverage (0.3×)
massively parallel whole-genome sequencing of total plasma DNA for detection of CNV aberrations
longer than 600 kbp [14]. This test generates amount of credible genomic data, from thousands of
pregnant women which represent a relatively standard sample of local population. We reanalyzed
NIPT genomic data from 5018 patients to calculate frequencies of CNV aberrations in the Slovak
population. All subjects gave their informed consent for inclusion before they participated in the
study. Informed consent includes permission to process the sample for further analysis maintaining
the anonymity but does not include a statement for contacting the patient again in case of a clinically
significant maternal finding. Therefore, it was possible to use samples processed in the past, but due to
anonymization we were not able to contact the patients and associate the finding with the phenotype.
The study has been approved by the Ethical Committee of the Bratislava Self-Governing Region
(Sabinovska ul.16, 820 05 Bratislava) on 30 April 2015 under the decision ID 03899_2015.
4.1. Sample Preparation and Sequencing
Blood from pregnant women was collected into EDTA tubes and kept at 4 ◦C temperature until
plasma separation. Blood plasma was separated within 36 h after collection and stored at −20 ◦C until
DNA isolation. DNA was isolated using Qiagen DNA Blood Mini kit (QIAGEN, Hilden, Germany).
Standard fragment libraries for massively parallel sequencing were prepared from isolated DNA
using an Illumina TruSeq Nano kit (Illumina, San Diego, CA, USA) and a modified protocol described
previously [11]. Briefly, to decrease laboratory costs, we used reduced volumes of reagents, which was
compensated by nine cycles of PCR instead of eight as per protocol. Physical size selection of cfDNA
fragments was performed using specific volumes of magnetic beads in order to enrich fetal fraction.
Illumina NextSeq 500/550 High Output Kit v2 (75 cycles) (Illumina, San Diego, CA, USA) was used for
massively parallel sequencing of prepared libraries using pair-end sequencing with read length of
2 × 35 bp on an Illumina NextSeq 500 platform.
4.2. Mapping and Read Count Correction
Sequencing reads were aligned to the human reference genome (hg19) using Bowtie 2 algorithm [36].
NextSeq-produced fastq files (two per sample; R1 and R2) were directly mapped using the Bowtie 2
algorithm with very-sensitive option. Next, for each sample, the unique reads were processed to
eliminate the GC bias according to [37] with the exclusion of intrarun normalization. Briefly, for each
sample the number of unique reads from each 20 kbp bin on each chromosome was counted. With
empty bins filtered out, the locally weighted scatterplot smoothing (LOESS) regression was used to
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predict the expected read count for each bin based on its GC content. The LOESS-corrected read count
for a particular bin was then calculated as RC= RC − ||RC− RC||, where RC is the global average of read
counts through all bins; RC is the fitted read count of that bin, and RC is its observed read count. PCA
normalization has been further carried out to remove higher-order population artifacts on autosomal
chromosomes [38,39]. At first, bin counts are transformed into a principal space. The first component
represents the highest variability across individuals in the control set. To normalize the sample,
bin counts corresponding to predefined number of top components are removed to reduce common
noise in euploid samples. Bins without sufficient coverage that correspond to the low complexity
genomic regions were excluded from the analysis.
4.3. Segment Identification and CNV Calling
Normalized bin counts were analyzed by circular binary segmentation (CBS) algorithm provided
by the R package DNAcopy (Seshan VE, Olshen A. DNAcopy: DNA copy number data analysis.
R package version 1.48.0. 2016.) to identify same-coverage segments. CBS partitions a chromosome
into regions with equal copy numbers. Segments longer than 600 kbp with abnormal copy number
(at least 60% gain or loss of a single chromosomal segment) were marked as maternal and annotated
using AnnotSV tool [40] and ClinVar database [41].
4.4. Data Processing
All computational steps were executed using Snakemake workflow engine [42]. Evaluation of
maternal calls and generation of plots were performed using in-house Python scripts.
5. Conclusions
CNVs represent an important source of variations in the human genome. They are functionally
and evolutionary significant and contribute to the population diversity and human genetic diseases.
As NGS has become a valuable tool in research and in clinical settings, the number of NGS based tests
has increased. Among them, CNV detection tests are also increasing. In this study, we confirmed our
hypothesis and demonstrated that NIPT can be used also for the identification of common structural
variations in population.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/18/
4403/s1.
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Abstract: The aim of the study was to verify if quantification of placental specific C19MC microRNAs
in plasma exosomes would be able to differentiate during the early stages of gestation between patients
subsequently developing pregnancy-related complications and women with the normal course of
gestation and if this differentiation would lead to the improvement of the diagnostical potential.
The retrospective study on singleton Caucasian pregnancies was performed within 6/2011-2/2019.
The case control study, nested in a cohort, involved women that later developed GH (n = 57),
PE (n = 43), FGR (n = 63), and 102 controls. Maternal plasma exosome profiling was performed
with the selection of C19MC microRNAs with diagnostical potential only (miR-516b-5p, miR-517-5p,
miR-518b, miR-520a-5p, miR-520h, and miR-525-5p) using real-time RT-PCR. The down-regulation
of miR-517-5p, miR-520a-5p, and miR-525-5p was observed in patients with later occurrence of GH
and PE. Maternal plasma exosomal profiling of selected C19MC microRNAs also revealed a novel
down-regulated biomarker during the first trimester of gestation (miR-520a-5p) for women destinated
to develop FGR. First trimester circulating plasma exosomes possess the identical C19MC microRNA
expression profile as placental tissues derived from patients with GH, PE and FGR after labor.
The predictive accuracy of first trimester C19MC microRNA screening (miR-517-5p, miR-520a-5p, and
miR-525-5p) for the diagnosis of GH and PE was significantly higher in the case of expression profiling
of maternal plasma exosomes compared to expression profiling of the whole maternal plasma samples.
Keywords: C19MC microRNA; expression; exosomes; fetal growth restriction; gestational hypertension;
plasma; prediction; preeclampsia; pregnancy-related complications; screening
1. Introduction
Most previous studies performed C19MC microRNA profiling analyses on whole maternal plasma
or serum samples with the aim to diagnose or predict the later occurrence of pregnancy-related
complications [1–10]. Nevertheless, nowadays with regard to the perspectives of potential usage
of exosomes as therapeutics in placental-mediated disorders [11–14], it is crucial to characterize
first the inner content of placental derived exosomes, and next to describe their impact on the
modulation of maternal immune system and metabolism through the mediation of distant cell–cell
communication [11].
Exosomes are small size vesicles (30–150 nm) of the endosomal origin released to the extracellular
space by most cells including trophoblast cells that mediate cell–cell communication through signaling
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molecules (proteins, lipids, RNA, and DNA) released after the exocytosis fusion of multi-vesicular
body with the cell membrane of the target cell [11,15–23].
C19MC microRNAs represent unique placental specific biomarkers to be tested in plasma/serum
exosomes during gestation, since only paternally inherited alleles are expressed in the placenta due
to genomic imprinting [24]. Nevertheless, since some microRNAs from C19MC microRNA cluster
were demonstrated to be also expressed in the testis, embryonic stem cells, and specific tumors [25–28],
we previously selected, from the C19MC microRNA cluster, only those microRNAs (miR-516-5p,
miR-517-5p, miR-518b, miR-520a-5p, miR-520h, and miR-525-5p) that were exclusively or abundantly
expressed in the placenta, showed minimal expression in other tissues and maximum diagnostical
potential (100% detection rate in maternal plasma samples throughout gestation, from early stages to
term pregnancy) [3,29,30].
To date, little data on first trimester exosome microRNA profiling is available in women with
subsequent development of pregnancy-related complications such as gestational hypertension (GH),
preeclampsia (PE), and/or fetal growth restriction (FGR) [22,31].
This study is a follow-up of our previous studies dedicated to first trimester screening of
circulating C19MC microRNAs in whole maternal plasma and its potential to predict subsequent
onset of gestational hypertension, preeclampsia, and/or FGR [6,9]. The aims of the current study
are to explore A) if quantification of placental specific C19MC microRNAs in plasma exosomes
would be able to differentiate during the early stages of gestation between patients subsequently
developing pregnancy-related complications and women with normal course of gestation and B) if this
differentiation would lead to the improvement of their diagnostical potential (better detection rate).
2. Results
Gene expression of C19MC microRNAs in plasma exosomes was retrospectively compared
between women with normal and complicated course of gestation (GH, PE, and FGR) within 10 to
13 weeks. Just the results that reached a statistical significance or displayed a trend toward aberrant
levels of circulating C19MC microRNAs in complicated cases are presented below.
2.1. Plasma Exosomal miR-517-5p, miR-520a-5p and miR-525-5p are Down-Regulated during the First
Trimester of Gestation in Women Affected with GH and PE
The expression profile of miR-517-5p, miR-520a-5p, and miR-525-5p differed significantly or
showed a trend toward statistical significance between the groups of women with later onset of GH or
PE and the controls. Decreased levels of miR-517-5p, miR-520a-5p, and miR-525-5p were detected
during the first trimester of gestation in circulating plasma exosomes in women that later developed
either GH or PE (Figure 1).
Figure 1. Cont.
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Figure 1. Down-regulation of miR-517-5p, miR-520a-5p, and miR-525-5p in plasma exosomes during the
first trimester of gestation in women with later onset of GH or PE.(a–c) Decreased levels of miR-517-5p,
miR-520a-5p, and miR-525-5p were observed in circulating plasma exosomes within 10 to 13 weeks of
gestation in women affected with GH or PE when the comparison to the controls was performed using
non-parametric statistical test (the Kruskal-Wallis test). GH: gestational hypertension; PE: preeclampsia.
Outliers are marked by circles (◦), and extremes by asterisks (*).
2.2. The High Accuracy of First Trimester C19MC MicroRNA Expression Profiling in Maternal Plasma
Exosomes to Identify Women at a Risk of Later Development of GH or PE
The screening of individual C19MC microRNA biomarkers in plasma exosomes directed to
the prediction of subsequent onset of GH reached a very high accuracy (miR-517-5p: AUC 0.812,
p < 0.001; miR-520a-5p: AUC 0.806, p < 0.001; and miR-525-5p: AUC 0.802, p < 0.001). The predictive
performance of miR-517-5p, miR-520a-5p, and miR-525-5p reached 48.21%, 57.14%, and 57.14% at
10.0% false positive rate (FPR) (Figure 2).
The combination of miR-520a-5p and miR-525-5p (AUC 0.808, p < 0.001) had an advantage over
using the miR-517-5p biomarker only (AUC 0.812, p < 0.001), since it was able to predict a significantly
higher number of women that later developed GH (66.07% sensitivity at 10.0% FPR vs. 48.21%
sensitivity at 10.0% FPR) (Figure 3).
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Figure 2. ROC curves—individual C19MC microRNA biomarkers—evaluation of the potential of the
first trimester C19MC microRNA screening in plasma exosomes to predict later onset of GH. Decreased
levels of miR-517-5p, miR-520a-5p, and miR-525-5p were detected in women destinated to develop GH
when the comparison to the controls was performed both (a–c). GH: gestational hypertension.
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Figure 3. ROC curves—the best combination of C19MC microRNA biomarkers—evaluation of the
potential of the first trimester C19MC microRNA screening in plasma exosomes to predict later onset of
GH. The combination of miR-520a-5p and miR-525-5p showed the best predictive performance for the
prediction of the later occurrence of GH (66.07% sensitivity at 10.0% FPR). GH: gestational hypertension.
Similarly, the ROC curve analyses, revealed significantly lower levels of miR-517-5p (AUC 0.634,
p = 0.022, 27.91% sensitivity at 10.0% FPR), miR-520a-5p (AUC 0.699, p < 0.001, 41.86% sensitivity at
10.0% FPR), and miR-525-5p (AUC 0.698, p < 0.001, 39.53% sensitivity at 10.0% FPR) in a substantial
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Figure 4. ROC curves—individual C19MC microRNA biomarkers—evaluation of the potential of the
first trimester C19MC microRNA screening in plasma exosomes to predict subsequent onset of PE.
Decreased levels of miR-517-5p, miR-520a-5p, and miR-525-5p were detected in women destinated to
develop PE when the comparison to the controls was performed (a–c). PE: preeclampsia.
The combined screening of miR-517-5p, miR-520a-5p, and miR-525-5p was superior over using
individual C19MC microRNA biomarkers or their dual combinations, since it was able to predict the
highest number of women with the subsequent onset of PE (AUC 0.719, p < 0.001, 44.19% sensitivity at
10.0% FPR) (Figure 5).
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Figure 5. ROC curves—the best combination of C19MC microRNA biomarkers—evaluation of the
potential of the first trimester C19MC microRNA screening in plasma exosomes to predict subsequent
onset of PE. The combination of miR-517-5p, miR-520a-5p, and miR-525-5p showed the best predictive
performance for the prediction of the later occurrence of PE (44.19% sensitivity at 10.0% FPR).
PE: preeclampsia.
2.3. MiR-520a-5p Represents a Novel Maternal Plasma Exosome C19MC MicroRNA Biomarker for Prediction
of Later Onset of FGR
The Kruskal-Wallis test indicated the down-regulation of miR-520a-5p in circulating plasma
exosomes during the first trimester of gestation in women carrying subsequently growth-restricted
fetuses (Figure 6).
Figure 6. Down-regulation of miR-520a-5p in plasma exosomes during the first trimester of gestation
in women with subsequent onset of FGR. Decreased levels of miR-520a-5p were observed in circulating
plasma exosomes within 10 to 13 weeks of gestation in women affected with FGR when the comparison
to the controls was performed using the Kruskal-Wallis test. FGR: fetal growth restriction. Outliers are
marked by circles (◦), and extremes by asterisks (*)
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The predictive performance of miR-520a-5p reaches 22.22% sensitivity at 10.0% FPR (AUC 0.611,
p = 0.037) (Figure 7).
Figure 7. ROC curves—evaluation of the potential of the first trimester miR-520a-5p biomarker
screening in plasma exosomes to predict subsequent onset of FGR. Decreased levels of miR-520a-5p
were detected in women destinated to develop FGR when the comparison to the controls was performed.
FGR: fetal growth restriction.
3. Discussion
To our knowledge, no data on C19MC microRNA profiling in maternal plasma exosomes during
the first trimester of gestation was reported.
We found out that first trimester circulating plasma exosomes possess the identical C19MC
microRNA expression profile as placental tissues derived from patients with GH, PE, and FGR after
labor [32].
In placental tissues, down-regulation of 4/15 tested C19MC microRNAs (miR-517-5p, miR-519d,
miR-520a-5p, and miR-525-5p) was previously observed in GH patients [32]. After the investigation
of maternal plasma exosome C19MC microRNA expression profile during the first trimester of
gestation with the selection of C19MC microRNAs with diagnostical potential only (miR-516b-5p,
miR-517-5p, miR-518b, miR-520a-5p, miR-520h, and miR-525-5p) [29], we observed the down-regulation
of miR-517-5p, miR-520a-5p, and miR-525-5p in patients with later occurrence of GH, which is in
compliance with the findings in placental tissues derived from GH patients during the delivery [32].
Similarly, in PE patients, down-regulation of 11/15 tested C19MC microRNAs (miR-515-5p,
miR-517-5p, miR-518b, miR-518f-5p, miR-519a, miR-519d, miR-520a-5p, miR-520h, miR-524-5p,
miR-525-5p, and miR-526a) was previously demonstrated [32]. Parallel, after the testing of C19MC
microRNAs with diagnostical potential only (miR-516b-5p, miR-517-5p, miR-518b, miR-520a-5p,
miR-520h, and miR-525-5p) [29] in maternal plasma exosomes during the first trimester of
gestation, we identified decreased levels of miR-517-5p, miR-520a-5p, and miR-525-5p in patients that
subsequently developed PE, which corresponds to a considerable extent to the expression profiles
observed in PE affected placental tissues [32].
Nevertheless, these data are opposed to the results of our previous studies [6,9], indicating first
trimester upregulation of circulating C19MC microRNAs in maternal plasma with predictive accuracy of
subsequent development of gestational hypertension (miR-516-5p, miR-517-5p, miR-518b, miR-520a-5p,
and miR-520h) or preeclampsia (miR-517-5p). Other investigators also observed increased levels of
some C19MC microRNAs (miR-520) in sera from 12 to 14 weeks of gestation in women, who later
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developed severe preeclampsia [7]. We believe that dissimilar expression profiles of C19MC microRNAs
between maternal plasma and maternal plasma exosomes can be influenced by compilations stemming
from several factors. At the very least, an expression of particular C19MC microRNA in maternal
plasma is represented by the total sum of expression of this particular C19MC microRNA in individual
cells located in different areas of placenta, which currently undergo apoptosis, release placental debris
into the maternal circulation, and actively secrete exosomes mediating intercellular communication [9].
However, the predictive accuracy of first trimester C19MC microRNA screening for the diagnosis
of gestational hypertension is significantly higher in case of expression profiling of miR-517-5p (AUC
0.812, p < 0.001 vs. AUC 0.752, p = 0.002) and miR-520a-5p: (AUC 0.806, p < 0.001 vs. AUC 0.688,
p = 0.031) in maternal plasma exosomes compared to expression profiling of whole maternal plasma
samples [6].
In case of preeclampsia, the predictive accuracy of miR-517-5p is nearly identical for maternal
plasma exosomes and whole maternal plasma samples (AUC 0.634, p = 0.022 vs. AUC 0.700,
p = 0.045) [9]. But, maternal plasma exosome C19MC microRNA profiling significantly improved the
predictive accuracy of miR-520a-5p (AUC 0.699, p < 0.001 vs. AUC 0.495, p = 0.951) and miR-525-5p
(AUC 0.698, p < 0.001 vs. AUC 0.475, p = 0.755) for preeclampsia [9]. In addition, the best predictive
performance for preeclampsia was achieved when maternal plasma exosome combined profiling of
miR-517-5p, miR-520a-5p, and miR-525-5p (AUC 0.719, p < 0.001) was performed.
In case of FGR, placental tissues showed down-regulation of 6/15 tested C19MC microRNAs
(miR-517-5p, miR-518f-5p, miR-519a, miR-519d, miR-520a-5p, and miR-525-5p) [32]. Maternal plasma
exosomal profiling of selected C19MC microRNAs [29] revealed a novel down-regulated biomarker
during the first trimester of gestation (miR-520a-5p) for women destinated to develop FGR, which was
not identified when whole maternal plasma analysis was performed [9].
This study confirmed the former hypothesis, that the exosomes released to the systemic circulation
represent unique non-invasive source of signalling molecules, including microRNAs, whose aberrant
expression profile reflects expression profile of the parent cells (in this particular event the trophoblast
cells) [22,23]. These observations support the idea that placenta-derived exosomes may be utilized
as a part of first trimester screening to identify a significant proportion of women at a risk of later
development of pregnancy-related complications such as gestational hypertension, preeclampsia, and
FGR [22]. The only weakness of this approach is that the screening of C19MC microRNAs in plasma
exosomes is not able to differentiate during the first trimester of gestation between the women that later
develop GH and those ones that later develop PE, since the down-regulation of the same biomarkers
(miR-517-5p, miR-520a-5p, and miR-525-5p) is present from early gestation. Nevertheless, through the
mediation of this approach, novel microRNA biomarkers may be identified at some time in the future,
which would be able to differentiate between women at a risk of GH and at risk of PE, to enable the
primary prevention of preeclampsia via the early administration of low-dose aspirin [33–35].
Nevertheless, recent findings confirmed that even in women at a high risk of pregnancies with
small-for-gestational-age foetuses the administration of aspirin at a dose of≥100 mg starting at or before
16 weeks of gestation is recommended [36–38]. Therefore, miR-520a-5p may be a novel promising
placental specific biomarker for FGR with a potential of early stratification of high-risk pregnancies,
which may benefit from primary prevention strategies as well.
4. Materials and Methods
4.1. Patients Cohort
The study had a retrospective design, it was performed in 6/2011–2/2019. The study cohort
involved singleton pregnancies of Caucasian descent only. Of 4356 women undergoing first trimester
screening at 10–13 weeks of gestation, 3092 women were finally followed-up and delivered in the
Institute for the Care of Mother and Child, Prague, Czech Republic, 1189 women were followed-up
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and delivered in another health care provider, and in 75 women gestation was terminated for fetal
anomaly or missed abortion appeared.
The case control study nested in a cohort involved women that later developed relevant
pregnancy-related complications (57 GH, 43 PE, and 63 FGR) [39–42]. Finally, 13 of 43 PE patients
developed mild PE, 30 of 43 PE patients suffered from severe PE, 10 of 43 PE patients were diagnosed
with early PE (before 34 week of gestation) and 33 of 43 PE patients delivered after 34 week of gestation
(late PE) [39–41]. Superimposed preeclampsia occurred in 5 out of 43 cases [39–41].
Of 63 pregnancies complicated with FGR, 4 foetuses were delivered before 32 week of gestation
(early FGR), other 59 cases were diagnosed with late form of FGR (diagnosed after 32 week of
gestation) [42].
Oligohydramnios or anhydramnios were found in 1 PE case and 16 FGR-affected foetuses.
Aberrant index of pulsatility (PI) was detected in arteria umbilicalis (above 95th percentile, 3 PE
cases, 23 FGR cases), arteria cerebri media (below 5th percentile, 3 PE cases, 14 FGR cases), arteria
uterine (above 95th percentile, 7 PE case, 4 FGR cases), and Ductus venosus (>1, 3 FGR cases) [43,44].
The aberrant cerebro-placental ratio (CPR), below 5th percentile, was detected in 7 PE cases and
47 FGR cases [45–48]. Absent and/or zero diastolic flow in the arteria umbilicalis was present in 3 FGR
cases [49,50]. An absence of flow during atrial contraction in Ductus venosus was detected in 1 FGR
case [51,52]. The presence of unilateral or bilateral diastolic notch in the uterine artery was observed in
7 PE cases and 5 FGR cases [53,54].
The control group, normal pregnancies without complications delivering full term, healthy infants
after 37 weeks of gestation weighting >2500 g, was selected on the basis of equal gestational age, equal
age of women at the time of sampling and equal plasma sample storage times. The control group was
separated into two subgroups and involved 102 cases altogether (the group 1 consisted of 50 cases, and
the group 2 of 52 cases).
The clinical characteristics of the controls and complicated pregnancies are outlined in Table 1.
Written informed consent was provided for all participants included in the study. The study
was approved by the Ethics Committee of the Third Faculty of Medicine, Prague, Czech Republic
(Implication of placenta-specific microRNAs in maternal circulation for diagnosis and prediction of
placental insufficiency, date of approval: 7.4.2011).
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4.2. Processing of Samples
Two millilitres of incoagulable peripheral blood (EDTA tubes) were centrifuged twice immediately
after collection at 1200 rcf (4600 rpm) for 10 min at room temperature. Plasma samples were then
stored frozen at −80 ◦C until further processing.
4.3. Isolation and Purification of Exosomes from Maternal Plasma Samples
Exosomes were isolated from 0.6 mL of maternal plasma samples using miRCURYTM Exosome
Isolation Kit-Serum and plasma (Exiqon, Woburn, MA, USA, no: 300101) according to the
manufacturer´s instructions. After the exosome isolation and purification, RNA was isolated
immediately from 200 μL supernatant using miRCURYTM RNA Isolation Kit-Biofluids (Exiqon,
Woburn, MA, USA, no: 300112) according to manufacturer’s instructions. After 3 min incubation of
200 μL supernatant with 60 μL Lysis Solution buffer, 1 μL RNA spike-in (1 nM cell-miR-39, synthetic
C. elegans microRNA, Qiagen, Hilden, Germany, no: MSY0000010) and 20 μL Protein Precipitation
Solution buffer were added into the mixture. In order to maximize yield of exosomal RNA, total elution
volume of 100 μL was used (50 μL in 2 steps eluting with half of the recommended total volume each).
DNA contamination of RNA was removed by the 30 min treatment of eluted RNA with 5 μL DNase I
(Thermo Fisher Scientific, Waltham, MA, USA, no: EN0521) at 37 ◦C.
The quality of the isolated exosomes was not checked using flow cytometry, electron microscopy,
or other techniques, since we were not interested in exosomal subpopulations present in analysed
samples or in performance of exosomal functional studies. The protocols of miRCURY™ Exosome
Isolation Kit—Serum and plasma (Exiqon, Woburn, MA, USA, no: 300101) are validated to allow
subsequent microRNA isolation using the miRCURY™ RNA Isolation Kit - Biofluids (Exiqon, Woburn,
MA, USA, no: 300112) and improve the quality of the obtained microRNA signature.
4.4. Reverse Transcription Reaction
The analyzed C19MC microRNAs and cell-miR-39 were reverse transcribed into complementary
DNA using TaqManTM MicroRNA Assays (Thermo Fisher Scientific, Waltham, MA, USA, miR-516b-5p
no: 001281, miR-517-5p no: 001113, miR-518b no: 001156, miR-520a-5p no: 001168, miR-520h no: 001170,
miR-525-5p no: 001174, and cell-miR-39 no: 000200), and TaqMan MicroRNA Reverse Transcription
Kit (Thermo Fisher Scientific, Waltham, MA, USA, no: 4366597). Reverse transcription reaction was
performed in a total reaction volume of 32 μL in case of C19MC microRNAs and in a total reaction
volume of 10 μL in case of cell-miR-39 on a 7500 Real-Time PCR system (Thermo Fisher Scientific,
Waltham, MA, USA) under predefined thermal cycling parameters: 30 min at 16 ◦C, 30 min at 42 ◦C,
5 min at 85 ◦C, and then held at 4 ◦C [3,5,6,9,32].
4.5. Quantification of Plasma Exosomal C19MC microRNAs by Real-Time PCR
15 μL of cDNA corresponding to C19MC microRNAs and 4.4 μL of cDNA corresponding to
cell-miR-39 were mixed with components of TaqMan MicroRNA Assays (Thermo Fisher Scientific,
Waltham, MA, USA, miR-516b-5p no: 001281, miR-517-5p no: 001113, miR-518b no: 001156,
miR-520a-5p no: 001168, miR-520h no: 001170, miR-525-5p no: 001174, and cell-miR-39 no: 000200),
and the ingredients of the TaqMan Universal PCR Master Mix (Thermo Fisher Scientific, Waltham,
MA, USA, no: 4318157). The analysis was performed using a 7500 Real-Time PCR System under the
conditions described in the TaqMan guidelines in a total reaction volume of 35 μL. All PCRs were
performed in duplicates. A sample displaying the amplification signal before the 40th threshold cycle
(Ct) was considered positive.
The expression of particular C19MC microRNA in maternal plasma exosomes was determined
using the comparative Ct method [55] relative to the expression in the reference sample. RNA
isolated from the pool of randomly selected maternal plasma samples derived from women at the first
trimester with normal course of gestation was used as a reference sample for relative quantification.
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Two reference samples were used throughout the study (reference 1: the pool of 5 maternal plasma
samples, reference 2: the pool of 8 maternal plasma samples).
Real-time PCR data were normalized to synthetic C. elegans microRNA (cell-miR-39, Qiagen,
Hilden, Germany, no: MSY0000010) showing no sequence homology to any human microRNA:
2−ΔΔCt = [(Ct particular C19MC microRNA—Ct cel-miR-39) tested sample—(Ct particular C19MC
microRNA—Ct cel-miR-39) reference sample] [6,9].
4.6. Statistical Analysis
Normality of the data was assessed using Shapiro-Wilk test, which indicated that our experimental
data did not follow a normal distribution (Table S1). Therefore, C19MC microRNA levels were
primarily compared between groups using non-parametric test (the Kruskal-Wallis one-way analysis
of variance with post-hoc test for the comparison among multiple groups). The significance level was
established at a p-value of p < 0.05.
Receivers operating characteristic (ROC) curves were constructed to calculate the area under the
curve (AUC) and the best cut-off point for particular C19MC microRNA was used in order to calculate
the respective sensitivity at 90.0% specificity, respectively (MedCalc Software bvba, Ostend, Belgium).
For every possible threshold or cut-off value, the MedCalc program reports the sensitivity, specificity,
likelihood ratio positive (LR+), and likelihood ratio negative (LR-).
To select the optimal combinations of C19MC microRNA biomarkers logistic regression was
applied (MedCalc Software bvba, Ostend, Belgium). To perform a full ROC curve analysis the predicted
probabilities were first saved and next used as a new variable in ROC curve analysis. The dependent
variable used in logistic regression acted as the classification variable in the ROC curve analysis
dialog box.
Box plots encompassing the median (the Kruskal-Wallis test) of gene expression values for
particular C19MC microRNAs were generated using Statistica software (version 9.0; StatSoft, Inc.,
Tulsa, OK, USA). The upper and lower limits of the boxes represent the 75th and 25th percentiles
(the Kruskal-Wallis test), respectively. The upper and lower whiskers indicate the maximum and
minimum values that are no more than 1.5 times the span of the interquartile range (range of the values
between the 25th and the 75th percentiles) (the Kruskal-Wallis test). Outliers are marked by circles,
and extremes by asterisks.
The presentation of no statistically significant results is provided in Supplementary material
(Table S2).
5. Conclusions
The down-regulation of miR-517-5p, miR-520a-5p, and miR-525-5p was observed in patients with
later occurrence of GH and PE. Maternal plasma exosomal profiling of selected C19MC microRNAs
also revealed a novel down-regulated biomarker during the first trimester of gestation (miR-520a-5p)
for women destinated to develop FGR. First trimester circulating plasma exosomes possess the identical
C19MC microRNA expression profile as placental tissues derived from patients with GH, PE and FGR
during labour. The predictive accuracy of first trimester C19MC microRNA screening (miR-517-5p,
miR-520a-5p, and miR-525-5p) for the diagnosis of GH and PE was significantly higher in case of
expression profiling of maternal plasma exosomes compared to expression profiling of whole maternal
plasma samples. Consecutive large-scale studies are needed to verify the findings resulting from this
pilot study. Nevertheless, the performance of that kind of studies will be highly demanding, since
ten thousand of the first trimester plasma samples have to be collected to get sufficient amount of
cases who will subsequently develop pregnancy-related complications such as GH, PE, or FGR. For the
purpose of this study we collected plasma samples from 4356 women to acquire 163 samples from
women that later developed relevant pregnancy-related complications (57 GH, 43 PE, and 63 FGR).
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Abstract: The reliability of non-invasive prenatal testing is highly dependent on accurate estimation
of fetal fraction. Several methods have been proposed up to date, utilizing different attributes of
analyzed genomic material, for example length and genomic location of sequenced DNA fragments.
These two sources of information are relatively unrelated, but so far, there have been no published
attempts to combine them to get an improved predictor. We collected 2454 single euploid male fetus
samples from women undergoing NIPT testing. Fetal fractions were calculated using several proposed
predictors and the state-of-the-art SeqFF method. Predictions were compared with the reference
Y-based method. We demonstrate that prediction based on length of sequenced DNA fragments may
achieve nearly the same precision as the state-of-the-art methods based on their genomic locations.
We also show that combination of several sample attributes leads to a predictor that has superior
prediction accuracy over any single approach. Finally, appropriate weighting of samples in the
training process may achieve higher accuracy for samples with low fetal fraction and so allow more
reliability for subsequent testing for genomic aberrations. We propose several improvements in fetal
fraction estimation with a special focus on the samples most prone to wrong conclusion.
Keywords: NIPT; fetal fraction; statistical methods; DNA; maternal serum screening; fetal cells
1. Introduction
Prenatal testing for genomic defects of a fetus before birth is an integral component of current
obstetric practice [1]. The primary aim of the testing is screening for the presence of abnormal number
of chromosomes. Testing is focused mainly on identifying an additional copy of a chromosome,
the condition called trisomy [2], represented as an excessive proportion of genomic material from
the aberrant chromosome. Discovery of fetal DNA fragments in plasma extracted from maternal
blood, cell-free fetal DNA (cffDNA) [3], opened up new options in the field of prenatal screening
called non-invasive prenatal testing (NIPT) [1,4]. In contrast to established screening methods [5],
sampling of genetic material from the mother’s circulation does not pose any direct risk for the fetus [6].
On the other hand, fetal DNA fragments constitute only a minor part of the sampled, mostly maternal,
genomic material and so pose a challenge for reliable detection of present aberration.
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The proportion of fetal fragments in analyzed DNA mixture is called fetal fraction (FF). A sample
with a trisomic fetus typically has an aberrant proportion of genomic material from the trisomic
chromosome, compared to healthy samples. A trisomic sample with a very low FF can, however,
be incorrectly evaluated as healthy, since the aberrant chromosome may cause only a weak deviation
from normal values that can be presumed to represent a normal measurement error [7], which is
particularly problematic for the detection of sub-chromosomal aberrations. Reliable estimation of the
FF is therefore a crucial step of NIPT analysis to avoid false-negative results [8,9]. This can be based
on relevant anthropometric and laboratory processing attributes with significant correlation with FF,
namely the gestational age and the body mass index of the mother [10]. They were, however, reported
to be too weak for use as stand-alone information for reliable conclusions, and so more sophisticated
technical parameters exploiting different characteristics between maternal and fetal DNA fragments
are typically used [11].
Count based methods of FF determination calculate disproportion of number of reads mapped to
chromosomes that differ in mother and fetus genotypes. Although they are quite reliable, they can be
used only on samples with male (XX vs. XY genotype) [12] or trisomic (2 copies vs. 3 copies of an
aberrant chromosome) fetuses [13,14]. In pregnancy with a healthy female fetus, the FF have to be
estimated by alternative methods.
Methods based on sequence variation in DNA fragments are, on the other hand,
highly reliable [15,16], although their application typically requires another laboratory assay to
recover genetic map of parents, and so it is considered too expensive and time-consuming for routine
diagnostics. Alternatively, FF may be estimated from the genomic location patterns that slightly
differ between maternal and fetal fragments due to differences of their nucleosome positioning
(SANEFALCON method) [17] and euchromatic DNA structure (SeqFF method) [18]. Due to high
accuracy and no additional laboratory costs, the SeqFF method is a preferred method for samples with
female fetus [19].
The length of DNA fragment is another promising attribute for differentiation of DNA fragments,
since fetal fragments tend to be shorter than maternal ones (Figure 1). Although the fragment lengths
improve prediction of NIPT tests by detection of false positive predictions [20–22], their potential for
prediction of FF has been understudied. Only a simple length-based metric has been proposed in [23],
where the ratio of the number of shorter (100–150 bases) and longer (163–168 bases) fragments has
correlated with the FF.
Figure 1. Average fragment-length profiles determined from samples with selected ranges of fetal
fractions calculated across lengths. Samples with higher fetal fraction (FF) also have shorter fragments
indicating that maternal fragments are longer than fetal ones.
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We demonstrate in this study that fragment length profile may be utilized as a fairly accurate
predictor of the FF. We investigate various methods and enhancements that lead to improvement of
prediction accuracy and propose weighting training samples to improve accuracy in samples with
low FF that are more prone to wrong testing conclusions. Although the proposed method is not as
accurate as SeqFF, we show that their combination leads to more a reliable predictor than individual
methods alone.
2. Results
2.1. Comparison of Length-Based Methods
We introduced a new method for estimating FF (NLRM) and also compared other statistical (LRM)
and machine learning methods (NN, SVM) (see FF ESTIMATORS BASED ON FRAGMENT LENGTH
in Materials and methods). The Y-based FF was used as a “ground truth” for each comparison. We used
Pearson correlation and mean squared errors (MSE) of the predicted FF and the Y-based FF to compare
the surveyed methods.
Correlations were higher when compared to ones obtained from a published method using the
ratio of shorter and longer fragments (median correlation 0.568 on our data) [23]. After picking the best
ratio of consecutive intervals of fragment lengths (FRAC ratio), we were able to significantly improve
this correlation to 0.728. To get even better results, we applied nonlinear regression model (NLRM) to
estimate parameters (or weights) for individual fragment lengths resulting from the FRAC ratio. Here
we observed median correlation 0.812 for test set.
Although NN initially seemed to be a promising method for estimating FF using fragment length
distribution, we observed only sub-par results (median correlation 0.778). LRM and SVM models
achieved best correlation with median value 0.83 and 0.831, respectively. All results can be seen
on Figure 2.
Figure 2. Boxplots of MSE and Pearson correlation of Y-based FF and estimated FF obtained from
several different methods calculated for 100 testing sets. Training was performed on 100 complementary
training sets. FRAC(PUB) represents the ratio of fragment length intervals designed by the study
(Yu et al., 2014), FRAC means our best ratio of fragment length intervals derived by the best Pearson
correlation with Y-based FF, NN—neural network, NLRM—non-linear regression model based on FRAC
parameters, LRM—linear model using all fragment length parameters from 50–220 bp, SVM—support
vector machine using all fragment length parameters from 50–220 bp.
182
Int. J. Mol. Sci. 2019, 20, 3959
2.2. Combination of Methods Improves Prediction Accuracy
We have chosen the SVM method (median correlation 0.831) as the representative method based
on fragment-length profiles, according to the best prediction accuracy in the previous comparison.
SeqFF performed slightly better on our dataset than the SVM method (0.831 vs. 0.877, see Figure 3).
Since these two predictors use different attributes of fragments for prediction (lengths and positions),
we combined these two approaches using a linear regression model.
Figure 3. Boxplots of MSE and Pearson correlation of Y-based FF and estimated FF using SVM method
calculated for 100 testing sets. Training was performed on 100 complementary training sets. Combined
approach is denoted SeqFF + SVM. Improvement for every method was achieved by adding sample
attributes (DNA library concentration, BMI, gestational age)—represented by “+ SA”.
Furthermore, we examined the effect of additional predictive attributes from relevant
anthropometric and laboratory processing attributes, namely the gestational age, the body mass
index of the mother and the DNA library concentration to improve the models. In all examined
conditions, the accuracy of the predictions was improved, although the improvement was only mild in
some cases (Figure 3, with and without SA). Finally, using a linear regression model, we combined two
approaches, SVM and SeqFF, whereby the best trained model almost reached 0.95 correlation when
testing. Comparison of tested data from a randomly selected combined model with a Y-based method
is presented in the supplement (Figure 4) showing no systematic difference between the two methods.
Moreover, we compared FF prediction between male and female samples using the combined method.
Similar distribution of male and female samples was observed (Supplementary Figures S4 and S5).
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Figure 4. Linear regression of Y-based method with the combined method. Black circles denote
individual testing samples. Dashed line represents overall trend of the prediction and the grey line is
the 45◦ line.
Finally, we provide trained attribute (i.e., feature) weights of four examined linear models with
different combinations of attributes in a separate table (Table 1).
Table 1. The table shows corresponding feature weights of four trained linear models. Each row
represents a single feature of a linear model and each column represents a specific model. Each model
has a different combination of features. If a feature is not part of the model, the value is empty (labeled
by dash). Since one hundred models were trained for each combination, only the model with median
correlation is displayed. SVM: support vector machine estimator prediction based on fragment length
profile. SeqFF: prediction of the SeqFF model. BMI: body mass index of the mother. LC: DNA library
concentration. GA: gestational age. SA: sample attributes (BMI + LC + GA).
Method SeqFF + SA SVM + SA SVM + SeqFF Seqff + SVM + SA
SVM – 0.0418 0.0269 0.0243
SeqFF 1.1325 – 0.0237 0.0255
BMI −0.0006 −0.0058 – −0.0019
LC −0.0020 −0.0005 – −0.0015
GA ~0.0000 0.0037 – 0.0016
Intercept 0.0204 0.1222 0.1223 0.1227
2.3. Weighting of Samples with Low Fraction
From the perspective of NIPT, it is crucial to decrease the probability of false-negative results to a
minimum. Thus, only results with predicted FF above a certain threshold are acceptable. In this sense,
we examined adjustment of the model that would improve prediction accuracy on critical, low fraction
samples (FF <10%) at the expense of prediction of high fraction samples (FF >10%). We achieved the
improvement with inclusion of multiple copies of low fraction samples in training, increasing the
significance of such samples on resulting parameters.
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According to the expectation, we observed decline of prediction accuracy of samples with high
fraction. On the other hand, the prediction accuracy of low fraction samples was gradually improved
with increased significance of considered samples (Figure 5). This suggests that weighting samples
may further improve the decision process with more precise prediction of critical samples.
Figure 5. Mean absolute error Y-based FF and estimated FF using SVM method (lower is better). Only
samples with FF < 10% used in training were sampled (weighted) with weights 2×, 3×, and 4×. Samples
with FF > 10% were selected once. Scatterplots represented by linear regression with weighted samples
are presented in the supplement (Supplementary Figures S1–S3).
3. Discussion
Accurate estimation of fetal fraction in analyzed mixtures of fetal and maternal DNA fragments is
a critical part of non-invasive prenatal testing. The main challenge is to identify samples with too low
a number of fetal fragments for reliable prediction of aneuploidy, since over-estimation of prediction
may lead to false-negative results. Conversely, accuracy is not so important in typical settings for
samples with a sufficiently high fetal fraction. Prediction models should be therefore trained and
evaluated with a special focus on the importance of individual samples.
Several methods have been proposed for FF prediction, each with its own benefits and limitations.
Early established methods were based on disproportion of number of fragments from sex chromosomes.
They are simple to understand and implement and require a relatively small number of samples
for training. Their calculation is therefore typically the first step in estimation, whether as the gold
standard for other trained methods or initial determination of fetus sex. Testing may also utilize
two separated prediction methods for male and female fetuses, possibly with different thresholds
based on their precision. With the rising number of tested samples, the more complex models can
be trained without the risk of overfitting. Since the number of samples should be much higher than
the number of trained model parameters, laboratories should reach at least hundreds of samples for
fragment length based models and tens of thousands for the position based models. This is a great
advantage for simpler models, since the acquisition of such a number of samples may be limiting for
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small laboratories. This represents a problem for already established tests as well, since beneficial
changes in laboratory processing may be halted due to a high cost of re-training.
Available methods are also highly diverse in the attributes they use for prediction, from the
simplest models that utilize only patient attributes, to highly complex attributes aggregated from
sequenced fragments. Combination of several independent, even weak predictors, can perform better
than any of them alone, as was shown in many other domains [24]. Fetal fraction prediction benefited
from such coupling as well, as presented in this study. Furthermore, the more accurate predictions
including more methods may indicate or even correct the potential abnormal diversions of any single
method. Present or future methods may be incrementally supplemented and so gradually improve the
overall predictions. The effect of individual methods should be however weighted to prefer methods
with higher accuracy. Assigned weights may also indicate that a gain from a less accurate predictor
becomes negligible and so may be excluded without significant impact.
We propose several approaches that markedly improve accuracy of prediction of fetal fraction,
making results of non-invasive prenatal testing more reliable. Firstly, the fragment length profiles may
be utilized as a reliable predictor of FF and achieve similar precision to the favored methods based on
positions of DNA fragments. Secondly, the combination of results from multiple predictors achieve
far better predictions, at least when they are based on different attributes of input DNA fragments.
The final combined method is free of systematic bias when compared to the Y-based method. We
conclude that low quality predictors, like regressors based on relevant anthropometric and laboratory
processing attributes, may contribute to the overall accuracy. Other methods utilizing their own set of
distinctive attributes, both present and future, can be similarly included, and so improve prediction
compared to their stand-alone usage. Based on these findings, we conclude that additional, possibly
independent, information can significantly raise the prediction accuracy of FF prediction, and thus,
should be used when possible.
Since the SeqFF publication does not provide a training option, we were forced to use the published
parameters on our dataset. As a consequence, we were unable to reach correlation reported by the
SeqFF study; however, our combined method reached similar scores. We presume that the combined
method can significantly surpass the performance of the standalone SeqFF method if its parameters
are properly trained on a similar dataset.
Finally, appropriate weighting of samples in the training process may achieve higher accuracy
for samples with low FF, and so allow a more decision regarding which samples have enough fetal
fragments for subsequent testing for genomic aberrations.
4. Materials and Methods
4.1. Sample Acquisition
We collected 2454 informative samples from women undergoing NIPT testing, with single euploid
male fetus, for training and testing of FF models. These samples were concluded as informative based
on their fetal fraction and manual examination. The hard coded FF threshold for an informative
sample was 4% but in some cases a sample with lower FF was reclassified as informative by manual
examination. Our work was part of two clinical studies approved by the Ethical Committee of the
Bratislava Self-Governing Region (Sabinovska ul.16, 820 05 Bratislava): the first one called “NIPT
study” (study ID 35900_2015 approved on 30 April of 2015 under the decision ID 03899_2015) and the
second one called “SNiPT” (study ID 37136/2018 approved on 11 June of 2018 under the decision ID
07507/2018/HF). All patients that were included in the study signed written informed consents consistent
with the Helsinki declaration which were approved by the above-mentioned ethics committee.
4.2. Sample Preparation and Sequencing
Peripheral blood from pregnant women was collected into EDTA tubes and kept at 4 ◦C until
plasma separation. Blood plasma was separated within 36 h after collection and stored at −20 ◦C at
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a DNA isolation unit. DNA was isolated using a QIAgen DNA Blood Mini Kit (Hilden, Germany).
Standard fragment libraries were prepared from isolated DNA using a modified protocol of the Illumina
TruSeq Nano Kit (San Diego, CA, USA) as described previously [20]. Briefly, to decrease the laboratory
costs we used reduced volumes of reagents, which was compensated for by completing 9 cycles of
PCR instead of 8, as per protocol. Physical size selection of cfDNA fragments was performed using
specific volumes of magnetic beads in order to enrich FF. Illumina NextSeq 500/550 High Output Kit v2
(San Diego, CA, USA) (75 cycles) was used for massively parallel sequencing of prepared libraries
using pair-end sequencing with read length of 35 bp.
4.3. Mapping and GC Correction
The first stage of data processing was carried out as previously described [20]. NextSeq-produced
fastq files (two per sample) were directly mapped using the Bowtie 2 [25] algorithm with –very-sensitive
option to the human reference genome hg19 (GRCh37). Reads with mapping quality of 40 or higher
were retained for further data processing. Length of a DNA fragment was determined as the difference
of the leftmost and the rightmost mapped base of the corresponding read pair.
Next, we weighted mapped reads to eliminate the GC bias according to [26] (with the exclusion of
intra-run normalization) to retrieve better estimates of underlying chromosomal distributions.
The corrected number of fragments per chromosome is determined by summing the corrected
read counts over all bins of the specified chromosome. The exception is chromosome Y, which is
presented only pregnancies with male fetuses. Even in such cases, low proportion of mappable regions
does not contain enough reads for reliable correction. As a result, a vector of corrected number of
fragments per autosomes, called autosomal counts, corrected number of fragments per chromosome X
(chrX), and uncorrected number of fragments per chromosome Y (chrY) were passed to the calculation
of the reference, Y-based FF (see below).
4.4. Data Preparation and Evaluation of Models
Fetal fractions were calculated using several proposed predictors and state-of-the-art method SeqFF.
Predictions were compared with the reference Y-based method. The robustness of this comparison
stems from using a multitude of training and testing datasets, thereby suppressing bias from a single
random sampling. Each model presented in this paper was evaluated on 100 testing sets by Pearson
correlation coefficient between Y-based values and predicted values of FF. For each such experiment,
the whole dataset (2454 male samples) was divided into 80% for training and 20% for testing.
The proportion of fragments for each target length (50–220 bases) were calculated for each sample
separately. Moreover, in the case of the support vector machine and neural network estimators,
the resulting 171 feature vectors of training sets were normalized to have zero mean and unit variance.
Y-Based Estimator
The Y-based FF was calculated according to the equation
FY =
%chrY − f emale%chrY
male%chrY − f emale%chrY (1)
from [27], where male %chr Y and female %chr Y is the mean fraction of chromosome Y sequence reads
of plasma samples obtained from 14 adult male individuals and pregnant women bearing euploid
female fetuses, respectively. %chr Y is the fraction of chromosome Y sequence reads of the sample
whose FF we want to calculate.
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4.5. FF Estimators Based on Fragment Length
4.5.1. Linear Regression Model (LRM)
Fetal fractions were estimated using a standard linear regression model provided by R-software
given by the equation
F = Lθ+ ε, (2)
where F is vector of fetal fractions, L is matrix of fragment lengths from 50 to 220 bp, θ is vector of
parameters to be estimated, and ε is vector of errors. The training and testing sets were selected from
the collected data. The parameters θ resulting from training were used to estimate FF for testing data.
4.5.2. Non-Linear Regression Model (NLRM)
We introduce a new approach for FF prediction—nonlinear function used in NLRM. Motivation
behind this method originated from a published method using the ratio of shorter (100–150 bases) and
longer (163–168 bases) fragments [23]. However, when we used a ratio of the same fragment lengths as
reported in the publication, we obtained sub-par results for our data. Therefore, we think that the
choice of fragment lengths is data specific and, in the first step, we were exhaustively searching for the
best fragment lengths to use for our data.
Let I = L50, L51, . . . , L220 be set of proportions of fragments of length 50 bp to 220 bp. Let I1, I2 be






To effectively compute the best performing ratio, reduction of the number of parameters is needed
when using optimization methods. To this end, we chose only consecutive intervals of fragment
lengths I1, I2 for evaluation. The ratio with the best correlation with Y-based FF (FY) was then chosen
for second step. We found out that cor(FRAC, FY) was maximal for the subsets I1 = L131, L132, . . . , L134
and I2 = L97, L98, . . . , L153.
In the second step, we applied a non-linear regression method for estimating model parameters
(weights) corresponding to fragment lengths. In this case, NLRM is defined by the equation
F = η(θ) + ε, (4)
where F = (F1, . . . , FN) is the vector of fetal fractions, η is a nonlinear function of selected fragment
lengths, θ = (M131, . . . , M134, N97, . . . , N153)
T is vector of parameters to be estimated, and ε is vector
of errors. Consider the non-linear regression model where for each sample (indexed by i = 1, . . . , N),





+ εi, i = 1, 2, . . . , N. (5)
Note that in the above, the nonlinear function η is given by the ratio of fragment lengths weighted
by parameters θ = (M131, . . . , M134, N97, . . . , N153)
T.
Similarly to LRM, the training and testing sets were selected from the collected data. The nlm
function from R software (https://www.r-project.org/) was used to estimate the parameters for NLRM.
The parameters were then used to estimate FF for testing data. Other optimisation methods from
R software like nls function and optim function using Broyden–Fletcher–Goldfarb–Shanno (BFGS)
algorithm [28] were also applied to estimate parameters for NLRM, but resulting variance of the FF
was much bigger compared to using nlm.
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4.5.3. Neural Network (NN)
A multilayer perceptron (MLP) regression model was trained in several steps for which the
datasets of normalized fragment length proportions were preprocessed. We selected DNNRegressor
estimator from open source machine learning framework TensorFlow [8] as implementation of MLP
regression. We tried two- and three-layer network architectures and several activation functions in the
DNNRegressor method. As a result, we found the following configuration to have the best performance
for the given input size: 55 units in input layer and 25 in two hidden layers each, Adagrad optimizer,
hyperbolic tangent as activation function, and mean reduction of loss.
4.5.4. Support Vector Machine (SVM)
We selected a SVM estimator from open source machine learning library sklearn [29] as the
implementation of SVM regression. Again, datasets of normalized fragment length proportions were
used to predict fetal fraction. Parameters of the SVM were optimized through grid search using
the method of sklearn (GridSearchCV) in conjunction with rigorous testing and empirical evidence.
The following parameters were found to give the best results: linear kernel, epsilon 0.01, tolerance for
stopping criterion (tol) 0.001, and penalty parameter of the error term (C) 1.0. Non-linear kernels were
also tested but all had poorer performance than linear kernel.
4.6. FF Estimators Based on Read Counts
SeqFF
The number of fetal DNA fragments varies in different regions of the genome and significantly
correlates with GC content and presence of coding regions. The position-based prediction method
SeqFF [11] takes a vector of Loess-corrected fragment counts as input, partitioned into bins 50,000
bases long. The fetal fraction is then determined using standard multivariate regression models trained
on a large number of samples (25,312 in original study) which exceeds this study close to tenfold.
In addition, published software for SeqFF calculation does not provide a training option. For these
reasons we used a pre-trained model and testing script from the original study to evaluate prediction
accuracy on our dataset.
4.7. Correlation with Sample Attributes
Additional sample attributes from requisition were compared with the reference FF. Slight
significant correlation was observed in three attributes, namely the gestational age, the body mass
index of the mother, and the DNA library concentration, with Pearson correlation at the level 0.1, −0.33,
and −0.22, respectively.
4.8. Combinaton of FF Estimators
A combined estimator for FF was built from SVM estimator and SeqFF estimator. Furthermore,
we examined impact of additional predictive attributes from requisitions and laboratory processing
of samples, namely the gestational age, the body mass index of the mother, and the DNA library
concentration. Then, 5 variables, specifically FF estimates resulting from the SeqFF and SVM methods,
the gestational age, the body mass index of the mother, and the DNA library concentration were
inserted into linear regression with Y-based FF as a response variable. Finally, the parameters obtained
from this linear regression were used to estimate FF for testing data.
4.9. Weighted Samples
The crucial step in the standard NIPT analysis is to identify samples with low fetal fractions
that may not have enough fetal fragments for reliable identification of aneuploidy. Such samples
are concluded as uninformative and may be subject to repeated sampling, typically few weeks later.
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Overestimation of FF may spuriously inflate confidence in a ploidy call for a sample where the assay
is not expected to be sensitive. On the other hand, for high-FF samples the accuracy of FF is less
important because the aneuploidy-calling algorithm is sufficiently sensitive anyway.
With this fact in mind, we tried to improve predictions in the lower range of Y-based FF targets.
All samples with fetal fraction below 10% (according to the Y-based estimator) within the dataset were
duplicated, triplicated, and quadruplicated, giving three distinct datasets. To evaluate this approach,
we trained prediction models on these datasets and compared them with models trained on the original
dataset. Prediction ability of FF in lower and higher range was evaluated separately.
Supplementary Materials: Supplementary materials are attached to this submission and the implementation of
the proposed methods is provided at https://github.com/rtcz/combo_ff. Supplementary materials can be found at
http://www.mdpi.com/1422-0067/20/16/3959/s1.
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Abstract: Recent advances in massively parallel shotgun sequencing opened up new options for
affordable non-invasive prenatal testing (NIPT) for fetus aneuploidy from DNA material extracted
from maternal plasma. Tests typically compare chromosomal distributions of a tested sample with
a control set of healthy samples with unaffected fetuses. Deviations above certain threshold levels
are concluded as positive findings. The main problem with this approach is that the variance of
the control set is dependent on the number of sequenced fragments. The higher the amount, the
more precise the estimation of actual chromosomal proportions is. Testing a sample with a highly
different number of sequenced reads as used in training may thus lead to over- or under-estimation
of their variance, and so lead to false predictions. We propose the calculation of a variance for each
tested sample adaptively, based on the actual number of its sequenced fragments. We demonstrate
how it leads to more stable predictions, mainly in real-world diagnostics with the highly divergent
inter-sample coverage.
Keywords: non-invasive prenatal testing; statistical models; z-score
1. Introduction
Advanced prenatal screening is an important part of obstetric care. Current methods of prenatal
testing, such as amniocentesis and chorionic villus sampling, involve invasive sampling of fetal
material and are associated with a risk of miscarriage [1]. Non-invasive prenatal testing based on
fetal DNA analysis from maternal circulation have been developed in order to prevent such risk. In
1997, the discovery of fetal cell-free DNA (cfDNA) in maternal plasma and serum has led to new
developments in the field of non-invasive prenatal diagnostic, opening up new options in the field of
obstetric research [2]. The fetal cfDNA is of placental origin [3], and it can be reliably detected from
fifth week of gestation [4]. On average, fetal cfDNA comprises about 10% of all cfDNA fragments
circulating in woman’s blood when sampling is done between 10 and 20 gestational weeks, but the
dispersion is quite large [5]. The advance of massively parallel sequencing technologies combined with
the rapid development of bioinformatic algorithms and tools brought about a new era of non-invasive
prenatal identification of common fetal aneuploidies, now commonly known as non-invasive prenatal
testing (NIPT) [6–10].
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In this paper, we focus on the last part of the NIPT analysis, when a sample already underwent
laboratory preparation, sequencing, and processing of the data (e.g., mapping, GC correction, etc.),
namely the interpretation of the resulting data. Traditionally, a z-score—also termed normalized
chromosomal value (NCV)—is used as a form of probabilistic measure of aneuploidies such as trisomies
T13, T18, and T21. The form of this test is, there is a proportion of sequenced fragments from observed
chromosome, and with them are the mean and standard deviation of the same value in a control
population of euploid samples, respectively [11–14]; while the method proposed by [13] appears to be
the best performing among the methods of this type. Model parameters and are typically trained on a
euploid population. While this is sufficient for the samples that have similar depth of sequencing, we
show that false positive (FP) and false negative (FN) calls may arise, if the tested sample differs in
the sequencing depth from the training set. As it is now common to offer NIPT tests in various price
ranges, the sequencing depth is what is usually scaled down in the cheaper tests. A possible but less
practical solution to this would be to have multiple training sets for various sequencing depths.
In this paper, we propose a mathematical formula for calculation of model parameters, and,
adaptively according to the actual sequencing depth of the diagnosed sample. Although the proposed
model requires some parameters to be estimated or trained from the euploid or normal population,
we show that these parameters are independent of the tested sample sequencing depth and can be
estimated from training samples with relatively shallow sequencing depth.
2. Results
2.1. Low Coverage in Training Samples Leads to Underestimation of Z-Score in High Coverage Samples
A lower number of reads leads to greater variability of observed chromosomal proportions
between samples compared to deeply sequenced samples (Figure 1). The z-score is then lower in
general, resulting in uninformative calls falling into the grey zone given by intervals (−4, −2.5) and
(2.5, 4). Both models performed similarly when trained and tested on the samples with the same
coverage (3M reads). 2840 euploid samples were tested, of which 39 and 42 fell into grey zone for
ADAVAR (Adaptive Variance) and FIXVAR (Fixed Variance) models, respectively.
Parameters trained on low coverage samples naturally cannot fit deeply covered samples. The
adaptively calculated standard deviation (SD) therefore performed markedly better in cases with a
great difference between training and testing set. In the case of ADAVAR model, one euploid and none
of the trisomic samples fell into a grey zone. At the hands of FIXVAR model, two trisomic and none
of the euploid samples fell into a grey zone. We observed 1.44× higher z-score (p = 7.431 × 10−7) for
ADAVAR model when trisomic sample were compared. Relatively higher variability of low coverage
3M samples thus leads to needless under-estimation of the z-scores in case of fixed model parameters.
We observed similar effect on real life samples with uneven coverage. Although all euploid
samples were classified correctly in both methods, the z-scores of trisomic samples were significantly
higher (1.24×, p = 0.0035) for the ADAVAR model.
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Figure 1. Boxplots of euploid NIPT samples for ADAVAR and FIXVAR models trained with samples
subsampled to 3M reads uniquely mapped to autosomes. Models have been tested with equivalent
samples subsampled to 3M (ADA 3M, FIX 3M) and 20M (ADA 20M, FIX 20M) respectively and with
original (ORIG) read count of reads uniquely mapped to autosomes (ADA ORIG, FIX ORIG). Grey
crosses represent trisomic samples. Samples in the grayed areas defined by ranges (2.5, 4) and (−4, −2.5)
represent uninformative calls.
2.2. High Coverage in Training Data Set Leads to Overestimation of Z-Score in Low Coverage Samples
Model parameters trained on 20M samples more accurately depict underlying chromosomal
distributions than 3M samples due to the higher number of observed reads. Although the z-scores are
higher for low covered samples, this led to more false positives exceeding the grey zone (Figure 2).
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Figure 2. Boxplots of euploid NIPT samples for ADAVAR and FIXVAR models trained with samples
subsampled to 20M reads uniquely mapped to autosomes. Models have been tested with equivalent
samples subsampled to 3M (ADA 3M, FIX 3M) and 20M (ADA 20M, FIX 20M) respectively and
with original read count of reads uniquely mapped to autosomes (ADA ORIG, FIX ORIG). Grey
crosses represent trisomic samples. The grey areas defined by ranges (2.5, 4) and (−4, −2.5) represents
uninformative calls.
Parameters estimated using 20M training samples do not fit testing 3M samples properly. With
a large number of testing data (5860 3M samples), we observed 1001 uninformative samples and
336 false positives (FP) in the case of FIXVAR model. This means almost every fourth test sample needs
to be re-analyzed or evaluated as FP, which is not acceptable in clinical practice. Adaptive standard
deviation reduced the number of uninformative results and FP calls from 1337 to 181 (6 FP), with a
specificity 97%. On the other hand, in the case of ADAVAR model, the probability for false negative is
slightly higher. Similarly, for 20M testing samples, the results are almost equal. All trisomic samples
were classified correctly, and only seven euploid samples fell into a grey zone.
When testing 5680 production samples with original read count, we observed a still large number
of uninformative results in case of FIXVAR model, 303 (19 FP), but only 45 uninformative and none of
the FP in case of ADAVAR model. In both cases, all trisomic samples were classified correctly.
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2.3. Training on Samples with Uneven Coverage
Real parameters estimated from training samples with original read count provide enough
information about the variability between the data. Also, in this case the two models have comparable
results when testing real read count samples (Figure 3). Therefore, if enough training samples with
wide read count range is available, both models provided high accuracy by testing. The adaptive
standard deviation is valuable mostly in the limit case of the test samples.
Figure 3. Boxplots of euploid NIPT samples for ADAVAR and FIXVAR models trained with samples
contained original number of uniquely mapped reads. Models have been tested with equivalent
samples subsampled to 3M (ADA 3M, FIX 3M) and 20M (ADA 20M, FIX 20M) respectively and
with original read count of reads uniquely mapped to autosomes (ADA ORIG, FIX ORIG). Grey
crosses represent trisomic samples. The grey areas defined by ranges (2.5, 4) and (−4, −2.5) represents
uninformative calls.
In the case of testing 3M samples, FIXVAR model were found 330 uninformative calls (30 FP),
which means too many samples for repeated analysis. On the other hand, the ADAVAR model is
slightly more likely to report potentially false negative.
Z-scores values of healthy and trisomic samples displayed in Figures 1–3 are
available in supplementary_table_healthy_zscores.xlsx and supplementary_table_tris_zscores.xlsx
(in Supplementary Materials), respectively.
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3. Discussion
We propose an improvement for state-of-the-art methods used in NGS-based non-invasive testing
based on adaptive model parameters that are calculated for each sample separately. The method
is based on theoretical properties of underlying distributions that provide estimates of variance in
random draw from multinomial distribution. We have shown that those estimates differ from observed
variance by constant factor, that may be easily incorporated into the calculation and improves the
model beyond the level of current best methods used in clinical practice.
We tested the limitations of the commonly used method FIXVAR and the proposed ADAVAR
method on boundary sequencing depths. We have also tested these methods on real data sets with
uneven sequencing depths. Although the new method did not greatly exceed the current methods in
ordinary cases, its benefits are in borderline cases.
As we have shown in the results, when training on low read count followed by testing on many
times higher number of reads, ADAVAR provided significantly higher z-score values than FIXVAR
(Figure 1). Higher coverage is typically required for more thorough predictions, for example, in the
case of repeated analysis, detection of mosaicism, or partial chromosomal aberrations.
As a result, the number of false negative calls is greatly reduced without increasing the number of
false positive calls. FIXVAR method also performs poorly, when the model parameters are trained on
samples with higher read count values than testing samples. Underestimation of variance in tested
samples leads to a high amount of false positive calls. We have shown that the new method is able to
partially correct these ineligible clinical results with respect to the number of reads and thus avoid
the high number of false positives. This is the case when a sequenced sample has lack of reads which
can be caused by several factors, for example, a large number of sequenced samples, insufficient
concentration of DNA fragments, or uneven distribution of pooled samples to be sequenced.
In the article, we pointed out the shortcomings of current methods and their partial correction by
our method. Although the new method ADAVAR has not overcome standard methods in all cases, it
still has benefits in testing of samples with highly divergent coverages, where this method leads to a
lower number of false positive and false negative calls.
4. Materials and Methods
4.1. Sample Acquisition
Altogether, we have collected 6117 samples with singleton pregnancy, of which 6053 were negative,
while 64 were confirmed for trisomy of chromosome 21 (T21). In each case were positive results
confirmed by amniocentesis. Negative samples were, however, not confirmed by any additional gold
standard method. Data analyses reported here, were, on the other hand performed only on samples
originally analyzed with a sufficient time interval to know, from a clinician feedback following the
delivery, whether any false negative results occurred. Note that the sample set does not contain samples
that we were not able to resolve (such samples were either repeated or declined to report). The samples
were predominantly of Slovak and Czech origin. All women participating in this study gave informed
written consent consistent with the Helsinki declaration. Ethic approval: Etická komisia Bratislavského
samosprávneho kraja (Ethical commission of self-governing region of Bratislava), approval number:
07507/2018/HF, approval date: 11 June 2018.
4.2. Sample Preparation and Sequencing
Blood from pregnant women was collected into EDTA tubes and kept at 4 ◦C temperature until
plasma separation. Blood plasma was separated within 36 h after collection and stored at −20 ◦C unit
DNA isolation. DNA was isolated using Qiagen DNA Blood Mini kit (Hilden, Germany). Standard
fragment libraries for massively parallel sequencing were prepared from isolated DNA using an
Illumina TruSeq Nano kit (San Diego, CA, USA) and a modified protocol described previously [15].
Briefly, to decrease laboratory costs, we used reduced volumes of reagents what were compensated by
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9 cycles of PCR instead of 8 as per protocol. Physical size selection of cfDNA fragments was performed
using specific volumes of magnetic beads in order to enrich fetal fraction. Illumina NextSeq 500/550
High Output Kit v2 (San Diego, CA, USA) (75 cycles) was used for massively parallel sequencing of
prepared libraries using pair-end sequencing with read length of 2×35bp on an Illummina NextSeq 500
platform (Available online: https://www.illumina.com/).
4.3. Mapping and Read Count Correction
The first part of analysis was performed as described previously in [15–17]. Sequencing reads were
aligned to the human reference genome (hg19) using Bowtie 2 algorithm [18]. The first stage of data
processing was carried out as in [15,18]. NextSeq-produced fastq files (two per sample) were directly
mapped using the Bowtie 2 algorithm with –very-sensitive option. Reads with mapping quality of
40 or higher were retained for further data processing. For some of our analyses, a uniform random
selection of only some amount of mapped reads (alignments) was chosen for further processing. Next,
for each sample, the unique reads were processed to eliminate the GC bias according to [19] with the
exclusion of intra-run normalization. Briefly, for each sample the number of unique reads from each
20 kbp bin on each chromosome was counted. With empty bins filtered out, the locally weighted
scatterplot smoothing (LOESS) regression was used to predict the expected read count for each bin
based on its GC content. The LOESS-corrected read count for a particular bin was then calculated
as RCcor = RC −
∣∣∣RCloess −RCavg∣∣∣, where RCavg is the global average of read counts through all bins,
RCloess is the fitted read count of that bin, and RC is its observed read count.
To remove genomic regions with common structural differences, the LOESS-corrected bin counts
were transformed into a principal space. The first component represents the highest variability across
individuals in the control set. To normalize the sample, bin counts corresponding to a predefined
number of top components were removed to reduce common noise in euploid samples [20,21]. Vector
of corrected number of reads per autosomes was used for z-score calculations.
4.4. FIXVAR (Fixed Variance) Z-Score Calculation
The reference z-scores of samples were calculated as normalized chromosome values (NCV)
according to [13]. Given our training set, the optimal reference chromosomes with respect to the
coefficient of variation were determined to be 1, 4, 8, 10, 19, and 20 for trisomy 21 [13]. Similarly
to [7], samples scoring 4 and higher were considered trisomic, while samples scoring 2.5 or lower were
considered euploid. The range (2.5, 4) was considered uninformative. We will refer to these NCV
values as reference z-scores or ZFIX and to this type of z-score calculation (ratio of chromosomes) as
FIXVAR model.
4.5. ADAVAR (Adaptive Variance) Z-Score Calculation
4.5.1. Motivation
Consider a multinomial distribution given by (n, p1, p2, . . . , p22) as a model for mapping of n
sequenced reads to autosomes (we omitted sex chromosomes due the different mapping ratio for
male and female fetuses). The numbers pi are associated with proportion of reads mapped to the ith
autosome, and are largely determined by structure and composition of the chromosome, such as its
length, GC content, repeat sequence distribution and so on. However, it was observed that there exist
differences between healthy individuals on sub-autosomal level (typically copy number variations or
CNVs) large enough to skew the theoretical random draw from multinomial distribution (Kucharik
2019, under review). Even though we omitted those parts of the genome that exhibited such variations
frequently, individual deviations from the central model, presumably due to random individual CNVs,
still exceeded the statistical errors expected from the assumed multinomial distribution. Still, an
approximation of the numbers pi can be obtained through a sufficiently large and diverse sample of
population even though a population-universal multinomial mapping model is unlikely to exist. We
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showed that with sufficient corrections, the approximate model can still be useful, and it outperforms
FIXVAR model in certain cases.
4.5.2. Definition
Formally, the model is defined as follows. Let a set of random variables X = (X1, X2, . . . , X22)
have joint multinomial distribution given by (n, p1, p2, . . . , p22). The instance of this random variable
represents counts of reads mapped to autosomes for a given biological sample. Let u, v ∈ {0, 1}22 be




vi > 0, and uivi = 0 for all i. The vector u selects an aneuploid
autosome (thus, we have
∑
ui = 1), and the vector v selects reference autosomes. Because we do not
want the aneuploid or potentially aneuploid autosome to be in the reference set, some other restrictions
further apply, namely uivi = 0 for all i (i.e., the trisomic autosome is not in the reference set) and
v13 = v18 = v21 = 0 (neither are three common trisomic autosomes). The reference autosomes can be
found by many methods, for example, through minimization of coefficient of variation as in [13].




where · stands for the scalar product. Observe that this is the model of chromosome ratio from [13].
With p = (p1, p2, . . . , p22), q1 = p·u, and q2 = p·v, ref. [22] showed that for sufficiently large n the
following approximations of mean and standard deviation of Y holds


















where n is the total autosomal read count of a given sample (more robust approximations can be found
in the paper). Observe that while the numbers q1 and q2 are determined by the reference set, the
number n changes with each test sample. Thus, the mean and standard deviation is automatically






4.5.3. Additional Bias Correction
As we pointed out before, this central ADAVAR model does not represent a general euploid
pregnancy in sufficient detail, presumably because of the random individual CNVs. Hence, the model
needs to be modified before it can be used for z-score calculation.
This modification compares the standard deviations with respect to the selected read count among
the individual models. We have shown (Figure 4) that the difference between these deviations is almost
constant across any read count setting. Let this constant be denoted by c. We set c to be the average of





Furthermore, prediction of the mean of the ADAVAR model and the observations agree (Figure 5)
and no further correction is needed.
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Figure 4. Comparison of standard deviations with respect to the selected read count among the
individual models. Observed SD mean observed standard deviation for FIXVAR model. The theoretical
limit denoting calculated standard deviation for ADAVAR model and constant dash line represents
additional bias across various read counts used by ADAVAR. The prediction of the standard deviation
of the theoretical limit (solid line) is not in good agreement with the reference/observations (circles),
presumably due to individual CNVs. Observe that the difference between reference/observations
(circles) and predicted standard deviations (theoretical limit) is approximately constant throughout the
whole range (squares), and adding the mean of the differences to the predicted standard deviation
yields a very good approximation of the observations (dash-dot line).
Figure 5. Prediction of the mean of the theoretical limit (solid line) is in good agreement with the
observations (circles). The dashed lines represent one corrected standard deviation above and below
the predicted mean.
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are available online at http://www.mdpi.com/1422-0067/20/14/3414/s1.
Author Contributions: Conceptualization, J.G., J.B., F.D., and T.S.; Methodology, J.G., J.B., and F.D.; Software,
J.G. and F.D.; Validation, J.G. and F.D.; Formal analysis, J.G.; Investigation, J.G. and F.D.; Resources, T.S. and J.T.;
Data curation, J.B.; Writing—original draft preparation, J.G., J.B., and F.D.; Writing—review and editing, J.G.,
J.B., F.D., and T.S.; Visualization, J.G.; Supervision, J.G. and F.D.; Project administration, T.S. and J.T.; Funding
acquisition, T.S.
Funding: The presented work was supported by the “REVOGENE - Research centre for molecular genetics”
project (ITMS 26240220067) supported by the Operational Programme Research and Development funded by
the ERDF.
Conflicts of Interest: J.G., J.B., F.D., and T.S. participated in the development of the commercial NIPT test in the
company Geneton Ltd. (Slovakia). J.T. have declared no conflicts of interest.
Abbreviations
NIPT Non-invasive prenatal testing
FP False positive
FN False negative
T21 Trisomy of chromosome 21
NCV Normalized chromosome values
FIXVAR Fixed variance model
ADAVAR Adaptive variance model
ADA Abbreviation of ADAVAR
References
1. Mujezinovic, F.; Alfirevic, Z. Procedure-Related Complications of Amniocentesis and Chorionic Villous
Sampling. Obstet. Gynecol. 2007, 110, 687–694. [CrossRef] [PubMed]
2. Lo, Y.M.D.; Corbetta, N.; Chamberlain, P.F.; Rai, V.; Sargent, I.L.; Redman, C.W.; Wainscoat, J.S. Presence of
fetal DNA in maternal plasma and serum. Lancet 1997, 350, 485–487. [CrossRef]
3. Bischoff, F.Z.; Lewis, D.E.; Simpson, J.L. Cell-free fetal DNA in maternal blood: kinetics, source and structure.
Hum. Reprod. Updat. 2005, 11, 59–67. [CrossRef] [PubMed]
4. Lo, Y.M.D.; Tein, M.S.; Lau, T.K.; Haines, C.J.; Leung, T.N.; Poon, P.M.; Wainscoat, J.S.; Johnson, P.J.;
Chang, A.M.; Hjelm, N.M. Quantitative Analysis of Fetal DNA in Maternal Plasma and Serum: Implications
for Noninvasive Prenatal Diagnosis. Am. J. Hum. Genet. 1998, 62, 768–775. [CrossRef] [PubMed]
5. Fiorentino, F.; Bono, S.; Pizzuti, F.; Mariano, M.; Polverari, A.; Duca, S.; Sessa, M.; Baldi, M.; Diano, L.;
Spinella, F. The importance of determining the limit of detection of non-invasive prenatal testing methods.
Prenat. Diagn. 2016, 36, 304–311. [CrossRef] [PubMed]
6. Chiu, R.W.; Akolekar, R.; Zheng, Y.W.; Leung, T.Y.; Sun, H.; Chan, K.A.; Lun, F.M.; Go, A.T.; Lau, E.T.;
To, W.W.; et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA
sequencing: Large scale validity study. BMJ 2011, 342, c7401. [CrossRef] [PubMed]
7. Bianchi, D.W.; Sehnert, A.J.; Rava, R.P. Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA
Sequencing. Obstet. Gynecol. 2012, 119, 1270–1271. [CrossRef]
8. Straver, R.; Sistermans, E.A.; Holstege, H.; Visser, A.; Oudejans, C.B.; Reinders, M.J.T. WISECONDOR:
Detection of fetal aberrations from shallow sequencing maternal plasma based on a within-sample comparison
scheme. Nucleic Acids Res. 2014, 42, e31. [CrossRef]
202
Int. J. Mol. Sci. 2019, 20, 3414
9. Stephanie, C.Y.; Chan, K.A.; Zheng, Y.W.; Jiang, P.; Liao, G.J.; Sun, H.; Akolekar, R.; Leung, T.Y.; Go, A.T.;
van Vugt, J.M.; et al. Application of risk score analysis to low-coverage whole genome sequencing data for
the noninvasive detection of trisomy 21, trisomy 18, and trisomy 13. Prenat. Diagn. 2016, 36, 56–62.
10. Stephanie, C.Y.; Chan, K.A.; Zheng, Y.W.; Jiang, P.; Liao, G.J.; Sun, H.; Akolekar, R.; Leung, T.Y.; Go, A.T.;
van Vugt, J.M.; et al. Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing.
Proc. Natl. Acad. Sci. USA 2014, 111, 8583–8588.
11. Chiu, R.W.; Chan, K.A.; Gao, Y.; Lau, V.Y.; Zheng, W.; Leung, T.Y.; Foo, C.H.; Xie, B.; Tsui, N.B.; Lun, F.M.; et al.
Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing
of DNA in maternal plasma. Proc. Natl. Acad. Sci. USA 2008, 105, 20458–20463. [CrossRef] [PubMed]
12. Fan, H.C.; Blumenfeld, Y.J.; Chitkara, U.; Hudgins, L.; Quake, S.R. Noninvasive diagnosis of fetal aneuploidy
by shotgun sequencing DNA from maternal blood. Proc. Natl. Acad. Sci. USA 2008, 105, 16266–16271.
[CrossRef] [PubMed]
13. Sehnert, A.J.; Rhees, B.; Comstock, D.; De Feo, E.; Heilek, G.; Burke, J.; Rava, R.P. Optimal Detection of Fetal
Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal
Blood. Clin. Chem. 2011, 57, 1042–1049. [CrossRef] [PubMed]
14. Lau, T.K.; Chen, F.; Pan, X.; Pooh, R.K.; Jiang, F.; Li, Y.; Jiang, H.; Li, X.; Chen, S.; Zhang, X. Noninvasive
prenatal diagnosis of common fetal chromosomal aneuploidies by maternal plasma DNA sequencing.
J. Matern. Neonatal Med. 2012, 25, 1370–1374. [CrossRef] [PubMed]
15. Minarik, G.; Repiska, G.; Hyblova, M.; Nagyova, E.; Soltys, K.; Budis, J.; Duris, F.; Sysak, R.; Bujalkova, M.G.;
Vlkova-Izrael, B.; et al. Utilization of Benchtop Next Generation Sequencing Platforms Ion Torrent PGM and
MiSeq in Noninvasive Prenatal Testing for Chromosome 21 Trisomy and Testing of Impact of In Silico and
Physical Size Selection on Its Analytical Performance. PLoS ONE 2015, 10, e0144811. [CrossRef] [PubMed]
16. Budis, J.; Gazdarica, J.; Radvanszky, J.; Harsanyova, M.; Gazdaricova, I.; Strieskova, L.; Frno, R.; Duris, F.;
Minarik, G.; Sekelska, M.; et al. Non-invasive prenatal testing as a valuable source of population specific
allelic frequencies. J. Biotechnol. 2019, 299, 72–78. [CrossRef] [PubMed]
17. Budis, J.; Gazdarica, J.; Radvanszky, J.; Szucs, G.; Kucharik, M.; Strieskova, L.; Gazdaricova, I.; Harsanyova, M.;
Duris, F.; Minarik, G.; et al. Combining count- and length-based z-scores leads to improved predictions in
non-invasive prenatal testing. Bioinformatics 2018, 35, 1284–1291. [CrossRef]
18. Langmead, B.; Trapnell, C.; Pop, M.; Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA
sequences to the human genome. Genome Biol. 2009, 10, R25. [CrossRef]
19. Liao, C.; Yin, A.H.; Peng, C.F.; Fu, F.; Yang, J.X.; Li, R.; Chen, Y.Y.; Luo, D.H.; Zhang, Y.L.; Ou, Y.M.; et al.
Noninvasive prenatal diagnosis of common aneuploidies by semiconductor sequencing. Proc. Natl. Acad.
Sci. USA 2014, 111, 7415–7420. [CrossRef]
20. Price, A.L.; Patterson, N.J.; Plenge, R.M.; Weinblatt, M.E.; Shadick, N.A.; Reich, D. Principal components
analysis corrects for stratification in genome-wide association studies. Nat. Genet. 2006, 38, 904–909.
[CrossRef]
21. Zhao, C.; Tynan, J.; Ehrich, M.; Hannum, G.; McCullough, R.; Saldivar, J.S.; Oeth, P.; van den Boom, D.;
Deciu, C. Detection of Fetal Subchromosomal Abnormalities by Sequencing Circulating Cell-Free DNA from
Maternal Plasma. Clin. Chem. 2015, 61, 608–616. [CrossRef] [PubMed]
22. Duris, F.; Gazdarica, J.; Gazdaricova, I.; Strieskova, L.; Budis, J.; Turna, J.; Szemes, T. Mean and variance
of ratios of proportions from categories of a multinomial distribution. J. Stat. Distrib. Appl. 2018, 5, 2.
[CrossRef]
23. Ehrich, M.; Deciu, C.; Zwiefelhofer, T.; Tynan, J.A.; Cagasan, L.; Tim, R.; Lu, V.; McCullough, R.; McCarthy, E.;
Nygren, A.O.; et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood:
A study in a clinical setting. Am. J. Obstet. Gynecol. 2011, 204, 205.e1–205.e11. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
203
 International Journal of 
Molecular Sciences
Article
Cell-Free, Embryo-Specific sncRNA as a Molecular
Biological Bridge between Patient Fertility and
IVF Efficiency
Angelika V. Timofeeva *, Vitaliy V. Chagovets, Yulia S. Drapkina, Nataliya P. Makarova,
Elena A. Kalinina and Gennady T. Sukhikh
Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of
Russia, Ac. Oparina 4, Moscow 117997, Russia; vvchagovets@gmail.com (V.V.C.);
julia.drapkina@gmail.com (Y.S.D.); npmakarova@gmail.com (N.P.M.); e_kalinina@oparina4.ru (E.A.K.);
gtsukhikh@mail.ru (G.T.S.)
* Correspondence: avtimofeeva28@gmail.com or v_timofeeva@oparina4.ru
Received: 21 May 2019; Accepted: 12 June 2019; Published: 14 June 2019
Abstract: Small noncoding RNAs (sncRNAs) are key regulators of the majority of human reproduction
events. Understanding their function in the context of gametogenesis and embryogenesis will allow
insight into the possible causes of in vitro fertilization (IVF) implantation failure. The aim of this study
was to analyze the sncRNA expression profile of the spent culture media on day 4 after fertilization
and to reveal a relationship with the morphofunctional characteristics of gametes and resultant
embryos, in particular, with the embryo development and implantation potential. Thereto, cell-free,
embryo-specific sncRNAs were identified by next generation sequencing (NGS) and quantified by
reverse transcription coupled with polymerase chain reaction (RT-PCR) in real-time. Significant
differences in the expression level of let-7b-5p, let-7i-5p, piR020401, piR16735, piR19675, piR20326,
and piR17716 were revealed between embryo groups of various morphological gradings. Statistically
significant correlations were found between the expression profiles of piR16735 and piR020401 with
the oocyte-cumulus complex number, let-7b-5p and piR020401 with metaphase II oocyte and two
pronuclei embryo numbers, let-7i-5p and piR20497 with the spermatozoid count per milliliter of
ejaculate, piR19675 with the percentage of linearly motile spermatozoids, let-7b-5p with the embryo
development grade, and let-7i-5p with embryo implantation. According to partial least squares
discriminant analysis (PLS-DA), the expression levels of let-7i-5p (Variable Importance in Projection
score (VIP) = 1.6262), piR020401 (VIP = 1.45281), and piR20497 (VIP = 1.42765) have the strongest
influences on the implantation outcome.
Keywords: miRNA; piRNA; NGS; RT-PCR; embryo culture medium
1. Introduction
Infertility affects almost 15% of couples globally. One of the most effective methods to treat
infertility is assisted reproductive technology (ART), which covers a wide spectrum of treatments.
Although ART has the highest pregnancy and live birth rates, it still has limited efficacy. Only 32.3% of
ART cycles performed for the first time in women under 37 years old result in the birth of a healthy
child. Patients aged more than 37 years old who commence in vitro fertilization (IVF) treatment have
only a 12.3% success rate. A successful result in ART programs depends on a balanced interaction of a
top-quality embryo with an optimally receptive endometrium.
With the worldwide move towards single embryo transfer, there is a renewed focus on developing
a reliable method of assessment of embryo viability. The ability to select an embryo with the highest
developmental and implantation potential is paramount to maximizing the probability of attaining a
successful pregnancy.
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Numerous systems have been devised to grade and rank embryos [1]. One of the most common
grading systems is based on morphological criteria developed by Gardner et al. [2]. The grading
usually considers the morphology of an inner cell mass (ICM) and trophectoderm (TE) for embryos at
the blastocyst stage as well as the degree of expansion of the blastocyst cavity. However, sometimes, it
is difficult to interpret data on morphological characteristics and morphological traits as they do not
fully reflect the physiology of the embryo and its chromosomal complement. Moreover, even good
quality embryos do not always implant.
Different biomarkers of embryo quality and implantation potential have been proposed in addition
to morphological criteria. They include noninvasive metabolomic and proteomic profiling of embryo
culture media [3–5]. However, these biomarkers have their own disadvantages. The metabolomic
profile of embryo culture media requires the use of very sensitive instruments which can detect even
slight changes in media composition. This is crucial because embryo metabolomic activity depends on
the media. Embryo proteomic profile assessment remains inaccurate, because one must enrich media
with exogenous major proteins to assure normal embryo development.
Cells and tissues that are involved in human reproduction processes are unique because they
constantly undergo dramatic reorganization during gametogenesis and embryogenesis at both
transcriptomic and proteomic levels. Recently, scientists have started to focus on cell proteomic
profile changes which are controlled by non-coding RNAs. MicroRNAs (miRNAs), small endogenous
interfering RNAs (siRNAs), and piwi-interacting RNAs (piRNAs) have the most crucial roles among
these molecules [6]. Most miRNAs are transcribed by RNA polymerase II [7]. The result of this process
is the formation of a primary transcript (pri-miRNAs) which is 2000–4000 nucleotides in length, has a
5’-7-methyl-guanosine cap structure, a 3’-poly (A) tail, and a complex secondary structure. Further
processing of pri-miRNAs continues in the cell nucleus under the control of conserved RNase III
Drosha and the DiGeorge Syndrome Critical Region Gene 8 (DGCR8) cofactor with the formation
of a hairpin structure, 70–100 nucleotides in length, termed precursor miRNA (pre-miRNA). The
resulting pre-miRNA is transported to the cytoplasm via a process that involves Exportin-5 and
RAN (RAs-related Nuclear protein) GTPase. The pre-miRNA is further cleaved by RNase III Dicer
and Tar RNA-binding protein (TRBP) to generate a short, partially double-stranded (ds) RNA with
approximately 22 nucleotides in which one strand is the mature miRNA. Afterwards, the mature
miRNA strand is taken up by a multi-protein complex that is identical to the RNA Induced Silencing
Complex (RISC) that supports RNA interference (RNAi) and miRNA-bound complex functions to
regulate translation. Meanwhile, another strand of miRNA undergoes degradation.
The biogenesis of piRNAs is less studied in comparison with that of miRNAs and siRNAs. It does
not require Dicer, because the precursor piRNAs are single-stranded [8]. There are several classes of
piRNAs according to next generation sequencing (NGS) data [9]. The class I piRNAs are produced by
clustered genetic loci. The piwi-protein-mediated cleavage of the transposon RNA target produces
the class II piRNAs. The last group of piRNAs originates from different genomic regions, including
three prime untranslated regions of some mRNAs. This fact demonstrates that piRNAs might regulate
the level of gene expression in addition to chromosomal rearrangement maintenance by repressing
transposable element expression. The piRNA amplification model and transposons neutralization
occur via the ping-pong mechanism in germ cells [10].
miRNAs are synthesized in the granulosa and cumulus cells and secreted into the follicular
fluid. The influence of these molecules on oocyte maturation and embryo quality has been already
shown [11–13]. The effect of female age on the miRNA profile of an oocyte has also been clearly
demonstrated [14]. Moreover, miRNA expression levels depend on the degree of oocyte maturation [15].
Elke F. Roovers et al. showed dramatic expression of piRNAs in human, bovine, and macaque
oocytes [16]. The piRNA profile in oocytes was similar to that in sperm at the pachytene stage. The
principal role of this stage during meiosis is the regulation of transposons expression and, consequently,
it controls genome instability [16]. The role of piRNAs and miRNAs during spermatogenesis is
described in detail in a review article [17]. This article focuses on the epigenetic regulatory functions of
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DNA modification, mRNA translation and stability, and the maintenance and self-renewal of germ
stem cells. The crucial role of sperm small non-coding RNAs (sncRNAs) produced after fertilization in
embryogenesis, implantation, and subsequent embryo development has been recently proven [18]. It
has also been shown that successful embryonic development immediately after fertilization depends
on coordinated maternal mRNA degradation and zygotic genome activation, resulting in embryonic
mRNA production and protein translation. It has been found that piRNAs, miRNAs, and siRNAs are
essential for the maternal–zygotic transition [19–21].
In the light of the above, the development of non-invasive methods for predicting the onset of
pregnancy and its further development is a highly topical problem at present. An example of such a
method is the evaluation of miRNAs specific for the villus and decidual tissues in the peripheral blood
plasma of women in both the first trimester of pregnancy and the day of embryo transfer (ET) in ART
programs [22]. It was demonstrated that MiR (miR-23a-3p, 27a-3p, 29a-3p, 100-5p, 127-3p, and 486-5p)
expression levels significantly changed in the group of women with recurrent miscarriage compared
to the group with normal pregnancy, but the clinical pregnancy outcome could not be predicted in
the IVF/ET (in vitro fertilization/embryo transfer) patients. Another diagnostic method for predicting
pregnancy is to evaluate the expression profile of sncRNAs secreted by embryo cells into their culture
media. To the best of our knowledge, very few studies have considered the interactions that exist
between sncRNA expression levels in culture medium and embryo implantation potential [23–25]. To
create more effective treatment for infertile couples in the IVF program, the implication of sncRNAs
from spent culture medium in the formation of the morphofunctional characteristics of gametes
and resultant embryos, as well as in embryo development and implantation potential, should be
investigated. Therefore, the present study was aimed at revealing and analyzing such interactions.
2. Results and Discussion
2.1. Identification of Embryo-Specific sncRNAs
Deep sequencing was performed to identify embryo-specific sncRNAs. A blastocyst of excellent
quality (4AA) from one couple was enrolled in the study. The fraction of RNA secreted both into the
blastocoele and into its culture medium on day 5 after fertilization was analyzed. Sequence reads
aligned to miRBase v21 and piRNABase with a count of at least 10 were compared by plotting Venn
diagrams of the miRNA expression pattern (Figure 1A) and piRNA expression pattern (Figure 1B).
Figure 1 demonstrates a wider spectrum of piRNAs (132 and 128 subtypes in blastocoele liquid and
embryo culture medium, respectively, Figure 1B) in comparison with miRNAs (49 and 36 subtypes in
blastocoele liquid and embryo culture medium, respectively, Figure 1A). Among them, 73.5% miRNAs
and 34.7% piRNAs are secreted by the embryo into both the blastocoele liquid and the embryo culture
medium. All of the miRNAs secreted by the embryo into the culture medium were detected in the
blastocoele liquid. As for the piRNAs (Figure 1B), 33.7% were uniquely expressed in the blastocoele
liquid and 31.6% in the embryo culture medium.
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Figure 1. Venn diagrams for microRNA (miRNA) expression pattern (A) and piwi-interacting RNA
(piRNA) expression pattern (B). The sncRNAs (miRNA and piRNA) unique to the blastocoele fluid are
written in red; sncRNAs written in green are unique to the blastocyst spent culture medium by the
fifth day after fertilization; sncRNAs are written in blue provided that they are detected both in the
blastocoele fluid and in the blastocyst spent culture medium.
2.2. Real Time PCR Analysis of sncRNA Revealed by NGS
miRNAs and piRNAs characterized by detectable PCR signals with Ct< 35 cycles (Table 1) and specific
PCR products (a single peak of the amplification product melting curve) were selected for subsequent
analysis by RT-PCR in 87 RNA samples from embryo culture medium on day 4 after fertilization.
Table 1. Small non-coding RNA (sncRNA) identification by next generation sequencing (NGS) and real
time polymerase chain reaction (PCR) (if Ct > 35 cycles in most of the studied samples, these data were
excluded from the analysis, “+”—data suitable for analysis).
sncRNA
NGS Read Count (Blastocoele
Liquid/Embryo Culture
Medium)




hsa-let-7b-5p 527/282 Hs_let-7b_1 miScript Primer Assay,Cat.No. MS00003122, Tm = 55 ◦C +
hsa-let-7a-5p 537/258 Hs_let-7a_2 miScript Primer Assay,Cat.No. MS00031220, Tm = 55 ◦C Ct > 35
hsa-miR-99a-5p 351/145 Hs_miR-99a_2 miScript Primer Assay,Cat.No. MS00032158, Tm = 55 ◦C Ct > 35
hsa-miR-148a-3p 194/136 Hs_miR-148a_1 miScript Primer Assay,Cat.No. MS00003556, Tm = 55 ◦C Ct > 35
hsa-let-7i-5p 239/114 Hs_let-7i_1 miScript Primer Assay,Cat.No. MS00003157, Tm = 55 ◦C +
hsa-miR-26a-5p 209/111 Hs_miR-26a_2 miScript Primer Assay,Cat.No. MS00029239, Tm = 55 ◦C Ct > 35
hsa-let-7c-5p 192/110 Hs_let-7c_1 miScript Primer Assay,Cat.No. MS00003129, Tm = 55 ◦C +
hsa-let-7g-5p 145/89 Hs_let-7g_2 miScript Primer Assay,Cat.No. MS00008337, Tm = 55 ◦C Ct > 35
hsa-miR-92a-3p 144/91 Hs_miR-92_1 miScript Primer Assay,Cat.No. MS00006594, Tm = 55 ◦C +
hsa-miR-143-3p 135/81 Hs_miR-143_1 miScript Primer Assay,Cat.No. MS00003514, Tm = 55 ◦C +
hsa-miR-125b-5p 69/57 Hs_miR-125b_1 miScript Primer Assay,Cat.No. MS00006629, Tm = 55 ◦C Ct > 35
hsa-miR-100-5p 77/50 Hs_miR-100_2 miScript Primer Assay,Cat.No. MS00031234, Tm = 55 ◦C Ct > 35
hsa-miR-125a-5p 63/36 Hs_miR-125a_1 miScript Primer Assay,Cat.No. MS00003423, Tm = 55 ◦C Ct > 35
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Table 1. Cont.
sncRNA
NGS Read Count (Blastocoele
Liquid/Embryo Culture
Medium)




hsa-miR-320a 57/30 Hs_miR-320a_1 miScript Primer Assay,Cat.No. MS00014707, Tm = 55 ◦C Ct > 35
hsa-miR-27b-3p 56/28 Hs_miR-27b_2 miScript Primer Assay,Cat.No. MS00031668, Tm = 55 ◦C Ct > 35
































Tm = 45 ◦C +
Two-dimensional hierarchical clustering of real-time RT-PCR data was performed to classify
87 embryo cultivation medium samples according to the degree of expression profile similarity of
the studied sncRNAs. The Pearson and Euclidean distance correlations were used to calculate the
difference between dendrogram nodes. The heat map for the RT-PCR data clustering is presented
in Figure 2. The sncRNA clustering patterns did not clearly separate culture media samples from
excellent, good, fair, and poor-quality embryos according to Gardner grading scale, or from morulas,
cavernous morulas, and 3–10 cell embryos. This may be explained by undulating changes in sncRNA
expression which depend on the embryo development stage. Certain patterns of the studied sncRNAs
expression throughout the development stages and inside subgroups of blastocysts of different quality
can be observed in the boxplot in Figure 3. For example, the trends of the piR19675 and piR020401
expression level medians are similar for the “morula”, “good quality blastocyst”, and “excellent quality
blastocyst” groups but are dramatically different in other groups. Meanwhile, the median trend in
the let-7b-5p expression level is similar in the “3–10 cell embryo”, “cavernous morula”, and “poor
quality blastocyst” groups. The level of let-7b-5p expression increases in “morula” and “good and
excellent quality blastocyst” groups and decreases notably in the “fair quality blastocyst” group. The
Mann–Whitney U-test revealed statistically significant differences in the expression levels of let-7b-5p,
let-7i-5p, piR020401, piR16735, piR19675, and piR20326 in the culture medium from embryos of various
development grades (Table 2). Moreover, blastocysts of different quality according to Gardner’s
grading scale were shown to differ significantly from each other in expression levels of let-7i-5p,
piR020401, and piR17716. The obtained data are in good agreement with those of Abd El Naby et al.,
who demonstrated miRNA expression dynamics during the preimplantation stage period from bovine
zygote to blastocyst [15].
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Figure 2. Two-dimensional hierarchical clustering of real-time RT-PCR data on sncRNAs from 87
embryo cultivation medium samples. E.q.—excellent quality, g.q.—good quality, f.q.—fair quality,
p.q.—poor quality.
 
Figure 3. sncRNA expression level fold change in the culture medium of embryos of different
development grade. (A) sncRNA expression level fold change (FC) with values varying from 0.01 to 400
(data are presented on a logarithmic scale). (B) sncRNA expression level FC with values varying from
0.1 to 3.5 (data are presented on a linear scale). E.q.—excellent quality, g.q.—good quality, f.q.—fair
quality, p.q.—poor quality.
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Table 2. Pairwise comparison of the fold changes in the expression level of sncRNAs in the sample
groups shown in Figure 3.






embryon”–“morula” 0.04 6.16 (4.08, 7.86) 10.1 (6.42, 12.86)
“morula”–“fair
quality blastocyst” 0.02 10.1 (6.42, 12.86) 4.18 (1.94, 6.71)
“morula”–“excellent
quality blastocyst” 0.05 10.1 (6.42, 12.86) 7.24 (3.48, 10.07)
let-7i-5p
“morula”–“poor








0.01 6.2 (5.19, 6.34) 3.26 (2.18, 4.52)
piR020401
“morula”–“fair








































0.02 0.06 (0.04, 0.06) 2.88 (1.09, 3.92)
* The data are presented as medians (Me) and quartiles Q1 and Q3 in the format Me (Q1; Q3).
Since embryo sncRNA expression patterns which contribute to the embryo quality and
development potential depend on the degree of oocyte maturation, concomitant diseases of the
female reproductive and endocrine systems, and also, sperm characteristics, a correlation matrix was
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calculated and plotted to reveal these interactions (Figure 4). The analyzed samples ranged, according
to the embryo development grading scale, in the following way: “3–10 cell embryo” < “morula” <
“cavernous morula”< “poor quality blastocyst”< “fair quality blastocyst”< “good quality blastocyst”<
“excellent quality blastocyst”. Considering all 87 samples (Figure 4A), a reliable correlation of sncRNA
expression profiles was found both within one class and between classes of these molecules. The
expression levels of piR17716 and piR20497 negatively correlated with the embryo development grade,
positively correlated with each other and with miR-92a-3p and let-7c-5p, and negatively correlated with
piR16735, piR20326, let-7b-5p, and let-7i-5p. In contrast, the expression level of let-7c-5p negatively
correlated with the expression of other Let7 family members (let-7b-5p and let-7i-5p) and piR020401.
Such a complex interrelation of sncRNA expression patterns in the culture media of embryos of various
development grades is probably a manifestation of the fine system of signaling pathway regulation
necessary for the implementation of the embryogenesis program. The crucial role of miRNAs and
piRNAs in the post-transcriptional gene regulation is already well known [12–21].
A correlation matrix with 48 samples of culture media from embryos which were transferred to
the uterine cavity was calculated (Figure 4B) to analyze the interaction between pregnancy, the quality
of oocytes retrieved, sperm quality, the number of blastocysts obtained, and the expression profile
of sncRNAs. The correlation matrix revealed that the expression level of the Let7 family in embryo
culture media can be a potential biomarker for IVF efficiency prognosis. For example, the expression
level of let-7b-5p negatively correlated with both the embryo development grade and the number
of M2 oocytes and 2PN cells. Moreover, the M2 oocyte number as a percentage of oocyte–cumulus
complexes (OCC) and the 2PN embryos number as a percentage of the M2 oocyte number had positive
correlations with fallopian tube presence. Many experts have assumed the effects of an epithelium
in the fallopian tubes on oocyte maturation and the ability to fertilize [26]. In turn, the let-7b-5p
expression level was positively correlated with the piR020401 expression profile, which had a negative
correlation with the number of OCC, M2-oocytes, and 2PN-cells. In addition, this piRNA was also
positively correlated with the expression patterns of piR16735, piR19675, and piR20326. As for the
piR16735 and piR1967 expression patterns, the former was negatively correlated with the OCC number,
and the latter was negatively correlated with sperm motility. Meanwhile, the sperm concentration was
positively correlated with sperm progressive motility and normal sperm morphology.
A promising interaction between let-7i-5p, piR17716, and piR20497 was found. The expression
pattern of let-7i-5p had a negative correlation with the piR17716 and piR20497 expression profiles.
Along with this, the piR17716 expression pattern was positively correlated with implantation, while
the piR20497 expression profile had a negative relationship with sperm concentration. However,
for let-7i-5p, an inverse correlation was obtained. A negative correlation of its expression with the
implantation rate and a positive correlation with the sperm concentration were found.
As for let-7c-5p, a positive correlation of its expression with piR16735 and piR19675 was observed.
piR16735 expression was negatively correlated with OCC, whereas piR19675 expression had a negative
relationship with the number of motile sperm. It was difficult to identify whether the analyzed sncRNA
in the embryo culture medium originated from gametes involved in fertilization or from the activated
embryo genome after the maternal–zygotic transition, but there is strong evidence for the contribution
of sperm RNA to the embryo developmental potential and its implantation ability according to the
literature data [18].
The number of OCCs collected in one stimulated cycle correlated negatively with the number of
blastocysts as a percentage of OCCs or 2PN (Figure 4B). The obtained results were consistent with
literature data, indicating that the number of retrieved oocytes in a stimulated cycle has a negative
relationship with the number of blastocysts obtained [27,28].
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Figure 4. Correlation matrix based on the non-parametric Spearman rank correlation method.
Significant (p < 0.05) correlations are indicated by a dot, non-significant correlations are indicated by a
cross, positive correlations are marked in blue, and negative correlations in red—the more significant
the correlation, the larger the dot size. (A) Correlation analysis of the sncRNA expression level in
87 embryo cultivation medium samples and the quality of embryos. (B) Correlation analysis of the
sncRNA expression level in 48 cultivation medium samples of embryos transferred to the uterus and
the following parameters: fallopian tube presence—the presence of fallopian tubes in the female of
each couple; sperm concentration—spermatozoid count per milliliter of ejaculate from the male of each
couple; sperm motility—percentage of linearly motile spermatozoids from the male of each couple;
sperm morphology—percentage of morphologically normal spermatozoids from the male of each
couple; number of OCC—the number of oocyte–cumulus complexes from the female of each couple;
number of M2—metaphase II oocyte number from the female of each couple; number of 2PN—two
pronuclei embryo numbers from each couple; number of blastocysts—blastocyst number of each
couple; pregnancy—the development of pregnancy after embryo transfer into the uterus; infertility
factor—primary or secondary infertility in the female of each couple; hatching—embryo hatching
before transfer to the uterine cavity; dev. gr.—embryo development stage and quality according to the
Gardner grading scale; embryo morphology—morphological parameters of embryos according to the
Gardner grading scale; M2/OCC, %—metaphase II oocyte number as a percentage of OCC; 2PN/M2,
%—number of two pronuclei embryos as a percentage of M2 oocyte; blastocysts/2PN, %—blastocyst
number as a percentage of 2PN embryos; blastocysts/OCC, %—blastocyst number as a percentage
of OCC.
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The relationship of the individual ovarian response to gonadotropins in IVF programs and
post-transcriptional regulation of genes responsible for oocyte maturation was shown by Cengiz
Karakaya et al. [11]. They found that a poor ovarian response to IVF is associated with up-regulation
of 16 miRNAs and down-regulation of 88 miRNAs in cumulus cells. It is possible that the spectrum of
sncRNAs secreted by a fertilized oocyte after four days of in vitro cultivation and correlated with the
number of OCC and M2-oocytes may be a consequence of the post-transcriptional regulation of genes
through cumulus–oocyte communication.
The PLS-DA model based on RT-PCR data was developed to study differences between the culture
medium from embryos which implanted or did not implant. The fold change of the sncRNA expression
level in each of the 48 samples was used for the model (Figure 5). Figure 5A represents the score plot
of the developed PLS-DA model. Three clusters of data points can be distinguished. The first one
has an abscise of less than −0.75 and represents the embryos which failed to implant despite there
being an appropriate quality. The second cluster lies between −0.75 and 0.5 of the abscise and contains
data points corresponding to embryos with similar morphological properties (excellent, good, and fair
quality according to Gardner’s grading scale) and molecular biomarkers (sncRNA expression profile),
but some of them implanted (highlighted in gray), and some of them failed to implant (highlighted
in red). This phenomenon can be explained by independent factors irrelevant to the embryo quality,
e.g., endometrial receptivity, chronic inflammation, or this might have happened because of the other
sncRNAs which were not analyzed in the current study. The third cluster is characterized by an abscise
greater than 0.5. This cluster corresponds to embryos with high implantation potential, according to
morphological grading scale and molecular biomarkers, that successfully implanted. The contribution
of sncRNA to the distribution of the data points on the score plot can be estimated by the Variable
Importance in Projection (VIP) score (Figure 5B). The following sncRNA have VIP > 1 and those with
the highest impact are let-7i-5p (VIP = 1.6262), piR020401 (VIP = 1.45281), piR20497 (VIP = 1.42765), and
piR17716 (VIP= 1.14438). Notably, the expression profile of these sncRNAs has a strong correlation with
sperm quality, the number of OCCs, oocyte maturity, and oocyte fertilization ability (Figure 4B). Thus,
one can suppose that these molecules contribute to the embryo implantation potential. In addition, the
Mann–Whitney test revealed significant differences in let-7i-5p and piR020401 expression levels in
the culture media from embryos of clusters II and III which succeeded in implanting (highlighted in
gray in Figure 5A) in comparison to embryos from cluster I which failed to implant (highlighted in red
in Figure 5A): 2.38 ± 2.25 vs. 5.20 ± 1.84, p < 0.001 for let-7i-5p; 1.85 ± 0.46 vs. 2.28 ± 0.35, p = 0.005
for piR020401. The culture media from the embryos with implantation failure (highlighted in red in
Figure 5A) differed significantly in let-7i-5p expression when comparing the embryos of cluster I and
cluster II: 5.20 ± 1.84 vs. 3.41 ± 1.79, p = 0.018. Consequently, let-7i-5p can be proposed as a marker of
the embryo’s implantation potential on the 4th day after fertilization.
Thus, the PLS-DA model developed by us reflects the implantation potential of an embryo
according to the expression profile of sncRNAs in the culture medium on the 4th day after fertilization
but cannot be used to predict the onset of pregnancy and its development. The fact remains that the
embryo transferred into the uterine cavity, and endometrial cells are able to reciprocally exchange
signals, in particular, in the form of secreted extracellular vesicles containing small non-coding RNA.
This topic is discussed in detail in a review article by Ferlita A. et al. [29]. Even if the molecular-biological
profile of the embryo is normal and the spectrum of secreted sncRNAs corresponds to an embryo with
high implantation potential, abnormal secretion of RNA molecules and proteins by the endometrium
can adversely affect the embryo implantation process. Thus, to improve the performance of IVF
programs before embryo transfer to the uterus, it is necessary not only to evaluate the expression
profile of small non-coding embryonic RNA, as proposed in this work, but also to assess endometrial
receptivity, in particular, focusing on the extracellular sncRNAs present in endometrial fluid during
the window of implantation.
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Figure 5. Partial least squares discriminant analysis (PLS-DA) of 2−ΔΔCt RT-PCR data on the expression
of sncRNAs in the 48-embryo culture medium samples. Arabic numerals denote the sample number.
Roman numerals (I, II, III) denote the cluster of samples depending on the result of embryo transfer
into the uterine cavity and the profile of RNA expression in the cultivation medium. (A) score plot
with the imposition of information of the sncRNA expression level on the results of embryo transfer
into the uterine cavity, (B) Variable Importance in Projection (VIP) score.
2.3. Identification of piRNA Targets
piRNA sequences were annotated using the piRBase database (Available online: http://www.
regulatoryrna.org), which contains information on the piRNA genome location (hg38) (Table 3). Studied
piRNAs are mapped to the transposable elements (TE) such as long interspersed elements (LINEs)
and short interspersed elements (SINEs), including Alu elements. These data are in good agreement
with published information confirming that most mammalian genomes are dominated by LINE and
SINE retrotransposons [30], where LINE and SINE are the most abundantly represented TE classes
in the bovine testis, oocyte, and zygote pilRNAs, representing over 50% of all TE mapped reads [31].
Some piRNAs, analyzed in the current study, were mapped to tRNA (tRNA-GluGAG, tRNA-AlaGCY,
tRNA-Gly-GGG, tRNA-GlyGGY, tRNA-GlyGCC and tRNAValAAC) and rRNA species, which are
specifically processed into piRNAs. Recent studies have also revealed that some tRNA-derived small
RNAs associate with the Argonaute (AGO) proteins or P-element induced wimpy testis proteins
(PIWI) [32], and the accumulation of small tRNAs and rRNAs and their association with the RNA
interference machinery seems to be characteristic of highly proliferative cells and tightly controlled to
avoid apoptosis [33]. Additionally, we found out from piRBase that piRNAs are mapped not only to
the repeat elements but also to the region of protein coding genes, and these piRNAs are referred to
as gene-derived, in particular, LY6G5C-, EFCAB11-, VAC14-, COLQ-, and PTGES3L-derived piRNAs
(Table 3). These findings are in accordance with the published literature and confirm that some mRNAs
in flies and vertebrates are known to be processed into piRNAs [21,34–36].
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* ”+” denotes sense strand which contains the exact nucleotide sequence to the messenger RNA (Mrna); “−“ denotes
antisense strand, serves as the template for the transcription and contains complementary nucleotide sequence to
the transcribed mRNA.
Recent studies have suggested that piRNAs have the potential to target mRNAs in addition to
their traditional transposon-derived transcripts [37–39]. piRNA target data have been collected from
literature in piRBase and related to mice and fruitflies but not to human piRNA until now. Therefore,
BLAST (Available online: https://blast.ncbi.nlm.nih.gov) was used to identify human piRNA overlap
with protein coding genes. mRNA was considered a potential target for piRNA if the mapping direction
for the piRNA–mRNA pair was opposite. This approach was proposed by S. Russell for Bowtie
application [31]. Lists of potential gene-targets were obtained for hsa-piR020401, hsa-piR019675, and
hsa-piR022296 (Table 3). We focused on the 25 gene targets of hsa-piR020401 and hsa-piR019675. The
expression profiles of these molecules correlated with the OCC, M2, 2PN number, and the percentage of
sperm with linear motility. A Gene Ontology (GO) analysis of these genes in the PANTHER Classification
System (Available online: http://pantherdb.org/) showed that within the molecular function category,
28% of genes are related to binding processes (including transcription factor like 5 (TCFL5), Rho
Guanine Nucleotide Exchange Factor 10 Like (ARHGEF10L), p21-activated kinase 3 (PAK3), Eukaryotic
Translation Elongation Factor 1 Delta (EEF1D), Polyhomeotic-like protein 3 (PHC3), RNA Binding
Motif Protein 28 (RBM28), Feline Encephalitis Virus-Related Kinase (FER)), 24% of genes are involved
in catalytic activity (Methyltransferase Like 22 (METTL22), DNA polymerase eta (POLH), PAK3,
member of RAS oncogene family like 2B (RABL2B), Lipoic acid synthetase (LIAS), FER), ARHGEF10L is
considered a molecular function regulator, Zinc fingers and homeoboxes protein 3 (ZHX3) and PHC3 are
implicated in transcription regulator activity, Eukaryotic Translation Elongation Factor 1 Delta (EEF1D)
is implicated in translation regulator activity, and Calcium Voltage-Gated Channel Auxiliary Subunit
Alpha2delta 1 (CACNA2D1) is involved in transporter activity. Therefore, it seemed important to focus
on several genes whose function may be associated with reproduction. For instance, Lawrence M. Roth
et al. revealed the role of TCFL5 in normal human spermatogenesis [40]. ARHGEF10L is involved in the
positive regulation of cytoskeleton organization, and thereby is implicated in microtubule dynamics,
signal transduction, gene expression, and enzymatic regulation [41]. PHC3 is a ubiquitously expressed
member of the polycomb gene family, encoding a diverse set of regulatory proteins that are involved
in the maintenance of the expression patterns that control development [42,43] and are responsible
for long-term silencing of genes by altering chromatin structure through the deacetylation of histone
tails and by inhibiting adenosine triphosphate (ATP)-dependent chromatin remodeling [44,45]. The
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loss of PHC3 may favor tumorigenesis by potentially disrupting the ability of cells to remain in
G0 [46]. POLH is associated with the replication of damaged DNA by synthesis across a lesion in
the template strand, which allows DNA synthesis to continue beyond the lesion. Observations of
Ohkumo T. et al. in the Caenorhabditis elegans suggest that POLH contributes to damage tolerance
against UV irradiation to ensure the successful completion of embryogenesis; this provides important
insights into its role in DNA damage tolerance in germ and embryonic cells [47]. ZHX3 belong to the
homeodomain transcription factor family, which is crucial for the development from embryogenesis to
cell differentiation, including neuronal differentiation [48].
2.4. Functional Annotation of miRNA Target Genes
Potential and experimentally verified target mRNAs were determined using four separate
webtools to explore the biological significance of the studied miRNAs. These webtools were DianaTools
microT-CDS, DianaTools_TargetScan, DianaTools_Tarbase, and miRtargetlink. DianaTools microT-CDS
and DianaTools_TargetScan were used to predict the target genes, whereas DianaTools_Tarbase and
miRtargetlink allowed identification of the experimentally validated targets. Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathways with p-values of < 0.05 were united with DianaTools (Table 4)
to identify signaling pathways regulated by several miRNAs at the same time. It is important to
focus attention on the regulatory effects of miR-92a-3p, let-7b-5p, let-7c-5p, and let-7i-5p on signaling
pathways. Their effector molecules might be involved in gameto- and embryogenesis. It is essential
to mention signaling pathways regulating the pluripotency of stem cells, the extracellular matrix
(ECM)–receptor interaction; adherens junctions; RNA transport; protein processing in the endoplasmic
reticulum; protein digestion and absorption; ubiquitin mediated proteolysis; the Phosphoinositide
3-kinase (PI3K)-Akt serine/threonine kinase signaling pathway; the cell cycle; the Wingless-type Mouse
mammary tumor virus integration site family member (Wnt)-signaling pathway; the Hippo signaling
pathway; the FoxO signaling pathway; the mitogen-activated protein kinase (MAPK) signaling
pathway; the transforming growth factor beta (TGFβ) signaling pathway; the p53 signaling pathway;
the estrogen signaling pathway; oocyte meiosis; and valine, leucine, and isoleucine biosynthesis or
degradation. For instance, the PI3K-Akt, MAPK, Hippo, and Wnt signaling pathways participate in
protein synthesis, cell survival, migration, invasion, cell cycle progression, and cellular proliferation
and differentiation [49,50]. The first cell differentiation event in embryogenesis occurs when the outer
blastomeres of the embryo form a trophectoderm, and the remaining blastomeres form the inner cell
mass (ICM), giving rise to embryonic stem cells which have the potential to self-renew and differentiate
into different cell types and tissues. The balance between differentiation and self-renewal in embryonic
stem cells is maintained, among others, by the Hippo pathway [50,51]. Moreover, it has been reported
that the Hippo pathway can interact with other pathways to promote and maintain pluripotency. For
example, the transcriptional co-activator with PDZ-binding motif (TAZ), the major mediator of the
Hippo pathway, associates with Smad2/3 (directly phosphorylated by TGFβ receptors) and maintains
the nuclear accumulation of Smad complexes, thereby promoting the expression of pluripotency
markers (Oct4, Nanog) in response to TGFβ stimulation [51]. In turn, the TGFβ signaling pathway is
modulated by deubiquitinating enzymes by regulating TGFBR1, TGFBR2, R-SMADs, co-SMAD, and
I-SMAD [52]. The most crucial role in embryological events has canonical Wnt signaling, which is
implicated in cell fate decisions, stem cell maintenance, body-axis determination in vertebrate embryos,
and gastrulation [53].
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Table 4. Predicted and experimentally supported miRNA targets.
DianaTools microT-CDS Algorithm for the Prediction of miRNA Targets in Both the three prime untranslated regions (3’UTRs)
and Coding Sequence (CDS)
Kyoto Encyclopedia of Genes and
Genomes (KEGG) Pathway
p-Value Number of Genes miRNAs
ECM–receptor interaction < 1 × 10−325 15 hsa-let-7b-5p, hsa-let-7c-5p,hsa-let-7i-5p, hsa-miR-92a-3p




8.44 × 10−8 4 hsa-let-7b-5p, hsa-let-7c-5p,hsa-let-7i-5p
Amoebiasis 2.48 × 10−7 11 hsa-let-7b-5p, hsa-let-7c-5p,hsa-let-7i-5p
Signaling pathways regulating stem cell
pluripotency 1.19 × 10−5 16
hsa-let-7b-5p, hsa-let-7c-5p,
hsa-let-7i-5p
Protein digestion and absorption 0.006789 11 hsa-let-7b-5p, hsa-let-7c-5p,hsa-let-7i-5p
PI3K-Akt signaling pathway 0.009286 27 hsa-let-7b-5p, hsa-let-7c-5p
Wnt signaling pathway 0.017555 11 hsa-let-7c-5p
DianaTools_TargetScan—Predicts Biological Targets of miRNAs Considering Matches to 3’ UTRs
Mucin type O-Glycan biosynthesis
(hsa00512) 4.43 × 10−12 1
hsa-let-7b-5p, hsa-let-7c-5p,
hsa-let-7i-5p
Valine, leucine, and isoleucine
biosynthesis (hsa00290) 1.79 × 10−8 1
hsa-let-7b-5p, hsa-let-7c-5p,
hsa-let-7i-5p
Signaling pathways regulating stem cell
pluripotency (hsa04550) 7.77 × 10−6 6
hsa-let-7b-5p, hsa-let-7c-5p,
hsa-let-7i-5p





Oocyte meiosis (hsa04114) 0.008317 3 hsa-let-7b-5p, hsa-let-7c-5p
Valine, leucine, and isoleucine
degradation (hsa00280) 0.026219 1 hsa-let-7c-5p
Arginine and proline metabolism
(hsa00330) 0.026219 2 hsa-let-7c-5p
DianaTools_Tarbase—Database of Experimentally Supported miRNA Targets
Lysine degradation (hsa00310) 6.06959 × 10−13 20 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Cell cycle (hsa04110) 1.13021 × 10−11 52 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Viral carcinogenesis (hsa05203) 5.62537 × 10−10 60 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Hepatitis B (hsa05161) 5.35744 × 10−08 54 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Oocyte meiosis (hsa04114) 1.75682 × 10−07 41 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Chronic myeloid leukemia (hsa05220) 2.5576 × 10−7 27 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Hippo signaling pathway (hsa04390) 4.05654 × 10−7 50 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Proteoglycans in cancer (hsa05205) 1.70389 × 10−6 64 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Thyroid hormone signaling pathway
(hsa04919) 2.7327 × 10−6 39
hsa-let-7b-5p, hsa-let-7i-5p,
hsa-miR-92a-3p
Adherens junctions (hsa04520) 3.42243 × 10−6 30 hsa-let-7i-5p, hsa-miR-92a-3p
FoxO signaling pathway (hsa04068) 2.15597 × 10−5 50 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
ECM–receptor interaction (hsa04512) 2.47672 × 10−5 12 hsa-let-7i-5p
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DianaTools_Tarbase—Database of Experimentally Supported miRNA Targets
Bacterial invasion of epithelial cells
(hsa05100) 4.61176 × 10−5 28
hsa-let-7b-5p, hsa-let-7i-5p,
hsa-miR-92a-3p
Glioma (hsa05214) 7.08143 × 10−5 20 hsa-let-7b-5p, hsa-let-7i-5p
Pathways in cancer (hsa05200) 0.000154251 99 hsa-let-7i-5p, hsa-miR-92a-3p
Colorectal cancer (hsa05210) 0.000634129 25 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Thyroid cancer (hsa05216) 0.000693712 12 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Prostate cancer (hsa05215) 0.001016403 35 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Epstein–Barr virus infection (hsa05169) 0.002168481 51 hsa-let-7b-5p, hsa-let-7i-5p
MAPK signaling pathway (hsa04010) 0.003378721 59 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Endocytosis (hsa04144) 0.003828609 62 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
Huntington’s disease (hsa05016) 0.003922408 50 hsa-let-7b-5p, hsa-miR-92a-3p
Small cell lung cancer (hsa05222) 0.004508148 24 hsa-let-7b-5p, hsa-let-7i-5p
TGF-beta signaling pathway (hsa04350) 0.006182085 29 hsa-let-7b-5p, hsa-let-7i-5p,hsa-miR-92a-3p
p53 signaling pathway (hsa04115) 0.007856274 20 hsa-let-7b-5p, hsa-let-7i-5p
Melanoma (hsa05218) 0.008148048 18 hsa-let-7b-5p, hsa-let-7i-5p
Shigellosis (hsa05131) 0.009612655 13 hsa-miR-92a-3p
Bladder cancer (hsa05219) 0.009747186 14 hsa-let-7b-5p, hsa-let-7i-5p
Signaling pathways regulating
pluripotency of stem cells (hsa04550) 0.01296196 26 hsa-miR-92a-3p
Estrogen signaling pathway (hsa04915) 0.01345837 17 hsa-let-7i-5p
Transcriptional misregulation in cancer
(hsa05202) 0.01729337 45 hsa-let-7i-5p, hsa-miR-92a-3p
Ubiquitin mediated proteolysis
(hsa04120) 0.01776272 34 hsa-let-7b-5p
Protein processing in endoplasmic
reticulum (hsa04141) 0.02539808 38 hsa-let-7b-5p, hsa-let-7i-5p
RNA transport (hsa03013) 0.02748059 41 hsa-let-7b-5p
Valine, leucine and isoleucine
biosynthesis (hsa00290) 0.03746544 2 hsa-miR-92a-3p
In our study, statistically significant correlations were found between the expression profile of
let-7b-5p and the metaphase II oocyte number, the two pronuclei embryos number, and the embryo
development grade, while the expression profile of let-7i-5p correlated with the sperm count per
milliliter of ejaculate and with embryo implantation. let-7b-5p and let-7i-5p regulate the FoxO signaling
pathway, controlling the expression of 35 genes (Table 4), among which FOXO1 plays the most
important role. Kuscu N et al. showed that mouse FoxO1, FoxO3, and FoxO4 proteins are regulated
by the PI3K/Akt signaling pathway and differentially expressed in prophase I, metaphase I, and
metaphase II oocytes, as well as in fertilized oocytes, 2-cell embryos, 4-cell embryos, 8-cell embryos,
morula, and blastocysts [54]. Therefore, they are implicated in oocyte maturation and preimplantation
embryo development.
According to Targetscan and Tarbase, the let-7 family regulates valine, leucine, and isoleucine
biosynthesis or degradation (Table 4). Perkel, K. J., et al. demonstrated that the individually cultured
embryos growing at different developmental rates consume pyruvate, lactate, acetate, isoleucine,
leucine, valine, threonine, alanine, methionine, lysine, glycine, arginine, phenylalanine, histidine
tryptophan, and tyrosine in varying amounts from spent culture medium [55]. For instance, significantly
higher levels of valine, leucine, and isoleucine consumption by 16-cell fast growing embryos compared
with their slow growing counterparts (developmentally delayed by 12–24 h) were found using the
219
Int. J. Mol. Sci. 2019, 20, 2912
proton nuclear magnetic resonance method. Decreased leucine levels in the embryo culture medium
correlated with the pregnancy rate in a study by Brison et al. [56]. These data show that it is important
to characterize the growing embryo not only by morphological criteria, but by metabolomic and
transcriptomic profiles, as well to assess an embryo’s developmental and implantation potential.
The miRtargetlink database was used for hsa-let-7c-5p, since no target genes were detected for it
by DianaTools_Tarbase. The miRtargetlink contains information on “miRNA/gene target” interactions
confirmed by reporter analysis as strong interactions. The list of gene targets of miR-92a-3p, let-7b-5p,
let-7c-5p, and let-7i-5p were subjected to ontology and pathway analysis using PANTHER Classification
System (Available online: http://pantherdb.org/) and were subsequently classified based on their
biological process (Figure 6). Among them, the common target genes of let-7c-5p and let-7i-5p are GPS1,
COPS6, and COPS8. GPS1 is a G Protein Pathway Suppressor 1 known to suppress mitogen-activated
signal transduction in mammalian cells. COPS6 and COPS8 are subunits 6 and 8 of COP9 Signalosome
and are involved in various cellular and developmental processes, for instance, in the regulation of the
ubiquitin (Ubl) conjugation pathway. Let-7b-5p and let-7c-5p regulate the expression level of High
Mobility Group AT-Hook 2 (HMGA2), which is an essential component of the enhancesome and acts as
a transcriptional regulating factor; Neuroblastoma RAS proto-oncogene (NRAS), which has intrinsic
GTPase activity and controls cell proliferation and anti-apoptosis pathways [57]; AGO1 (Argonaute
1, RISC catalytic component), which degrades and represses the translation of mRNA bound to
miRNA as well as performing transcriptional gene silencing of promoter regions bound to short
antigene RNAs; IGF1R (Insulin Like Growth Factor 1 Receptor, implicated in cell growth and survival
control); TGFBR1 (Transforming Growth Factor Beta Receptor 1, involved in the regulation of cellular
processes, including division, differentiation, motility, adhesion, and death); and TNFRSF10B (tumor
necrosis factor Receptor Superfamily Member 10b, causes cell apoptosis through adapter molecule
Fas Associated Via Death Domain (FADD) and effector caspases). The only common experimentally
proven target gene of let-7b-5p and let-7i-5p is TLR4 (Toll Like Receptor 4, transmembrane cell-surface
receptor), which was initially discovered in D. Melanogaster as a gene controlling body patterning
during embryonic development [58] and plays a key role in the innate immune system [59].
Figure 6. Functional classification of genes targeted by let-7b-5p, let-7c-5p, let-7i-5p, and miR-92a-3p
from miRtargetlink and the PANTHER databases.
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The essential roles of the let-7 and miR-92 family in determining the blastocyst developmental and
implantation potential were confirmed by data from Kim J et al. [60]. They showed a significant increase
in the expression level of let-7b-5p and miR-92a-3p in outgrowth embryos compared with blastocysts
and non-outgrowth embryos. Regulation of the «Mucin type O-Glycan biosynthesis signaling pathway
(hsa00512)» under the control of let-7b-5p, let-7c-5p, and let-7i-5p according to the DianaTools database
(Table 4) as well as the regulation of the expression level of IGF1R under the influence of let-7b-5p
according to the miRtargetlink database (see above) emphasizes the important roles of these miRNA
subtypes in implantation processes, since Mucin 1, being an integral transmembrane mucin glycoprotein
expressed on the apical surface of the endometrium, acts as an inhibitor of embryo attachment, whereas
IGF1R increases on the surfaces of the endometrium during the receptive stage and contributes to
adhesive interaction with the embryo [29].
3. Materials and Methods
3.1. Patients
Forty couples aged between 27 and 40 years with reproductive disorders and IVF indications
were enrolled in the study, and 87 samples of spent embryo culture medium (Irvine OneStep) were
obtained on day 4 after fertilization during IVF cycles. The morphological characteristics of studied
embryos were evaluated on day 5 and were as follows: there were blastocysts of excellent (>3AA,
n = 32), good (3–6 AB, 3–6 BA, 1–2 AA, n = 16), fair (3–6 BB, 3–6 AC, 3–6 CA, 1–2 AB, 1–2 BA, n = 11),
and poor quality (1–6 BC, 1–6 CB, 1–6 CC, 1–2 BB, n = 6) according to the Gardner grading scale [2], as
well as morula embryos (n = 14) and 3–10 cell embryos (n = 8). Out of the 87 embryos, 7 morulas, 3
cavernous morulas, and 38 blastocysts were transferred to the uterus at 5 or 6 days after fertilization.
When ovarian hyperstimulation syndrome risk was present, the freeze-all strategy was applied. Before
initiation of the IVF program, the following information from a couple was analyzed: medical history,
hormonal profile, rhesus blood group system, blood coagulability, infection status, Papanicolaou test,
pelvic ultrasound data, and spermogram. There were no statistically significant age or anthropometric
measurement differences between patients enrolled in the current study. Patients with normal ovarian
reserve, a regular menstrual cycle, and without any extragenital diseases were selected to minimize the
influence of maternal factors on embryo implantation. The inclusion criteria were as follows: patients
aged 20–37 years old with normal ovarian reserve, tubal factor infertility, and a regular menstrual cycle.
The exclusion criteria were patients with contraindications for IVF treatment including extragenital
diseases, stage 3–4 moderate and severe endometriosis, polycystic ovary syndrome, endometrial
pathology, intramural and subserosal myomas of more than 4 cm, submucosal myomas distorting the
uterine cavity, genetic disorders, congenital genitourinary anomalies, a history of invasive surgery on
the ovaries, or severe male infertility.
Forty patients with tubal infertility factor were enrolled in the current study. All patients
underwent a short antagonist protocol. Gonadotropin stimulation commenced on day 3–4 of the
menstrual cycle. Subcutaneous administration of the gonadotropin-releasing hormone (GnRH)
antagonist began when the follicular size was more than or equal to 14 mm. All patients had routine
monitoring via transvaginal sonography and hormonal profiling of follicle-stimulating hormone (FSH),
luteinizing hormone (LH), estrogen, and progesterone levels. The mature oocytes were retrieved
after 34–36 h of human chorionic gonadotropin (HCG) injection. The collected matured oocytes were
fertilized in vitro using IVF and the intracytoplasmic sperm injection (ICSI) method. Progesterone
vaginal suppository or dydrogesterone enhancesome urred daily after oocyte retrieval and continued
until the result of the first blood pregnancy test. All embryos were cultivated in microdrops in the
incubator. The assisted hatching procedure was done in individual cases. Single embryo transfer
(SET) was performed on day 5 after oocyte retrieval. If the pregnancy test was positive, the patient
continued progesterone supplementation until 8 weeks of pregnancy. In the case of a negative result,
the medication was discontinued.
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All patients were divided into three groups depending on the IVF program result (Table 5).
Group I: 22 patients who had ovarian stimulation and SET in a stimulated cycle with a negative
pregnancy blood test.
Group II: 18 patients who had ovarian stimulation and SET in a stimulated cycle with a positive
pregnancy blood test.
Group III: 3 patients from group I who had implantation failure in the previous stimulated cycle and
frozen-thawed (FT) embryo transfer with a positive result. All embryos were thawed at the blastocyst
stage. The endometrium was prepared with the exogenous administration of oral micronized estradiol
forms and progesterone. FT embryo transfer was performed on day 19–20 of the menstrual cycle. The
endometrium thickness at the day of embryo transfer was 9–12 mm.













Body mass index (BMI) * 22.1 (2.0) 22.2 (1.4) 22.0 (1.8) >0.05
Menstrual cycle length (days) * 29.9 (1.6) 28.4 (0.9) 29.0 (2.7) >0.05
Average age (years) * 32.3 (3.5) 32.0 (3.1) 30.0 (2.4) >0,05
Follicle-stimulating hormone
level on day 2–3 of menstrual
cycle (mIU/mL) *
7.8 (1.4) 7.2 (1.4) 5.8 (0.5) >0.05
Anti-mullerian hormone level
(ng/mL) * 2.4 (1.0) 2.4 (0.7) 2.8 (0.5) >0.05
Antral follicle count on day
2–3 of the menstrual cycle * 8.2 (1.6) 7.8 (1.5) 8.3 (1.0) >0.05
Male factor infertility ** 18 patients (64%) had malefactor infertility
14 patients (78%) had male
factor infertility
2 patients (50%) had male
factor infertility >0.05
Primary infertility ** 13 patients (46%) hadprimary infertility
8 patients (44%) had primary
infertility
2 patients (50%) had primary
infertility >0.05
Assisted hatching ** In 20 (71%) patients, assistedhatching was performed
In 10 (56%) patients, assisted
hatching was performed
In 2 (50%) patients, assisted
hatching was performed >0.05
Number of oocytes retrieved * 7.8 (3.7) 7.4 (4.5) 8.0 (3.7) >0.05
Number of blastocysts * 1.4 (1.3) 1.4 (1.2) 2.8 (2.0) >0.05
* Data are presented as an arithmetic mean (M) and standard deviation (SD) in the format of M(SD), specifying the
significant differences when using ANOVA test; ** data are presented as absolute N numbers and percentages of the
total number of patients in group P in the format of N(P%), specifying the significant differences when using the χ2
test. Comment: Group III (successful implantation in a frozen embryo transfer protocol) coincides with Group I
(implantation failure), since patients from Group I were transferred to Group III after their previous failed IVF.
The ethics committee of the National Medical Research Center for Obstetrics, Gynecology, and
Perinatology, named after Academician V.I. Kulakov of Ministry of Healthcare of the Russian Federation,
approved this study (Ethic’s committee approval protocol No13, approval date: 6 December 2013).
3.2. RNA Isolation from Embryo Culture Medium and Blastocoele Fluid
Twenty-five microliters of embryo culture medium or several nanoliters of blastocoele fluid
adjusted to 200 μL with 0.9% NaCl were treated with 1000 μL of QIAzol Lysis Reagent (Qiagen, Hilden,
Germany), followed by mixing with 200 μL of chloroform, centrifugation for 15 min at 12,000 g (4 ◦C),
collection of 600 μL aqua phase, and RNA isolation using the miRNeasy Serum/Plasma Kit (Qiagen,
Hilden, Germany).
3.3. sncRNA Deep Sequencing
cDNA libraries were synthesized using 7 μL of the 14 μL total RNA column eluate (miRNeasy
Serum/Plasma Kit, Qiagen, Hilden, Germany), extracted from embryo culture medium and blastocoele
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fluid using the NEBNext® Multiplex Small RNA Library Prep Set for Illumina® (Set11 and Set2, New
England Biolab®, Frankfurt am Main, Germany), amplified for 30 PCR cycles, and sequenced on the
NextSeq 500 platform (Illumina, San Diego, CA, USA). The adapters were removed with Cutadapt. All
trimmed reads shorter than 16 bp and longer than 35 bp were filtered, and only reads with a mean
quality higher than 15 were retained. The remaining reads were mapped to the GRCh38.p15 human
genomes miRBase v21 and piRNABase with the bowtie aligner [61]. Aligned reads were counted with
the featureCount tool from the Subread package [62] and with the fracOverlap 0.9 option, so the whole
read was forced to have a 90% intersection with sncRNA features. Differential expression analysis of
the sncRNA count data was performed with the DESeq2 package [63].
3.4. Reverse Transcription and Quantitative Real-Time PCR
Five microliters of the 14 μL total RNA column eluate (miRNeasy Serum/Plasma Kit, Qiagen,
Hilden, Germany) extracted from the embryo culture medium was converted into cDNA in a reaction
mixture (20 μL) containing 1x Hispec buffer, 1x Nucleics mix, and miScript RT, according to the
miScript® II RT Kit protocol (Qiagen, Hilden, Germany); then, the sample volume was adjusted with
deionized water to 200 μL. The synthesized cDNA (3 μL) was used as a template for real-time PCR
using a forward primer specific for the studied sncRNA (Table 1) and the miScript SYBR Green PCR
Kit (Qiagen, Hilden, Germany). The following PCR conditions were used: (1) 15 min at 95 ◦C and
(2) 40 cycles at 94 ◦C for 15 s, an optimized annealing temperature (45–60 ◦C) for 30 s, and 70 ◦C for
30 s, followed by heating the reaction mixture from 65 to 95 ◦C by 0.1 ◦C to plot the melting curve of
the PCR product in a StepOnePlus™ thermocycler (Applied Biosystems, Foster City, CA, USA). The
relative expression of sncRNA in the embryo culture medium was determined by the ΔΔCt method
using hsa-piR023338 (DQ601914, GenBank, available online: https://www.ncbi.nlm.nih.gov/genbank/)
as the reference RNA and culture medium without any embryo incubated for 4 days at 37 ◦C as a
reference sample. hsa-piR023338 was chosen as the reference RNA due to its identical expression level
in all 87 analyzed samples.
3.5. Data Processing
Scripts written in R were used for the resulting data processing [62,64]. The Shapiro–Wilk test
was used to test whether the analyzed parameters were normally distributed. The χ2 test was used
for comparing categorical variables. The ANOVA test was used for the analysis of the three groups
of normally distributed parameters. Finally, the Mann–Whitney U-test was used for the pairwise
comparison of the non-normally distributed parameters. Absolute numbers (N) and percentages of the
total number of patients in a group (P) in the N (P%) format were used to describe categorical binary
data. The arithmetic mean (M) and standard deviation (SD) in M (SD) format were used to evaluate
the normally distributed quantitative data. Non-normally distributed parameters were described as
medians (Me) and quartiles (Q1 and Q3) in the Me (Q1; Q3) format. The Spearman correlation analysis
was performed, since both quantitative and qualitative data were analyzed. A 95% confidence interval
for the correlation coefficients was determined using the Fisher transform strategy. The threshold
for the statistical significance was p ≤ 0.05. The p-value was specified in the p < 0.001 format if it
was less than 0.001. In addition, the morphological characteristics of the embryos and the obtained
experimental data were analyzed using PLS-DA [65].
4. Conclusions
In recent years, the attention of scientists has been drawn to the study of the role of sncRNA in
embryogenesis. In the course of the present research work, a complex interrelation of sncRNA expression
patterns in the culture media of embryos at various development grades on day 4 after fertilization was
revealed. These findings probably reflect the manifestation of the fine regulation system of signaling
pathways which is necessary for implementation of the embryogenesis program. The pathway analysis
of miRNA and piRNA target genes emphasizes the role of sncRNA described in this article in the control
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of chromatin structure, genome stability, DNA replication, gene transcription, protein synthesis, cell
survival, migration and invasion, cell cycle progression, and cellular proliferation and differentiation,
i.e., the processes that determine the normal course of gametogenesis and embryogenesis. Correlations
between the sncRNA expression patterns and the number of oocyte–cumulus complexes, metaphase
II oocytes, and two pronuclei embryos as well as the spermatozoid count, the percentage of linearly
motile spermatozoids, the embryo development grade, and embryo implantation provide evidence of
the roles of these molecules in human reproductive system regulation.
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Abstract: Extracellular DNA (ecDNA) is studied as a possible biomarker, but also as a trigger of the
immune responses important for the pathogenesis of several diseases. Extracellular deoxyribonuclease
(DNase) activity cleaves ecDNA. The aim of our study was to describe the interindividual variability of
ecDNA and DNase activity in the plasma of healthy mice, and to analyze the potential determinants of
the variability, including sex, age, and bodyweight. In this experiment, 58 adult CD1 mice (41 females
and 31 males) of a variable age (3 to 16 months old) and bodyweight (females 25.7 to 52.1 g, males 24.6
to 49.6 g) were used. The plasma ecDNA was measured using a fluorometric method. The nuclear
ecDNA and mitochondrial ecDNA were quantified using real-time PCR. The deoxyribonuclease
activity was assessed using the single radial enzyme diffusion method. The coefficient of variance for
plasma ecDNA was 139%, and for DNase 48%. Sex differences were not found in the plasma ecDNA
(52.7 ± 73.0 ηg/mL), but in the DNase activity (74.5 ± 33.5 K.u./mL for males, and 47.0 ± 15.4 K.u./mL
for females). There were no associations between plasma ecDNA and bodyweight or the age of mice.
Our study shows that the variability of plasma ecDNA and DNase in adult healthy mice is very high.
Sex, age, and bodyweight seem not to be major determinants of ecDNA variability in healthy mice.
As ecDNA gains importance in the research of several diseases, it is of importance to understand its
production and cleavage. Further studies should, thus, test other potential determinants, taking into
account cleavage mechanisms other than DNase.
Keywords: cell-free DNA; nuclease activity; aging; obesity; gender differences
1. Introduction
Extracellular DNA (ecDNA) is DNA outside of cells. The presence of ecDNA in blood was
discovered by Mandel and Metais in 1948 [1]. The ecDNA is proinflammatory [2] and procoagulatory [3].
Apoptosis and necrosis are the major sources of ecDNA [4]. EcDNA is used as a biomarker in
non-invasive prenatal diagnostics [5] and oncology [6]. In addition, donor DNA can be detected
in the blood of the transplant recipient, suggesting that ecDNA could be a biomarker of transplant
rejection [7,8]. EcDNA is also a therapeutic target. In several diseases, it has been shown that ecDNA
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leads to inflammation and a release of more ecDNA—this vicious circle can be stopped by the removal
of ecDNA, as shown for sepsis [9], hepatorenal injury [10], and metabolic syndrome [11,12].
The knowledge about the normal ecDNA concentration values and the variability of ecDNA is
limited. Currently, there are no standard physiological values for ecDNA in plasma. A recent study
evaluating human plasma ecDNA showed that both nuclear and mitochondrial DNA vary within a
range of over three orders of magnitude [13]. Regarding the technical variability, the amount of ecDNA
found in body fluids depends on the processing of samples, and on the technique used for DNA
quantification. It has been shown that the extraction efficiency from plasma has a coefficient of variance
of approximately 29% [14]. The discordant methods of sample processing and quantification make a
comparison of ecDNA concentrations between studies difficult [15]. Apart from technical variability,
there is also a high biological variability of plasma ecDNA. This is best described for fetal DNA
circulating in maternal blood [16]. Deoxyribonuclease-I (DNase I) does not affect the fragmentation
of ecDNA in plasma [17]. The pattern of fragmentation of ecDNA was described in mice deficient
in DNase I and DNase 1L3. Mice without DNase 1l3 have more longer fragments of ecDNA [18].
However, if mice are deficient for both DNase I together with DNase 1L3, and their neutrophils are
stimulated, they die because of the inability to cleave ecDNA in blood [19].
Interindividual differences in ecDNA can be caused by differences in the release of ecDNA,
its cleavage, or protection against the cleavage. Deoxyribonucleases (DNases) are able to cleave plasma
ecDNA [20]. Obesity inducing the release of ecDNA from adipocytes makes body weight one of the
candidate determinants of ecDNA [11]. Aging is associated with an increased production of neutrophil
extracellular traps—a major source of ecDNA [21]. Women are more prone to autoimmune diseases
associated with anti-DNA antibodies [22]. This suggests that the concentration of ecDNA in females
could be higher, although the mechanisms are unclear. Understanding the variability of ecDNA could
be very helpful to overcome the diagnostic limitations of ecDNA, but it could also shed light on the
role of ecDNA in the pathogenesis of inflammatory diseases. The aim of this study is to describe the
variability of ecDNA and DNase, and to analyze its potential determinants. Our hypothesis was that
older females with a higher bodyweight have higher ecDNA and lower DNase in their plasma.
2. Results
An analysis of variability revealed high coefficients of interindividual variations for total ecDNA
(Coefficient of Variance (CV) = 139%), nuclear DNA (ncDNA; CV = 50%), and mitochondrial (mtDNA;
CV = 149%). The total ecDNA minimum is 100-fold lower than the maximum concentration.
The maximum ncDNA and mtDNA concentrations were 10-fold and 1000-fold higher than the
minimum concentrations, respectively. For the DNase activity, the maximum value was 7.5-fold higher
than the minimum. Based on the 5% and 95% percentile, the normal values of the total ecDNA,
ncDNA, mtDNA, and DNase activity were determined. These are solely specific for the type of
sample processing described here. The normal values for the total ecDNA in the plasma were 5 to
266 ng/mL. For the ecDNA fractions, normal values were also determined. The normal values for
plasma mtDNA were 6.5 × 103 to 6.4 × 105 GE/mL, and for the plasma ncDNA they were from 1.6 × 103
to 7.5 × 103 GE/mL of plasma. The mtDNA copy number is, thus, approximately 4 to 85 per cell.
The normal values of DNase activity in the plasma were from 32 to 125 K.u./mL (Table 1).
Sex seems not to be a major determinant of plasma ecDNA variability in mice. There were no sex
differences in the ecDNA concentrations in the total ecDNA (t-test; p = 0.52, t = 0.64; Figure 1A,B),
ncDNA (t-test; p = 0.26, t = 1.14), or mtDNA (t-test; p = 0.41, t = 0.83; Figure 2). A statistically significant
sex difference was found in the DNase activity—the male mice had a higher DNase activity by 59%
(Figure 1D; p < 0.001, t = 4.65).
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Table 1. Descriptive statistics of the measured variables, namely: bodyweight, age, plasma extracellular














Mean 38.06 226 52.7 3.3 × 103 1.4 × 105 59.0
Standard Error 0.72 14 8.8 2.0 × 102 2.6 × 104 3.4
Median 38.53 195 31.1 2.9 × 103 6.0 ×104 51.0
Standard Deviation 6.16 122 73.0 1.6 × 103 2.1 × 105 28.4
Minimum 24.62 99 2.9 7.2 × 102 3.1 × 103 25.1
Maximum 52.11 468 423.2 9.9 × 103 1.1 × 106 186.4
Coefficient of
Variance 16% 54% 139% 50% 149% 48%
Figure 1. (a) Total extracellular DNA (ecDNA; n= 57) and (b) total ecDNA divided by sex (females n = 34,
males n = 23) (t-test; p = 0.52, t = 0.64) and (c) deoxyribonuclease (DNase) activity (n = 72) and (d) DNase
activity divided by sex (females n = 41, males n = 31) (t-test; p < 0.001, t = 4.65). DNase activity is
expressed in Kunitz units (K.u.) per ml of plasma. The results are presented as mean + standard
deviation. p-value is indicated as *** for p < 0.001.
The correlation analysis revealed that the total ecDNA was positively correlated with ncDNA
(p < 0.001, Pearson’s r = 0.66) and strongly with mtDNA (p < 0.001; Pearson’s r = 0.90). NcDNA was
also positively correlated with mtDNA (p < 0.001; Pearson’s r = 0.63). The DNase activity did not
correlate with the total ecDNA (n.s.; Pearson’s r = −0.11). No association was found between the DNase
activity and ncDNA (n.s.; Pearson’s r = −0.02) or mtDNA (n.s.; Pearson’s r = −0.02). The bodyweight
of the mice did not correlate with the total ecDNA (n.s.; Pearson’s r = 0.01), ncDNA (n.s.; Pearson’s
r = 0.07), or mtDNA (n.s.; Pearson’s r = −0.01). Similarly, age did not correlate with the total ecDNA
(n.s.; Pearson’s r = 0.03), ncDNA (n.s.; Pearson’s r = 0.04), and mtDNA (n.s.; Pearson’s r = 0.04; Table 2).
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Figure 2. (a) Nuclear extracellular DNA (ncDNA; n = 57) and (b) nuclear extracellular DNA divided
by sex (females n = 34, males n = 23; t-test; p = 0.26, t = 1.14) and (c) mitochondrial extracellular DNA
(mtDNA; n = 57), and (d) mitochondrial extracellular DNA divided by sex (females n = 34, males n = 23;
t-test; p = 0.41, t = 0.83). The extracellular DNA of both a nuclear and mitochondrial origin is expressed
in genome equivalents (GE) per ml of plasma. The results are presented as mean + standard deviation.
Table 2. Correlation matrix describing the relationships between the analyzed variables, namely:
bodyweight, age, total extracellular DNA (ecDNA), nuclear ecDNA (ncDNA), mitochondrial ecDNA
(mtDNA), and deoxyribonuclease (DNase) activity. The data in the table are presented as Pearson’s
correlation coefficients with p-values indicated as p < 0.001 for ***.
Bodyweight Age Total ecDNA ncDNA mtDNA DNase Activity
Bodyweight 0.60 *** 0.01 0.07 −0.01 0.19
Age 0.60 *** 0.03 0.04 0.03 −0.11
Total ecDNA 0.01 0.03 0.66 *** 0.90 *** −0.11
ncDNA 0.07 0.04 0.66 *** 0.63 *** −0.02
mtDNA −0.01 0.03 0.90 *** 0.63 *** −0.02
DNase activity 0.19 −0.11 −0.11 −0.02 −0.02
3. Discussion
In this cross-sectional study on healthy mice, we confirmed a very high variability in ecDNA
and DNase activity. As ecDNA and its cleavage are likely involved in the pathogenesis of several
diseases, it is of importance to analyze the determinants of this variability. However, using correlation
analysis, in our study, we found no association of either ecDNA or DNase with the age or bodyweight
of the mice. Similarly, no sex differences were found for ecDNA or its fractions—ncDNA and mtDNA.
The only sex difference was found in the DNase activity, which was higher in male mice, confirming
previous reports [23]. Thus, to explain the variability of ecDNA, cleavage mechanisms other than the
action of DNases should be taken into account. These include the phagocytic activity of monocytes,
cleavage by the liver, or excretion via kidney [24–26].
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There are many age-related diseases that are associated with high concentrations of ecDNA,
such as autoimmune diseases [27], myocardial infarction [28], obesity [11,29], and others. It has already
been published that aging is associated with increased levels of ecDNA in humans [30]. Dying cells
release ecDNA to the extracellular space, and this ecDNA can activate toll-like receptors and induce an
immune system response [31]. Neutrophils can die while releasing their DNA. Neutrophil extracellular
trap production is increased in aged mice [32]. Nevertheless, in our study in healthy mice, age did not
affect ecDNA or DNase in the plasma.
Regarding ecDNA, there is one published study investigating sex differences in ecDNA
concentration. Men were shown to have a higher nuclear ecDNA concentration in comparison
to women, but there were no differences in ecDNA originating from the mitochondria [13]. In our
study, no such sex differences in ecDNA were found. In comparison to humans, mice have a much
higher DNase activity in the plasma. Whether this affects the interpretability of the results of the
experiments on animal models of diseases related to ecDNA is unknown. From the available literature,
the variability in ecDNA and DNase activity is high [23]. This was confirmed by our results in mice.
However, except for the sex difference in the DNase, the determinants of this variability could not be
identified. Other factors should be studied in the future. Magnesium and calcium ions, for example,
are needed for DNases to be active, and can be one of the determinants of DNase activity that contribute
to variability [33].
One of the proposed determinants of ecDNA is physical activity. DNase activity and ecDNA
were shown to increase in response to high-intensity exercise [34]. Circadian biorhythms affect DNA
damage and apoptosis [35]. Similarly, in females, the variability of ecDNA or DNase activity could be
influenced by the estrous cycle. The hormonal changes might be relevant in autoimmune diseases
related to ecDNA and their animal models [36]. Revealing the determinants of ecDNA variability both
in humans and in mice, might help to understand the physiology and the pathophysiology related
to ecDNA.
One important aspect not included in our study is technical variability. It has been shown
that even the isolation of ecDNA contributes considerably to the overall variability in the
outcome [14]. The optimization of protocols is crucial in achieving accurate and reproducible results.
The centrifugation speed and time differ between studies, which makes it difficult to compare the results.
The most commonly used protocol is two-step centrifugation, which removes apoptotic bodies and
some microvesicles [37]. The choice of blood collection method is of importance. Serum is not suitable
for ecDNA quantification, because of the release of genomic DNA from cells during coagulation [38].
EDTA plasma, on the other hand, cannot be used for the measurement of DNase activity, as it inhibits
DNase I [39]. So, in our study, we have collected blood into EDTA and heparin to use plasma for
DNA and DNase measurements, respectively. However, a further reduction of the technical variability,
especially in the quantification of nuclear and mitochondrial DNA, is surely needed.
In conclusion, for future experiments, it is important to consider the high interindividual variability
of ecDNA in healthy animals, which is independent of body weight, age, or sex. The observed sex
difference in the DNase activity needs to be taken into consideration, especially if confirmed in other
strains and species. In addition, the underlying endocrine or genetic mechanisms should be clarified.
The major contributors to the biological variability of ecDNA are, however, yet to be identified.
4. Materials and Methods
4.1. Animal Procedures
The CD-1 mice were purchased from Anlab (Prague, Czech Republic). Both female (n = 35) and
male (n = 23) healthy mice of varying age (7.5 ± 4 months) and of varying weights (females 34.1 ± 7.4 g
and males 40.7 ± 6.2 g) had ad-libitum access to food and water. The animals were maintained in a
temperature-controlled and light-controlled room with a 12-h light/dark cycle. Blood was collected
from the retro-orbital plexus from mice in isoflurane anesthesia (AbbVie, Bratislava, Slovakia) into
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heparin and EDTA microvettes (Sarstedt, Nümbrecht, Germany), and centrifuged at 2000× g for
10 min at 4 ◦C. The mice were sacrificed by cervical dislocation. The plasma was stored at −20 ◦C
until further analyses. All of the methods and procedures were conducted in accordance with Slovak
legislation. The animals were housed and procedures were conducted in compliance with the Ethics
committee of Institute of Molecular Biomedicine, Comenius University in Bratislava (Ro-536/18-221/3;
date: 26 March 2018).
4.2. DNA Isolation and Quantification
DNA was isolated from the EDTA plasma using the QIAamp DNA Blood Mini kit (Qiagen,
Hilden, Germany). The isolated DNA was quantified using a Qubit 3.0 fluorometer and Qubit
dsDNA high sensitivity assay (Thermo Fisher Scientific, Waltham, MA, USA). The fractions of
nuclear and mitochondrial DNA were estimated using real-time PCR on the Mastercycler realplex
4 (Eppendorf, Hamburg, Germany) with Sso Advanced Universal SYBR Green Supermix (Bio
Rad Laboratories, Hercules, CA, USA). The following PCR program was used: one cycle of
98 ◦C for 3 min, 40 cycles of 98 ◦C for 15 s for denaturation, 60 ◦C for 30 s for annealing, and
72 ◦C for 30 s for extension. Primers were designed for the amplification of mouse mtDNA (F:
5′-CCCAGCTACTACCATCATTCAAGT-′, R: 5′-GATGGTTTGGGAGATTGGTTGATGT-3′) [40] and
ncDNA (F: 5′-TGTCAGATATGTCCTTCAGCAAGG-3′, R: 5′-TGCTTAACTCTGCAGGCGTATG-3′) [41].
The quantified ecDNA is expressed in genome equivalents (GE).
4.3. DNase Activity
Plasma anticoagulated with heparin was used for the determination of DNase activity. The DNase
activity was measured using the modified single radial enzyme-diffusion assay with the GoodView
fluorescent dye [42]. Agarose gels (1%, 20 mM Tris-HCl, ph 7.5, 2 mM MgCl2, 2 mM CaCl2) containing
DNA isolated from chicken livers (0.5 mg/mL of DNA) were visualized using iBOX (Vision works LP
Analysis Software, UVP, Upland, CA, USA), and the radius of the circles were measured and compared
to the calibration curve from the DNase standards. The DNase activity was recalculated and expressed
in Kunitz units (K.u.).
4.4. Statistical Analysis
The results were analyzed using GraphPad Prism 6 (La Jolla, CA, USA). For the evaluation of the
sex differences, the student t-test was used. Correlation analyses were conducted with the Pearson
correlation test. The test results of p < 0.05 were considered statistically significant.
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